var title_f39_12_40128="Groin hernias";
var content_f39_12_40128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Groin hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inguinal hernias typically present above the inguinal ligament and extend below it. Femoral hernias typically present below the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40128=[""].join("\n");
var outline_f39_12_40128=null;
var title_f39_12_40129="Right paraaortic space opened";
var content_f39_12_40129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right paraaortic space opened",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40129=[""].join("\n");
var outline_f39_12_40129=null;
var title_f39_12_40130="Clear cell carc MRI A";
var content_f39_12_40130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance images (MRI) of clear cell carcinoma of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 365px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFtAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyfwE7W0gZeCB09aw/iNqP2m/6fMDzmtnwhGrebIZACBxXNeN54mnWNQDJnlqAOZjYGXc/P0rqNHhMzIsXGTjPpXKxjLqPeu18MwtI6iLHHJoA7GRnsNNUKQxxziuI1eRp52ZoypPrXYSRtO4UBiiD5uOK5XV7yNr14yAyA8EUAY9pbgyGVRhx1z6VoGGNhvjXax61VDgA/MFU9KdA8u7HVccYoAnMcQOJB1/SokUGU8H/AGWpoEzO28ZUdTUyqyqOhT1oAVciQLvGT39qsQoBIVkbcPrTREdwJXk9KXEnmFSvPUUAPRCsxWfhD900kpeJ/LU4B6GpjLuASdckdDUdxE0ysxJUDpmgBZLcGISBhvHah7Jp4cqwRz696qwbo/vvlh0HWrlvMtw3cOPTpQBnyaZLCpVhnPRqzZ7DH3iC30rpkSd1cqwKDrmqbpC4bJO9aAOYurIwgcHcegqm6MjYYYNdNP5ezjLN79qpXNkJEBfIY9DQBiUVams5IlLHlfaq204zjigBKKKKACtzRNJe/iMggZ0HVhWJXQaNNqkMO21dUhPXJxQBeXRLR12pGwcdcmri+ErdkH3lPpmptLuJklBnCkeorp4GDyBiQDjgUAcyvgq1kACyOGPvUEvgdQ+1Lj8c13dsvl5Z9gJpHUxvlk3K3SgDzubwZLnEco47+tLYeFpUnBLA44Neg7W34mUhj0xW1pmmIYDJKm1v0NAHmeraHBbQbt+SRnFYgt9gI5xXpniS3jKHfEc9siuPli8mI7kHPfHSgDitTB87PGPSqVaOsbBcnaSc9s1nUAFFFFABRRRQAUU5VLHCgk+1SJbTuPkhkP0U0AQ0VbXTr1hkWs//AHwaBp16WCi0uMn/AKZmgCpRV2XTL6IZktJlH+6arvBKn342H4UARUUUUAKPenoSJMxqf51HUsMmzIPQ9T3oA1rGPdEwiXb6salit2lhdcg4OeKjE6W8CQg5DenWrOlSiQt5YOwdzQBmTQLCQbdiezLms+TbvOz7vat7WI/LiMgTZu7461iu29FVUAb1HegDttJv4oIXOMALn61x2p3Bub2SVhjJrRmlkW02leQOaxSS7fMetAEttCZX64AruPDcW0edGxGBjFcnY2xmkRA2D6etdxayJptmFdcsRQBPretyx2JgtlVXf7xz1rjn/esojxu/iz3pdXufMnwsmCaqfNuXDgSDv60ASlcz7ZAcdquI01oOm4Hp7CoIVuZ1aQL8qjk1LBM5QjO4E4oAuwAyqTESc/eFPEZRCT93PFLYxXEeBGMFqtGNlRxIcjv7UAQRQykCQv06UgmlG58Zx3NXbaaCK2ZJBuU5GfSm/uZIWU4VfWgCmd7xGYMN/pUM08oI8wZoKjqjYxTcfvAVbPqKAJVgS5BeN8MPWp7K1kZ2CYQ+pPJqmpVJDjhP60PM4bzXkwB90UAadvp935zIkmD35o1GNUUIsQBB+Zh3qhY3F08xZJCA3erscrzOyPIGIoAoXMP7sOiYFNit3a3MknKDtVu5lcNsfle9ViDFKGt2ylAFRo/MbMa/L02msy8tHZzsU4+lbzMVbdINpNNTPmE4GwigDkzE24qoyR1pu0g88Vr3aBXYxLjPOaypVAOd2Seo9KAJYbYysqhhuY4Fem6ToEVto6Nfy7ZWGVUd688054rWRZid+OfpXZ2euQ3Kp9pkDEfdFAGpY6VgssI3g9iOlaNlayW7bZoywPQ+lQW+v6dEyiGdVl/irch1jT3QFblGPcY6UAQPa4ddzN0zUsLPHMwQb8jv2q39vtHx+8Rl7HinxTW0uRbsoboTnrQBkLcP5jCY5x0f0rejv3u9OEScSKPlPrWTPbxoxDAFTyQDWp4duLK4DRTAJ5fK0Acz4huLyS3EU6bHHRq56RXS0/etkN1NdX4vv1uWYLwF4XFcpeRN9lIkf5iPlUUAcLrKBLxto4NZ9W73fJcSbj8ydqhji8wfKfm9KAIqsW9pNcY8pC1a+kaDLcyL5yMEPeuz0rR4bLjA49RmgDkLPwreyjc64Qcn2rpNO8LWscKvIvmMO2K6ZVOzKMMdMVYsyyIwZAHPQetAGbBoNtbosn2ZeevFa1ikIdVt7OLA5we5pZ5LiNd7sGYfwe1X7P7NPaiaM7LjPPtQBZOoPbRhprGIemMHFaUPiGK1hTz9MheOT/loAMiubulEJ3PP5pbqBVuAefbY3jyl5KkUAdRZavpF6ptrqwiCMOHx61V1HwHoWrRmO1nSOVz1yOKwYWDxkIMRj2qKeX/nzdlYHJOTQBieIvg5cW8nlWsobglXXnNeaaz4T1bSnl+0Wr7E/iA619DWHiiWztI42U3CrwT6VuwGz12Ha8UbLIMFSBQB8ekYPNKnJAC7j6V9BeNfhrazb/s8It+4YV5TrPgzUtIHnRfvFHcCgDGRdyK0KBpBwyntWzplm25RHjL/AHgKytMjkiLtNlA3XIrodJsjcOBBL83agA1+xEdqonkLr/dHY1x8TKlxiYkIM49q7y+td4eAndMByc9K4u5slDuI5N7Dr7UAacFo0zeV1LDk1najElmxt4wGbuetdZpckKwOdoJReprkL2487UHYLjLYNAGn4dto/N+0SMdq81Z1TUPtMrLEwIHA5qr5i6fa/L8wfqPSsuS4DSkoCB6jtQAoXzWbz/vDoangjMinaCW7GoRPGqd2c1Pb3EoZQqbcUAWbWO4hQiU4DcYzU9qCJPlHy55ppmeWQb8H39KsxRmN8ZBz6d6AJ1eVH3K3ynipnLg/MS2etJb3UacTrgL1q5cXdlLakw8fWgDNXO/cOEHUGmSy4LA/cPpSE/uyCSW7Y71HJKGh24GR1oAEZQpXqfanxhJGDJnIPNVoZTzsXj1Iqe2t7raxijytAEl3GHkUqQqjoKZ5E7Pkxk4/hAoeOXZ+/BVuxqeK4uIADuDMBxzQBWhZo945UHgj0pxe1SPAlKy9c5q9HNEyF51AJ6jFNSPTZdxkT5u2BQBHFJbNEFd8v35q1bR25RkJwp/OqTR2pJaFTvHFMiYO5ZtwA7UAPmOZfK6qp4NMaDzXxG20jtSy3Ks2zy9voQKUSdE2jOfvUAWrDSXukkQIGI/iFc1fWBhunUrgr29a9f8AAdiZSBCpIxzms7x34dFtetIV2sRwB0oA8hMBY5QEDOMGpTC0ABdH56V6R4L8L/2sZRJGAy5xmukm8P20EflXFvHJKp4xzigDxmFYYn3SJJv9q0YprWNMq0gY8da9PHhe3lKkwRhe9OuPCGmvDlIgD9KAPMknSIgR3LfNzgtTzeXMR3x3XI6DNdzL4NsWbEcZ3/Sqx+HscxZVuGVz0oA5GTXdSjUM0u5iasWPiO7SdXj5Y9cVp3PgO4gOzzTIfzo0jwPqMV+hRCyEj3AoAsXl1cSqJ50IZhwMVjXLvDHJ5rbpHHHtXWeKdOks0SJ2AlXpzXE6wZIxjG6U8EUAc1MWeR1A3MTyR3rqPDmhRyqklxlecknvU/hzQXndXYDaTlq7K4t4G2W8Q2pGOo70ACwxRKiQ48sCnGCWR8lSE9akgMcKs0q89FHrTzJcBFJPynovpQBFbAiRtqE4/Spw5kRmkYb16EVOt03lDZCAAPmNMWKIsswztPVTQA6y2xtmYly/BzzV43EVsSvl8HnFVnVPtAWNRt7ZqMtvmJkxkcbexoA0Ibi2jhZ1t2Zz3IzUT3cW1UiUq5OT6VDdzN+7SNQoPJpWhDSKByOu6gC/KkckAeA4dOSvrVeOQCNmmQR54zjH40y0LwzAkEq3XNWrtociJwzK3p2oAht8WsbxIUPmd2pIry4splEcoXBzgcZqEQ7bz96zC1HRj2qLy0SaSQEyxgYUmgDvNE1KXWIyt9jeo4UdSPWo9U0UXaFIyu3+JTXH2H2hW+0QXBW47JnHFdzo11FelNswF0oxIoPBoA848R+B0t1a5gXdH3jHWuT06E2NyYwhV2457V9Dy6at4JBE3615p4/8Iz28i3NswUA5Yg9aAON1KzMKGXzBjHztmvPtT8pr0m1JSI9ST1r0UR+fBIJj8ijkHvXEahaQt5hB24PAFADFvGjtmMbnDDmsmOfEm5l/GklbaTtBCt2NMBCKyOvXvQBLLdNJLk8L6UI6srJ0XqarE5Oal2LtVgfqKAJoghOVXhelW7OZ2kfzV69DWcJMPg52elaVnORGREu7NAGnb2YnhJik+buKnki2JgHLgVWtEZTuQlSetTPMQrA8tQAiuPLJl+Y+lNBVCPMiKg9BTVmWJdygs/pSrqkzOPNiBH06UASW0ypd4C7gw79quPa2wDbZhvJ5rNmcIhkHVjg1XzEFBBbJ96ALskILKVfai9QO9WG1S4WdEgA8kcEVl7gkoGSc9KlQMAVPDHoaANS4muJc+ZHviI61XVVhiLtyD0GarGa5RAqPjHXNSSziRUMmBgYx60AI0olwh/ChIwSSpwF61GQFkGeM0+aRDtWPkd8UASLkKXQAA/rSr54b5o+DULyNu2p09Kls4Li5mCqSGzigB8al2IChq2PD+jXF7cDZExBOOnSun8MfD6a/uonLbM4JB717V4c8M2+lKYZYAZSODigDA8G+GpdPhBCcsMk1i/EuyZim+P5x0OK9otBHDbCKIDI6k9q5HxYttdXaQPHwxxmgD56bTvF0Uu7RYpBCerKMAVpaVba1BIft7s8jdcnpXsusajb+H9FNpF5ZlcfKccivO4xOym4Zg7Mct7UASW8r+UY5WwyjrVq1kLwsWTGOhPenRwxvbMwGSeajE7vGIEABU5zigCUTxoy7UyTUtuIIy5kU7m6VBcXHkIssqZxwaqSXMlwhkQbFbpmgCSNW80xBcu54Y9q7Tw7p01pCCwWVGGSxrg7y8MDQRynDZ6jvXXaH4gnuJUtYozsAHJ70AcV43svP1hwTtHauOh0Oa+1hIVjJkJ4OOte5eJfDtvqdo13OwhmT7o7tUXhHQ/kW5mgAUHBbFAHK3HhYaNaR5bEjD5hiufMASZgOY+5r1P4h6eBaoY2Pl8fN6V5ldqJZBvbZs4A/vUAV2tWZB8+5e3tS7kTbEPmk9aPOHnbVDADqM1EpA+YjpQBckujblUC5BPzCiMhrpZG+WP0qOTynVZFOXIwal2iCE+YQysO3XNADkD/aSWGA3CtST24WURyPhjzuqoj3Ey7S+1B0B61YfHlqXfJWgCx5kCYjk+fb1qES+YzGAcDkLRbmJmJRcse5q3ZKIy0jDbN/DmgCOK4uI7hWvYjGo6DHWr7EDdcQJuJ42moVnmDl9UUMB0I7UrlZGDWrAoeuO1ADZpjNZmCaPy0blm9Kryq8UKpbjEI53Z61LdxJuBuJN0a/wioo4zcIZQ48pfux0ANjszJmcEq/QVNo05stRV4STIx+c08QzwwGSNwQwxj0qnI80ds21dr9d1AHsOnTWwWMpyj43ketT+ItJt7mzaTG9duQg71yPw+vpbmJI3IZ17V6Z5TmQIibmYcnsKAPlbxJ5tpq0p2lIgSCntXI6xAJJFktRiI/er2v4leH40u7iWQjzMknHSvH75Pt8scFu6x7Dz70AcUzkk7gM/yplKzZ96QcmgB5jIj39qbyKsOuIBtPyjrVagBUGWA61tWKgAYG0VnafD5s3XAFb0USeTjdkCgCyyKyr82B61UfKswBz9akcsUCxjd/SqtyhRRl8H60AWrNo0y04/Klle2ckwk575rPYybQT80eKarvnMUYyaALvyoGw24nsagbcpUKq4PWhbSYEYQ7m6mrc+lTNCu0v65xQBTkZVcfMoNOe5VEA3A+9a2l+G47tlE7PuPT5a6aD4dROyrDKWVuox0oA4CSZJSpVyMVMrKV/eAkdjXfyeA4oz5NuheXucVJF4Cu3KxGIqP72KAOBNqx2uzZU9AKv2WlTzzBbVCSfWvU9C+HIadY33Mg5JYYrpm0zSfDkmcK8nTHXFAHA+GvhtdXrCa5AjXvmvSNG0LwvpDKLsB5l6sPWsO6128ui8Ns4igPcVmswlQhyXZepPegD1u38QeH7dV8pcBeAwrpLO+sdQhjmilUk8DJrwSKXyoSHj/dHsa0tE1KW2lwkhWPGQKAPaL/AMixhkkdwBgk4rwfxh4+8vUJfKVSYiQrV1Ot+ICNDnaWTc2NvJr5w8UTyGd3EpKuT9aAO7k8QLrEsc91cKrHggntXUWdzZGFEiul2kZbJr59VmlkBExDAdM1ds2uy2ftTKn1oA+hLaS180CKdSo6jOalxbzM6xHaOpavELe/ug6pFcMcd81eTxRfBWhZ8Y7560AephkkR1kYyIvTnOabGhNufNGI2+4F615XF4mvbclXAK5z1qVPG19E52qXI7dqAPQdRgVVRirySpyO9dBoty04ia1RVuVAGBXkS/EG4ER/cDLdSadZeN5YblWt2KOTmgD3C8ur+81GGyuwVBxytdvYQT2dsiKA0QGTXmPw31W41m9NzftvUV6i0++Py4AQh4oAyPEWLvTpI2GEwenavG7yLZcPFJ90Hhh2r2u4sppLgRgnaRzmuE8XeHJDLJPZqWVc71x1oA4dpGQlUCtn+KlVSB5co+Y9MVXYOrGLYyN7jFX7T/Wr5h3svQ0AUnV4PmYbSOw9Kkgm8lvM+/u6KfWpryRTcmVxkAYAqGPZNE4VdrjkcYoAqXlxJFJ5kgKnsAMClsrmS5c7Vy7cEVTu7i6v547dI87DjdXU/wBnLptpG8Q3XDqMn0oATTp1iVoZISAOd2KjkeeS4VnBWFT8pxzUoncMEWMN3cmnSTTSv5iANCn8NAErztOwt2UmMjliOlEdvHGjRWUvKnLE0yRnwFXCtJwKcYFiUwuSkhBOR3NAEa3EazAFC+ODmrS2aF3mgbG4fd7VmxxyyW8xkwGH3T3NOt7l4oBDKCrdnHegCcSJBby/aZGD54UUpdZNOFxOcRr/AA96rXDo0fnmPe6dFPeqpuXaD7RIoJbjyh/DQBu+FtRSx1FJbZzmQ4x6V7vpLM9krFxlxkseor5rs4gt/A0XRmBOP4a+hPDqNdaHE5bHlDOAetAHDfF+3SLSpWDcHqx6186GOFiRCzrITw1fUvxMitr7wzK86eW6DhT3xXy1eTsZpIkiC4JAPegDiquWEKyuOCzDqKp1raJGySGTHGKAIdTAiIReKoAZq7q0m+6PHSqkRIkUgZPpQBr6bEUjD7cE9qvZ2k7AQD1qHT7a4mBOcVYmikSAr1z+ZoAgSWeF2aNhgiqxhaeUvuzntXS6D4ZuNWjA5Rz0U969T8N/B3dbJdXEoVxyUPpQB5Rofha91I/LlITxyK7OH4fRxQReZMN59q9DudB/s+LbAuYk/ud6wNR8WjTf3NzYyuM4VsUAZ0HhB/NVYCr7RzxWhZadDZzut5Yl1FaOla3a6jGsrE27dgxxmtwXLQR8COVW74zigCpp+l2MsBlgs1Vs8dK1bPTrRI/MMeybHNUBMZJAkU8cZz90VOJb9cl9r9hgUAbVjawxxloIA2T8zeldHFbaVa2H2vVpI0hUZxwM+1cIL670qFp5pUCHqlcL4l8Q3uq3I3yMLNf+WYPWgDs/E3ja1kuGh0NBGgJXPqK5GS7V2kLMZ5m5I64rBkm8tTJtGT0AHIqxZPFLEEwVmf8AiPpQBNbx+c5Icrg8j09q3IoI54FbIUL+ZrFbMdwsJVsd2HerszMEIjJKgdqAHzSE3CovzZ6ACkuont33K3Xkr6VX0djHeNKwLdhntVi9j/0oytJjd2PagDD1m6e5heIMVVeMZ6157eaa07MSh68Cu+13Kjagwp6msK78yRAiFQx6HFAGHaeEhcRoclCe5rTPgCRVWSOfKdxWnYLcwIFnOVPTFdTZgx26s+4DsDQBxMPg5YpOJfmbrULeCpwzky57g16MIo5HEgyJPemSRu0uwHbGfvGgDyqbwpqMbbjJvRTjpVW40jVIQTFEzhunHWvXvJt4z5QbK+5702aMiMiHaWHQGgDxOWw1IqRLbsrDnGKs6PaPezqskJV04Jr1WW5ieFkmij3gcsBT9A0yyumaSPau3vjGaAOt+FmkLaWxk6se3pXpqlhBuZcMOi1y/hCEiLam0AcDtXVEFnG7qvT0oAYJ1dw23a/Q5qnqEsaSbwmc9a1tvy7to9CaZLbRXirEuFY+vWgDgfEugwXURukjCueelcJNZx26ny2xKfWvab/SWiTyJwyADjd3rkPEPhT7SVmtGAAPIoA4JVjEYVwFk9Safb2qX7iDesbDqeKl1PQZ2mJkfbjgNVS28MzyEzC72sp55oA3NO0GzjnAknUSL1PrVrV4Y0AMOGRepqtbaNHFaiRbkuwHPzc1CsskpZTkRp+tAEM9qJo98RCJ/EcVVt5oY5CiyqIh1J71bh1KGfdbyoUiB5xWBqdtBdXJggZkRe+etAE0l9Eb/wAxpAI1+6feo7jUpLmf5TuHQNWDd6Y0uUjZuDW9o2mR+XHDMxHvmgDTslRgsSPvkbqKtXKi3dYnUMP7tRJD5N2I0UjZ0k7VFIga7adpNzjoKAJJxEhEu4KegSqVwpjJnx+8botWoo7a4laWfcXXoAaZeTxlxI4zt4AFAGeJTbLiI7p5OTx0r2n4TX0k1iIZAZCvXPavGNRhSKWO5Q4D4JFeqfCe6MzCKz2q5+9mgDW+LMX2ixY5AVRjaO1fK+qQm31hyZAdxzjHSvqD4gCUCWHJY85I6V82eJYmhu5HZcjPWgDzqtfTJXSAoBnPesitewdo7UhVznvQBnXTFpjk5pLZS06hRk0XAAlYfnV3QkD3nzdhQB0NoJo4RsU5PoK7/wALeFPPsV1HU0KDgpGR96uPsrgx3MIkG0KQRkV7HpF7LrVvBHCod4QPlFAHVeFPBols/trRCKUD92oGBWjJLNo1pcNqLkKATj2rY8G6u1zGlnfJ5EqDAyKz/HUP2y7MPBjC/N70AcX4f8TJrWqvBbgG3U/Pu6102vx6Nf2TeXbRN5QySfWvIv7LvdD1W6vrAt9k3dBXSJq9sfDapJIUu5zgIOpoAl0fRibe4v57XdaoSIwozis77XILlAjMqscAHsK9e0i2ax8H29uyBjKAxz715v4us47S5imVRuU9BQBq3fgs6pZxz6ZM6XIXLCuD1qfWdClkikuCXAx16V7t4Rn8rwyb+4TZ8nHftXh/juCa+1K4uwT9nycHGKAOUfWdRuyFv52wTxzV/JaJQ5O4DgdjWeI2miO+L5F6Gp7ectC3yguvAoAVbgQEl1L+ox0rYtvJuoUwgGTwR2rIjlDISyfOamgkePlGwvUrQB3EdrawwKWIkcjjnOKo6vGkFmwQhS44IrDi1aKMfMxXn7xqxNMLlEUS+ajdPagCWwDLEoC/NnOcUt2u8l2JyP4aiZbu3CrgLH2NKbsmQZjy3T60AYGqRTzrt+6pPAPao7HwrdXBEjzMsXXOa07l2m1FY3G0MQK6DXbq103TYrVZB5zDoKAOXhWWymMZXzkB6nmtpb5XhCTRgemKzLYuzgFsA9auw26s7Mz5UdB60ASyEyMpiBAB5NOmvI403bmZsYwKmhRyuHAValksIoVDBVLnpz1oAymmSWMkJhz2xirBQLZ7t+0gZ461HLHctPiNMN3NR3KOw2hslfvCgDFn/wBY+9iIz696k0feJG8lmCdqdeIJVyyjAqbT4pIomkhXAHU0Aem+DJpEtw07nBPFejWWyOBWlYNuHBryzwTJ9ohPOVU/MK9Fso45I1/eYX3oA00gNxnyjj2NZ19cQac6TzvteI7to70XtzLaKeQgA4bPWvMvFGszy3MixsZRnBIoA9DvviboV+htJInE2erdAfrTrSWz1BfMtLhRj7yZ614nMm5BLGNxP6U+C4v4JFlhlZNvv1oA9oudFtbqEnAx3PvXM6rpC2sZMCHbjsOtQeGPGAuIzbXj7H6D3rrjIJbYK2HBHy96APLb6NljZ4tyeq1SM5ESqCGcnHHOK7DxJaNbh3ZMqw9OlcE8f9npI6HeX6Z7UAMvNtq3mXIHIrLeUyHcqgAngirl2Be2yQu5aU9/SizsFtIy80m62Xkk0AXrTTLhbYSXMe1G6PjqKmtQkM/C+avpVVNcur9RbxndaqcACnrNsn+U7MDmgC1etKVLptMZ6j0qCzMax/vRnd+lRySNJ5jxSBY+/vVe1mjhjLSvvck4WgC7MPJYvbopBHOetR+VFCpuWbehHKHtVS7uGnH7tyh9AKhZ5J08qEESDr70ANvb6OfIRPk6Aeldp8Lrz7HMRuKs3GQOlcNKEUA8K6/e966z4dyA6osk+FtycDPc0Ad345nZbUkgmNxy/fNeBeJokYyJvIGeCa+jvG5ittK3SReajD5UrxzxHp9jcaQ07xeXOOi0AfPtaMErxWRZTnHas8AscAEmrNzujRU6ZHIoArsxZiWOSea1/Dq7pmHQ561jVu+GXRZ/3n3c9qAOwW2eSMN5ZKgYyK9I+C7NpOqM1wMxSHgtzXLrpUs9iJ7eZUjAyFY4q9od/eWCKZkDbCNoXvQB9J3lhaT2bXaIEnA3LjjJrznxFqcsCvLe5jA+UZ7iui8J+Jn1DS4nmjIKjgEVyXxbuY722RVXDd8UAXNLjspdM813WRJu3XFcb4o8LnTvFGn3MT74GkB2r0HNJomqix01IGDFBxn0rdTUN8UMsgaSMnhiOlAHr+xG0WKWcr5SRCvCNQ1eO98SPE5zAJMYr0PxR4n2eGYrSyGWYYJPSvNF023VBMzATtzxQB6taX6S2UGnQuGiI+YCuI+Ic0fmJYLH5UQ5Jx1rKt9UuNHfMbFpSMAelVbxzqUwfUp1DsegPSgCK2iE0Qt0VWAXHA7VQHhK9m+0SWTBtvLKK7W3sLO1sg9i+6QL82TnIrX+HV2h1KdjCzhuGUjNAHikQkTcs2Q6HB4q6m1pVLc5x0r0f4meEoLd5b6BfLSbqAMYrzSOGSzARmBB5DE0AQ6jYtdy+QFIyeo4rodM0sWNkkaktJ79qztMMjXyOGBCnv3rqbrEj+arBWA6ZoAy9RmdWUSsG/2RTZCsSrjG9hwahkQS+ZL/AMtB60zOWDkknpQBVjugL8pKuSvOaw7/AF6xuNRIunIZOhJqW9DnU5Cr/L39q4PXY45Lt8MowetAHfrrdlGQ4fe3YA1eg121lUlV2uOcE15bYWrsVeGUFx0BNbllBMZDvkQN35oA7RtbDxkM+COmKkbWEEaLJIdx756VxxkkjYEMjbaZPqkjSqfJGBx0oA7o6mrlY0lDA9W9KibULff5EbfN3bNccLmcLugT5T14qKS7mCN+7O4d8UAdnNcRNCYomHHWmWWppORaytsVf4vWuAlv7x+VBBq3oIluJ/3z496APcPArp9uCwN8gODz1r0WSYBSOi/yry74bs0cpRFJBP3q7vWFdIGEb8kck9qAM7xRqTzwGITDYO4Nefx3sttI6nDK38R5q3qYlkEhRzsXqc1kwPsy78xHgetAF4ywRKfJyZG6+1T2g3IxzuB6+1VLVIBvTcMv3P8ADV2ymMCGONMx/wAT4oAprYNHI7R5yeQwNbXhzxTd6TcrHdbp40OKpNcb5dkePKPX1qpcwEzFYHGOuWNAHsq6lYa9aLJaKPNYYaM1zmreElYHYnytzj0rg9Ov5tNmWS3l2zjsp4NeleG/ETXtuFuSPP7qaAPOLjQZLS6k3qVC9M963LLRbbVNKNtN+6dsAknrXd6xbwXcG8IFkHbFcnLDPaSF5VKoem2gCvL4X0rQrBVt5h5pPJJzXOanZ27Sr5TBw3Dbeoq9r0s2oW5icNEinO/pkVkQpEtput5GIThi3egBklnCh8hZh5J5OO1NiSyjDRqdzDo/amK0bsxTdsbqTUkpiW2220eSv5mgCYCOyhMgTzWPTHao45Bcxv8AZwFkA5PpVaCaWZvN3KirwVJqBbiOC5k8tiA2c0AVyFjeSS5+cDsO9b/g2eOW9jEuQN3yoOMVzOoTpLF5dtneDkk9DXZ+B7hBJbqlurXPAJI4oA9W8WrMmgxGNRIAo5I+7XjmtqZbeU71LDrjpXs+q+ZFo0iXL4ZlztH9K8T1W3ZoZ4/mROeSOaAPB4ZmhuZAyjqTioLqc3DhmGMcVPq8fl3smCCM8VT2ncBjk0AJWroSMZGb+Feaemg3U8W62UyEDJAFaegaLevKIZUKIxxyKAPQvD+rWd7YLDcAqY8DC810nhqwfVNWDWpJt0BJDDFUfDHg+bRf39yBKrjco9q6KfWrews3jsoPJuG4ZhQBRv8AxZNpOszWSKFhTqQazJ/EA1tnjUjIOOtc5rEbXFy024sznJrIt0mivQu/YucmgD0azsylsycODyeao6nqs8UAs4wFiWui0n7E+goYZRvx87e9cR4gtp0uzNG+63J7UAdDZ6ncalaLA+I44/4getNM8SvmR923gZrj7K+milJViUPG2tea8tzbDy1+c/eHvQBpTz+Y/mfeJ6H0qpOLUE75GM/6CoLSS5MfyxnyvWrkNpHdQseklAEujavO14kCKEToSDXf/wDCT2vh+2/0SGP7bKOufWvPrfSJldRFMFzXcaZ4Gh1CzEl1eL9oX7vPNADvEmvS6j4XJuObgjOPSvKrmYSIm84UdRXsfibRbPRPBkssxDXW35a8YtSLqIno2cigDRsWit8SuSqt92tQnfYu4YiQjhq56R2Yqm3JQdquxXcxjCkZi7jHSgB5n/c7JCVc9+uauWtuUTpkMOKqhUeTgFj1BFbOixs28svzAHAPpQBwGu200F1N5bZJ61x0uiT3MxYuRk12viqRo9VJDBQTgiq+Aiq/lkg9xQBzUXhK9HMU209iOKefCWpkMxueR15P+NdvamOWMbjt9KjkV1mB5KYxmgDh5PDmqxYKzFh7GiTQdZGH80k/71d8bdymcEA0RWiOVWNiTnk0AcJLpmuYURyEL3w1QT2utxN8wLj1616I1l/pOJmKoB0qMW212MThl9PSgDzR4tVYnMbDvmtLQGnLETAqR+tdrdxKkeCoDNWNJ8reWseW9RQB6x8LhKbdm28dq6/XWkkgKMuz1NYXwwh3aTljiTtW9rouIYv3mCD0yKAPOtSkYTbT8kA7etZl06BgVGF/hWtPWFVZybg5Y/dFZpBBDS9B0x6UAWNO+z3bYcGJh14rUsbcBHxJ+59D3rNSaORlkRQAnBUDrWis0coSMRMmejUARywi3O+NTsNZkzGS68sZCMeo7Vs+LNWhgsoLaEAOvJasDTW1S9mWWytmljHBwKANsWtpDa7myZAPlOO9U7ae9gvElDFSD8oB61ppYahb25nuIzIrfwj+Gse4W9kuVmRT5SnkDsKAPVfDGvQ3qi3vAqT4xz3rfuNOiuYs4yB1yK8eFwIHW5jY7x0Ar0vwV4mGrWq2lynlTqOuetAFTxDonn2hEQAUfw1w09rD5TwmLYqnnHc17XdR2kkiEL8y/exXNa3ptqZGlto13HgrigDx+9RwAsIEcC8ZJ61lNqEi3RSMLuHGM8Guq8caSkVr/rxFI/bpXE21oIH2GXdJ2egC7GWk3NOdpJ6CjUYUiSPygGRv4jSQ28sc2/dvXuPWpJjgbWP7o9M0AUU8ssUkXZ6MO9df4Mae3lTnYobh+9clIEkIQnMg6V2GggG0jm27gvDIKAPX9cdZNGhlOJH2/frxfWri5N9OZ1Uw84UfjXrE0kjeFcRnELLnn+GvCtcnKzzLbyE7M7jQB5HrZ2ai+0YAPGarW7tJdRkgHB6VPq0m6/kEmDj0qnA5jlVh2NAHr/hXULa2jQyoowOa6WTWLCaeNra36HkgdPevM/D1rLc3EbljsOMivR9PtLdYDHEgAA5Y9aAOpuTJLawEy7YmA5z0pLzwlrdxALnTbf7RaDkkDJNYNvbXR2NNODZR8hc8mug074o6jpExgtkjNkvCqcUAclqGl3/2lUmt/JDHady4x71hav4YkhvBGs4ZmG7g9a6jxDrd9rtw1yJAgY9FOMUR3tvGsMMu5roYwxH9aAOQXVLqyheydHjCfhuqmuv3MymPaTH6Vu+Jt7XgkmjX/gNYaWskhZ4otuewFAFu3tpmUziPbEeScVaMbxosmAVPapbaK6+yiEklfQVdSzQ24VpfnHbNAE+k3LI6wgBt3UCrTPEkzLgp3PpWZBZ3KN58DYwckk1eSb7TGQEQuB8xoAVb4RynzQwGflIqfTNWvNP1mO7edmgLA7c9vpUFlIZHKS2wKLx0zita4060msN6Mwk67aALvxO8XPrGlx21lA3lkDc2OK82sITwgOCOSfStjXNRuUsfsUUHlkfxEYJqloulXN1F2XPUmgAXfDIzpyF4z1zUqyKIsngv2qxDaGzn2XBJHp61LO0SsHljXYOgHegBLJ2EiRhQAedxrqbWURW8kjqFKrnPrXP6MjT3oJXKHgD0rR8YXP8AZumsgwSw/KgDy3xVeifVHLHjPatXTo2FgCpDKRx7VxuoTNJOXY5LHiuq0GXy9NO4nHX6UAX4Uby9rcAnr6VdtQTMkagMpP1rDl1QMhVCBg8+tbXhU/abhCW5PIoA7TSvDxuG/fOohPYVpXfhiKGJfs23IqS0cRlVDMxHJFXxqdu+FYlWHqKAOU1rS2SJGwN461z87RwEDby3U12XiPZJAxDkA151e3qRuY2YNg0APdWuJyv3l7Edqwr55I7vaAFAPU1s6fcBJG2MCMVzeqXAbUHMr42k9KAPcvhmI204FnHmHtmt7xHFJMAjvtx05rhfhbchrfcGyRgAV6Jqts01nvkPze1AHnN988vlumVX+LFZxRJZgA3yCtbVV2SkBvk71js8STEEYVucAd6ALUTWXm4+4y9c9DW1HfQzW+wxxiJe4HNco80cshgZACej9zTkuPsIVmLsB/D2NAHXQaZp2rsA0TFV6HvXSaZDBoMTtCipHg4Vu9c74cvbxLy3mtrVGhcjK10utX0S6gqX0WxGHQDpQBhRXMvnzSMwKSHAUngUSmOCExoEJY5NR6rrFhve3jTDAfKQKwkDzxu7zbH6KPWgCxqFukihrVcEdc9Ki07UbvS7hJ4E3Ln5sdRVdpZ1jC557/Sobm5k82MQHEQ++DQB7V4X12HUrZXRAx/jyKv3kEFyjPGNre1eRaRqclhcRy2r7IG/1gzXq1vcI1rDLat5glxu9qAOM8TeG7a7iLXkvI7g9K4DW7PT7YBLZHJTq1e1axY28Vu5djIWGcV5H4gIgWUiJepwD3oA5qO4U7hACF77qW5QpbdN6tyCO1RT5Ch0XbnqBVYGUFvLf5B/CTQAtrF51zswVkHRjXd+F4pNhOAQPvccVxWlwzTSiSUgEHgA8mvSNFZFgWOIYYj5xjtQB21vbJLojqsmY8fNjtXgvifY2szqE8uFCRu6bq+gtPEI0WVVyqEfMcd6+evG27+2ngiyYC3LelAHjmoENeSlTwTUduAZ03dM80XTbp3PTmmJneuOuaAPXfB8MOEeIDaBls/Suz0WzTUL2SPeEj7qO9eeeF5WXTwgfBxzXo/w5UTXMm4EkfdPrQBvt4UhngZUuDGAOlcBr+i/2Vcszz+aDXuV3aCLSme/Pl55UDgmvN/EVtJqaLa6XaSPJnBY80AcRYRPPIBFnjnNWtSud8flLCVuEP3q6eDQ73R7YSXMX1GOaydRXz7ld8WzPTAoApWOnXN7B5ty+WHTNSWlube4dHALdhVlrt4cQqu3HQioGle1u4ru4TKn9aAOo8MNpsCSi/jBkfIGR0rH8T6OLdjNZ5aOQ547Vau4ft4We0YKpGSMVoNv/shomGXzxmgDn9FJmQWt1J5YPAyK2x4PntVF1ZT+Zn+H1qvaWaXEsSyg7u/austfPspALRvNiwAc84oAwdPtLy4uBFaW+Zj94VV8WWOo6RPDM9owA+8MGugs9XudI11LhY1KOwDEjpXqd5c6XrltCZDE7FcsCKAPl/xTrcuoGJjaiEJ1961tNtJG0tLtp9kS9hTPi3OkXiBra2RUtl6ECuWt7+5htDCxdom6DtQB0t1NHMA4GUHG496zpnDXQIfco7VXS5kktPIzhOvvTbX5iflOF70Adb4fTYXuARtUdK4X4h64ztKivnJxj0rVmvp9LhZ2LeQ3avMNcvvtd85wSGPHtQBRDs2G3555ru9FdbjT9iDCAc+9cAiKudhy3cV2eguw0zMf3vSgCKSxeGdy5+Q/dArt/ANqfM+bmuPnu3C5kQk12Pw6u/Pu9sYJb+7QB6XNbCNUa3Qn1NWHs4gqGaLJb+L0q6CEiQ7OB1FWVuopAVK/uyP1oA5rXrOOOycnkEcV4xdRNNdyBVIOeK9v8VmOLR5mj7cgV48t8hJIUFs8igCW1s47LT2kZsyEVxWoASXjH1Oa7C6uz9leNEPzDjiuIvFllkKfccHPPegD0D4Yah5d55KPtIPTNe4xXMlxYMoXJC8+9fMXhS6Nrq8JbKkHBPY19LaJcLc6UpTALKOaAOK1rYJmDIVPeubkDvMGQ5QHpXoviq1Asx5cYMg5yBXBXSRo+7Ox+4oAltI4jch+p9DUqW32q/EUcW4E4z6U20xcRrsGMdWrc0i4+wXouigaNOo9aAN+zJ0SW2dTmIY3DHQ1jeMdXlv9cR7f54CO3QVLD4nl1fUZUjsnMByNuP1rSvdCtrTR3ui2JG5K91oA4dNiectwSzHlX9Kmt0M8Ae4G3Z933qA39o8gt3XAJ5Y1etoGlcx+YPI6igCKSRGbfGMv06Uy1t2uXwsefU1ZbS7slhAMxf3hUmnreWMbxsm2Nv4yKAK09p5eZH4jXsO9db4G14J+4m+VGOFJNclMkk2WZsIDnHrUCTSwXCPHzGD90cGgD3F1juIApXg/xVwPjbQoUzcFsKe2K6vwvqkWp6YsTsA4HPNT65ph1Ow8rGdnSgDwfVP9FPlldxP3W9KxZIWeZGU4C/exXpfifw1N9l2QJiceorgJrWezcwsPnH36ANTSo4IrlJzJvTso9a63S5pVvwrxlC/3DXHaP5LS/u1IjGMhvWvQtNtlZIvtBDBjhWH8NAHcqhj0GRrghSBzjvXgfi9G+2mS2jxGx6ete7+IXhsdEi2sXjK5OO9eCeJdT36qVUjaD8oxQB4fcDbM4znmmoSrgjqDTpyDM5XpmmpjcN3SgDvPCU6pFtcHB717Z8MLXz7eVkxu/hIrwbQJZNwXA2EYFfQXwVkSS0uIw37wD8RQB2cOlGKQPq90Z3J+SMNkAVv2McFjuKQIjYOWxRZ2duuXcZm7M3ao9SDzr9lVvmbgMO4oA5uVV1Oe6uJmP2WPJ56VxNtbLNPdXDqGhyVj9q9C8WwNZ+HPscCbZW5YjvXOWVvDaaOkcmd7deO9AHP2mkrDbS3MmJGP3R1xUU6xyWZS8iATtx0rt7nTY4fDzSxtiRuhNcl4lmt7TQonlfMh6gnrQBl28lvp8XllyQ/3T6Vr+GNZtLjUPsWorhD91hXH3TC5gE9uu6Lbk81L4KmS41pFnXMRYDJ4xQB65Y+H7Oa8Z4JBg8qM1ZfRyFeKImN++e9Pv5NN0VraWOcF3HTNXItQ/tJ8RBSccMDQByd7ZRW8gE7A9jk9a5LxNfXOhs01rM4jccAniu88V6TJJEJ3+RY+frXjfjPWZNSuVtUUBU+UY70AZ1i7a7qZk1Jzj3NaN+1ukxit0DRLxkiotP01PsoLsVl7e9JcDYoiAx6mgCtGsasz5JXPSr+nGEAs+cdgay+UJPp2plxeCOAmRcNjg5oAg8aaqqReWuGTHSvNZZldyVxya1vEd4ZHOG3N6VzpPOaALChkuVZOp613ekPusFSJNpP3mxXDWjLJcAsSvpWw1/c20QjiJK+1AHQyWEsr7lceWOeteh/BrRnutSmliXASvFo9VuEOS7BR2r6E/Z4mkmsLuYtj05oA9I/s0wozsOO4qzaaIZrlJNgCkcAVbhYmw3yruOeldHp8RZoXHTA4oA8/8UaI02m3zeXjapwMV83fZnWS4jVcNu5PpX1/r5RtP1Jtw4RsYr421TXDFqF6FAwHOPzoA1ltpktcMBkdCK5DUwWlcsdrjitXS9ckmOyXJVulZWtExTsz8g9KAItNuBDdRtKAVBr6C8EXpudMiKn93gDjtXzdDIrnJ6eleq/DbWZ7ZPJHzRtx9KAPc3tIrjTmiJJkYcNmvL9a01oLt0kXIB6ivStHvA8KRzKADzuBzxWF4xtdl0JIG3R45zQByNrEiR4jJz6GkN7NGkke3OOxpkzEsxjXaexq1aWfmQnzH/edcigCXSNS8iAvbiNZ84xmti6urm/tVjj2sSMuPSuNuYAl4DHuVVPLAda1bB7jzQ1i7Z6HIoAzU+zw3si3EIwvfFdXZvplppazSljI5wFrB1TR76W5EyqdnV61kjEtqhFtuMfrQBsahcfY7K3a0XckoGV7isnWZwY1Ej/L1GDVbUr640+ITEZHTb2FY8VzDPmSVyd/Y9qANCD94hkYEKO3rWfdeWJd6krnjaTWmL2OCNUChgazJyj3W5kyD+lAHXeCLvy7jaEfBNejbmaBmt3+bHQ15V4OuZ47/ATMR6GvQr/U0t7f92uGxliKAKl35tzLmUEOvUjpXMeJfDH2tlu7ZW8wD5gB1rK8QfFi10ud4Vt/MVeGbFY2lfGtJLjC2o8otjBoAswWE5l8qS0eIngYGM16P4O0N7SAPe5ZeoVu1dD4b1fSdY0eK48iN5mXg+laOoTQiD+6wHGO9AHDeNdSNtbSBkAt8Ywe1fP2qXcc+ptIgPlBq9V+JGqBLOQXMhUHouOteLi4WKQOy7o3PAFAHEXsfl3LrjAzSWkBuJdgq9rjrPdvLjBJ6CotGC/agWOKANaxU2kygEl/rXrvwe1n+zNULXh2RvwFPevI7qc/ak8lCeetegaNZyyWEdyAfOXoBQB9IRarDfyHz5Vgjz8o9a0cwQiOZmyV+6K8p+HrW2q3I/tW5Mc0X8JPHFd5BexXd/5Ftl4ojyw5FAE+tebLKLm5H7sj5Qax9ajin08Spw6H7vrW14xmVrGMwnlOoFcil5baldW1vA7JIpG4HpQBZ8QXLvoFtE6GND+Zrzvx/ZzpFbpOrJCfuEnrXqXxDRYYLFI3Q+XglR3rzj4l+JDqJs4JI1CxDHAoA5/R7edbchjiLGAPWnyr9lUeSvlNnOagtr1QQyOQqrwD61C+oSzuyuAQTxigDYbV3khQ3sjOU+7zW74S1LUGvk+wTZLfwGuLNqk6II2LSE8j0roLXdpUkEshaFxjDDgGgDqviHrGq/Ylt5SUY9ccZry6JfOmV5VyV61ueLPEE2sHarZkUdfWsazkMdsx6yd/QUASm6LT4wQi8AVXklba7H5jn8qjtXaS5Yvgc/nSXj78iEBcdc0AVZHaNdxbdkVi6vdSpavlvkHStK+mAjUoeO9cvrlyNpj3HDUAc9cyPM5lAIBOKi27Ad69RxS7dzBFPy1OqOBhsFRxQA6yt2JDEcHpitDb5NwAo3g9RU+jWwl2ruC9+TWxfvaRJgLiVR1oAxb2Nf7Olcp8xr3b9nuIweF5ZXYqznivDJbuKe2EYYby2MV9A+BJo7PwxZQwgBiAWAoA9c0x8W6ImGdjXRL+6CKPvN1wa4fSL7dex9QorrbuXf5UkBHvQBha65S11BAflMbZr43u4PtOsagMYUOev1r611y4DS3IdguYzkV8ualJFFrd9sIEZfmgDPso0hkikcfKD371HrwWS+EisGGPu+lTXWJniEXKE1T1K0cTgZIbHFAGNKAsrbBwetdj4IviLlVjOAK5W5QxRGNuXPer/h2U29zGMgc80AfR3hy/89VXfuCjnHatXxTHBJpu4PjAz9a898HXSk7SSrHoSetdLq8xe1AkONvQetAHOXO9YVO75OwxzU9td7Yo1hUt/e9qyZ5neXcwIYHgHgVds97kbAB6tigDprGxjvUDzgLD3HvXRWOmQRRqLKDJPf1rjtBtZp70vLKfIT+EHvXV2WtT2t4qxJlQcbfagDSnayt5Y4rkrGWOCDU1xawSWrLZFVUjrxVHxPY/b4Fu5VIlYZAUY5rk57PWLSInzSI2+6AeRQBb1yytl04wyuDPnr1zXPXVnam1Rdm1h39aHu7qzuY01GNpFP8AEOauTvDLeLIq5T+76UAZflO0ewcOB8uaWzgnllEO3LnjpUjO4u2UISh6Edq7HwboktzcG5blF6+9AF/wpoAsnWVxuB6j0q7rls3lv5LB+xUVp3MkqxSzRARKnGG71x9/rawA7H/fEkEMeKAOC8aaHZy28kkUQ83HK+prym00eaPUSTGVTPC4617sLuxmllRzvlK5OOgNV9Gm0Jrp0v4h5wb5eOBQBtfCS1nt9PyxZUPY13WtX1ukQRxjHQ1QtLu2SGFbYBYv9mqviHUYWjaBEzkZDY70AeRfEq8i1C4xtI2dDnrXnJZS52rz6eldr4rufNlkDqFZDjBHWuct2hmljOzaGPPtQBxmpSJFM6ryx65qrpwJu0AOPWrPiCIx6jJlcZPWs5GKMCpII7igDsba3PnoF5DECvYPDunNHZxDgKQCSa8S0G+eW4gDN8ymvftF/f2tv5rbU2jIBoAZcaFBeO7RXP2R8Y35xk1L4NvrvwZqzRalKLmwmP8ArAd2Kfq+nQ3cipJKVgA6jtU+n6BbITHLcGeDHAPagD0mfxp4Qig82aQOqruwRmvC/FXxAs7nxel9oti0NnGwBwuM12Efh3SLiV1MXyp1BbrWhBoGlup/0SNYQMY45oAyJfFOl69DhZ2S428BzjFcPqemXGoTTCBxI6dya7LUPBFjcCV7BTb3H8PJrnprG80VY48NkH94+O1AHOm0uobfE0DAjjIHWqqxvtJDYkPQGvoDw2fDt9BBFcPHIrKMkgcGvH/Fenxx+OJ4EOy1LHymHTFAGh4QmhsYibyDzJm6cdKreL9a+2yraRR5weuOla+kxx2FjIJD5s38JrDv4WExkEeHc8mgDCljkj2HOMcGnxz/AH0TgN1qS6ieIfNli3tVYq0ZQfxPQBJFJHEjIvL+vpTzGbiH5OPUjrS28G2YqqbmbtVmOA2qO0nOe1AHO6qFitZFY8ivPtQfdKBuyBXW+Lrowsdr5DDla4pmDSFsYBOcUAW4Yo4pAWIOR69KljCiX5vu5qhEVXLE8joKsRNKXRm6Z6UAdHaGFWViSpHQCr1lYLcmaW76EcVziTt9rVFBye3pXa6XGfsPK73I6e1AHK3lrZxSKIlcMrZzivV/AWpIyQozHCrxjmvO9SJF3s+z7VA5rpPhjdRnUpwy/ImRg0Ae36LfoLllmYFj0Arq5r1gqJG23vXl/h66ge9eXG4g8CuvuLoMd69QOlAHM/EDVX0+Kfn94ykda+ep45Li6kbcd0jc4NeqfEq8Z7aXc2cmvOtHiBZFddxY8N6c0AXrDR5rSJd5DBhkHPSszV1lSYxyY9m9BXbm2SNFVJgxxnHpXN6naLLI6SycmgDmZ0UJ87bj61DaRulwrBsjNak9jFDAUds+lUEwj/uxwDQB6Z4duSnku2Cox0rvZD9stPNB+ZBwK8q8JyySShgRtHBBr03Tpo3QQwuNzdQO1AHOX7PKSx+VV6+tWNJnkPyqP3JGMnrUmq2aWuoKZmyDztApIJ4/tJVB5K46UAaVhczWNwfK+ZScnPSu2geC4SCa2TMo+9xXB29zFJMYkbA7tVnT9R1a0vnjijJt+SG9aAOy8S3lzHcwSwcqOqnpXO6hqc95drskOOhX0qO51a9uY3+2p5LDoaoRXEcDCUDLN94+1AEl3G9tN58somB/gJziszz3V3uMYHt0p1/GZLjKP+7PJ5qTTwlyy27cqDgcdaANXwzE9/IFijyj/eJFemab5en24tLcYJ5YisrRbGOwtojCgjkIwRjk1rXcy28ZkGGY9aAOe8TamqRSmaUxoi8AHrXhHiLXZZnnZXC8nZjrXoXxJvHnhPloST1I715Dc2ZNwksjZ+b5koAv6Pf3yRqQhO48uRziumhAkuoZIAruPvCtTTbOzfS43kkSJMYxxXOtby2+rt9lmJyflxQB7DpEcX9leeG5xynpXP8AiHVAIiiJgep4qxpMk9vojSPnzscisG9n+2SLu6E8gUAcpIn2u8eWZTIFH3QM1QNtFLebU+QsfujtXWzWsllK01km5cfOKo6Jor6jqDXf8QbpQB5H4rV11KUdUDHBrDrpvGKBblucEN09q5mgCe0laC5jdDggivf/AABdNPaq0j7/AJRXz1XrXwu1EkIHJES0AeyLaNJCxiUlvftUlgmF8vYwkHrVjT3d1/dNhHHB9qrTC6tnk8pQ7UARJFMl47M4AHb1FasVu8vzmUD/AGc1zKpqLl5grdfSr2k2+oOxM5IYngUAdJhzD8wAI6EUya1iu7bypolMbfeOOtQ7541Ef3z/ABCnrcMOGOB7d6AMUeFtPilLWUzR9yC1JL4dsrwhbnkj+PNbkcqu7CWNQSMZA60yILvwR+7zycUAVINBsI1CYLKP4z3qabw7aXUDLIVB/hHc1rQ/MypGg8r1qa9iiR0kGdw7AUAcHqfhoRIESLIPf2rAuvDiI+X4Hr6V7B9mTCzSEMpHA9Kqy6dBLLuZNyd+KAPJYdG+zyMI2Dk9GxxWfrcL2lvI8nJwe1ewalplhBbGeDA7kHrXi/xK1BIbd4434b9KAPI/EM2+diWLMx/KsYDJwKs3LCRiBlnz1qe0tdpDOpOfSgCkyFCNwOKmtCDNtDHB6Zq9Np0zsC3Cdq0LHSJGZFFuwX129aAItMsw9387Ac9TXoS3EOkaQrQgSSEdetZdlohiXzZY2WMc5IrNv5CZfLjJ8vpg0AY+p61K967TAZI4q94CvmjvZmY4JPbvWHqce2d/l3jGc9cVN4WuRbySls4Pf0oA9y8LXn7tjCvz55zXSfbHW3kmkIJA6VxngiQyWfmAAA9cVra1cfZraSRGJyMbTQB5/wCNdQ89yN2VLcj0rEiuFsJ4PKIZG657VDrkgu5H8skPnpWRbJIbgI7EuvQUAenAW95pckkJKTBepNcVc3LREpKCzZ4bNXdOmu5IzDwmRgAd6p6vYXlrtM6gZ5BNAFeV2nGApDgdKzHLQKxmG1uwrVtvMuVO1droOG6VjajFKWZmbfjqKAOm8K3ao+yV9oboa9D0C5WGVwmWPY+teN6VO0EyblLKTx7V22ja20N2sZxuboaAPQb8SXC/aNpIHqOlZ6tHIjG5TgdCO9Wmna7stzSiMqMlQcZrOkVpwkiEKFP3T3oAJIiVLR5Vc/LWvDeXUFvFErB5D3x0pLIx8eZgkjGKlhgaFpSyHax+U0AJqizXQjy4ZgckCs8xzSROqYAHarE8/wBjgZMne/AY1miOQSCTziAeozQBb02ItE6TuN69B611PhawEsy3jQsBH/DjrWP4esxqF4FAK/7Rr0y0tPsdskIZFbFAE6XO0+aygsRgKO1ZGo3a7ZDK2DycVZ1WazSWMJcqs54K7sAVk6xEbWFpHKzRsPvLzigDyHxjrl5LetGTtgBwOO1cpcO6S5Dbnauo8S6cbueR4WJwelcnLbSpMrgMVHX1FAG1pBku4/JuJCATwAcYrt/DulwrcRIoaaQnr1xXI+GIJROWKFlYcZFeyeAbEw7iYgZWP8Q6UAJ4mhXTtI+Y7EYfMT2rzmMNETPE4KE5XJ616j8UQiaGEkO/1A7V4/dXXlaZleGH3RQA2816Q3gjkcLj+HpXceCbX+0l8yKQRqCC2a8dicXlxk5M3vXr/wAPrKWG3RwW2MRuxQB4V47t5bTUnWcbixwK5Ku2+JBLag5U5QPgGuJoAK7HwRNJBMjg5QnBXNcfXR+FZ915HCgx3zQB9L+FJvOtB8uOMj2roI4mALrz61yPhGR2tkjZhjH3vWu1tyqIN75xyVoAY8EpjJgx5Z4IoRA2FEv7wdxU0iGQE2/yoRyKpNGkcDbQRKOetAEjSRxTEb8uepNZ11qFtAxH+sYnr6VlaldSTbcKUx15rLS8jW6MS8k9T1oA6U6onnRqOQeOlXIZwsjI4yrc9K4+K+t2ufLIwQegrfsbn7RcqijA6YoA6ezbzLcJG2wLV9YgyqeHI45NZihtm3pVu1VjKgVtuTQBct4w5aNc5PX2oji8lypYFB61MzhbkQkbcj73rVe7ZP3ikkYoA5vxPOipM6noPu+tfMfj++M97IOgzzzmvePHd99mspWQ568186eKJhc3Jl9+lAGNFEpAZeD/ADrZ09pPKztz7GqOnxLLKNwwa6iy01MiRZAAOooA09Fjt5lU3EY9q3F1D7FGyC3Rz/DxWSqMFVLUgJ3NWo0u0fDR5A5BoAdc31/fxCExCMVk6zZlEVvL+cdSK1h9qmcmT5AO+KsPbyG0YMvmK38QFAHnt8qJCZQfZhWfbgKqvGuIj1rsbjSbeZTE/wAuTyc1Tn0XyW2wuGQckUAdN4BvQ4MKuenANafie8WKzkEjKJBnoc1x/h5hDfMYwU29aTVN95cOTKWX0oAx1R7qQyJgMD0q4tkYmWUoDL6Gn2+nSHJVtrLyo9amtY755zJdErEnTIoAtLGbdo5g+5z29K2o5bfVIfs9++HA4Y9arac1o2WkQjPBBqSW2tvMLx8Ac7aAM2bSDFvFu+YhmudvLAxyllYqD1BrupVEcazRggd1PesvXrcS2vnFMFumO1AHDsrQzbV5J7+laVjnz1Yvkjv6VSELqzhzkHvUtkwtCW3bsnkHvQB3+iags0RjclnwME1o3E58kRnIcHkj0rk9GuXMyNGPLB7mu7isJZoBLbjzGAy2O9ADtKlUxZHzkdSatveThTk7iegzWXYsoE26MxKud4PNRNe2mwtBL9M5oAsStMzf6WQEHQUxCLlgkaEAdwOtTwWUmpmMJu80ng+td94Z8PCxw1+oZsDHFADdAtGs7JJGQLnHFYXjnWLmyiaa3mbOOAD0rvbm28ljGDuD9OOlcJ4+0rzLJlhO5gPmoA8P1LxReSTO0tw3mk8HPStDSviFfw232R52kRuu41yPiK3xduyKVIOCKzbWP94C2R6UAekz67KWSVF4buK1NJD3swCQgluorkdDdXjMMrBiOg613WhB4rcTwkCUcdKAOk0LS5TOCqBNpzivXdEgSCzW4kO18YPFcN4ZsLid457mTap5Ix1rtNSu47G0Jkx9nC9KAOG+KeowRp5VtJ5jvwwPQV4nq9+UHlA5PqK6fx1rC3moSi1BCg8HNedPeOsrLMpPsaANPRSGvFBO12Ne9+Bbe7hs1KgEccE14b4Thia5DStuLHgD+GvfvDtqWsYlFzsK9GoA+a/iIjLqLqPuq3SuOrs/iS+7UzjIyea4ygArW8NStFqSEfcPDGsmrNhKYrpDnjPNAH094AMRt1yWYdq9Gs47fyhMwO4fw15H8OJTNDD5JGAOterRb3RXUcKOfQ0AO1Gd0kVrdB5Z6jHSqDOxZxKQARxitHfg5wCvQisXVFbzWKkhcd6AOP8AETyBnSBh61RtjbyFFkYLJnqK0dVjj8uRmJWTsK5O9VILhA8g+Y9c9KAOnnS2XEkKM84446GrunTlXR9uHP6Vz0F59mYMzxmPH3ia6TRrm3liLs8Z3cZB6UAdbayyMET7+erV0KxLJFH8u0j86xdBkjjjWBtrL139a3EvBcTqqx/Kh6jvQAqIEmAkO4Ece1UdUuY1jaEj/gVbNxGnM2MnHSuT1VopEkEj7APSgDyX4kXTxpIu8bO3vXiFyHmkdTksTXsHxMeKeICBixBxXlVzE6SLsHJPJoASwguXdYlXIXktiugtlnGWH3E/WqdvObCMvnJIxg1Bb6hMJ2dW+Q87ewoA05ZppGV42ZGBxt6V0Wn3dzJGkcrrvxxXI2+oMZWdkBA71btrxwxuVJwDQB6PpY+1sLe4j2qvJOOta+pX1hb2BjtYCQgwcjvXMeEtTkvJgsp57V1Gvz6fDp8i3Biifb64JoA8b1/WHF0yx4AJ4IpumxzXMgfzzkdietZmpeSbuUglkLEqa0NK8uFAzPtbtQBu6bayi8coVAP3uKbHayiWcoM5zzVi1uoWfEbkA9SKltbqNGlRJct2yaAMC3up7a5PmjlT0rpNGntr+5RpzgA/dFcdqF1L9pkDdc/eFO0W5YXAEbfNng0Ae3XOnadNZJLHCqTqOFA61xmqosd2sirhx1XtW/axzppKTPLlwOOelc893G7yxuAZCOvpQBHeXizEbtoQDnFUvtiXETxggIvTNZlzsiEirKSCckE0W6QOihpdgPYUAVdStoVQsr5NY2+OZxHjDg8HtWzd2iSSELMStZE1uFlHk/cHU96ANa2BUxLO5AXGNpr1zwdc/LbqnKYwT615HZATshIyEHQ9TXofgu/KvkR/uhxjHSgD22z8PaPfr514iKSMFRxuqKfwD4eUmaG3Kg/wYpPDfksqTSyFsn5QTXYRuY3DSxptI+X3oAwrLQNO0+FVjiByOGx92ie0jijPzF27c1ouwXzW5IbkKaoSzKsBLKPMB4WgCpKiG2G9vn9DWZc2ETxlJASGFW7mSMqhJzM3QUklwYIWSZAzdvagDzDxJ4Dsr6V22CF+SOMA15R4j8LnSZi2QwHAx3r1Txn4guGZkVvLKHhhXn97ef2iwa4lYOvr3oA5/wAPWMi3YlkVwCetek6S0SlfMU7F6VDo01pdxpHNGqKnH1rdi00yShoFBTtxwaAOm0u/Wzt/PlYlTwqZ6VyXjbxHdSZ8p/3OOVzXSzxx2lhiZMyV554luIbh9kPy5HzZNAHner6nNc3pMYwoqjaATTtvkBfvk8VsXlrmZ41T5f7wFYtnEgu2QgqAeTigDufBtirXSbiFTPU969q0y0WxgjM7N5bjKkV5B4PQPdQrI3+jqRjnmva+LyyjV8BEX5DmgD5u+KgH9qnC4G481wlej/FSEC4dmOMNx715xQAUoODmkooA9g+Fmt7fLhUkZI3e1fQGjSs1sI92Vx96vl/4bTRtMsZXa2eWr6I0S5QwRxROfJAwWJ60Ab00blgYTlh2rH1v7QqAOQpPOc9KuyTLBJ5du2Wb+LPSsXXUuJY2gD+Y7dxQBzGuSGY7GcfKCN1eea1LI1yUQ5IOBXXTaVfJdP5+8IOgJ61zl7Ys1yzA4KnoaAKlppl5qKhHmdIgeTzXX6R4cnCrHBcueOMg80ui6klhBG15aEwr1YDrXVW3jbRbgr9mtyky8KtAEOizXWlXf2K6dnQ9DjpXoGiai0qtEFAVeQ9cN/wkEH2oyT2jO7fxAdK1bG/Vl3wuBEe2eRQB2s15JBEXKiQ1xviK8t5V64Yjn2q1qOqGG0xE2VxzzXH6jexkNKfQnGaAOI8VmIXLrF8wNci1uiIzEZPX6V0Gs5nlkcnBzxXO6lO0dqVTgnrQBzupXDyz7Bwq8VVt52EpQHGe9NunLfe5BoigPktJOCP7tAGlZvIrEE5Q9vWtv/VRAhQFI+6f51zunRSLtIbezHgV1bK726JMmx8fe9aAI9K1GfT7jzLflvT0rP1fUbnVL9mvpWwegzTnlKbhEMSDgk96z2kcSKzruHcjtQBesII5GKBCVHeobtEEu0ttUcCpLS5Pm/ufSs+aQ3Oq7XU7gegoA7jwlYxJG7y/vQw4HpWLqkf2TUJdvygknr0rt/B+noNOMykhscA9q4zxrA1vds28FyeQKAKUdsb2J2QbueRUi6YsMKG3k/e9x6VX0i4ZUZoThwMkGnfaWG+Q5EhoA6zQNfe2k+yagxZDwDVa7dW1JvJ5DHiucgDtMqk5Z+/pXU29si2oG8CUDhiaAOf1yLFwSvyHqeetYUlyd2UY7geRXR+IIZTEhkOT6iuavR5ZCoACe9AF6ObKIQ5JPWroMTFf4T6etYcIeOAgnk960IAzQqCMt/eoA04onS6XYdqntXY6LK8dyu1wI/4hXE2cpLFeSV71saLOqKzo5ZuhHtQB7v4XvoZoh5YIRepz3r0GKZZrMb3yqjivFPB2p7QqR42n7wHavVNLvWuI1t0XG7vQBeujJHEJD8x/hqnfQiNY2Vy0j8mtFYnU+STuH61Tu3jjlCbSQKAKLwB5dsGTKByapXT+XA6ytkjvWjPMsCN5KEs38XpXF+Lr2+tLfMMTP60Ac/4u0c3sZeJcAd68sv7NhcmJ1wB0aup13xxfxWxjaIpj1Feet4iuZ7xhKMox54oA7LRLcrGI7hz14avV/DexrJAy8jofWvMvCIF9+7fleo9a9c8KWjqm2Nc46ZoAXWIWFgzSxHaR8teMeK4mtFZmONxyCK+iNWidbPbKAQ3B46V4t4+sYAxVWBUD8qAPO/7QM8YjQYHc1kTsbafIwwPam3U6R35jj4UH86WUxNMrseeuKAOx8IP5NxHIz4UnlK9z0jyzpged8xMPlAHSvANHkha4hUkr79q948JwyzWShP3kYHbmgDw74vN5sgk27VB4+teX16b8WZgZdgHIPIrzKgAoopQcEH0oA7vwANk6eahC/TrXvugzxyWADAA9gtfPHgu9lE438qTgV9C+E7aMwQCNjJI3XPagDeiRplA2FffFX9JsY45C9xh2JwuetaCxvt8tUDBRyTVS2YMzkvjBxQAvifSfPsyY1XftOT6V4JrUbQX0w5O08ntX0JPch7R4nkKxY+ZzXk3ijT45buRbQDyWz82etAHLT6jLPo4iwnJ4zXPWGn3MN8r5AXrn0rXns5LKX94Cy55X2q5HeWlwFjRSiLwcjFAHT6FdI1nKjhJMDgnrWNqtxc26h7FyPm5U02S3ESLLYyHy2/hq8EiKKsrbT1NAFK38QXdsE+2IWUjpiqF5qIdpJGJCt0X0q3qUiRuFADhemawdSdNpLqAT0WgCne3SSqRnDetcnqUzS3Pk5Ofatq+kEcZMS5HfNc/ATJdlguW9T2oAnsNPaeTYELP6GtO50fNqAx+b07Va0yfb9zAkPU12C2cc1tE3lHnqR3oA5DQNFM06RhSG7Gu11TSdtiiyqNydSK6zw5oEbMrkBeBg0vjCK202xdpXDE+nNAHj+vKgZPJjxjqQOtYj7UcKAST1FdVqJglj8xJAEP61yt1KonKpgn+960AMKbMvCCPWixIEpeUfNnhqaZpJCIlGB396dcssZVSu1BQB674PdI9HaScqFA4A71594tAu9VeTopOFq3p/iKCDTisjnCj5QKyLOWXVL8s33M8CgClZwy2kjK6/u36EDmrU8beWEZcDqD61varpU8NkskLbj6GsErNLGFeQEj36UANiALoQwDL29a6PT7dpZ4mlJMZxxWRp+n7mBY73PQ56V2fhqAx30SFA7E9D2oAZrPhy6ltxP5bfZwMgkVxF3ozSTGTDYXtX1F5LXenC3miVUA7V5/rnh+HzmWCMK2etAHiVzpzowYnKelXtNiKxkSqdmOMeld/qOhw2aiMqHL9z2rO/sw2iuHTejdCaAOIuHWG4Pl/cPWrVhMI590Q+U9c0moWpWdiqfOT93FQwJIJAqjAz8w9KAO20C+aKdShxGx5PpXrWh6g4WJEkwpH3s814fpUnluUByveu/wDDk7lV2sdin1oA9utnleNDkeZjj3pLiBT8zgeb3ANYOh6j5qqC5IUcV0SBZ4S8ZzKOpoAybjzNrJEuQvXNc14gM/lboNrL3BPSukv52Y7UJVwPm968s+Ievz6dE62rEMepoA5Hxbol3c3TSMilTyAtcjZeE726u2WKFt306Vah8YXguFMsrNhu9ep+EtaW6KS20SbiuGIoAzPBPhq4tJAG4Zeo9K9b0iylhgAjGxiKo+H4wl48rx5384rsoGhljEbLh+woAxNVhJssSScjk89a8O+IzNNvhRSgAPzdM17nrkQ3lCx6dq8T8fAZmSQ/KpO0jvQB4pdIUuDGeST96kh+SQpMct2NT3oeaY4T5QeDTlgjk+6fmFAF7Q55orjMigpnjFe4+B7q/htUW3cmN/U14fokrLKUkGXBwK958A3EcdhGjpl26f7NAHlHxWtQLmVc5fOa8tr1z4oSrLdSywrnd19vWvJD1NACUUUUAdX4KZY7yPzDlSe1fT3geGB7dPLXaSBhj9K+W/BgY3q8Arn8q+rvhv5ZsVBwwA7duKAOpZGksnjiO1x1JHWuZ1bFuU6q4PzV3UACxlnTnPGBWdeaUlzI0igMSOT6UAc5d7Lm1QIT5ZHzc9K47UtMl+0D95xn5B61181hJbySJGf3eeQaqnTpARLsaQdjjpQBx7WE1zLsS33TjsR1qpceHGlDs0HkSr1+tde4mtr8TIV3Y/Kqepa9GyyRzLtbHUdzQBzVppcixDDevBqpqdmYZRsfe/cCpZ795GzHvU9snis65kYs7yllkI6k0AZd05kmO3jbxyaoyK6sXcbyw4HpVhlLyFX+UH+KpJLffCShztoA5rVIZ2RlQYXvWFcOlvAQeCeK7e5t0ntypcg9CawLmzs/PHVyvb1oAy9NlCxjDEnqK9a8Du91Zj7SwEadM150ywpMpij2nPKkV0730EOlhbWYo+PmGaAO41DxPBAGtIGwRxuFc9f38muqlozbkB5auf02a3lDyzvnsB3zWvZrZWqrKkuJGPC56UAa+o/DOGbSY5/tAVAvQV5lq3h6SzvChb92pwDXr1pr0sSorkvbqOQea5fxJqUF/dPIY9qHgcUAeeNEsEh2sDL2xVG5mllcxtGSx711a2Vptcu4LtyDVNI0kcpGqnb/ABUAYawmKAK8ZLVZgvHtJI2jiYEHmukjtfLTzJ1XHbNJKbJV+4Gc9qAHvq32qzGVKjHOc1hy2jTKWsiSe4reFzbQWpUICxHIqzoeoWcV1HuiXk8+lAFbw/ourSRgxRMI+7EV0Fn52nX8fnfKQRya1tR8RJbmKO0ZFiP3sVlapdi+KrbkN/Q0Aej6d4mEqLGWUgDtWXq2rRtdH7Oc+oriLZZIEOJQH6HmnJLGsgk8zDDr6UAbMlybqdlYhV9O5rM1bUEYeUw2BPuj1qtqGoW9vG0gfdMemOlYJ1qGfctxGWlPAYUAWdQX7TibhXUdfWudaXyrkuoyejCtWK6S23MSXQnoOcU+4MATzrdcs3UGgClZsHk3ElVPau30O4IRUEgxnr61x1u0Zl2Fclu1dDptqwK7GO4dKAPWPD16AigoQcc+9dhplwjsY1kCZrzLQzdBk3Mpb0rp7Fmt7k+cx+buO1AHUX9qHOwEEH+IVwvjjwT/AGnB/o0nz45967GzJ4+csOuc9RUstm81yjwszeoFAHyhrfhe/wBOvHgltX2k8NivRPhdol9YxGa5DKh+4DXuk2kxSFVntY5j/u5Ipf7IgEgRECqBnp0oAztKWQRjemJD0PateJ1klIxhwMk+tOUxxxvCEOwdDimKIfIG58SA8DuaAM3V5l8uZypyMivDvGXkfvpC+8tnA9K9W8T6mICdxyuOQOteJeObuHa7QN9/8hQBwU7SIz4xg1QgfE2c5fPQUtyWJG5jn61Ak6xXAEQJHdjQB0kYw0UqKAw61654Au2cIUwYwPmFeMW0hMybmzGe+a9Z8LRLstzbEqpxkZoAwviVCsdiBt2luSfWvF5BtdgOgNe//Em0U2o807k6gehrwnU1CXjgDAoAqUUUtAG54ZuRFeRqhKkkA+9fT3gDUbeLTo1R9rEDOe9fKOllkvE+U4zzXtHhnWj5UAZSkcfGaAPpjT5c226Ng/HOe1OiXaHkUlB3rgvDfiFLsLHDJhgMZ9a720v4ri3EMifOO4oAjuLSCSDzm4Y9B61ko0sDtGFXaexrW1J3NvuEeAowtcrqc0/lljIVftQAzUNPWRzMrbVHWuN1mGAXB8wL5ZqfWtTv8rAjfJn5jmuVvI7ye78p5/3ZHX0oAkmaRHMaRoyfwtnpVe7tZZUV2CkLyQKrDT72KR0huS2P1q3DZ3UaAi4LnPzCgCBdNa5G9owseKlt9IkUncAFPT3qdrHUgQUlyh6CpZIdSmgw77Cg/OgCpdaEjQN5YGP4vWuJ1TTvs8x8oYIPBNd2sN4IS6T7h0IrndYtZml/eMAD6UAcXMHe6w/ysOpqO/kVc+UenXB61t39osULM4DA8A+lctdqEIy3yHpQA+2uHZvkJD56Van1Y2xBlJaVe1Z9vFLJMHb5FHQ1be3gUtcMd+KALtr4hvLteCY0HGOlMa4uZc72yv1qnbukrDAwlXoWjMpCj8KAKs91LBCwGTVXTLyW4uFWJipzyKv6nLFHCwVQHPWqnhW2NxqalFwc/nQB02tGYWcTByRjkVyH9osLxhkhuleha7AtvbNlcnHftXlt8uL0seATQBthpnVmUkt1NS2CzyOAo+XPJqbTZk+zLuA5qy0nlL/o5wCckUAaD6czwF0mcsB0rG0/ULmyuXwxAB6GtiDVbcWpjAPnY5PrXM3tyjTvsXc5PQUAbU2ryytvjY4/iqG7vZZdgiYiM/eNYaTGOPj75/hoNy7qBnae6+tAGpe3RyiRncg6mnpdEbcRAAdSe9Zm/LJn8q0IGMkyRkZSgDTLLKqmFcH+LPFPjyuVTjjmpoYwx2uuEHetC2tQ6lVQketAEOl2n2kHaAHB612ek6esSR7n/eN3rAtrSQOoj+Va3wksMaEkke3agDZjf7BNgyMXPer8V+XYMz5+vesAXbSlYJojsPSSnKxlcxsSmzlfegDqk1jYRGr4J98V0fhzV3d2SEqzjrXld3qNvDlbhSLjtgVXXxE1kFeCQq3c0AfQ1tO/lmbqe9G4P84PB5x3rzrwp8RoJLZY7vbwMAE9TXTwa5ZSguJlV2HCZ6UAal7chByFAHQetcfreuW8JdxIof2NRa5rcUczLNdKqmvIfGd28MzywXXmQP0GelAGv4p8TxCF1aQtK3fNeVa7qTXahH+QeoqpeX0nmETvuB5Bz0rNlmEwPmtnHSgCRo/NUsrYCjvVeykUNIsoAHQcVBI0hXA+UUoCLsz94UAbenkDCkblzxXt3gbA0yNwqtjgD0rxfSIiGQ4zk/dr2j4eQPCnznCsPumgBnjGEzQMJc5AxXhHia28i7OOmcV9IeL7F4wGYA768L8bWKx3bDvzxQBxNKTnFBGDSUAT2k7QTo+TgHkV3eg6o08iwBSA/AbsK8/TbvG/7veux8OyTmI+XDlezAc0AezeCxb2bKl5MFHds16zp2v2MMIELK7AcHrmvnfRvOluY2mVniXqor1TwzpPW8nzHHj5UYYoA7b+2nkjlafA67c1wut64s7MrtsCkke9UPGOvrCGhjYj3rznUNY+1yYBbA7560AdPdalLKXMLZJ96y/txGI33GQnkg9KxZbyQABNwbt7060S7uDvIHy9SaAOkjmhDffIbu2aat4LcOhVih/izVK1sTIgm3gY6g1oxWU04EQVSKAHwaisiBVZsLz1psmsRzLJuY7l/Wrtt4cmuRmNQm04PvWhB4RCFTsDM/U0Aci+rmWzZIwyMOpJrInvN8Wd5OOpr1ZfAcZwkgXJ/uisfW/CVrZxEIuT/dHWgDyXVL4iPZESc1Q0/TJbqVTOpwegruLrwvFHMJLhxHGeme1bWj6Xp8fLTqzDpQBwGpaMbWLLHHHSsW6jK2v7sE+tepeKrSGW0MiEADvXm91CIAzeaCp7Z6UAYcUjwnB+6atJePGhAGSehFVZbmBAQeRUDXsKD5AzfWgBmoTTScyHGO1dL4CUveq7EAVx80rTMSTxXT+FL+O1KMwOKAPR/EK5sGDAZ29fWvGtV3C7I7Zr0TxBrmYQHPDLxzXm9yfMunw/BNAGrZyGGHg5p4meRCWyDVC3nUAKuDjrmtOHDupJG00AQPM6R529e4qzpFvuukG3Ifuav21pDkqXVt3QeldJpOi+T5bEjGcigDm73RJLW/DMpKt0NW4vDXnyqV5b2r2BtHstUsImBj3xDkHuKydQ1Cz0gkQwgsBg8UAeWX+gXVvdABCR3OOlOt4JIJf3a5Peu7tfEmnXl15V2gQnoauSWemXEm6FgrdevBoAwdB0+6uCJFjLKSM8V6RpXhWd4EKx7A3GSKr6AEt0DLtC/wB2uoi1G6mjCI3loOlAGevhqxs583UiiT0J602TTreNyYsSIc4FasVmt0d1+Tlf4qqavcW2nqrR8qaAMefSZI0Zsgxnp6isTUoXhiLKcuvTFW9a1R5I90Un0UGuWuL+8WI7wWJ9s0AQahr4to/lt/OlPDEjOK5i+1eTBESFkf73tW39jeXLJ95uCDSf2QqjGBg9RQByD6hc2x3RucHsKv2PjV45VM00gkXjOTit06BaySYYnjnFXU8EaXcoZCuWHoKAMTVPE1tcR+f9oLE9QWrlLy8WdGeK4Yg/wkmu/k+Fa3pDWchSL3qjefC6+sxhY2dT0YCgDz54jPHgvznvVZ444ThmznvXRanoN7YkwzQsD2YDpWA9lcKxR0Ygd8UAMb95GqRHcantrWaR1ULnHfFSafbyJJja3PqK67R9MZQAisxbnOOlAEmgaWyssjH5s8CvX/DVs/lxmf5QRXL+HNAlBXzASnX6V6PZ2C29qhkYkdhQBF4nspvIyzkgdK8Z8c2TKuXjzu/j719F6zbRy2QLjJwDXlPifT4ysu9ty9hjpQB883tsYJG549KrV32q6LbzhmYkFT2FUY9NgSdUCjHfjrQBzuk2L3k21B0rtdBWaA+TGcSD+E9D+Na2meHrQkvHlD7VeXTo0faGO9T9/HNAHQeHrqDSFF3OFd16oT0qHWviO8l2TDhIwMBRXKatuGUDkDkGucubdfU9M0Ab9/4rW8nMkkWfWoxqthIQY4due2Kx1gWO23Dk4zyKmtCvlmRkBYD6UAdzosdjdxqZeX6812FjpunybJDKFAGNvFeRafeyRklOMj1rpNH1OVp448HGf71AHqdhoWkrMzTSYV/u1s2Vjo0H7tHy/wDfxXJaNeNcXUcci5QcYzXcW1pbSTRxiLaG64NADw2lQnJlCjpnFQPqNnApMZ3p1Bx0rcTw5YFyjIxB96pXeg2kVvKIwRjpQBx2o+MVt45FSMl16HpXC6j47U796k3ByBmu48Q6ZDJbbfukfxACvLfEemW8FwAozigDF1bU73UZQWc4NS6ZJJFJ/EQOaITHgqIxkcZzUOoXkkSL5eFoA6CXUU1C0MbfIV7HvXN32lQtucv8voaztT1aaBQEUAnqc9axbzXLtk5bj60AT31paRkqQDn0rIvYo1XbDF0/iFINRlJ+fDE+tX7K4LRFmUHvQBjx280jBUjY5OBxW7b6TexS26GMjNdHo8sbtCDAg5HNdreJE95aoIlHAJPrQBwPiPRbkpCWJxiuO1Gyls5tsikZ6cV7l4ktYpJoflxjjisPxXY2wjiVogxwOaAPIkysg3ZWrUZeRv3ch47it+4s4CxVkBFYlyBEzLGMAdKANnSbeUtkth+2TXWWdvfnaWmAjB6ZrzuLUrgQ/e+70rSh1a8MC/vmHbg0AeoQiQKBbXpEo7bqy9QW6edvtDfvB39a4qO+uA8ciSMrfWukW9mngVpm3EAYNABcW0caiSeP5/72elXLOdDCNr844NYOoalO2IgwCk113hTR4bjyvOYsCRxigDq/CVjczRrLKGdWPy9eK9E0vw9cDbPMxwe1XvC1hbWVmixxgjjr2roZD5MYC8g9qAOP16dNNtmWUbgR8teW6zrKsJBJyc8L6V3fxFuyIWGwcdDmvEdRu5BI0n8WeaAJJdVm89XfJAPyj0q/DeSlg7/NuHSsiKXdGJXUE+lalmA8iuRz1oA2ra4gMW0xjd3b0qteSEBcJlB901IB5U0YX7r9RTNSuDbglFG0D7poApNOEbfgb/StCw1tYgBs+X+KuSlv5WmMnH0q8x823U4xnGcUAewaBqNvcxxpkKuPlA7129oq3EXkhV5HfHFeE+G7yWG4i2EjB9a9W0vUZXZQe+AcGgC/qfg+yvYHEiBuuTiuHvvhxC+42yqU9K9YjnMsUSkYHfFLc2yKBMnynpj1oA8UPwxdR5sagxg5Na+j+ERbLiSFcV6PcRlEzG20HtjisayEj6uYJJS0ZOMYoAz7HRGt3/0YhlJ5HpWjPJbrEsJTkdW9KvpCFnmSMldueR3qrdQLPZShuCvcd6AP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T2-weighted single-shot fast spin echo image shows a heterogeneous mass in the right kidney.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ivan Pedrosa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40130=[""].join("\n");
var outline_f39_12_40130=null;
var title_f39_12_40131="Colon cancer on CT and colonoscopy";
var content_f39_12_40131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Colon cancer seen on CT scan and colonoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Computed tomographic (CT) scan showing a filling defect in the ascending colon (red arrow) along with an involved lymph node (yellow arrow).",
"    <br>",
"     (B) Colon cancer identified in the ascending colon on subsequent colonoscopy.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40131=[""].join("\n");
var outline_f39_12_40131=null;
var title_f39_12_40132="Cephalosporin side chains - common moeities";
var content_f39_12_40132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Side chains and side chain groups that are shared among cephalosporins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 793px; background-image: url(data:image/gif;base64,R0lGODlhZgIZA/cAAP+mTf90dP+ZM/9UVDMzM/8yMpnWwkK0jqysrIiIiJxlZcDAwP/Vqquz1SIiIv////9CQv/ZsxAQELu7u//Llv+/gICZ/zCsg2K9oVBdjgAz/9DQ0BBA/wUacf/58v/Dh8zW///lzLCwsP+6dXBwcJCQkBhmz7EsKSFO/1F0/9Chof8hIYSW2+Dg4ODm//+tW9DZ/zZIlWZmZv/y5YeRu/+0aP/r1wAAACKnevDz/6DZxv8REdq31X8AAM1GRp97XmdFJRAvrwUszHkhIbalpkREREBA/0BAQDtJylBQUGB10j47POCJMkiMz9JnZ5q3qGBg/5djME1SdExJStvHtcTH2HlFPRBYQLWKiwCFgsTK498wMOkiItcwUD8AACgo/yIfIFJw6eLX1H1mXAoPJlVERFVVVWxrbKCgoPDw8FRTU2BgYICAgACZZv8AAJGPkFlXWMjIyPLy8jAtLpmZmd3d3cDN/4ig/4jPuO7u7kBm/0Rp//+IiLvJ/3VzdJmt/+Tk5NbW1szMzP/u7v/w8GaF///MzP/d3f+Zmd3x62bCo7vk1t3k///Q0Hd3d/9mZv/AwP+AgKCz/5+dnv+goP/g4ISBgjBZ/8Dm2YDMs2CA/3CN/7DA//+QkP+qqpCm//+7u/9gYP+fQO7x///PoP+wsODz7PD59tDs4//evnDGqRCfcJDTvLDf0MDA/1C5luOkpKOkp84ZGdDT4ICGn2VjZBBB77DG9YSDhLm1s8HK8LG74+Dj73FvcO/AwEZFRklHSPLi4gUGCfHS0kB73xAQ/zo4OfGiooCA/2BfYAEv7PFiYqCg/zAwMEhT91IlJt+fX5Cs9bqdgHCsz8Z+OOGtupCi52BleGhnZzBT30Fe156Njnx7fEBJRuMDBMiHiPEyNeNkZONzdHGCfZ+Pf/Lr5XaJ1UBTTeFKSkCfqVBPUB8TBiJ8X9/Tze+iVunDnZCQ/ygzYDo1M89JbyB5vB+LZxCUdvGBgtbPye/p46CnxeTXylSpjYGX8BghR/BzeSH5BAAAAAAALAAAAABmAhkDAAj/AN88GEiwoMGDCBMqXMiwocOHECNKnEixosWLGDMaFKixo8ePIEOKHEmypEKBYEyqXMmypcuXLVPCnEmzps2bK1PKxMmzp8+fQHcCHUq0qFGPOo8qXcq0qUGhTqNKnTozKdWrWLOGhKq1q9evC62CHUsWLNeyaNM2Fau2rduiZ9/KnVv1QVy6ePOSvKu3r1+MbP8KHkyRL+HDiAsGTsy4seHGkPsujkzZ7+PKmNtOzszZ7eXOoL1uDk366+fSqKOOTt0RDWuWp1/LJrp6dsU1bEjY3ru791q7vjWucb1Bd3Ckx5MPra1c4XCCxZsDlk7dJvPqBJ8XjI5dYuzu4C9e/8eu3SD38A2/o18PcTz18gfPs0eofr79hO6bw0co//7A+v4FCByAve2XUH/3ESigffkdZ6BCCM6n4ILsNejbgwtFuN6E4KHh2oIW7oYhQxqGxyF2aKwxInohzrYiicYxSKFCKQ70YnctvnYjjAnOiFCN2X3Y44mh7dhQidURqRyQBRnZXI6oOXlkjCz6WBCTBkl5HJSkaTllhVYOhOVBXvbGJWhlflmllWMilOZsZ3L2pprgKdlbmwnNyVqcmOlJJ3Z22oanc0LWCZx0fjqEZHCByjboQiRsUGWjiSX60KJmUogGGxVFauKhyZEgwkuY2kYpah5e5CmOoAa3KqlUKv93KmmpYvQqdXwydiusuAZYa0a7ytrqbsHy+qR/v2pULKPDzrasscnNylmyHT27W66EWQsts/NR65G2smErGLjbZsqetx+Rm5q4fqlbrqnnFjqSu6Sxqxe974a7Hroi4duZvXj5m++e6PE7r6TMSvuWwDCV+m94BpPEMGUAyzVxw7ES3F3EJV3sWLOgeYwxvCjK+5LIiFXcFsoj61sdxyuxPJjKackM0wJruCwdzCzZbBnImPkM06OcKTwYzy0JnRfNZCk9dM7r7mwyTk7PxTRYVT8d9ZJT85S1Z0BDhnICRfRENMVcH/W1Wld3tewEN8gwENxyGwT3QGSLVEQCE53/DZnReiFt09potZ3Vs3DfkMcDMsR90N0P5O2T34wBjpfgNxFOluFXWQv33nlIQIDcCdxwgwOCOGC6Awk4oDoBixdhehF5FEHAAwhIkIAEiydAANyqS2CG6Y48sPcDNxBgOh2Rm06AIAlRnnJwmFONcGicT6Ut3HSwLkMRMggiAfSOmAF563WETkfreeRBAN8EmCHBBA84wLz9cNPvQNl03GA83zfgW+sEcQPofY9GUCuab6rntes9zHJUARfc6qA6QYCvf6Y73fnKVj86yKBuCZBbHW5QvMgVAQEOeADkjne3492Aft3r3txSiMCH7YaBPdGcaMI2GHJNMG/gEx/0/+amOBMOxH7sywPrHhC/Fz4gdO9Tof/+J0UqOrF7BISeGThYw8xAsC04JIgTa6JDrWSvKeqaIEHA1zzTycB9p5Oc/Yw3u9qZIXLje4AjeFdFKrYQgDBMYemSN8SFSO8vX0wLtWRXh4Ew8iDHQx79QjLGhpQRK2dcyiUZEsmVHFIys/GW7Io3whs00iCRrCQZHYi2RGqSlTdBQBFb8smlOWpqRSgC7xzByDooL24YvEH/fsm8CUjgBhKgA9wQwMQPcrAIjmid837JzBe27nV58CXxDLJJqWTSKN0cSi3p4kqw8At8RaBDMk1pBhGOL5UCTKHuHqDOPORuiw8YYR30if++EfLtgNZ0QPqSaYY7im+SBAnnb8pZFIWKM4GVY43BLngD85lSdRmkQyoDqc+BmJJxs9ybI0jHQSfmzZoctN8cjcc8bsIyMd8cikOJMs63MFQrEWPj/CbYzoJA06OBfMA8d2fP/XFwAg7Io+RMWjaUHpEOBX0AARFakJkaJaY/sSpNIXqYm2KFY2wk4j5/aUoM9i+oxkSmMguoxLoRgINLpd9JJyBHOmiThArR6nJ4OBe9bjWitOqaS0JH1X69dGZ8XdhhE1PTtHh1KmEEiSNupxK/9gSr1utMY8vy2KhEFiuWxQlmB7dYyGx2LJ1tymcPV1pbpnYm2krDAnJDWzb/1JYEJVjAXNKQhK5qdmoLEIFth8sGESwgDWMJbU1GC9vFtqAEaxAVchXSghSRAA3TRUsa1pBdwbz2KMkSAQlIUNzjGiS4ublud0HbWqsltizLWgB5WzCRDUSXvmTZ7noRmZlayVdUESnOGkalFeXChLkuKRbOBPuQNLBhDfj1in5hiplULXi/EEkRg5liYJcguGewbEESSuARB5MAw1KZMIUp4yH7bhgiC0iCbtnr3fd+JVgpQvFFNpCE9h5FxSs27aZODBLo6viV/P2uSYJ13Y6RmCpADjJjNiXjkYjYxw3FMmdtXGBWpuEIWrYICbjKlChLGTFoIEESjiycF4Mz/8xm4TKNC7LdCHcsCRn7MXfRNuUjkHkkqyWtXj58MIOYmSTNWIDDcHLoMx/Nzy5Jgpuz7NqVwfIIdi5JGqYo3qU02tF/SfOfS9IMSzUXL4QGSbDWAOeLLKAZBCnBpGnyaVD3xba9dcmmH0CCGVMFzOSUs1O2C0sRPJkluWlSpn1Sa1vnZThrfokIjjCQaEMZ2HJJtUa+DEvevuQIBB7IdonSbGfTZThsaHVGkv0Ab1+F29kWtqexzc1lm+QGmRbBrFlSbnPLZTgb4BRMwE0QfWMF3mBTckYQfl6Bt2QDZ7E2T/rtb7c8Z88wuUF3JT6VL9sbtfI2CsMNwvGVQBchLf9w+E0oXnG1PMfgN4NKwLGygSOwuSvarsjIt6NylmxBBXm6uUpY3nK0aCfXMDk5N4U+lJozPSs5n8jOq/p0j7iBEAlZwL5FQvSik0U7WqdJAYBunmM7xenxVjhFpk6Qcb8EEgVYCNJn0nWvg6U8eV4JIdyQkLkzBe1p1wrbCYKGcLckEgFYSAk+PnSMo0btJimP22FSCghET900AXzgD07vPM0EApTIkNlbUnfAzgU+IjC8SxCfkDTkvek2R3XIezL4qs5kB5VgyOtJUnrTv2U/uzcJBErhnL/HXvaQd0jtoTP6lTRiBZZ8Se993xYDjXolV1cIG6o+E80HO/kMWX7/wX3dkkokniFsYHxIvK8xi5vMwTSBBPQVYtyjsN+94FeI+AnS858sgPwlcX9bU33ApXot0QmhsBDPZRQCuHnD1nm6x4DNJxIN+Hjud3k0MQChtxD91xMVaFOzR2sQiH4v8QhucIJ80BAdCBIfWBr5lxEjsoIrUQq5BylEsWiOFYIwsX8GIYMiEQArYAgPAAo7kIIcaBIt6IIux2A+iBNN2H3B54BKwYM96BI74AkEwQdxd4QkkYRKaHQb9oQhAQoFcIIFIITaBxQ4yDY6SHoj6BBiiBGVQHyH4AagQBCIMH9pOBJe+IVf92Jx6BGHsAOPMBAQsAKDsIceGIX4N2+Y/xeIBaEBGgACD/AHGpAQkACEO3B+V5iFW6iILHh8W1IWOwKJGqGFBdGJCWGKAciIjfhjb/gQrmgQGoACKFCJl0gQLiAJKcABXfAIkFAQjxCEQ1iECwF/6yeKozgWRsKKGPEIlkcQK4AIebWIEZV/VLiKFKEBd8ABd2CJA2EBl6ABKfAJjJAQJoiCDPF/ych99cKMs7Z4KpGJjfAAqEgQqogQs9iKHwN+2ZgQ8igRGvAHd8CNuSgJnPARaACAGdGH7dcVUsKOE1GQKTAQKHAHB+EC1TAAO7ACAXAID1CHhfgAh5iICIGMNrGGUvgT/5h1BtgQAzkKKCCJ8xKK7uiHWv+hJSlHEd3IAX/wABdJEDAgjhqgBJ1QgwRBhmaIhgghkTWhkitJe7E4Efs4EAOJi7kYElVJIsp4LBC5dTbCkxfJATKJkTDAASigCQmJEemXklv5iiw5lRNxfQpxlUCZlR/heh7hkDqDFWnylneAAqPAAYUQlDkAA9/ilpWRai2JfupHE4XXEXzZl1TxJmjQaoH5AAXJjSFBl0j4lt8Xl5gHIRO4EDCQA5EnmV3ZK34JlgXRAluZmXeJkR+RepkHmqEplaO5EJ55EBxwmnowEnrZkKvJmpXpmlkykbeIi7TpEb3Jh7iZm4wmlxexkBABA7coCZcwEm2JEZNJMlORKNb/6ROwCYUPNHHUeRHu5hCbsAkPoAmfwHW51gYGMBAG0AYBVpxJcpzOKRG7+ACoGRLd6RJQCUqd1ZgSwQYMmRCXkJC/KRIKOhD0aZ/4eSn6uZ9SYWoPEKEQ8Qma8J4WABLDSaDRWWk2gaBz6RAuwAEPYAfLKaIJNKEPcJ8WepPXkqHIqX/PSRANCpSImS6PuX4laqIiuJsRYWwN8QkV2Z4iAWEE0QZQGqWKcqGAEhUaWnCTlgMacJgvKpkqhwc4QBA4gAdCqoQ3haK38ZgpIAlAaQchgaRPWp8zWqEZQqVVikYL2hEllxC8+AAW8KEfwXFgKqZk+hEFWmMMVWdrl6cN/8FbOpYGwpADgNABIdECXCWjNFqnNuobL5hQRhp+fpcQ5fgAPfotrDSoAzGmhjqkBkp3jhdgzXADrwoRJSICsKZ0JTarmEqn/GGnrIJkJjFbDcEBLuACeJkRaNB8eBClUFqoGnGoiOVKvVcCN7B9RwAG6jYoa0BiR5CjCfGGrTClm8otavOpDxExu5AND9CnkplnqPoAqvqsrPoziVR6vIWtsXYDpckQm4IQErABmzauB1EsrBCmXCmwnKoU+FJcFjEiJOAHD5AE+iCZo/au8eqd80qvujarDrEAEmBt5gVxvnoQY7IAKYEG1NYRbHcKq4AJBzsj+UcvLXAEzSABuP+JIfiKb8/KsQNhsc5qEdDqWxBUeuQgAYXCBhIwKtslAYyqEDiTXeP1ANtKsYeVCQfwsjD7Zkdqsw/QAs3QDJhXAv23ARLwALaqEWnGEKzgsu0KL5ZTdzPwAu5QbDaLXGjAtRLBYwgDBqMiAUHqEDmWEC6QBaagqVaSfO7ieklbEEiLnCLwqg8mtc7ITfs6ECzLtg2ZsYi6EnWXCqLwAdRFs5Litc3wtz0YKWUrAhxiqS9JECngnhAyshtCFO6yAc1wfBNmsnvqEJbqa80wKvgKtFXGEBiAAW17o0bzaTbwAgIgAC/AAAPhARUgCqmggvo6ECRgtBPhsRIABnircw//dmR2wAEB2qsIKyxA4S7vsA4qx1tM225JELwTAV0t0AIaB3EW4Xrb1xCosAqFm7kJqzC19gIUMBCkALrLWwMecClgEHsey7PxwQZHcAPNIMGyWhGwSQJBegnxeSCyCyZZhWUeMAIAYAM/grclIAGT62BJ0Ftjtna5YbrEkAnymjCaBsED8QI1YBCiAL0RsbRKe62HVV1r0L0Dll22261M91wj9reS0KXm8cE+i6E5hGUhIAojsMAJQbqSksSmexBJcATX2rr0N15fzAmCCcA2LJw4PBA28AHNWwMmrMUTIQJ1+wDUanbyFasjdlhp8LXppaCKNhD/J1zjFZAP4QI//xofRAYRU2ycmWUQFNC8AvABWkwBohABcCgBJKa4ZHwgKZxBY6agOrYAJTBen5wQKMCmGBstbaijVfcBL4ARMwu2DyCyJZAEFAxgjVpq4vZ/m1JeTXsQe8CZjKABfcAfW/nI0vFaweK5M/AAyzsDcfsCJvwQuotcdtzI+pci3jscaUC2riFbtUVc5CUCX2wQFhCcrezKlEJxzzsQH7DD63YDkvLAaJDO7ebLGrEHM8kIx5zM5vGWy8qsP4u+mfNSnhsCBZEKoCsR7qtbtfxSsxWrR1ACrCTOJcEBbrpjxrGrbhsSLDfJzfsC0awR+BW1OsfPGLEHhbAHexDQA30QzP9cEDWN0KukEKTAvKJAChhxt8aBtE9WXUnQvdIFIdo7Ei7Qzg8A0nDyyobWxh6WyuHH0hbh0n1gkAI9EBFy0z1rsPB60K4saA1hA9RLy197zw3svU18KUmdEVmdxi/t0QXh1PpiJ9MXAgBgqGWLEX+8owrh0g+QApK41Rri1Q+A2OR6ajptydIsCgy9bilbasN8IG99EXFdCA8w1xXRH8wKpSGtslLNEKJw0soC2Mdo1RMh2MeMzFz9egUdpWItITm9ECHAvM3r0x9hv5uq0RiR1ZbYB5xdXxlj16/BJ9NHEBXgwxrBtyqr2g4BAwkp2Jvt2iywe4itA5mw3dt9pzD/gS8hYNoakcveedkUkdWM4M/DHWB5ZtwEcyLJTRCpMMso3dfP/ZwwoKRoCbsHoQQdwMoJgdgH8NnenWCtttwf0a0Nad4Sgd4gIIl7QNwJ4d5RwyHxXRClPd6orXzQPRBx8AZwMAcxoAmSsNQIkQPa0AEaQKwKgdiogAkwDuMPwQCiEMfXDBquJDDzXWIa96wMDhHoXd0Rzt6fMiEXXhAInhEEQNVSV2py4OEgDgZL4AcIAAgNkeKSqAHbiRGqcABefrUN4QECUL0jzNw2lDSYJ+biXZ2hCrQ/rhC7qAl2EOTHHOGSAOAZ8nqo8OVergqhrXOjHRE7jhEramXC8AtT/wAGU2AJE/Dkl7IGM5nl/H0QqODnDNHlX+4QYq7bFojmFzECZn4RksbXGwYICKAJM6kHFmDiBiEJK77IB7J7mPDZYP4QJF3JdByt+RvoEeEBTJAPGOGhI+EHtZAAYMBMeasbOTCOWd7RB6EKls4QphDjp+AQDFADzevY2OPpFxEB9O3XPc7XZGbqfrAEYAAHFuDsCKEJWb7lsU4S0CzNJj09AHLkCKEOlesQpQoSgAAGpr4EEk4Q7C6J5IsQOIAKDpEJUYq5mk7A7xgzn6rmGdEAUkCBEpAzgTAJMjAHcyADkxAI0Z3lkjjp28GIsx6lNPwQC70ULQAGrAYbIWfvP/8CaxZhrOX7EXDwBnKwBIX1JwPxCZKoDBlA6WDNEJjA3f+rEKmQCnL8AB7wAqQQAbmOGYDDMiOgyRgxqiKRDDcABnNQCx8/EeMr8ur+2g9hCtydCQzfEDstAD1dFH+dvc3grQ9hITJ/kjpbEUoqEnEwB3IA4smeEJxgC2RwvQWBAdFuSWK8WCFQAwCQCiNAySPwAI6P9UthW8tVWeY6EFTwAxihpawOEnMQB2wAsRYBA8y+4je/htytAxRh1tU7FC0sbmhQsxrMG99x932Xo3qA5x4xBZMgB6NP5AoxC7H6rwWxBCD/EBN8Aws6A9NLAVMv3wDwApF9FJhPEwpjMwH/exHaORKBAPAygOwWkQN6kOUVORCdJhFRWusK0fg2cMALbNYMYP0/sQbNsF72JQEKDhAPBA4kWNDgQYFgHihEeDDNmjQNJU40iCbJAzYZNbKhYcHjRwt2CLrIQdFkQQRLHvjxc1LgBhIU0xy50WxgIJUuG8rxw6SCB4oUBIyJo9Po0YMZkS41yJDpRBIbniJMguZpik9TG05qOQeQ1geaNGjoUOIBmjVIMa1FJXFGDVEMHoR4IcAuqQcMRNWYAVYrGgktEKZBA0YCG8F+Fy4++TCi4oZpbqTZqLEjSI92+mhAMepBoT2QHyxBAAjM15MwXa65EfOBJUs6F9y4cYTg/5s5Msq5lFNijh/UosEqFX7SqfCoxS0+1eCi+AMZk3AqltSBNpu0SGfXRuihggAKQBt6EPpB/HOKCyRInbiAdRIRfhUel+gYvcGqOjejKPQ5tOI34IAuttRccwmNGxYYLRCdNjjiCNdSgqOoo3ia4w057luKOA0Rok+x5IqT7LGjYLgEvTkCmUQGyDaQ4AYJSDTKQQgN6i2KCvoyaYYRgMCww4NctKqxEsAAgw0ZkZrPJPuAFIiEZirLiAXMMtvsDw36AE0xOeaII445MjRJtaMWACOOnIxaYIE44CBtqkDgmAMBJ13isM6BPgQrxOeaQQONBwN9UA9CCyUUBiADmf8DuklEY+NFA49CI6PEBEJgDjiCcwkQORvFM40otUvihjUUXGrJiZp00kUSpGSDyio104CRPfj7D6wAFHgAjjcKZMrFKd4QdlhiiyWWtgsVQxMYPCm6s1k9p+LzuRKSaGFNbNe0Y1tut81hP8+2FA0BFpdgUDG00hg1PqRoSlAgNJegcKk4ppC3zmayW6oFNowc0ihUI4PoUwnM0m9WEMa6dapK3DiEEi58fQoMYyu2GAwxIROm2YmexTNapqZ9roXJDubPP+H8mASQRdHVl4QYkdpgzTQ4ndOvS+E49741mklyqRJsOypghwbGM9+jNmPkMw0WfiqUAB5YgZIxIz3/lSmQn7qBY4k8rjPro0QeuSZBAzXUUBiuzFJcyMwl1+WCAF1qATbOoDhjsOTArSX0ivwZaH11IrogVZ3sGSmlH2CkabAg2WGQTgqoGiywJaocqa25RogGGjRnbE/2NAS11Gyx7bbbb2etlW2/WF7J078CH6gXYOCw/Xbcc8e9GWGm0BQyQCRAD7DQtfKaosEHKhxIvz03CIJICNkBEorI1OpyD4vL3HmCPPIce4rEfi4JoQ9mJGHGIYNljAeG2PkptA5CAAw/vrT/fvzz96NX9LYXzUV2+eV4E0neA5bXoQash3sFCcAgIgGB6lltYljT3gK7Z4Hvgc5JbPBZ0mbF/zSnaSUUnWgYWOJ3kCUsgX9HEdZ9/KeYNEjgX35plZI+pzyj1QkGHNiFBQ1SCUJMxHqUo6BwXsg972kOfA0Rn3IU6MGlLS6EU1kBJCgBwamc0CApaSFSuvicI2pldMI5gqkAdkMD5tBJOUABBn04IwlOZYkFmeNJwui5JHKtjgVponBcZMY3PqCEAYhEFmVHkCVM4ItGWaQRhUO+4pTRhsc5YIf0oIlA8mEHbnDDAAYhkSHKp4iiuaPm8sixPQ6kj6LJQVkCSZBSQLAA1GOKFrcooEa6JJeQKeVSoPQ3rUhyaDes5H00cYmS+NATbkDEAw5RgAE0JJSivJoj33hKaP+FrHj3ycElMPnKgRCSEG6A3yEHcgp2FGWXJlmnX3p5lA3cYJuKCcwkCafGieABBwPBAR6MIgkOJNOHA4iaQAzhhk8aZJrUtKE1fYjNj/lynug5JjhhCUSqLcWWBsnEAQTSzomAVCvvNEoawGAwh57xQ8U0iD756U+dcABRgVwBHwZyCIcpNI4MHWZKFwjRryFllaL5BAoEatHYSeQUq8DER1fIyKf6VCvqAeZUSJo9PbGUIC4VSD+RqhOCDuSgCR3IQhWTygcIoYJfzaZRhgoZTsiUrUmVSEcHItKG4FVrjzTnVFogPHsWraoDwUMbDGtYf7YiE02dK0IQwUxnQrP/IGY9K1M0sNbG+qUNBhCIAdpAR6O0oK8I4eoDvOqSHXJirprkpCeNstGDvIKxD9DrQWq7lKuWVAKABMsCyqdSgQ32AaX1KiYwcIE2NGETnEjmWEDwACwhlbWdJOsDKFvZpVxWqifxQA3sIgq8TMW50NWucDbb2c8SpI7XLQhxYXoSTmSFrcts5jOjeaDR5jWqutwvL4tTJNH49mpZ06p7CXKKW1hAD5x5AGdQQN7MEoS9PDVKef2LFAq8QCAMqIFWHAzh4pz3AZ4FLTx32tJ9dvW9EaZIWA2K0JPAdiAiJvFd+2sSoComt0c5AhsgI+DABrchBkaISDRwBw7cIbos/54whXViYR0vJcM6AsuRk7xk8x7WsCU2sUkKq2V/4gADrGgLQcCFsrnW9KY5pYiMZ8zZEafXqUvJsTufI4gOOEeAJyYgGgXrFw384Q5HhjJbm+xklxQaLDsuiAc+IAoBvEAu4hU0oSFjCgzsk8ZyTsiv+CwQA6OCFa/AAQf0EJLUnYx1SHXxA8ba5vw+YNO3uTFF6rxo9GxCD4oZYJ8vp9VE/2EUKBhLhA+N6JOIZLtGYYAAznMU1QZ62GPJwUyfguk2YMAUsoZzjfP0FPYSeSAukMQmLmEBtWlpiq98bH0lOxE3E0TLW7Yxnd0IRvSwURIC9HGQU4VPpASavIoG5/+xkY0n0Q6E0QQZQXj18myXcAIFuxY4ljRgBw5oQs9Hwba234xeLi/luuI+iNJWt+5XTte1Eom3vLvN6dsW5NYjvU9cj8qUNaAUuI0BeIX/IBBiN9bgB5fIeLF8FMq0JiIluEEShFsQGzyAFACwCwBC4AGITwQGekDBvhv88wcEPQea4IAFbj6RHFjAFh53CVrL+mmXKA19KGdx3GL98TjT2t4u1FAKNgEWYQ5zicB2SQ42jtShgyUQe/zw0XVSmCMIxkzNEMEaCmaSEACgwwaJgCgoYJIcbEIDZqfI1lGgWoqkPeOHNw5YEl/yDxYifXVn+d3x7m3a1pp7Cz+KCzj/oOynBH7nLiG8SSSx66++Hk5zOFP+vqSL03mrwUhWMsFBeQQwxKcFSZDhQMx0hIkKxAZwiUBDQlADAKRCItbgQApYPxFJTHymeziy4rKkevdXUyvKN/MHpUj72vOLmBOIQUsBoLsDzEKPTziRqWgG3mo7P5OJnjOKHOCA9/Mh/mMKRUEAOACDJdAdONCGszmUrxu0QcsBPQC++rA8JEk6EvgZNrgBJCkITokCUsg6zqOGeykIM4kHXUAK1du3WpmVxemDFEjBCfKLDATAx7O9kxjAB0AyDvg5FEBAsEiDSuE9pJCvkhIBNqCJDvI34ptAndCEvys4uBOODVyJKcAb/5OQNmK7rE/ggE04O4IoAQmwlgcQATAAv4ZoAewzFZ64G53ImXMBxO57CpJ4gD0AjT0oQiJSjCUkiE+wQwBsOaOQg2A5ijuoQg4YNivMIgnIDskIIAvKgQaAkpogARF4OsuJQCYhw5OAARNAQ45ZQz9ow6OouGJ7ABfgOtTjwWZwQOvCPlNsCMBIgr35nZPQmzloFaVTjEbcjEHrg0iUxDQ0CT3wOiYcCEzUCU3EFIu5DMzYt04cBQ4ohCqcCt8CA1MBDOyLPOfJAU4wNw1AAlZ0RZMoIJ7Tx4a4AB0IpEk8ClzUxV0Eu6AbiLjKgEp5AO4zizQgARn0R3VRg3lZCv9AAIZmaEiwaMQHSIGxsMbr8aNshD8G7MazcEKT0MT6mYILMRZyBAlzfLBBq7+leIjDEIh2VJCkm0H0MLrLggF7PDUVrCy3K76G0AGP8qFvVMObyUU39AucRKkSWLo85Eg86bWl8MjFyZJrbJGSlAi56sambMYpaIlLeR+T6ESgqz9LlAg8XAPBwMl+GwhABIMZEo3GuyxJCAkN4ccx9EeDOIULYEqVVIwN1ESDfI7vY48FaAZ35B6lQEK/8EimEUk5eo5JnAYMIMvDnAiWfIC05MQHIy8ELLu35EEwIEaMGEWsFAg+9EPhsLLqCyq3Ewh1EUyLKkv1AQMEUMyoLI7/GMSOy1ugySxKcLpNUArLgzCFVTiFS2ROiQjN0fQL00POgti+4py8ByScGHxBv2iuShs023S9I9DNQOJNxaAEN4AF4KyTDWiG8/Sh45wr5VzOqTiAgKy7P+GSs3yASUgR4ZhDTbBDF4wI7cxLiUBEBTWKXyxNOOxFIAHMGZlPnViENkgEgVCEpWwW9fQL9qQEQrACOAjO+9DKrPQxylSMeyM615NOglgL/mxQjPxPPxDQ4siBFLCFY4xNqTjQMunD8EM70SO9rxs4gbAD5EMPCq1QwcRQDX0ADuWYDwULStgBES2AZeAaFK2T+oQM69M/9BjIzOpPv2iEIWiJG1VL/+FogD6sFDZgFx99ikcBz5MABAtov8MTuLC7LDtYQDuwNuFoUid1CSjd0A51kirViittBEIogFDQnC51ElqghQdYUUATjfuMoKM4AEUQiERog0WYKzMFi0bYgUhdUyCJyJwsK2MEC+3UOYRwxjDAToPQg0swtTMsDkItVJPAUC1L1A5ZVEZthEGAVM+ZVCDxHkytMk1dFeb0VFAVVbYqVa041UhdBitg0/uIz2bYgIicyB9bze60FEzh1oIoLyX9S1gENwudiEOVUmG9D2L1i06I1GSty5/CoGb1sGeFVp2Q1gcI1VFFKmudilPthAcIhQIIIo55lKt8jkfBp3rZQf+KsECBEEp23dTJeteGiNcpBZJ6RQpQKABOKgBDsCBl7RBmtVXL+leAPYkDmLeCBaeDfYpKwNKFbVjPIRkNEa3itBnY0UaXHdR2nQoHES6QnVfl+MypOIQdeASBgIAVqC5J1Vck4teiRYoOgNmYpQiBJdjdpFGmoB6GtVqO0cIyGcZeIESdwIry1EyPtaCRRQo+kJyB2AFPME6sdZ6WJSWv/VqJCFtqfaWb9YtQcFjnUVukwIVaYEYca9GN7da5dZ66RYpHwCKBWIFmksy+xSOtBVzI4NgGgTvCrVmmJFujeAROcgObeiPGxRNJMEAn6VV3Rc+m5Zq7JQi95dtrCt3/C8MujiFTzTlcpAiAFUhZUNiB17Wg2K0TLciAuKVc3IWMy10KnJLaB6BatH3Yz9UcF3COfrWqwMUT4vVQ1TWK3hWI3fWh53US05he6vWc62WKkj3ZlPXdV4KB1MSc8jVfGOUe40UKnAKFgUCEFYDdCCNdX1uVyhVZp0VJO/leCT6IG2iB6j0IBu4yFhvgpVjfB2hf542wKbjI+7Bd88xgjYrgCjaJlX0O+kNASCSlNcg+FwWS86XX9MXc5H2A5W3eBXpfJ5mQ2j1aP3rg56jfFjaIFy6OIWSEGZbKGDwLCZDHzFygHFaOHV4K1uUkIA7iCLME3RtdIz5iFcavJS4O/0AwBgquk0bcg0f0Sr8ojCqOiHBt433EwABW1C1OY4WLsDcgkA5BYUlEYrjxY8gIUDZeoGkktD7QBCOdG2OcypcIxFHC4j3WEA9G5IIQYiBpkyLe4DExZLriZK2QAzeJAzaoBUbuD5DMkl/kAG7UCaDV18dkzWR8TeQRyExO4j42ZU/ukHoJZc1J2tw1Za2YgN+QgwkwDD8wUSfhypBMUhS4hK0tiIn9m7i0Y5jBYw1+pSyGn18GZhYT5W8251E+44pgYWQeCDmQgTmYgHeOZ1T2Hc+xTNnDzAfIU42jiNgsV9x8yJcoAy6gpdYD515Gl3Em5wgb2hMu4/mdY3Zu5/8HQBMZkAOLzhhVtaix8wduACYHwcuT4E6B6IQdGIBKOGiEXqBNpug/dmkxHF5SRmOYNgpCEIc5mAQ5sISc3iLfTL5XJQi61M1HUYAgGoRQ2IFC2mWLCucDWWhkDmY/JmS5PWMlTmNIWAEIqIRAmIJMQQhF0ZWvgjz2wEM9RIoW8IEdUNgHgIQCYOtXRLyE1iioNuUJkOo0puqqrqWJRuZIWGvaohjQBAeeRaqkq+F3mYqshoBGIAiVs1p07q2+RoqWhul5xusl1uu9lpTJ5uQCKIBGqAR0KAN0LQhCCIUVaOyvIhUEUYy/Lij6iqz7+rZq7eynrumJyGjMbmHN3mz/msZtlyiFBzDpgnIJk84oi8ocqa6EjGq1V6Pt2uZj4J5VnqaTOLgBOpnuPI5seJppgrhqlOxi130AQhiAKkIKSMCiAOCkFTDgEX6A3Zaa5sWpQ1CvMrVtlqtrP+7qTNnp35gDQdbuhujtMfXulBRwhEBe5WVepFbcpeCDHn6Ex3nv+HZuGINuUsXvg6hsin4DMGgU/v4KQPBqaBZwAi9w4QJvlARhEZ6KAmjeHejc3ROI+G432Q65DPdlBB+IEZ8CBvHwoeUJc9nxpoBoma4qFe/GAj7gBAYLzh0ICPhizVFu9HhsHM9x0eBwZO6EZ4iNHudW3JgAIrdv7v6VB0YD/1kdc4FgcbzVihfPWxlfXBpXItq7ai3n5EqAANAG0GRpCGXGAjVfjDI38yS5c9x+hB7+Yb/QpJSV8O5N2znXo0u0bUP34ysNAEJAZYttCDEAhwFwcBM38mK+CG/Ub5gWbyl/ivV2g/Z230hHJSa83Epf4vI+71J4hmc+ifJGWSI/cRx2jVkPdIaOb6aedHEm8kHA9EEYgB0QbqMIgOnZcV//9WAX9qkgBNV2dfimc8+k60DP6pU7iit1diun6GnHYVO39qdI70DyAoFwd0lHySqtdia08lIA7Kdw1AeIbfty6XNX93Zm9zcipwcgeFiXYPWkdwDk93dLab+w8EfPbP9RB3gBF3gfIniDbyuEd0KFB0CIFw01Ewj6NveJp/jptngLwnhur+Bv7HgADHlnYjPF+Ph2/neTR+R2+IFAUvl4b+GWc3mPL+7nVgwb73eSH/SbrztMYFrP4fmDX2I3A3oALPp3E41yr/mST3qYXvqdF4iMjyg/hi2pr/dNoi6th0CkP/vG4nqAT3tFDZyxV3vgtnm5R0m2V3e3f3uBiPvMgoDW1dy6R/vAV3NT2E+8R2a04PvB9/esX3zHd4lD8HtWj/OgQvx0f3ztpnvMn6vTXaDP/iQ+cIP8BfvNL33ebnzTp73Od56hb7XKT33YB0DNj/1AWn3PeSyCeATtJX3/2u99+0R932ermdUy1OWa1i/u1w9+5X+l2Z8rQXiRImiIOrgBOhB22/ecFSgA0Bf9pw98OqCNBDgJGXCA5eee5tccR6CNGyCA8D8IAnAEgSiC9tf669ecyGdvyi9iYa8DMwCIGwKLTHhg8OCDPDcQIGzo8CHEiBInUqxo8SLGjBo3PgTzwCPHkCIlEnBQ8IEjMxAlnCySYCTMmDIhHlBkMFGbRTN38qwIsifQoA/qSCBQZ6iMlw4F3RDq9CnUqBk9/pQalM4NQUsJCHT0oIjAGwnCOnhwQ4aEG1jpfA2rMo8DpXQc1KnD9YbKBwkcgFVrUNBdr1YHEy5ssKrhxA1l/zjI45BOWglsw96oA7irQbwCCTje+2DCjb4yZAw0mKdvEceKV7O+SLV1TBkEHOaRIOOBIMlmWyo1W+SoWbYHmTLMfdSBVr5D4+qV8DKBhIS2ceuGbf26T+yJHQhGCJot1jqgTU/PPdlMHri3PYP2Cjo1UYZFOOchcFs7/tWv82csUsQhAtEZNNpuBrl00A0nBdfQgXrJQMdLTGmlV1kJ/DdUZQEeRCB/HVqHmIdCieVQSgc5QMd4D2g44G0JGuQZe01ldhIBCSg04Vwh6vjUfjtKJJtDY1HWIm8IKugXHX2NaBBXBoEG3HgWGlRHZUKGdZ+PWUYFopYyceeQkgKhKP+jlQIRaRBWFH4mY4FfJQAaZWV1OadIPdJ5EFYTHoTAbA256KaRCNJB5X0NJnCoVxK+WOGFVNbB552RBsWlpBsxptpBjnTnpIyQ+nmSI7PFGKibCmFaKaoU2SlpSSclgJ4EEx7aphkXthkcUwVNwFxu6bH0gHJ1MCclhnXUJmtvqSprEaXLVkSUUQklNYGAeZgxQYrHvvjSiLk9V1aKbR7YIB1YOrvsqpHmQdpmETqwWUF/CvJuWX8uyG5JNjL3wFx13ZUXsY7i9u4NBCh4LsIONZtwRIIoeS2/Yf0W7rzwmkWwYKPOaOBL9QnkHMPKphsyySVrt7DJPNmbMssKf9T/MswxE4ayzCKtXHPKI+O8M88b0dwz0EE3pLPQRRv9s9FJ10y00k0v7TTUQDMdNdUkI1011iK/nDXXJV/dNdhdTh022WKXfTaqY6O9Nn9fs/12a2rDPTdrbtN9t1Vy4723VHbz/XdPegM+OE9+E354SIIjvjhHhjP+uKpbQz65TI5TfvlBimO+eeace46R5p9fbrnojIdeOuSko3746asvrrrrgLceO+Gw07737Lf/bbvudOfeO968A//278PPLbzxaBefPNvIM082VWBIPz311Vt/PfbZa7899917/z344Ys/Pvnlm38++umrvz777bv/Pvzxyx++5M9T7rz9XS+f/z/0/N9fv/9eF8DUAXCAtTOg6QqIwN0tEHH7a2DU8AfBpD1wgk2ToAWFVsEMHo2DfNtg0zbQDDQYEIMe5BkIk7aBI6QBDSQMoAlPiLMUFm2FaTCIC2Eow7vRMGg2REgO+RfDHcashz37YUOCaL8hErFlRtwZEh2iROYxsYk5UyDboviQKRqvim8jwQsx90SZaREiXASeF9dGgg2sIYz/S2PKyhiRM+oOjmVbo0HaKEYslk2OEqEj7ewYNjweRI9vnJsfJwJI1wmya4REiCEJ2EiEJZIii0TdJLH2yIZEMoGZXFYlK3JJ0X0yapt0SCcdyEeuhdIio/RcKZ12yoek8v+AsZRUKy/yys3dMmmzhEgtZbfKquUSI7sc3ep+GZFgfnCYUStmRo45uV4KTZkSWcMGVElNLUFTI9J83DZ7Zs2JjPN4zgwhC53yTQF+rpzkzObgxniuboZknaxrJzxF4s61yROUSbhhVOwZT8/tsyIFLVs/U7UBEhBGoAzEXBqwuZODhi2hlVqoYRyKO4geIZ8zoaj+zulDhiZGozy8XBo6GhSQZs2id8Loakxqzsml1KM9YWnVXDonmLJGpsSjqUqfgtMIihSKJIWNT/kJuZpKZahO02mWeGqdpJ4tnCVjqlWcqjSo7kiq16Fq/xaH1cFotYNWhY1XscPMAyJurIT/KasGiwqztGpnrcI8nFsLA1epyZVldMWPXZtJuLwaZq8o7KvJ/pqfwAZvsEFtjWFniFiSKZY/jPXd4Ai7msjKjKv4qWyHLgu3sypLs6zhLMw8ix3Qeki0zfubaSFr05ZOlpJH3UiDFONa5fEttrBB7RVJaxWvjkU4xQ3ShXK7k5td042CvZtvrQNcr9UWlLd9UcEM8i7hIIRYytWtcxsL3ceGaLohUy1r6LoXkyAALGwxw2aYYqb5mGkogRGWV0IFnc4Y7AbvkgB8b+CVBIGGK7FqS2hO9YDdVnS8s/WQeROGXsX8dS8JkIEZ1pIAzjygRt79z5PMoJLcTIAoZqAL/7DYciLQFEQ5aSKwi4qQlMbUJ1l5DO9M4Rbd/ET4XBM2jGL3QqXoqIVdZvLuSxx1IgOBZyEvKgICwCWjA40Hxizi0IVpieOf6pi8WuoxuqqLy+s2xDNm4BaEOPyiPh3IUSLGTYJMjOLa1GhNHLOzlR8wmr2kZ1+o3LJS37ZjCD+YgmJ+KZnLLKfMvDcsdMjNWdpcGbt0RVgvMQOHHSEBx6SIyk3JM4FQo2BIArqqgvYyncCctkPvNNGF+S5QGJxTtg16R6qW1I+lwtqoIOAGo451qRuMtlr76NZ3yjVUdo0wWUNNuDoidpaMPSdkO0XZCWP2Bc8G7S8XumfUDoq1Gf+GbUOTbdtdknaWvt2TcIds3EVzNn/MbRFYJwbdO1L3TthNMncHDd74IfZx9eKXMifXxjKh9zvNSllX74zf3gYbtMfSp+0i987XsbeH8B0T0C6gBGtgw8fZIHI2kIDkbEBDC5zl8J35+zrbXu8E2uuXABNAvpG+y20oLWD8oqRGm9ZLf/8bYK+4pMA3OLCoIYLxtrGaP39tQQlIQAIRpHwiHSfBGkSgrJU/LWvmtjCGNcxhDycXxJV5M4nlfBwVj6nF/0lT0WM84/TUWendTm3TP5voBaxhqCLoe9UlxfUieh3VFRHy0YNj5LMguVhL/kqTGaIXKEv5zuOJ+5Xvk+X/iCz9ZHlfLZnRcIRgW6QFJA/8nQbvRKzJW01nDs6GMbXhO7t5xHEG8JyL8pJO774pmNfz3OFi8IZ0/joa54hX+U76jKRB6gBN/fI7SLWIoj4jnhHUAwKsFkjLQNL+qjRzMO0YTXN6yr13U4pCPZBfE//uJju+RqTafDYIpQVJ0HqkVP/+6a/h+fxBOFAUX9x8XmtI1QYkgfvFxA30X/5FX79FTUT5X370GvutVAIyDPxdhFShAQlIIFAsQDMcoAdmif6dF9REoCxdIMJkYEVIFRuUgFSA3AO0XmukFG01DQpCjQAmBgtOhFSVYEQkwQtFlApiRw7OmtIcoUMsABqA/9zIjVzJoUERSsoOFkYPRoRUgdFgSADqSVSWtAAD3qDRKKFBbEDUgdHdMaHUlUD1nUsVDsYVPsQGOuDGCchBpFQbOl06cU3LWYUSpoHHsWH8sYEQhswb9g0BEoZULQDDBQUaJIFDpME/6Qg9PWDRHGHzwRXfscEIogoCskwcIoT8QSJhrAEMOgQbhUglWmLQ5GAanN5O2N8pOgsNakkoluF1TeLMLABElAD+5ccqsmLP5OACfOIHGuOy1KKP3KJXocEv+iGbPIQuakcwCuPOoGDzzWJQpAEY0B8tGp6zhKIIXJckGgYRHIFEtEAjJkY1WmPNoKD9TSFHpMENFGMn3v+JMoZIHKLBGjgEG+ThU1SCGwDkQZAAQQLZHiLUMDJgO2KECKAjGB7knORjh1whP0biOgZFKUAARTTfdTSkO8IMCupbSJCcQVCky4HjqrXcRfqjRAZFAERCRfwjWiWkqeHMSGbkThzBL6KkdfgkdrBgS6JSYhQAJFSEOhagTd6kzIxkPw7GDfifJN4jnQDlhyQiUAxlEj3jYLgBIVjEU1LYUjKlSDLgVA7GAoCIDX6jPOoI/GklJyUGJBTARYgAVw4GSEpfWQJUErwkT3icHOqklmSdj2HlTsAlQkRUYkRCAGCEYK7bWPLWXhqELxZGIT5EZW4dHS6jYcoEYiKEXcr/5VFexGPmW2RKJsvkYFIWhgR02zQK3mZy5ll9JkKUJmsIIl6eJmqazBG+plS0gB0+xGrCJgZ25kjQZm0WxiFAgBu4wQogggbGpkjkZbalzBEyoWFwARFMBE02oAmGE3ImJ2EUQAEMwgPwgRsYwkV4Y1RQZ3VeVRgaBCkSRiPsQEfaplpJZ7oZJ0eE50GYHmEYghuYp0EMQGNaBH4in26+Fnz6H3YWBiUMwEz6JWDp535Sk38exALw4mAgghsgxCM8wnq254IyaMiQYVgSRih0QkUoZpcAoef1UoZqKIcGZCdQwgMIKIE+gIGSZrKVqIkmDBkCqGGswGhSRAcOpoXa/yJ/GlOKUgRuakQfaAAKjMIDFMIePAQPBMAK7EAojOYKlOd5pueIVhuQBum5kOEDROlgEMKHWoQILGkpyumFItWTUgR7SimVFsKVZqlBuIAkpIAGOMM/HKlBLGdzPidG5ClkUmWOpWl8QlJibCRG3Kll0Wmd9pSlcmdITOkfaEAfYOkDuMAlaEAKSAIj9ASjmqajPmoyRup/auNgQAKO+qiOwCjTfdKM+mOrQsSUMsIeoICoPoAdOMWqyoR7Yk0fXoSa4lBbllSNXirhZdKuOoQIRCtG/CoIaIAG+OlTHCtMJKuyQuo9JmhiQF1rYarZTFK1LiG2XsSvXmm3RoW5Sv+EuI7rq1IluDoFojondNrqYqnrupbUplrEBuhnvDLCvELFvipor55UacGqQ9RrSJCneaKnelpEw64Grupjk5pRwZZpzdyrGFZKszbExvaEjh5EjyJowLLcx0pRyAKsRlgALp3pRqHKySLEAtxlUDRCKTyAh4KoiGpshR4WHLWrRJirHaDAA0iCHuwUzuaspOwsz77rRXArCDzApz5EDpRCKKzACsjkyhbogc5kXQnsscXsQSitRJTAs27CJjxACnxCl5BsSFWtxELEhoYElTpt1x6EC3yCHmgAOERCIyBEmF4smcIp1iZGx8qmVbhtOsqqRaAAJzwAB7iAUyxCGyT/gkEowgGMBN7mLT7uLd8+bkVowB1wwB0E7iagAAdogiTkwEP0q6JeRN/CRuRKbkDN7EYAr0O4AAc8ACc4bed+buiObkiUrulOJOqmrt/+wR2wrgYYxCcUqyM+a0/0ru8+BeVCKYUexCdowgPI7VN4Lug+gOg279TeFfQ+LI1O7yigALdGRcpGhfd+r1D4JygUQHMWQMYiZf4ihB5IwgOggPYKhee2gQO3AfPGX5LCUlVGb0Q86EZowB9w7f0yLGT5LMzGkH8ewg4ULQSswI5ShPDeoTLkAAwUb/oqL/tGMEaQ5ENpidVKRAE/hAYbhP3S62lx73eqE/DyAV0exA54/4LuOqDorek1QIX6Lq8EY1KX5PDSasn4BqAQD7EjCu8jcORB5C5YPqwpPkAzgPBORPEMZ4QNw++OWLEOhwQM2C7LHGKMdrFFGDFCJDFGLEABcyE9yq9IYIIOIB/F3vCzWbBBcUQOaIALp4DJ2PEd98SMdgIhHIIbmDAKZ4RBUkRaPsAjRoUIHEAmbEQbD9QbK3JFXOtGQO0DlG/JSPIkHybpQcIKQEAlPMD/BrB6xiSzzifnMVQSWO66XQEOmPIhu3GHwPF9boQm2O0lZC4Dy3D7ktUW7x/yjBIhhMIOsGhENEIBhMJXrjIxIwQY8CIXQkU32EMrTHEgUaJvisQKN//E5jYyHQeFGldzU10zNtPyRBzDDgzAOEvEIEBAAQx0wkEEcD6ACDQDVKyBEqSDO7+zh4gr3GZE0z4tJCfv+uozVMhyfuzPJQECHJyAoVIENyduRRwBQHrcQiWzItGCLcAAG8M0KuuhILeobaJv3cbwA0PwPo+r7VzSG8yBJciBRlDCDhxDi8JqCzVDWPDzH7GBJphvDdv0TX/W+5KmICuw5nIuR0vxR0t1cMXEIgXCFExBIIQEJDyDJTT1DfkxVB8B3KZBM8yzN62BHXDAPbegq+UzDU8TTjMrGi9hOQsnGTB0DEAxNQe2FvMhqwGSHFjCHLwBTKC1DCB15YKBBID/wdRJ5V1nZT+mgM1qIMMBNi8B49QuQFo8Zjz3Yj/2Qi8wdkc7Nk+AdMYdGiDFwRLAASDIhBzAwRT8dkOkwThy9jCDo13j9Uy+UF9TRGWh9h5R49SSgASgXDOEYEX4sUWM0EeQ9UScAiYEdUhZziK9gbnIhB/MwVo/gBkewQ00AxtEKwmU83LLRBpoLQeb9kQ08APbdgKtFs62QHYHHhtct0G9ZCBvQHDWn0cLBW57rONcEm+X4U4gABgkQWe3USeKQF8+xH2PhIf/7X77NUVINzJ9JM6igQQclQjEtQS8dmICsxmhI2BCxTm0gSmMdf8YziuBASAs9IVr931yYiSG/zZH2B8Jsa7rBq4P1oNNPABO6IRDoPj/WEcxeYAfSEC0ajgvSiIYuJ8IHLZ8wuAZQ0Uv1IMq8HiPb8QuyQBDhHlMPKUfWLbu1lKIY4Q6GvkDaHD1Vi90k0BN3EROPISVC3ZN9qoNAAA0eCCLk1QJ3MDGeuFKtEALROVTiEAG2MMpCBV4dxZiHdMk+MGCkbkrObQcALlGbCLq5bknl5z/aXD9djAWMtSgS3mh904sFRMDCAADRASBa7cILehpNjQo0/i6kcAlRIOn85bbSFMgLMGxw8ToPcAkwEFImN4ww5OrP8Q4aqFD9PCnXm+tG8QB/HSuN4QOHAC7szsqpHZ62f+kDbyAAAjAC/z6A3hADQCADeCpBMBgREkAGp9lQ4ChBBy8qY9ESlkD8kL4pz/Ns5fmHAR5g2sEcN7QEkieSEAd1r2gBIRlC2xo1JHcizeEHVgAAvdwAl+vJEizKB7VrU/5Q2QCuo/3dIulBL4ABRgEKXzAA4SAKFSAB1hEWk6iCLQ4Fu4hI0L1MB89c2NERPECByzwYx9EzKc7UdmNNMH5A7SmPvVjIMzBuoGgBIhcCWxoG8ZBPxTuJWwC1R+EJGjA5r48Qlw9lc/EvNf7vY/WasjRC9QAQsyAKKQC8yXBOT9ACxwBkUtRMyRBfE+dKH48ULBRGlhA1Dp8Q9i9ULv/efSN+gMMs0h4vR+8NVB0+wPIwQS8ARyAwRSYAyc8N0JsArdqwOW793Vp/sz/tM1XhM7zvM9zGUKOoA18QL3XQL/XU9kbxIGHkXGvAXLzJEQw+NP74CTCAFhXfd1HuczPmo8vX7SvKbLrEqpPvFDcN+pbwhSwviVMgGZLhB3MPrfabBtjQibUfybsuEX8vXgVRi4BxIcXDwgWNHgQIcEWzZq1eLAATBI2zW4cYbOBYJo1IhI+2CBhTUeRIzVoAPHgj4aRK1mSwIjwQBuZMhextHkTZ06dOw2CeeCT5wM0aGzOAfQx6IMjRBHASXozAZgpYOC8ibOTE4eSJVmQ6Kgq/5NNTJnIYsJp44MAATVsPHX7Fm5cgkDl3txwJI3IFwwIfqgBl40Eh2hAisiLsASJwwc/hnSrUQMKFChV1i3osuMBRQQTtalpGXTonT7p8hzKUsakBxJe6mwhIe8UBKILwpk0aclTGChKCulwqiMOVDYzzQy7UyBt5cuDlmZO8O7ihBTUCngxI+7LJCVWtlhDFGHjpyXWpNFwh8OdlDc1c/Y8EnPmzQ86f35+XzRpt6dHTpLxYDueSAgpkDmYM+oNP9zK4RLfNEghIVRwuMkUTCw0ZaUZKojggb36quEFDvEbcUTnmIsuJw8sE8wmNNZYIDyQTEsCxgc0+OOO8ypjqf89+t7rKD753LOPxCLd0m8/8Doq8AHyeGLtAT8sWS6Q3GSYza0N4ikpCDoQUkUVnNi44QY2RPKAugpUpE6t6yIAoIYQjJwzNBOVQxGnCEaoS4RmcnJRSeiaccymNNBIItAbR+Ftx5V6rA/I1g46BTg6LYULySRHmiOQDexcCQ0/5TBquUkUJPWpDbz6pIMbWDSIneFuQuOIpTpiQJQasBuJAlEq2PXSYHn6NDQ8cfJAABXjWoM7nUQYkKOMBl0pjWeDLOhGyhodKaaZfjzo2oNYwUEHYc3VKVNNO0ptNYdysrUp5q6sMkuvCFpAghv8LIjenBb4FyEErHhBTps8qCD/il4AOZfhlYi1zNicRhARrld3qnYNEtgQYYFpD1pABDZIICFag+yQxMY/COKNvfkgBVdShHCQidyGbU4oXXUD/g/RnF6LDUvljDI1VXsL2oAiMwmyZMqcyLzBoDjgOGKCnQDxY4435LiZ65+eizgnBvaEq8+4FkBjojJFZmPjGg3SxQI9NLjkk45ySAFCkR79lqBwD0LF2wMQ8qAGtUQhpWs6c9bZIEAMbMHdmwZ8gEkqDWQ3KFUTSuOIG2pcIhCd2FYaEBmyfioQOJYIOnFzH84Or6RmSBauNZSWKw2PD5JjgjfgACOGTTjJQSQG5yZeSB+J9PsgDGZaBcODKBjo/wEG/mq9yMUZLwj0i/OSkjn/HuA0c6MTWgOMNPrVCe0N3gDDkq3fmmCJKa7CPtjX3wJ7pxDhIiNmcMmdY3hnialMwRITkN9IjKeHHAxvJ8w7yCpm0orpXAd/c9Le9qKkGp6MamHLSU3ldqI5UCWBaQKSAFVCKJdJzEEGC8xg9u4UO7eI7S2cmExociEMY0ylKve7iQu0ookHbEIDRuyIDsIEM5boYCYY6IgHPiAK6/BlhvfZ4PYQsAQ4WOINYZxAHMi4kngxB3QI+E8JzTeSWDhgCnCQ4xzpWEc6LmEJQrSMHIrgtiyWiDb848kMqPEWTWxCNJaoBRv0JxJNGFETx/8TyStY4USWvEImF6jUSBhAuz8uZ4uMkwMZwxjGOU4FDKmcowxKuTrmVOIZD1BAoOzSxpHEwX5k1OUuecnLSTiFNkfw4yfbYACCGKANdRKNIIPSjJIFhQMwEA0cJjCBKbjFAseTBAeQZ5BTtCF6fQvg5q4gE1kZJAIcGgHiqieKDxTsk/nxmmj4g5NRkhEBpVQQcygxgAesoBE6MeFNpBaUggZzmH8s5jGTCZpGltCGcXFSUnZDGzDI4Q1NS0oONsFRDUQTITq4gEEkiJgbCOMJBwlBDQCQigeQAgBqAUAIevWreCrzoUGpZ+tC0YlK7ECgtlzJQXdC1NAI86YEWej/A5CpTIhFNC6vecomEBkaXD6AmnCxQ2RgYLuD8KOS4sQJRZJgkBnUQBRYnGIFREEBZSUVU/OkzU67BlBKQCAnA8WJUXPCV8sgNanekolT5cJMtzgzKSiQZmgy+hMZPkUSvFiDvgwiBzCEsKThcdVhAEEOAbjVJjaoATW0Bte3hDIudLVZJdzwgFBEAid63Sswi0rboyY0i0ttqkPrYli3OGl0wWWBBYhbXAvYwSAuoA01r4q7ZiTBO+BBwDUfkFmEkMBzD8DoHPwArJvgQ3WsM+1o5Koc1TLsrg8oACRqaVDb9vW9f8XtDHXbUMvklCW+zZIEHhDc0Q3XuMS1Qx8i/zOKBxRiD3XCqEbjkobcUfYB7LIuQiTgFQTMAQ6hCwr94KDH8eIEtXI5r7kgwV7Y2kS28HWvcgB70/oSNktQrdMzWUJgFBTiwAm2zFWzapncNWQNLbjshA/SJ1zmES5vgGELP2yTEIuYljdNsYp54te6tDiprzCLPPcnVNCswSL+ZQOAAzzgG2mgDwgGTYJ+wmTcaQQM3JgCkQ+iBmPMwYNxkYMlwFDaJrPkyVA27ZSpXFsWzzeLB9gyjMv3HBFIQMxsI7NxzcyIPdxYx3WBAwLikBvaOHgqySjlqEldaj/0+bFxAYQ8cvFnQJf3OSOmEygK4AY3FMAQIyF0oXViZf+5YPmmirZovb4mARrXWAOMAEFJMi2XyxJtORJIQKmpTW387gTYrkZIoOsi6yIdYgePIAgEVjCIjuya1+mW73iFzeVGMycNYGhWTgjMiANroNlwacQKHjAASiyHBNfuyaG1PRJudzvKc+JDAQyyA08kBN3qvokd9EBw07ab0Xn1Mmh0R+9kP4AR+LZMJ0LxgB1UQjm98FRSBP4uRBf84AgX1iPwWpAVICI8Gzc0TyhucbgSA7nuDup91tAM6ZzL3/tWDmZaPhefF3zbsB6Rt++z8IY/3CBo0PnOd9JzhI5XD0HPOIq3Lhd9wIZrJ++EP0PDuZc0XepXfrm2Y24ZqjP/5xBuEPcDyG3ugrhox/GdeMW/btqwD3voz7EDB2bBtUYAdQCdaPsRWgN3uNsk21B3+uXhcvfl0NrWuM46oeTia5Z4XTSZ/+PhhU72+8CAAyjjmiEC8IAABNTHlB94c56u+YLUHTSeLxLgQWP6laD+tmAXO29jW/a4MMgCvqeW7nc/rN5LH/jBT7iliF98wQtL9VmUhHJbr2vnx0UPeZN+R9wedd4Xfv2bN5fwY036wO/ExgZWM2jC/5ZDQMDWbu6mHiriCmIR2iARCEIRBEcnNuESuulmQO/Wcq3BqO8gLO/6fC/7QoP+zMv+7k8nbAzH9g8uWqP/3KIACsDc+MAN/yiwLkriJNaD+fJLxjriABPwARZQJ4iI/LgG3Pau7wTIAi+Q5TJQ8zaQA7cPP7pPNPzg+0aCwFIizfItKBbgCOiiGW7HMgzBDfyu32rPMiJjMmTwvmKrBhHiBhWQAV3N6grC4d6i/ToC7oTACKEOCZOQTpgwNLBmCartDQKsuB6g3i6NBINCIyDtXq4QDJph7ngCEVqrIB5h714QPdRjW+ICv/TrAAPnAXQgExbNtGjOIATwKeJQDpPiEuUu/n4v7i6lA0XsAy3DD6YgEGQAfqgNEIlLEJNt2UQuKUoAJBziEJUmMMqjLrjQCwcADOPCBXLgRnIkR8ZO187QABFQDf8foBUw4ALagBiEp5tgkDKwpw0J4g2TwhRPMShS8dca8c/ukJ6UkJ5isS5mUQ4KRLyQzd4KwRd3AiIYkSCKMXIe4BDn7SkooeRWQAUfgAUNAfcWJJskQVEY5QE4YbEwEaKOziDSMAfX8AFO4RbiZm4IQgzDsXXyDgjLzRyHEB15Qh3j4gRdzR3fcQnlUS7o0R7x7+NCLsH0QBMgcCRaIAkkoFn6cb46xh+DAhIKYAXY6/8CEOdWYAX+LSk+gQP0QLmyJSVUgiplL64u0gatcSNFYrHOIz3IMHEkUPQMUSVXcidaEi5esh1bUVheUadoMi5scg7ucaNSgAM4gVrGRDH/HgAoJQAeCQIYoUsnKgECdkDyRoISoJK9dGIXUOASxC5bHoBlHmDxMGCTnqLp9AsnnlFHVjEj1pItdcIt3wIumywm56ow30IPQQMv9dItdMgqO0IEwED30gAwMZL91gARbaIWvSESCOEmHhMCPEwkpGYJuHIlTuEALgAV8GBCCAIH8ABdkgI0bSIiS4I0z9FhkmL5+I8dWVMu5+81kyI2ZXEKeCcvRYOjOIAGGOMKoyU3TXMlOgYMXu5qsiYYduIbMEw5G8d03mAnMqEVqLMgrjM7tZMacwIrvTP+wDM8b2Y1eaIp3YAULaU1zSs9d2I95YIQfKA9EQAMaFMudIEh/1ojZPLiLsDg2HLiMAOSILbLD9wsJ7ZLBnAUo+An1XBCQa0TO3OC87aTJFQGM1Pzwyi0Qj0OBfSPCt+yPHkiBVewBS+lQz3U7uzyLQYhBQnBRFHUMgIjMDMCu9jAN3UiDUggOAmiizIMLmy0hV4IDnBUJ/BAsIYUxPbnQXewBzWPSUciEAROBHNMgALjMGwlNJCxIJQRS8+TYehSJEI0LgihSinhGcQUNFrgCmFkRnurPo+sauriaiSgFybAGH5hQHciSB+AQYm0BPsUJz5BiQAVP0XCRMGgl3TJDnrVV3t1F6WwEIPiPjGCN10FMS3jEQ1CEh+V86buQ0GFS93CS/8LgBAoYQdAwUgIY4WmlH1WKM9Agw3mYA6AQQufolVfdU9jNU1zwgU0wCf/LFBx9USnwovsSA/yVV/zdRctDdNS5QrBo1jXtE3jglEJwlHrQg7sVCSylDkkdfSWowBKDlsbskjSAGqUw8GUg23661yTIl319Cae9Whk1SZSoG4Kbl47IkzlII5+VCTqrRejtFDO1EXr0yBe1FtFohJgCyGt1BCMM06VLFxfjWShVT2n9S3Yq2IvJWOTqmM7VliOFjpMdiVugR5U9lZZNi9ddp88Lh9FThdxgjAQc03LxDcJ4whoNCcIIRLcoPYyVAALAAIiMymUDE5hlWrxgw2iNWL/7yMSLHZOnvamovZjNeip2vUmcAAUx2tlE+LCAsFreaLeQE7kYOASKpMl9LNGypZtDeJs0XQnOmEHIADlOsJtd2AATlcn3nRVw3Nv8eM72Edpg4IPdsDWBsALg4Vw48lwXQc0jPQrpKjJHjdgOGVyLYMqO6ojvCM4OdcucPYmJoEL1ssmBiESdiAUGDYhOs2VeC92ZTdaKfUtPMENcO4QCoDthKV3P+l3p7ZYrLYjTGGklnRrIRd5p+BrLcMF9AAFGgAhijEvnPdwQUU3P9cg3lQFEjMcwOBGhyq8jgRSE2d2WYJ83yJhH+Bgede03jd/lkl+fc94DwIW8nd/Q4MT/8ggWYUCsATYEMdEdBGCOTV1JPrTzw6idLIGZvUWrip4Ums3KVaADwoi7w7BXNr3jzz4UUFYcRNCI3XwpkbYILB1GJJ3OQiWIB9CN3c2ITgVDALFhuEih2/4alDNIsOXRHwYIS4YLjJ4g522g81Eaj84kEL4AZ6YI7NIiguiYgnBCk54OSBC9ziVMPlENzegR/1gh6sMDuYgAeS0LhzWSNT474D4KR4RfdX3XJA4i5SYQ5djAywZj+NpjwmijyfWSMZkssq0Lo6VhUQjFoQBDAjgCHgLjYuEktlYLm43d3cXjuHKkxXnRM7vjgUrj/GnlB+AdBvh8UpuTjwlRuWiBf+i2WyOABCs0JabzId1Of44eYaCGXGH+SZGWY/vNyFur5kv5UJvBpuxuQxveZKJgpu72bQiAbbsGXi/xvnIOYOS2SACwJktZZ1tpp1r+Z1dbQ0SmjRtwpszCJ/xGX7vowD5GXv2GC1dMFgGumEKOptdzW/pGa4e+sToWKKJ+Y/2+AfHDSXBj4sZhqMPeqFjmiAaGn9EOp/xowA/qZTH0eSwLqNb+lxeOpInWKa1jaaxx6YjekRyeoY0YpxGQhRtDudYGq6E2tmIuqj/7KhbJ6lJeqlNOnE0ookTgqfL8aerupbdeajhOattZqsTpxJQLq5vmkSYOqyNcSdMUqV9mU7/NNql09qg17qtV1EO3nqwre+ZwbphxDopLvpc/DqoAbujD1vzJmAODJuyYZVO7Hqx8VrbINtcrPqMM7vg5ABrJgCzb4aX3UB3lTqxddqzPxuozcUXfOABanuySfvDOi2GHuAGDPSmzDeT1/eTL4Wzg4WxNQ+0hQUS8Kq5c1u34coS8OwBAAEOCGAKevuT3LgLvXqzFXtOklu5Z5u5nbvmBDu64SoQpmAKFsay40cOZIAWP0mIidgNjHiJg+W4jUS8xxuunvu5YTq942kS+ky7TEePlGxUZ4i7+ZqGzGW/R6S//TupAPy8r5qtB1w0GoFEQycOYCjVLqxoWweTHyB9/4lbmM8lwp9jwin8piwcujW8dUgXtvbsPZdkCfzAwblmtVvbu/UbvK84tqWPAMg7WCrh35A8xmX8ZhRzKSnHi7iXIEa0AFiXyQ3OZlZcNFoc6tZbGIwc+7D6yuekFHYgAMztHsBgxEUiFHZAcMecCLM8yEGDywuuwN9guddPkuE8LiihFB6gElJwGHSCEtxAKvk8zuUcuYcc6qx7vpvBS5Kqx3e8CDMc0VnCsQmCxoPi8cAw05nc0rVzzgWI0QvuwuLHuufAAQA5g4TbxDUZvS/dSFKa71AyAJ48KQYhoGg9CEE9cbT8MUrd1eIbyV4I1V92u5fxjU9LzGXdMsr64f8qgdJ1AtqvPNSL5mKF/c8sO4aIXYhMu3uyqL4Joohj3dlHJKoJYkPjIt3/aapl/NqxHT/qvMkIQQHmoGq4PdVeiIYZpsHN/dyrjuHc0Kfjotp9HXuAPSfo/cMgYQUGABBsfMFleA4YjMTP99VRnNnjPeDJXe/22jL0utannbI5Xt41VtvHaxACYAf+rdPgYJEfoA5OYACEVhxxl7VJnrxMvuM/vS58XsN5XtRRfqyTqhHo1oixgLptghAGoADevKj3vOOn3kiEfujbLuXHqwAk7+jBQcNwInv//LClnurLXov+SOE3J+ubrBPcYKR1oswbs63J3uyNhBIO3do/Ke3/QXft/yjTyQ3qcaIRGlNu313Pm73uufrtER7tR53viz6LeB0lKcHm36JKFfJK44/uE39EIHrMrb7L4LDv/+jg5WKDMzjMQZ/z68Lz817KRp3hk6rd1x0uljUSJzH1V3+8Wp/x42nFY1/SB54cCx4uTn8Zc1/34eoJUgrOVb8EFRv4k0rke70ufhbzMVoDET/5G4Ys+Nz5n3/hRz+pgD4uCp80N3/7laP7m//DmDr60//D0B/+Q2P9P7/JCvD959+05F//AeKBwIEECxo8mCnTwYUMGzp8CDGiRIZgJlq8iLHgBhIN06xJkzGkyJEkS5o8ebJiRZQsW7p8CdOhDh0x/2vaHLjy5s2NCz2C1Ak0qNChElUSPYo0qdKlL3MyLcmzoM+nVKtadWj0qtatXLuSdOpVYlSBU8OaPRszK9q1a9sYEGigDVuhYOcujFrWrt69ENXy/cvULVy5gGHWLfxgY17EjPX6bQzZpuAHcSOjPIx4Q5KfljuHfew5dMk2pEuLHon5tOrVQ0Gzfv1wcmXYE1PTvo0b9QPbuWnLJty7Ie/gxIsbdB1akIQbRUzWuUHn72/jC4cbz0Pgxg2TMhxQX4vcriPtNwgkWEjA0ff1fYmP125+oSMCDBM0Z285PFsCDiYIdGTGQhL4h1+BxwXHH4EALmTGeQvZZyBk+qFFx/8NghgkSHY3qFcEeXQU4eCHD0ywoXZ1JKBdfw8kIEEeAjlwHnQPFEHAcjBqSCAdy0kQXYRdWedZhRcWlKF26qGonQx1aBggieTV0aF2AeYBo0B0OHCidyRGKYMM2t2XR5RFuOijTROeJQN9BeUhgQwPKBfdDQSCaGVzJLr5QIX+seiiGerREeADMtJ4YRE8PjDfiDJWWEeZWwHZWZoGsekmnDM66EBzdVQJIZE3IPCmBI06cGECWm6o6Jh1SAAqjXlgh6ejhu1WWBH3EYSABAN1KeicIdq5nUBmBPrAoVRCSeagDnaKwHYLvtijrFVBapmtBuW6q5t0CmKhQKaueCv/QXSuKAMdy546kJwCmZdHt3l6J21TtAImaUFIkuemupfWqehARcQ6ro4OChrduJ2SOCN52kUbL1PURlYvQfcmuS+JjfbbaZ5R3jBwdgN9i7BA+oLoJHnwNszSmWYJWRACahI08q/9CkussQRserGy3t6HsCPqoXzVw5CxjOvL/p7H7ZDfdvocngYnkMDPIAfbq0Agtksm0C6pbFaC3prBptIxEmhGcxkCO5CeK7b4QIPgilzwsjxvN4GuD+RhBoFaJyU0ZF6vCLYEYu/7QKYPbHoen2+qO0GVyr064Iroiuwr4XTEuvdX8wKWh5fwIe0AfP7pu+kNmaL9cYp7sl14/4xx7yxQyBV+eXHmR/XdWOfkxSdI6OX5N+6SUgqEnYme85cAlSFiOXW6lRd/gwQD2y4S19Rf/xTu2G8flPXcf08X+OJPu/n45iOl/fnq65b++u5f1P778rcX//z2V3d//peVr3//GdXvv/t5L4AEFAgAC/i+ASLQfwdcoPoU6MD8NTCC44MgBec3wQt+z4IadF8GO4g9DoLwfB8coe1EaELxlTCFWkMhC7m3whc2zIUyvF4MaygrGuIwczfcoY906EOg9TCIBQIiEeM1xCOux4hKdFQSm2gcJkIxQk+cYnCkaEX8VDGLuMEiF7+zxS/CxotiLE4Yy7galYBhjWxso/8b3wjHOMpxjnSsox3viMc86nGPfOyjH/8IyEAKcpCELKQhD4nIRCpykXrkHxpD+EjwkTGSXaQkDB1pyb2dMZP5wSQnUbbJTzZmkqJUTShLWRhSojI0p1wlX1Tpyk7GcoaenKWBWmlLtsAyl4jBJS/Psstf/sWXwvRKMIvpGGRSsZbKJA4xmxk0ZkIzN8+cJlWOaU2zVDObS8EmN3/0zShKU36cGeE2i4MGNHTQm/hZw2ZSeM7goGEN6dQgO9dDz8XY04HzFEg9KXhP6tCTLB8x5wL7OZB/OjCgxRnoQPQZwXjeBqEEUSgCGRochxIEoguUKGwoWhCLEhCjudGoVAr/ekGPsgYNJWiISBk4TvGZ1CAcHWkAX2oQnEowpt+b6UFqCtP+6TSn6rSpSi3j056gtKNCLWpEhio/kr4mqQwB6k7zB9WFZHV9Ul0NVTuyVJveb6tadepOj8qYrzrEqhgcq1kvQtYK8tR2an0IWxNov7i69K1Rneve6gqRu3J1fnp1SGG311XPADYigiWh/A5rWL4OFq18WaxEGitX90H2IZvloV8bZtmJYFaSmpVsSTrbws9KK7QWGe0l1YdaiMSWlpSdCwkWEBPXQvJ8s5WtaUlb27WQYAM20S31gmuX3j71t5dErlmGqxPjenZ8L8UDDgaCAzycRLk/VG2EoAsU/+mmVnw4tS52tbtd5trQuwUCb1DEC0rymta8AskuS7hbRPayx71CgS8SwTdUPJSGNOhFCX7Zk1i+8Hco/s3h96BK3wfYtyUHBqN+qbNgojS4TM71SlYjPGEKqze1HbZKho+y4WVib6sgLrCIgZu5EyMlxfm9XoVPO2La7k3GSaExgm2cY4JgQic37k2ChUtcrfjYwraDLHBsUuRKlngpPGbKksWZuc0+GcpB5vCFcVPlp1zZmVnuckG2zOX1ThkpYabKmI28N9SeYChRfs2RvdLmqry5kkCLrRuIUuc0fvk1ebbKnmmz5qTM9s+ANvOPEx2UQl/l0HZGWW8Z3WhNDv9aNZJWclg1HS/lQkLRjqbOna/S6a1Q2pShLvVWAu2ZU1cl1VxZtWggHRRYC0XXkZH1U2jtEH1p+NO0dBR3H+GGZPNBKbwe5aY70+YOXUzaBhmXsE8SMrsSW1q4vgl3A7ACQzwAFDtYNqn/222X5LlD6nnODWp3NMopxdayjBB+d+CJgfChAEtpdiqfDZlC26pFjpC28G5QLg+VZ2Ergo8gWFSHVV3pPGxCQBF8d/Ho1QFhNKLYwX9G0HJy20f4PYQbQDEQRKyAKf4eJsAZI+l/FUFHjDKDm1YlCGsnjlTdkkFz5hOfK71rRs1RG4w4Dqw6DCtUensAvZ1toArjW9///Ga5qxH98sJ0+l8Vytu7fbcwa/vnSkIfEbwcoCY2TYAArwsZybZDp+dsqkczP6nIvVygGz8i3OMuN1Vansx0myTV/yrWBCxmc3H9TF1XSlrbfn7xZdXIaudxewI4fh65L51bTQ/5f/ETZWQr2yqAn4uvh0Lrwsfu3Qd/9+zUJnQkEeDhDsgDt6LTLgfRyfKYPxzrNQTygrTgCHe/JeivfhEIUGLWyGe14EcCbJvULWsu2QDxHbwefzdiB6WoCmvHmHW9RN8m6bGJ9Yv/4+8AnhI7aERJRO8Gc2fk+6w5vU7Gz5jz4904pX8A+91/EYRQCQIBbuJGbvKHEfTnfMGB/3+NoX8qhk7NNxKRIAtyIBGV0AkF4AaRIBBTJxD7NhIKeGvhh2QOsQAiwAYpqIIigFuR8YA1Rhz9RxBr0AzoNxCGEAAFsAOhQAmEIBAmh3ICoXIkIYKxRoJncWJpIAIksAZswIIGcYJssAZrIAI2OBcvmH7yJIEmQYMLIQJrMAQrEArdZxAe+AAgSIRb6GzPNxEZtgBMKAIT8YW3lRnXp0XEQQJqWBJp0Axr8FDzJAHNcGKj9gB7Z4B+VxJF2GtHiGdJllBH0HxoAImFgYWmllF6aBJ8SE9JcAPNUAItYBCEQAkDsAMFMICFmGzxhxKKuIa0wV8LkAR6iAZJ0IJ8Uf+JZtQbrOgSaSABYIAGd4eBA+AGENAJp2gTuvhvbPgQ7pUGJMAGLcEGJGCFZuGEWUgbyFh9EhCHA7EBbNAMXjAAlDAIQ5EEjkhNjKgV7rUBa2COKLGO7bgWMmhMuIGNL7EGLfWGYCABVIgUYwFnysgQ7oUG0phbJLCNbCGP83iNmNgUR9CLdJgU/viPqyGQHAFlEsCQ3paRUDdVG8kSaXADJQCPRCGRE3kaAumRB9GECWkRLKmQrFGPMCECR/AUJWmSoSGQz6gTzYBbeWgWLvmSqhGTMOGMTGGTNwltjniUu0g1DZhm3eVVKdkSR3CQ/WiRFgaQA8GM76QTM/lQXKn/FUD5GVGJFjcwjeZ3lVjpGfy1BqAIFNFIEEvJbFIpIUJJlyyxAM2gFHKJlI3xii0VFFRZECVQi393lxypWIeJElIYkWm5ROiIYuVYEEkwFGZpEJRZFWIJTKIxlDYRi1a5TGyYBkfQjmhQmDexAIexAIq5XMXWGZ1pExLglkPBl2T2fKMJj34oFE6gAAuhm/3GmogJGbBZExtgN7TpmHcoeLiZU1WpEwVAiAYhAsHJEJoJHq9JnRuFBrPZkpgpFLWJi+nGnAbxm0BBCJimknM5XsOZnQTRAknwkFU4EfeInA7WbeMpfDoZFKUAAQ1BAty5a+3JGMpInBaxAN7YiWxw/5rVsaDFmZzGh2v4OZgjWROREAANsQGASWcCOqDsaWhfqI9J8Ik9QTU6AZ6WCGkSWhAPahMQQIYBmWnThRgFWhItMIu9SIXl5JVAcaIoyhcquqJE4QY+6J8belxpxaEY0Y1HkKC4BZcmyqKhuRdAGpftCQkr5xAimWtJKpx7QaMwoYQkoI/7CKAvAVIjN2VUShBPOBRE2hAnCBTW+UqF8aU30QI3AJ9gkKNmWp7oZhdqShD6OWmCGhNyOqd/UaeouRJL2okQaRJn6qdsAaiBKhTwh4ALQahmyqWLWFmbehIl0KdhCgZ4qqUiAamRihaTShBR6hIF2HeXahCs+qieWv+XXkqrJvGZC2Gja4CjvwhXfRpfyKWqlAoUZoiGDJGpLJGo4KcXy6oTEkChGlECTCqIDXoQp6pjZzGsxHoTQJhyWIqsMeGslWYX42oTLXCcErGEzVCmOQWsQgSZJ7Gtq4oRGqABIPAAf6ABDFEJo7gDHZhvH1h1MGqPt8qpbGGuUOadFPau8EpZ88qtE6EBKIAC+bqvBWEHm9AFbhCOp2iIr+oQyZqIBnuwaJGwNoEOKsCniBWvJAGxESsRGnAHHHAH+ioQOSAJmsABKLAJPHAQlvoQIhuCJFuyZnGyNuEGxmhgDUtiXvGyFRWtDKEBf3AHMnuxKaAHn+ACJrGaLXH/tPW3Fl8bE40Arku7QS0bEk9LEHBqEVM7Cihgr2ZqrSEhtoJ2FnULE50QCgwLY6pGmtB3EVNrsRfbErJ6EXjLas9FtCgxAJ1wX0zrWRKltrEauH8gEHD7EoY7n4vbGZTllF3Bd9sFuZGrZH9LEmxwlkPRAkJ7uJzbuWHxuVxRCf8quuZzZ5N7EBuwuKWahm3VFbHLFY1woY86uieEtpdlurhqESnACQ8gCTnwEgsrEohLrlsBvKqBrSxbTbjLECMasy7gAoTLEhk6sgLEFdd7GtmrvW6WvPKquQLBCZfgvCmQuSAxHZt7VagWtYUBChroBgUgbqZavGomZu27mO16/xCasAkPkAKS4BKrKxD3GxHUi3X6KxqHsAOPIBAQsALjmBHq21xWZsAo4RERgQIwkAMasLVe+xMS/BAUXMGztr+FcawPYIYtOcCQhEvcGxGE+RAwULHx6xILoKEDRhoT7Lp2SxXoexUD+Aj9ORArgAgYAcJn20o8LBFguRAWoAkPoAkW0BJpsLAuzBAwfBvVxMQvUbX0+wAocAcOAQmdQIrtV8M3/FQ5vL4zNsIvwZcxsAsPIAQw4LXmSMYqmcRg+2szTBUzywGW68YG4QKcsAnz8L88CIAmp8EPwMEeLBFV3LcatscNUQJg4Jyd/Ft3mhgn86lvVcgFYcZ8RmWKvP/IbswBb/vGDwADn6AJcKsHFsADbkoQ/ZtsAIzDZ4ViodwTSQAGJSABBHkRBqlVlEkC79vJ1GzIF8UUaRwTd4ACo8ABheDGmzCxmvAJggwTnqxCx7tR28YQqflOw9cMsryiI/mZzVDKImGTpnBdL3zIzJoU2rzNFVu1MgsDK1wT6JzOYTRabCABGioQDO3QEuGo6dIC6IoSS7gQGIAB/LxQSgHQAX25MktkeJzQ/cXOBwHPjkgC7+TOqevKZiUCelkC0ivAC4EJq3AKDvHKV/TP8mwV3CwQ+nrLB03SJR1eJ20QqcAEzkwW8IlbYgwGc1udKNWED5CrI9GMv3UACtH/EDvN00fx0ZGB0LZ7vI3lAR8gCqmgVc0sEMzMundBi7uxASDp0m8qmQshCSag0/0My0IR1pAx1mSdRPrkATUgAAIgCqQwEDbwAjUwAw3RAs0Qz4nRDEeAwA0hhQ1NAnopEi1QlAyRAyjQvGXM130NFH9dE0JsB3YAZUUt2DcBURTwAgLBADVA26JAAREB0U5HAtp4WSC6HDdgzcI3hZctEBagB11d2qZ9E6hdE5uwwCnwCUTNVD3EUbL92AMxAgAQAhPR0g8gAs1shd3YDDdwBGxAXJ7d0L/KBsYtEC7AAaztm13WYoMVaT7NFSf8ACpcqLrZyh4EmTV11qIgAC/A/wAPEAEecBFiLAG4ldLCd6N6Kp8aIQHNTJjolwZEDIcSwQlgPN8TUd8PdN+FAQMc8ABCfM76+d+TlVtIPRAMIAAKHhJowNYPsNvrSqrubZzbiYJNqIIp6Iwi4N4W8X0h7lj3h99cocte7OEuYVErLuIrZFUjoNgPwACiIOMhEdmTvQDaUa0TseMmsQcizQga0AfXbBECNmAullk24dw3cQnNq99OzspGrD9exFakAACHzd0mgd7gza4ZEeYksQdwywhlfuYvXRBGThCM3uYx8eY2kcI5AMSaahBQ7lgf9HS++dYOMegisQeFsAd7gOiKvuj7LGFsLhCOns41EelkAf8TsZABD0ADSkDnB4Hpr/2RLm4QM/ABLAGtI/HpGRHqfWC1iS4QEz0QrP4AzH62kJ7kJLEAgTjkGCGiD2DPL4brb0EZaIZXE2RcopDdJSEC9TPsFxHqDGyvyC5jal4aqn7n0D4UDI0G9N4SsonK98VXOV3dJMzrC1EBB86Fw80Q5z4R6V7mZp7s0ers5pu50d7Zkp1k0/7vERHTDzCL+n4QB8AK/Z6JFX8QqTDbJhHsJmHwDGEHyL2v6f4AhWDmMNAB+tAQzJ4JRjxkIq5uEB8S4X2VoAjVOu/KHHHVOHYQN83vBaRD/iUA4y4SqTm+GMkQcjABb5ABGnAJm8AJ0Gv/EDAvBCig9QfB7DpwAGM/9qgAEVd+2DVgA66JEpHuEb4tEOiqkyVwA53eF8R1A9XemgeBAzTh8VgN8gwxAgIPfQT/EMMu9ZYwBWAwBbgwAV9/EJLQAUJgr2wsEpiQEAkBER4gAGrtAYPP9oMH9BfB2D8gchsg2aCI+nYo6Lpy8bO6EBGGzfGzYREw8iMRBLNQfTeACwjgB4sPB28QBxYIEVJA+faqAQ7MEH7fEDVvGg/B+VUOr20/+hYB47m9EL2tTm9/z7rth1VN9AeRA/EdUV+WYpzP9BhR6S4RBw4ABnMwBXHwzBtgBxyA/Bxg0AXRChfwEABhCtNATA8MHkSI/5BBDQECPnhIGFHiRIoVLV7EmFHjQTAbL5LY4DEjA1ENa9gw6GEEAJQVF0hIkuaBCAkkRBo8kiSJhJA3E6JBQ9GCHp9FjR5FmlRjx45F06yRqfTBmBJHN22SmnDKJDlzAokEaRDGJQ1lL03EwAqjjgNtUW308IJCVrp1lTZNGrauBwGpHqhk8CCEqBEQL6ZJAiZki2bNel5sgWaNBDBrktyIahQoRRcaXNgFHVq0T6ZOodJFk+QoCjt2ESx54McP2McPcugpq6GfxFWm1rY98NZiiJN/X5AanVx5QrxH9e4VgPxgKlERPJaQwMYgGwlBKYog0exGkhKP1zTLfHMzxf8UWJW2MWDQQJvl9e0/KH3zaXqlaTAXhYEDu+RYYgJAwADEo+cQ0kQDIW5YIKFWLtCohQUWaKGiEACgYISGBBjhAVEqMOw+E5NqrqgF61qooYc8mOGmDZo5IsOXYkJogxIua4YEESY6jz+N1qNIkxw0WqSNRAxS5ICE4JOPvhOnrCs/j/YDLQnvbtpEE7vegOMBON5QsLaEGrjhBjDSG+cJjdhIUzuJbKihOolmqECUuajk06MUb1oxtLj2VFGCHxEDYwER1gBDgjXQyNCiIEUiUqkkl3ygySfje2C+Pj89ykqNsAQttaI+aY2uruKIYw45Ngo0oZfGQ2iOBDNagA3/NiJMCJAR9CxRIuIAmABUYyf6s8zRiEMpLumMemkNgy47gg0zLzov0owqPagPDVAY5YFC9tjoUiadRKgNddc9tt2l8LvytND88y9Ne2/oIDd9ibpDgxQMQuGOrCyZDY5JYL1Wohlv8G6CKTw64gibDpLDEjCkCbYiBspYIg53201Wo1jpmsHDhkJMKo0f8Us4o8lajojbbr8tRFxykVxXXXQPgrJTKT8GWiJRD5NXtGa2zOgODjj444GApToQkNcQHvUICTL04+CN0jzioEnmkOHWjRCYA46vguYzZIxGRlthtV3m6SKZZ/5Dgz7GLVfJczeNsm2/4X07IVJH29Gj/zsC5mCUp5WSwZIHlkBAZJgpOu8BW4uaYIkpPPZJjjfm8OPVv+0LnCK2RfvAOqlImNiolyuae2ZG9kABb5wx1TRdTj0dPeihKRp8tMvutTdffcviF1wOClkcKUie8TzMjE6HfYmOWcU+e+2zjxgOyJMCxI85yOxdudIloj40BlC+a+WjXpcodtlBKOvmjMzNdOfyy/9douBFC4+QLHK4B/RLAwJLCgQiUY4TcO4jk7sIHKYABwpW0IIXtKAaJGAJ0SklDhLYX3LOl5D0hWYGopDKBkCoFPghRH62yYG3GCEuDZArB0dCCkEGIpwQHqt/givaaNBwNZEQ0GkHTAolVv/wgEhAIGMTKWFF4OBAj2yuLjfooWhGeJAohuYFfsmLtKTSwgfMLQec2ARZJCHDBzCihjm4xFkyogodTCRnbdDfRSjwoYdkkS4/PMj/QrMBCN3EiHVD4FFWQIlKuKESa4MgRqbok0nSBYt+tMsWH9BF9VWgfXSBX6Wk5ocpKEMPFkhVROBYFgtkZBU8TEgmZCnLOmaEOjGywQtihMm7wAt4QRRNGrpzrE4U4AGhCAUkk1JJkTBTKpfkZVa2yEkTohApLVghKHmymVEuAQxjoqJEXIACfaWSIjqg0ERMMctMFMSWoghBNA3SwVD50n/AnFczxGisFUACEjsgxAOV4sz/jRA0KdCUJ4ow8pRI1ueLSPmEEkBTBAksQQZzANskzoaRHKRAXyjAIUUOUEuJYCJnmdgIKV4gAFE8K4SZG59CQybI0GhCCkArRScEOtBwasSgSEFoQutpkTQcoaH1oYAnj3IJToBmCr8wxhQ2KpJN6OtfFDHFKk4hGhuIAozlAwQc5oCAOHivWEb54REECBoLXCJcWaSmRX4qyZ4CVai9rEhRj1ofMWTTJy4QkF2G6DnHGUUS+voERTCAgYusK48TCYEHSNHHrqZCdX+rGBje0EGywUFsIvmhZJYjCQ7A4Fh82IEb3DCAQVgkrnKtK12veFeFAs+oQAOD+27yCS/V/wUN2HgYHM5qlACVxRYt88pFgKMKi9AJniFYaUNIMQMA1CCebfta2CLiOTBw8CaAFO1oAtRUY3nCDYh4wCEKMICKvBa2lIytUYJK2+/adq/3IcE+b8JU36LhDY4DAz2L4oJLKIMMzZAIAh4GGV0hLSF4AhZFKDCiXborDpqL7wMAcVGtbQSQZdRvXXKAgsQeawABOIgh3NBa9N3XpxmWIoxvMl/6+mkiekWbCgesgZAqZTPCjcOCk5IDKaSpdQcxGEYWwDWJyOEdFL6IByogAGl8tk8bnkOHE6IrhAS5Yx6250TCa8fd/Swjl+jtsVbAh4Mcwg2HaDFo5hpBGYuExv81fldEcNw2xVjoQn9egB0EPWhBhzQHkkCNdwL8X7rAqZAHOZCAb3yha33NDy3JyAwsMT5J34e73p3IBo6QKIRk18oU+bBBxhyRnvFOI+Rt14lTvOKIuFe2N8lAnT1yZzxjJFm39Rvr0BAxYkdMD8dG9rFNWyrvXFhMkUONBCSQGYK9KU28ekDmrHiTQHgP2ifq7Kklgp0kaCuzm71IqlUdYp6V+QGn2KofEXHe9K631i72yJwtogdzKoXXvbZIsh71tw1o0iBlAcED6pYUIr1hNgiyiwpVY5AvbytiIen2946ibV1Lxcsdf8BTsoOQsI414GGGHbsfcEf66KANOMD/gA6WbZA9INGNfQAaalXLWhLiO98gRwi/Zwtw0ALJwUDrDqD/TGhCH+lbKFC4BpBSKTiQFTagSUMzqpK5m4SP01IxtXK8Tj6RLKAZpD7IhbctNJSnnNXuNggmWNEEFHDglDmgnQYYcfMQ2vrFPhG6JYtCEpNgmpdqGzjahljsYic72aY9IAfusHDNONhWk5jNvPyQiwmQdXufx14tbiABP4j7KHJgg8G5DbpOb4Tc2nrA577NnLa7XXd9i4gLJLEJvI9rD3wvn9//fpPAZ+XfFeGLXwCT0Lcl/mOExLcG/tCvflU+IYGAjQxmb5dWYdD7GFQDARIgmuMnpaz9mYyc/wzyBrLT3uCrbrWZJbKHQnirXzjvnfCHL5LiP9MnfHEp5pOUo/sUbCLAi5A+xSmLopCZTnCCB5CFYBiN87sJ9iO/5KBApVgA/bJAtlO9VdsI+nsAj7Kb/PM5+PKJTZg5//OJFnGIJ9KImhMY4DuR0nE+UMm6I9sI6Ys6qVMPAhwASmiEJZpA6RGJDgSN8kMKCoSUukBC91MPlbsIEXSjEvwb/SsooIu4g1BCixiUosi7vbPCGsSIG+yTJOgan+DBI/rBidiBSugE9ipCn3jCoRMNCjwCbJOKOuSI2sMIEMQIEaQh/GsbLMxCkUC4qDOKFpiMDPEP2NMIZjGOAAxB3/+jQRMZITOckgCikthphB14gAHQqTmswPazw9DAQz1UCj40CHWjCECkL0PciLXTiKdTRJ/gjtMYomaoibWSCAaYgZL5kBCJABicwvo7oDHERI3QxPuQBCE4QYY7wAeIwwdYgUbAQCP0CFZkwTuUnjx0QlPsQ9VzISm8CE5Is6CRRY3wAzDQwsibPB/0CBEAA3A0O1JrgVHTrYlIheoyvIOok8uyCEkgsQcQQRIkxGVkxmlMjgDpN/t4oQDohEEAxWykQ3E0Pot8AHCkC250RdvziBzwDLRZx4wgpSkAg5RUSZUUguMpi9aQPuqTOkTLiHwcJpFTP4OgiXKbiH2oAQD/EMiI2JAXoALgsQAOuARJ+AwqLIs++Awy3IhmTI4c4ACaPJEXMpEM3EaM7MbQqIKb2khVTAqP9MONgMWL0IRWApqSxAhSkoNAMLkd/AMFlDo9YA2ighM2kIlcFKA0IAEJqAqE6DZ5oABjTIgIKAKCYsQbCAM7cIEGcQFBLAS7QQG1vA/Vk8rQgKN0vA+szEpt3Ahu9LfkcAUjMIgY0IJwRJayNEtzpAg7gLqPYcuLcEu43D6M4MG68cFP4AAjETMJqJEHWAAwaAaxlJXGCAk5EB90C02wSZAFsBoSiAxt4IBNeMqICBCrrA9yzEy70AQ5ukqGNAidWy0W88aLvMDR/yhNmntIpCBLcowf15wIHGgFd5lNi6jNuPSINSSng3CBFOCAXUgIUcutB7BJ8UQI7jAD0DG9i8iss2ODFkg9MKCBHpOI7LxMn+jOhMADHDgIHMCDjSBIC60PzzQv9FIvOTzPUkxP0VjPB+i/VeTKj/xD+YwIVniFdrnPisjP20wKTvCH4DSIZtCONIATEvDFiWiBM9DCiMgFY/BL4DTOicDQ7SyKDT2IDv3QENWIHLhO/ELQUEQxg1Ax8wQNrdwIFqCBFg2NF43RsZxR1qQUG0WIU2gD3wCVHaWIHp2XvwxMVatHSLwP/9gkQb2IXYBGK73SMNVSgwDRB2gFPA0aLP81iDVrszcjRZGwAMu0iy40Cjdtz6N4T9Sg04OAJT7R04lwSwQAAx+lC7NzDALdxynx1PiJG/N5HwTFgzsK0VdYhVV4BVSZGXCxmROhVIOQNTKltRXVVE49RdAAVdX0QN8q1WNJ1YgghAI4gVNgVVe1C+7IjiQlnWh8AOww1CpBig1t1Ad4VINABR34Tg3QgzWimWK9j2M1iHlDUXvLVI/YVDaFVtOE0VA1ilGl1saCOxPxS3K9iWwtAA8ggla9DxFIQ2PhyCstTqXTWKUT19VEitNZ13ZNiDOyA2+pm7uxn+XA14MgT57r143419CoVZ94URWU1oigUY/Ayvg7kT3/qw+HJQRKkAUiMBHobBctcQqDkAAaYbymLTafg897o4iQ5dKJkCHasR2VDdNPQVONiNkkTA5GYAbRMFjBYkieHVRgq49BKAAICNodwMairVhQ4TIZAaESWBMRWh2GNQgZop8aqo+V5ZOuzQhBA9gsKluzpQiWS1u+FYlISCZKgNspMdpjyYVc8AkiFaZZzaSs0D82msyUFQ3BHVzQPJaZNRx/AZhEyorEVVyJQNvl8FkTKYXJpdy5/RQKIBTX6wgSwN3QiFooYlg2ciPRBQ3SLd0iUl2nYd2urAulYRrmvSaJQQjXfV2+8Zn6mN3ROAQIUK0VQC9CiNvbbRcGUKqN/xCmBYC+5Qhe4Q0h5OWTSTDdi4DepmmeoyiB1kHdjTgcpVGc5r2SvIwK7nLVnGXAo4vd0dje0SiAAmgtPnADQ/iUyjUW4hCJNZCWI6hWpGhf902KSyBYFtraY2HV+R0gxPlfpBjO4jSIElCTEuhYQ1Ie5gFgjRhOIX2AcEM1OZUKz0yOBRaNMj2IZOUTCgYV6PKIl1CZaVPUusBCC+BMUBphYyEbi1nJlfQHl5TXAprh+xWJFtiJwFzhC7EavfQ4SyAgA7oDZBjbjQDjYTKIjzu5Dh6SKa4LIBaNeUOIR3iECf7dPhEAP6kKMMhJvQUN/esMEhXhECKbQJCDKcg8jf9I47Ko4YXiDiQ10DBGiA28gTU4V40YOyMipztwhS/4AlfICOyQFyzTsh2m4zqeEjwO4mUVUz92F/bBCDZAsNTL0NDQvxSAtayAXypp5EeOZEmOzVF+gE/40ougx9sy0l6UiMVcgym1CM9hPS42CEQyCHgoBmeYIYqAVV7B5tDJCAOeOjtOGbW9jxVw4AeAYAnuEyMOIWzaAGziXC0aDeHTAcaSYkb2CmOW4W1GIk3ggBKziHwEA+94ZgiK5ovFiMwxG46CgmJAhrcioZEziNeY6Hd5ZbNUZ6OQ5eTo3u9FL1sGFQ9gCJaiRIlIAptYgz8ejY82HXI1hTaIt0Xen2L/hmS6gE09WEHBIYEbMGMCHeE0wNuFvoiM81EYcI+IAAEk0LgEjZSyKpCio2lYVo6RJjpxlmkToYAXMIiFmIF/TAiaSIMlc1wbSw6/ewW10Ony4eljzgoL0ABnVTXgdMShNmNKSUkYbrLlbD07IAqKkOieUs6Yqq+s1upgYueutuGvvo+wrrAIAAABqIEPSIUKO4gM0WC6MIQC2LkdVg5bw4T6TIphnhIiCOieDg0Y0Aa0MwhG4ZUh4kloKeP0CDuJsIN9qYjPMef1Y9CiQOceDumqWWv6omcq8YAPKIkXCIwHmIFUoIAaiALg3JWoGKIY1giK7GNDsFS2W45rHcAQ/xLaQAAE1yYcR4mKSLlHay67NejkFlA7GSNsjBi7w64nxgZprHtsyNaIWJDsKWEAAXiiyPBdNUmMQkYKT6hIeCZCnLUP8ja6EOoEuG0E0NHenVgZnLSLxXQAb02I+84IqxZxj+4TH76S/wZwB3UE4DSWEZAOkjBMg9CRG0jufI1wUHADj60PakrgqDxuKgkFDN+BB5zYeuTLYOLuPinuRMsKrm7xiLgwGciFAa8PUrhsAQCA67oINsByj3Bwlo1w2sOv+wpylxnyKSnyRvjEZOrZoYbvKW9FHlYOFT8MFqfzidi0gzkDCTjxtkmDApUK734A8GYz8T5zjUhzbFnzE/+phGv8xEjok/0FuCfvL6SQ8j1/gECYgikABE9XA1yYg8LKIjR45UbQqdAebR9fdIxgXCHHpEX6FEvvNUzPdKfQc06vXs2KPV/v9CmQgdb7m2pJoEiIhFE8uU1sqEannEe3j5ZtrYCqdV535XbBc8HZdWuvBAlCb29HCDmQAanKopf45IwohWu03WVndoTFvTKE9vo40XpT0Wq39mnFdnXedDq/cCyQgyrutM8Zrv3BYKMghEUaADhPtz6hHmePCNU2ESIWYlCxdTzDdWZD323n9EqAgH4S94qbCAQ4gUTfn/Qtiib6JzOtCP5WFmGOd/sI7/TCVIq/d3x3FxXf9xb/r90AIIRSABtiT7EVCAVqLx8w94lKgNsCUPaF/xRZhPgTkXharvSal3CWT+c8z/GECoVSGIQA2IFq0AhCgIACeKT9UWqRUAAnUIEyZ/qmd9ynPxF9pffTpXooDJoXynk6h4QVcFuR8PqAQoTUcgOSBxp6bHKDmAAJqAMJmHMzz1OGhfspkXa6r/txbJvYyXuAewTVGvwHIIQdWHqPeCQeR695A4W2MfaNqBbfZWtjsbXIr3yEqPgau/jkkJnM77UAWAEJBoUdYDOiL4oAUNEB6OMcu4Fz/wkwaIHjb33X9znYj30ujH7A+ZtKwf1e2wFPYFljSgo+ZlkICLaJOwxD/0l9MLNPF4P+6X+A2aev2r9z77h+PHOz09dxpRD+IS5+tBEmEtAVgGAjcCBBNkkkkJCQ5gHDhg4fNgQDcSLFihYvOiSxAWNDEmg4ggwpciTJkiRvmEypciVIiRJZwsSIBk2aIxtj4sxJcoenhnwKxATlBtEDRG5A6Uz6QETBpk1vLBz5UulKjRytUs2qVSnKrV5zuvwaE02zm2LPqny0wtADUDv44ES0w40buGjFrmFDcurdq2YpYu0rePCDroQPTwyLeDHjlY/o1m0s+eICCXsnQwyc+S/mzioNe+6rODTp0qY7N/sokq9nzR05n45NEbRsraNr485N0Y1ukWSlnv927bp3bEBTaBPHeTs589O8m1+UsGB17MDDoXueNOcNcuwpl3sPz/i5+Ids1lCvvvF6+cVy4CyJU1hO++8PWNfPf5Z8/hY9KoWEH2kkrAGbfoRNMIclcrx3wxSBHEidgBFSqNMJFIYSSYC4tVDhYXLIMMcEDyS44BsiengReCmyqFIbFEKyw4Yt0hhSHEvIwGCIIzKEwByT1PjQikESedGLFEJASUtFMukQIZb8+MCNOT4UyBJ+0EfkkE1yydCREVKywpJdEgnJCj4AIgeUCFD03hSAaHkfmXM69GWEK0DC0YR0HhjJDp08EMgUcMBpkSWy5FnjlnwGeYCHkQygJ6P/HjZSQAEAbgPGGyBR4oaSNC46qajNERKApKPqV4kbGlZSwAl1iNTIDqGAKieqt3pnSAF0RVrRnriS+kAnO5hK0iCWEsJiqMDWhwcODeGAh2yJtJEIQ4oowtEgOzzygCEr2JUYs83xMZcbAwzyACED4KlSKKUwVC6v6da37LjiOQuttLFRa+0D2HLkiYzxiknRr/eW5slQDxxSQKSGBJAsTAoT1XCv7dmLMHb5MhTttNVemy1GiBTcFn9CaqzbAMV66wa9OK3ckCEu12trygfi0YbOOu97GrU7t6FIJkC3YQVkdEEgsE8lQ3TwzZiB29AhbhyiU9QMTV01xjY/3eyz/x33bFq/IWvLrbdXi9t1bDEzNPPLMbHd8tvhZay2bhw/4DG/IP8rMka68mqR03YvZlTFDidlOMOI1zw44bnhrbfPfAMM1uOmyXvu3CVFcnS85qKbX93eCSLBDUVcNIEDD9BxA6wQybD65bE5fmAeBNzQ3UWxQ+T6Aw7IMDtjo5vmSO43EJAARQQ4wpHqwmNXe2/G5548RY4QwFACqK/kO/TDc80cAQ7w6IgZFEnAY+qyf5+c9LmNX/75E5mh/APbs+R9+4cRH1rrgkBEELi7QfOKcDw61GGA83sA9Rywugm4DoLHc10CHni63MlABrnjXh4MeLo87O8r76vN/yDSwf8N5iEBx3PABOswQeVJ8Hh1qCBD6GA6FsKqCMGr4AC3lzv7CTB3zQshS/rnGRlk7yF5kEDwSkeHwvDIAairgwOUV0FY0RCCr3tAHhxwviwSkEQfrIME2FQEAuThdsEjom3yg8SJnDGNBAheEeyHv4eoEIQM6eIXLTgiQfhOh/eTwBNV2DwE3CCNTHyAE9moEiN2pgjccwgCLMOQDEKRkTcA4P1WZz0SWXCLZnAACMHYkBvwKHl52GQN2efIpIxQNpI0IStZt7o6am+SDkFlQ0ZZytWZ75Q53CH3ILhHVFayIZh8ZUkgiZk34nGCNwgeL7XIEGPyEpRifJ0KOWlKhmT/s44xzJ0rmakcNybRIeO8wS3tOMkEDDCb3dReO4X5AEHe0ZjgnIAKJ7hGc0oIOyWkZDpP+cda0pB81wylJu3XSTEalCF1XKUeAaqUWMZmoA2h6ENweT/u2dB+vASkQ2koA4cGkpjXNAwyC2pR4GC0M/HTnhmW6E3lZVOKD6Ci8k7KxSKEko8O+WYm76k8j9Lhny8ton5mer/zIZWOdpRAKal6P1QKtSE0pMP8jDfMj67UoDbVnkOXqqLwJScPGqye8gTBQuSNKJsJzN38bkfXULauhUQNp/LsegMJlNWs9smPWo9nPb8C1qh7HGAQb2AGVOZVhjR8wFof+9V8svSPxW8lgPoE6yu0eja0ghMtaTHizNIyM6aofeVpV8tG1bqWiK2N7f5gS9v2zfa20LOtboWX295ejrfAfdxvh2s34RpXbcVN7tOQy9ybLfe5GnOudBEW3eqOi7rYZdZ1t4sr7Xr3Vt0N76jAS15Rjfe8jDKvevmU3vbOib3wJdN758sl+dq3SfXNb5Hwy984+fe/ihKwb0FL4OYeOLgGTvB0GUy4/Tq4QgGOcIQgTOEDTfjColuwhsXb4ZRJBA4f1piIR3wvEQcEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several cephalosporins share the same moeities at the R1 side chain position (shown in the boxes). The more similar the R1 side chains, the more likely it is that a patient allergic to one will also react to another. Specifically, ceftriaxone, cefuroxime, cefotaxime, and cefepime each have a methoxymino group (circled) within the R1 side chain and cross-reactivity is observed in patients allergic to these agents. In contrast, ceftazidime has a different structure in the R1 position, and cross-reactivity with the other agents is not frequently observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Antonino Romano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40132=[""].join("\n");
var outline_f39_12_40132=null;
var title_f39_12_40133="Chapter 7B: Exchange of water between plasma and interstitial fluid";
var content_f39_12_40133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 7B: Exchange of water between plasma and interstitial fluid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40133/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/12/40133/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supply of nutrients to the cells and the removal of waste products from the cells occur in the capillaries and postcapillary venules by the diffusion of solutes and gases (O2 and CO2) between the plasma and the interstitial fluid. Equally important is the maintenance of a proper distribution of water between these compartments.",
"   </p>",
"   <p>",
"    Although osmotic forces contribute to the distribution of water across the capillary wall, the situation differs from that across the cell membrane. Since the capillary is permeable to Na+ salts and glucose, these substances do not behave as effective osmoles. It is only the",
"    <strong>",
"     plasma proteins",
"    </strong>",
"    , which move across the capillary wall to a limited degree, that act as effective osmoles and therefore hold water in the vascular space. This osmotic pressure generated by the plasma proteins is called the colloid osmotic pressure or the plasma oncotic pressure.",
"   </p>",
"   <p>",
"    Fluid does not continuously move into the capillary because the oncotic pressure is largely balanced by the capillary hydraulic (or hydrostatic) pressure. This pressure is generated by the propulsion of blood from the heart and tends to push water out of the vessels into the interstitium. Although less important, oncotic and hydraulic pressures present in the interstitium also contribute to the regulation of fluid exchange between the plasma and the interstitial fluid (",
"    <a class=\"graphic graphic_figure graphicRef55674 \" href=\"mobipreview.htm?14/10/14507\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The relationship between net filtration from the vascular space into the interstitium and the hydraulic and oncotic pressure gradients across the capillary wall can be expressed by Starling's law [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;Net filtration &nbsp; = &nbsp; LpS &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     (&Delta;",
"    </span>",
"    hydraulic pressure &nbsp; - &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;",
"    </span>",
"    oncotic pressure)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;= &nbsp; LpS &nbsp; x &nbsp; [(Pcap &nbsp;- &nbsp; Pif) &nbsp; - &nbsp; s (&pi;cap &nbsp; - &nbsp; &pi;if)]",
"   </p>",
"   <p>",
"    where Lp is the unit permeability (or porosity) of the capillary wall, S is the surface area available for fluid movement, Pcap and Pif are the capillary and interstitial fluid hydraulic pressures, &pi;cap and &pi;if are the capillary and interstitial fluid oncotic pressures, and s represents the reflection coefficient of proteins across the capillary wall (with values ranging from 0 if completely permeable to 1 if completely impermeable). The interstitial oncotic pressure is derived primarily from filtered plasma proteins and to a lesser degree proteoglycans in the interstitium.",
"   </p>",
"   <p>",
"    The normal values for these parameters in experimental animals and humans in the resting state is uncertain, largely because of difficulties in measurement of each of the parameters, with the exception of the capillary oncotic pressure. Furthermore, capillary hemodynamics are not necessarily uniform within an organ, as both open and closed capillaries may be present.",
"   </p>",
"   <p>",
"    What is clear, however, is that capillaries in different organs have different hemodynamic and permeability characteristics (",
"    <a class=\"graphic graphic_table graphicRef59422 \" href=\"mobipreview.htm?3/31/3583\">",
"     table 1",
"    </a>",
"    ). In skeletal muscle, for example, capillary pressure is much lower than systemic (because of the high precapillary resistance) and the capillary wall is relatively impermeable to proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; the interstitial hydraulic pressure, in comparison, has a negative value that appears to be generated by the lymphatic removal of interstitial fluid.",
"   </p>",
"   <p>",
"    The net effect is a 0.3 to 0.5 mmHg gradient favoring filtration, with the filtrate being returned to the systemic circulation by the lymphatic vessels. This gradient is not uniform within the capillary circulation. Although the mean hydraulic pressure is about 17 mmHg, the pressure within most of the capillary is higher at 25 to 30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]; thus, filtration occurs throughout the capillary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/4\">",
"     4",
"    </a>",
"    ]. Most of this filtrate then reenters the vascular space in the highly permeable postcapillary venules, where the hydraulic pressure falls to 10 mmHg, a level below the oncotic pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison to skeletal muscle, the alveolar capillaries have both a lower capillary hydraulic pressure (due to perfusion from the low-pressure right ventricle) and a lower transcapillary oncotic pressure gradient (because of a higher permeability to proteins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. The result is a small gradient favoring filtration, which is slightly larger than that in skeletal muscle. Once again, the fluid that is filtered is normally removed by the lymphatic vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The smaller transcapillary oncotic pressure gradient across the alveolar capillary wall has important clinical implications, because it means that the rate of filtration is relatively unaffected by changes in the plasma oncotic pressure. As an example, a fall in the plasma albumin concentration (called hypoalbuminemia) might be expected to promote fluid movement into the interstitium due to the associated reduction in the plasma oncotic pressure. However, the interstitial oncotic pressure will undergo a",
"    <strong>",
"     parallel decline",
"    </strong>",
"    , due in part to less albumin movement from the vascular space into the interstitium. The net effect with mild to moderate hypoalbuminemia is no change in the transcapillary oncotic pressure gradient; as a result, a low plasma albumin concentration alone is not likely to produce pulmonary edema, which is a potentially life-threatening condition (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Safety factors'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the glomerular capillaries are unique in that they have a much higher hydraulic pressure, due in part to a lower precapillary resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/8\">",
"     8",
"    </a>",
"    ]. This is physiologically important because the high pressure gradient plus a 50 to 100 fold increase in net permeability allows the glomeruli to maintain a very high rate of filtration (see Chap. 2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Capillary hydraulic pressure and autoregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average capillary hydraulic pressure is determined by the interplay of three factors: the arterial pressure, which has a normal mean value of 85 to 95 mmHg in humans; the resistance at the precapillary sphincter (",
"    <a class=\"graphic graphic_figure graphicRef55674 \" href=\"mobipreview.htm?14/10/14507\">",
"     figure 1",
"    </a>",
"    ); and the postcapillary resistance in the venules and veins. The precapillary sphincter resistance determines the degree to which the arterial pressure is transmitted to the capillary. This is important physiologically because the ability to vary sphincter tone allows the capillary hydraulic pressure and therefore the rate of capillary filtration to be held relatively constant in the presence of changes in arterial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/9\">",
"     9",
"    </a>",
"    ]. How this occurs can be appreciated from the relationship between resistance (R), the pressure drop across the resistance",
"    <span class=\"nowrap\">",
"     (&Delta;P),",
"    </span>",
"    and the blood flow (Q):",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    &nbsp; = &nbsp; Q &nbsp;x &nbsp;R",
"   </p>",
"   <p>",
"    Thus, an increase in resistance elevates the",
"    <span class=\"nowrap\">",
"     &Delta;P,",
"    </span>",
"    and a decrease in resistance reduces the",
"    <span class=\"nowrap\">",
"     &Delta;P.",
"    </span>",
"    If, for example, the arterial pressure is increased, a rise in precapillary resistance by constriction of the sphincter will increase the",
"    <span class=\"nowrap\">",
"     &Delta;P,",
"    </span>",
"    thereby preventing an increment in the capillary pressure (and in capillary blood flow since the elevations in pressure and resistance balance out). If this did not occur, then every patient with high blood pressure would tend to develop edema (defined as a palpable swelling due to expansion of the interstitial fluid volume), since the increase in capillary hydraulic pressure would act to push water out of the vascular space into the interstitium. Although neural and humoral factors may contribute, capillary resistance is largely under local control, e.g., by stretch receptors in the sphincter wall and local metabolic factors, a process that is called",
"    <strong>",
"     autoregulation",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these events at the arterial end of the capillary, the resistance at the venous end &nbsp;is less well regulated by local factors. Consequently, alterations in venous pressure produce parallel changes in capillary hydraulic pressure (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasma oncotic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between the protein concentration and the oncotic pressure it generates can be estimated from van't Hoff's law:",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp;Oncotic &nbsp;pressure &nbsp; = &nbsp; cRT",
"   </p>",
"   <p>",
"    where c is the solute concentration in moles per unit volume of water, R is a constant with the same value as the gas constant per mole, and T is the absolute temperature in kelvin. Since R and T are constants, the oncotic pressure should be a linear function of protein concentration.",
"   </p>",
"   <p>",
"    This expectation, however, does not hold true. As depicted in Figure 2 (",
"    <a class=\"graphic graphic_figure graphicRef54939 \" href=\"mobipreview.htm?23/18/23853\">",
"     figure 2",
"    </a>",
"    ), the oncotic pressure generated by the plasma proteins is greater than that predicted on the basis of protein concentration from van't Hoff's law. This difference is due in part to the Gibbs-Donnan equilibrium since more particles are present in the protein-containing compartment. According to the Gibbs-Donnan equilibrium, the product of the concentrations of the major cations and anions in one compartment is equal to the product in the other compartment assuming free diffusibility across the membrane. If, for example, Na+ and Cl- are the only diffusible ions in the plasma and interstitial fluid, then:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[Na+]p &nbsp; x &nbsp; [Cl-]p &nbsp; &nbsp;= &nbsp; &nbsp; &nbsp;[Na+]if &nbsp; &nbsp;x &nbsp; [Cl-]if",
"   </p>",
"   <p>",
"    The Na+ and Cl- concentrations in the interstitium will be equal at about 145",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    &nbsp;In comparison, the plasma water Na+ concentration will exceed that of Cl- by about 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    ([Na+] &nbsp;= &nbsp;[Cl-] &nbsp;+ &nbsp;15), which is the approximate negative charge on the plasma proteins. Thus:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;([Cl-]p &nbsp;+ &nbsp;15) &nbsp;x &nbsp;[Cl-]p &nbsp; = &nbsp; 145 &nbsp;x &nbsp;145",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [Cl-]p &nbsp; = &nbsp; 137.7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [Na+]p &nbsp; = &nbsp; 152.7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    The net effect is that the total number of milliequivalents of Na+ and Cl- per liter in the plasma water (137.7 &nbsp;+ &nbsp;152.7 &nbsp; = &nbsp; 290.4) exceeds that in the interstitial fluid (145 &nbsp;+ 145 &nbsp;= &nbsp;290) by 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or 0.4",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Although this difference appears small, the normal plasma protein concentration is only 0.9 to 1",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Consequently, the total osmotic effect of the plasma proteins is increased from 0.9",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    equals 0.9",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    to 1.3",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    by the Gibbs-Donnan effect. Since 1",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    generates an osmotic pressure of 19.3 mmHg, this effect increases the capillary oncotic pressure from 17.4 mmHg (0.9 &nbsp;x 19.3) by concentration alone to 25 to 26 mmHg (1.3 &nbsp;x &nbsp;19.3). (Other poorly understood factors also contribute to this discrepancy between the predicted and actual values for the oncotic pressure produced by the plasma proteins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Safety factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the mean gradient only slightly favors filtration, it might be assumed that a small increase in capillary hydraulic pressure (due to an elevated venous pressure) or a small decrease in plasma oncotic pressure (due to hypoproteinemia) would lead to fluid movement into the interstitium and ultimately to clinically apparent edema. However, experimental and clinical observations indicate that edema does not occur until there is a relatively large change in one or both of these parameters.",
"   </p>",
"   <p>",
"    Three factors contribute to this protective response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphatic flow is able to increase so that the excess filtrate can initially be carried away.",
"     </li>",
"     <li>",
"      As fluid initially moves into the interstitium, the oncotic pressure will fall (both by dilution and by the lymphatic removal of interstitial proteins), thereby minimizing the gradient for further fluid entry into the interstitium.",
"     </li>",
"     <li>",
"      The increase in interstitial fluid volume will cause the interstitial hydraulic pressure to rise; edema cannot occur until the normally negative value becomes positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of these safety factors varies from organ to organ. In skeletal muscle, for example, all three contribute. In comparison, the hepatic sinusoids are relatively open and freely permeable to proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, there is normally no oncotic pressure gradient across the sinusoids, since the plasma and interstitial oncotic pressures are roughly equal. Thus, the hydraulic pressure gradient is unopposed, although the intrasinusoidal pressure is relatively low because most of hepatic perfusion derives from the low-pressure portal venous system. In this setting, it is hepatic lymph flow that is primarily responsible for preventing the accumulation of excess interstitial fluid.",
"   </p>",
"   <p>",
"    Although estimated values for Starling's forces in different organs are listed in the following table (",
"    <a class=\"graphic graphic_table graphicRef59422 \" href=\"mobipreview.htm?3/31/3583\">",
"     table 1",
"    </a>",
"    ), methodologic difficulties make the accuracy of these measurements uncertain. In subcutaneous tissue, for example, where clinically evident peripheral edema is usually detected, recent studies in humans suggest that the interstitial oncotic pressure may be as high as 12 to 15 mmHg, rather than only 8 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential clinical relevance of this issue can be appreciated from the mechanism of edema formation in patients who have hypoalbuminemia due to urinary protein losses in the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In this setting, the fall in the plasma albumin concentration leads to less entry of albumin into the interstitium and a parallel decline in the interstitial protein concentration. This change maintains the transcapillary oncotic pressure gradient at a near normal value and therefore minimizes the degree of fluid loss into the interstitium&dagger; (",
"    <a class=\"graphic graphic_figure graphicRef74352 \" href=\"mobipreview.htm?26/17/26908\">",
"     figure 3",
"    </a>",
"    ). If, for example, the respective plasma and interstitial oncotic pressures were 28 and 8 mmHg (as in Table 1), then loss of interstitial proteins to balance the decrease in plasma oncotic pressure could account for a maximum safety factor of only 8 mmHg. In comparison, protection against fluid movement into the interstitium would be increased up to two-fold if the true interstitial value were 12 to 15 mmHg; as a result, hypoalbuminemia would be less likely to produce edema.",
"   </p>",
"   <p>",
"    &dagger; This response is similar to that described above for the alveolar capillaries, where the protection is even more prominent because the interstitial oncotic pressure is higher at 18 mmHg (",
"    <a class=\"graphic graphic_table graphicRef59422 \" href=\"mobipreview.htm?3/31/3583\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies in both humans and experimental animals with the nephrotic syndrome are consistent with the latter hypothesis, since primary renal sodium retention (induced by the underlying renal disease) often plays a major role in edema formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. In animals with the unilateral nephrotic syndrome, for example, there is unilateral Na+ retention, indicating that intrarenal rather than systemic factors are of primary importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/15\">",
"     15",
"    </a>",
"    ]. Increased collecting tubule reabsorption appears to be responsible for the Na+ retention in this setting, although how this occurs in not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative importance of underfilling (due to hypoalbuminemia-induced plasma volume depletion) and overflow (due to primary renal sodium retention) in the generation of edema associated with hypoalbuminemia appears to be variable in different patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/13,18,19\">",
"     13,18,19",
"    </a>",
"    ]. Two settings have been identified in which underfilling clearly occurs: acute hypoalbuminemia in which there is not time for the interstitial oncotic pressure to fall; and severe hypoalbuminemia (plasma albumin concentration less than 1.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    in which the transcapillary oncotic gradient cannot be maintained because the interstitial value cannot be further reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/20\">",
"     20",
"    </a>",
"    ]. An example of underfilling edema due to acute hypoalbuminemia is saline resuscitation for massive bleeding, lowering the plasma albumin concentration by dilution. It may also be present in acute onset nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/19\">",
"     19",
"    </a>",
"    ] but is less common in stable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40133/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This text is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7893?source=see_link\">",
"     \"Chapter 8A: Effective circulating volume and the steady state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/1\">",
"      Starling E. On the absorption of fluids from the connective tissue spaces. J Physiol (London) 1896; 19:312.",
"     </a>",
"    </li>",
"    <li>",
"     Guyton AC. Textbook of Medical Physiology, 8th ed., Saunders, Philadelphia, 1991, chap. 16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/3\">",
"      Taylor AE. Capillary fluid filtration. Starling forces and lymph flow. Circ Res 1981; 49:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/4\">",
"      Renkin EM. B. W. Zweifach Award lecture. Regulation of the microcirculation. Microvasc Res 1985; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/5\">",
"      Davis MJ. Control of bat wing capillary pressure and blood flow during reduced perfusion pressure. Am J Physiol 1988; 255:H1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/6\">",
"      Murray JF. The lung and heart failure. Hosp Prac 1985; 20(4):55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/7\">",
"      Zarins CK, Rice CL, Peters RM, Virgilio RW. Lymph and pulmonary response to isobaric reduction in plasma oncotic pressure in baboons. Circ Res 1978; 43:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/8\">",
"      Maddox DA, Deen WM, Brenner BM. Dynamics of glomerular ultrafiltration. VI. Studies in the primate. Kidney Int 1974; 5:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/9\">",
"      Johnson PC. Autoregulation of blood flow. Circ Res 1986; 59:483.",
"     </a>",
"    </li>",
"    <li>",
"     Curry F-R. Mechanics and thermodynamics of transcapillary exchange. In Handbook of Physiology, Sec. 2, The cardiovascular system, vol. IV, Microcirculation, Part 1. In: Renkin EM, Michel CC (ed.), American Physiological Society, Washington, DC, 1984, pp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/11\">",
"      Fauchald P. Transcapillary colloid osmotic gradient and body fluid volumes in renal failure. Kidney Int 1986; 29:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/12\">",
"      Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney Int 1988; 33:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/13\">",
"      Humphreys MH. Mechanisms and management of nephrotic edema. Kidney Int 1994; 45:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/14\">",
"      Perico N, Remuzzi G. Edema of the nephrotic syndrome: the role of the atrial peptide system. Am J Kidney Dis 1993; 22:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/15\">",
"      Ichikawa I, Rennke HG, Hoyer JR, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983; 71:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/16\">",
"      Valentin JP, Qiu C, Muldowney WP, et al. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992; 90:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/17\">",
"      F&eacute;raille E, Vogt B, Rousselot M, et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest 1993; 91:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/18\">",
"      Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/19\">",
"      Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40133/abstract/20\">",
"      Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol 1999; 10:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7254 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40133=[""].join("\n");
var outline_f39_12_40133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Capillary hydraulic pressure and autoregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasma oncotic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Safety factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7254|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/10/14507\" title=\"figure 1\">",
"      Capillary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/18/23853\" title=\"figure 2\">",
"      Proteins osmotic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/17/26908\" title=\"figure 3\">",
"      Oncotic pressures in nephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7254|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/31/3583\" title=\"table 1\">",
"      Starlings forces diff organs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7893?source=related_link\">",
"      Chapter 8A: Effective circulating volume and the steady state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_12_40134="Dirofilaria immitis life cycle";
var content_f39_12_40134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Dirofilaria immitis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 477px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHdAjQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAq6pdtY2EtylvJceUNzRx/eK55IHcgZOO+MVJZ3MN5axXNrKssEqh45EOQynoRU1cvbD/hGtdW1LY0fVJWMGTxb3JyTGPRX5IHZsj+IUAdRRRUMNzDNNPDFKrywMFlUHlCQGAP4EH8aAJqjuJoreCSaeRY4Y1Lu7nAUDqSfSlEiM7qHUsmNwB5X61yEDnxrqIl4bwvaSZj9NQmRvvf9ckI47MRnoBkA6+CVZoUljJKOAykjGQafRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFchotw+heLrvQbuWR7XUN99pryHODn99Dk+hO8D0Y/3a6+sbxXo7axpqraukOo2si3NlO4yI5l6Z/2SCVI9GNAGzWT4ttre68NalHdqWiWBpODgqyjcrA9iCAQfUVU8PeKrDVLdI7meCz1ZPkubCWVRLDIPvDB5I7hsYIIPetDX7d9Q0DUrW22vJPbSRKMjBJUgD9aAOX8Pz3Fj4rU6g2Rq1hBJvJ+9KiYbI6DrWloF1HDqni2eZ0SGK9XLdOlvFnNMuW07xF4SNxbkA2qEjd8r28sY5VuCVYEYPH5jr5R8E49c8Tajrkfie7R7ZpxeNHDIGDufl2tyQQuF9OcZHFAzt7GS61+KC3maeC016eaWYHKv9njUfIPTcCASO2e549Gt4Yra3jgt41ihiUIiIMBVAwAB2AFc289vc+N9PtLEiQ6bbTG5EYysJfYEVj0DEBjjrgZrqKBBVCw1SG/vr63tlZ1s3EUkuPl8zGSgPcgYz6Zx1zWb4p1SeOSDRtIcDWb4HY2Nwtohw87D0HQA9WwPWtTRdMttG0u3sLJSsEK4GTksSclie5JJJPqTQBdooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAritJ8cXur6VZalp/gnxJNZXkKXEEnm2C743UMpwboEZBHBANdrXzf4s+yyeA/gjb6pOltpb29u9zPfRiTT1C2iFRcISA2WwFyR/FzQB7BceM7qza2bU/CHiCxtprqC0+0SyWTJG80qxIWCXDNjc65wprsK8A+GrSf8KO05HS4CR+JrFIndiYpU/tS3w8AI4h5+Uc9Dya9/oAKKKKACiivKvHPxhtPDuq3OlWelXN1qED7H80iJM4yMdSeo7Cs6taFJc03Y7cDl+JzCp7LDR5nv02+Z6rRXga+KPit4n50jSzp8DfdZbcRgj13THn8KcPhx8RdYG7WPE3lI3WNryV8f8BUbf1rm+tuX8ODf4Hsf6uwo/73iqcH2T5n9yPd5ZY4QDLIiA9CxAqk+t6Uiln1OxVR1JuEAH6141D8A2kYve+JGZz12Wmf1L/0q6vwD0sEbtavSO+I0GaftsQ9qf4i/s7Jo/FjG/Sm/wBWerx67pEq7o9UsHX1W4Qj+dcnq/xM0nRPFR0nWAYbaSNJbe+jbzI2U8fMByPmBGRn8K5aT4B6SXPl6zfKvoyIT+fFec6n8L9Yk8S3en+HLS7vbKBtn2y4jEMbEfewScEA8cdcVjWxGJglaH6npZblOSYiclLEtpLquW3ndu1/LW/Y+prO6t722juLOeOe3kG5JI2DKw9iKmryH4afDLX/AAxcpc3HiM20bENLZWq+ZHJ7MX4z2yFz6GvXq7aM5zjecbM+YzHDYfDVnDDVVUj3Sa/P81cy9T8PaLqkxl1PSNPvJSMb57ZHbH1IzVGXwb4d8kqumQQKBw0JMZT3BBGMVF488X2vhOwieVDPfXJZbaAcbyBySeyjIyfcV5DqV9rXjGBpNYvFj02TCPDvMcO8nhFH8RwCcNnA6npWpwmn4u8R2Gl22r21rqAm1g2zJLeWyq0N1HtKhrjkAOo4yMk44B6Dz/4Q6jpmg32pCLWHg0q5gRZJbONjKTuyq5YAplf4scZ6+ndTaRE2gX50qz8vT7K2lluriRM+bJ5bDaFPLMoyoBxgkk9hXN+AbLUrvSNR1nWI72/MFwsVx9rtlguBDsIwAMgrg4Huq9gaAPYNB8N3t3p4b7a+h6a3zW9lpUoLYP8Ay0lmIJkc+3A9WPNaE/hfWAALLxlrEIAxiSG3l/nHn9a8ostR1XwxMs/hW/aXSlkCSWkiF4FYnBUj70R4znjGcHJ4r17wR4utPFVlK0SG3v7dtlzaO2WjPY57qccGgCz4Z8PJov2mee7n1HUrpt1xe3IXzHA+6oCgBVHZQMck963KKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXHeOUGqaroug3MrRaZd+dcX219nmxRhQIi391nkTIHJAx3oAsXPjrRxdyWum/bNXuYv9YmmWzXCp/vOBsB9t2aYvjzSopY01aDUtH8xgqSajaPFEx9PM5QfiRXTWltBZ20dvZwxQW8Y2pFEgVVHoAOBT54o54ZIZ40likUq6OAysD1BB6igB4IIBByDRXIfDjNrb63o6sXtNJ1F7W1JJbbCUSRUyeTs8wr9FFdfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwvh7w54x0HQNM0iz8SeH3ttPtYrSJpdCmLskaBQWIuwM4AzgCuw1V2TTLx0YqywuQQcEHaea+dvB+s+NJtO+HUep3upiwjvLR5L95mzqa3UfmKjNnLiPEisDnPyGgD17UfDvirV1tLfVfEGiNZRXtreSJbaNLFI/kTpMFDNdMFyYwM7TwTxXa14E/wAVdX07w/bOlzomnvHp0N3FDqInnl1F3mdGSFmmDfIEGSS5+YcAV0WvfELWNM03UtRuLrSbO1i1ibSLZWsjKXZGOGkkkuYY0G1SOWAzjB520Aet0V4Bo3xI1+7u7bXZ7zT4zPoE08OjbG/064hnnUpB++I8w7FOQJCFIHPBrufhB421PxgNU/tIaY8dssLRyWUsBILhtyPHHczlSNowWKk5PyjaaAPRqpLpWnrqUmoiytvt8gAa48seYQBgDd1xivEvDvj7WdM0uOy1HxR4eSc6jqEVzealDI39nlJ5jHHMDcA5kAHlglNqJgb+K6vxrqt5rnwOj1Sa2W0vruOymMLhgqO08R6HDYzzzzik0nuVGco35Xa56fRXiniP4m+JNBkudPuY9Ja4ttTkspdT8lYrYKLaKZAUmuo1Vm80jmb+A4B6VDd/GDU4Na8O2mzTBJeNYJe2gETlftBUF4ZhdZkX5gQUidexb0ZJ7jRXinhHxRc+Kfih4aub690szpp+qBtNtY2WfTz5tuPLnYyNuchR/CmMHqCDXtdABRRRQAUUUUAY3iTwzpXiNbcatbmVrclonWRkZM9eQRwcDg+grnPEfhvSvDfhTVL3SbTyruOPf9oJMkqLkByhbO07c9MdK7ys/wAQ2v27QNStMZ8+2kix/vKR/WgDmfiRb2uj/CjXILGCOO0hsmVYlzt2nrnvzk5PXkmuL/Zat4JPAWpSpBbpFcXrKUhlaaMgIowGYknqRiut1mC58U/Bd0so1mvL3SUdEcZDvsDYIOe4xiqPwM0a98JfDCMeIoI7G63y3VwixrGEHqVUADhc4AoAk03wjaXsmtW1ndPA9pObWO6jAZnQojmOVTxJtLABj83A545Z4M+Ht/4f8Zf2vLf20lr9meHyo0cMxYqeckjaMcV03w9SR/C1vfXCBLjUne/kUdvNYuo/BSo/CukoAKKKKAOc+IPiVvCHhS81tbL7aLYoDD5vl5DOFzuwf7w7V5JF+0ZCQfO8MyKe229Df+0xXv1RTW0ExzNDHIcYyyg16mCxWCpU3HE4fnd9+ZrTtZafM56tOrJ3hOy9LnjNt+0NoDH/AErSNUjH/TPy3/mwresPjf4KuiBLe3Vp/wBd7Zz/AOg7v8mu0u/C3h+8GLrQtLm/66WkbfzFYGofCjwTfA+boNvGT3gd4sf98kCuz2+S1PipTj6ST/Mz5cVHaSfqjU0rxz4W1XaLHX9NkduiNOqOf+Atg/pXRqwdQykFSMgg5zXjuq/s/wDhq53Np97qVk56AusiD8CM/rXOP8GPGPh9mk8J+KRgHOwSSWzN7YBKn8TR9Qyuv/BxLi+04/qtA9tiIfFC/oz6Gor52/4S34t+EONc0ltStU6yPbiUBf8ArpCePq2a6Dw7+0Bod2Vj13T7rTZehkjPnRj3OMMPpg1FXh3GKPPRtUj3g0/w3/AccbSbtL3X56HtNFZGgeJNG8QweboupWt4uMkRuNy/Veo/EVpT3EMDwpNKkbTP5cQZgC7YLbR6nCk49jXizpThJwkmmunU6lJNXTJaKKKgYV4Z8QfDuu+I/jItq40+9sIdKFxY2t1I8cUY8wJKWwjBnJxjIxjHcV7nXPa74ce/1WHVdP1S603UooGthJGqSI0ZYMQyOCOoHIwfepnBTi4y2ZUJuElJbo858IN4h8E+ONE8PaoY49I1ZZhDFHctcxI6IWOxnVWQ5x8vKndkYINek+LtYuNKtLWLTYI7jVNQnFpaRyttQOVZi7kc7VVWY45OMd815Jcate3/AMbfDmgeJryETaHLJLHcCMRi7aVGMZ9Adu1ceob1Fel/EHNg2ia+VZ4NIvPNuQoztgkjaJ3wOfl3hj7KaUIqK5UObcnzPqa/hfRE0HSVtRM1zcO7T3Ny6hWnmc5dyB0yeg7AAdq16bG6SRq8bKyMAyspyCD3Bp1WQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAISFBLEADkk9qwbbxp4WubKe8tvEuiTWkDKk08d/EyRsxwoZg2ASeBnrWzeRPPaTxRTNBJIjIsqAEoSMBhnjI615Tp3whvE1E3ureJm1GdnsGkaSCZzJ9luPO5MtxJjfyMLtVc5C9RQBu+M9R8EXujRa9q2tWdzYhW+zKNbaK0u3jJYJsWQRSncO6sePbFdJZ+JLA+FNP17Vri10u0ureGdmuZ1RIzIoIUu2AeWx2zXH3nw0uhqt7qOla3b211dtfLJ59h5yrFdGMsFAkXDgxj584OeVNb9/4OW88I6DoT3g26XNYSmUw5EwtnRtu3dxu2Y6nGe9AGhpni/w1qt0ltpfiHR725dDIsVtexSOyDqwCsSQMHmiHxf4am0+6v4fEOjyWNqwS4uEvYjHCx6B2DYU+xrmLz4Y2922JNQKRvqWoX8nlQbXYXcEsJQNu4KiXO7BztHA7VT8NL6a3mN7rGnT332a1s7eRdOlgSGO3ZmRsR3Cv5uW4dZFAxwooA66Txn4XiFkZPEmioL1d1ruv4h543bcp83zDII4zzxVyTXtLWHzE1Czly0saKlxHl3iDGRBlgNy7WyM8YOcYNeYa38NvEVtpF3/AGfrq6tdXgs1vVurX99P5M+8GOVpfkUKej+YSE65JNay/DO7XVVca9ENKiu9QvIbX7CfMV7tJFYNL5mGCmUkYUccHPUAG5pfxI8MX17qFo+rWVnPYxRzzC5u4AAjxq+4FXIIUMAW6Z6EjBq3eeLbJU0y70+W0vdFuTK1zqqXSi2tYkUne0gypJbaoGR1JzxXKt8MLxIGt7bXrdICunyAS6eXIuLNYxG5/egGNvLG5CM88MK2oPBUw8La5pt3e2d3favdNeTzSWbrAsh2fdiWUMAAi4/ebt3zZzQB1Gkatp2tWQvNHv7TULQkqJ7WZZUJHUblJGRV2sPwdo15oWirZ6jqsuqTiR386Tf8qk8IPMd3IHqzsfetygAr5h1fx941PiTWobbxRd28EOqXdtDFHaWrKiR3Dogy0JY4VR1JNfT1fH+ouI/Fevu2cLrd+Tj/AK+5aDxs7r1KFCMqcrPmX5M2PF3jf4geH01JH8X3r3FpC0g3afbICQm4ZV7dWA6dQPb1r6or5B+L+s2/iC68R6nZpKlvPbNtWUAMMQhTkAkdQe9fX1AZRiJ1va80uZKWnoFcz46vpEtLTRrMuL/WJfskZTrFHjMsv0VM/iV9a6auQ8Ik69reoeJZExb5ax005yDArfPKP99wf+AotB7J1NlbRWVnBa2yBIIEWNFHZQMAUt1BHdWs1vOgeGVDG6noVIwRUtFAHKfDaYp4ffSZZZJbjRZ306R5BhmCY2N9DGUP411dcsqrpfxCYjIi1u1yfTzoOPzMbf8AjldTQAUUUUAFFc/4y8XaT4Psre71uZ4oZ5hCpRN5BIJyQOcADnGa0tH1aw1qxS90m7hu7V+kkTbh9D6H2PNauhVVNVnF8r620+8lTi5ct9S9RRRWRQUUUUAFc54k8EeG/EgY6xpFrPK3WYLsl/77XDfrXR0VpSrVKMuenJxfdOxMoqStJXPCPEHwDEE32zwdrU9pcIdyR3JPB9pEwR+R+teaeP8AXPG+lx2/hzxXel5rSeO9gl8xXlUgMFYSKc/xE/NzwOlfYVcbf/DLwfqF7Nd3ujRz3Mzl5JHmkLMx6k/NX1GXcSuMl/aC9ols+VOSfrdfqcFfA3X7nS/noc58F/ifD4ss49L1eRY9fhXqcAXSj+Jf9rHUfiOMgeq1w1t8KPBdpfxXtro5guoXEkckV3OhRh0Iw/Fdw7KiMzHCqMknsK8TM6mDq1nUwacYvdNLR+Vm9PyOqhGpGNqruzF17xRpWhzR297O73sq7orO3iaaeQeojQFse+Me9ZD3HiPxOUSzguPDelMMyXNwEN7KP7qR/MsXf5my3TCjrT/hlabvD0et3caNqmsE3lxPjLMrEmNM9dqptAHQY9zUfxR8QT6NocVrp0oi1PUpPs8EnH7ldpaSX/gKg4/2iteZOShFylsjpjFyajHdnAfECDwR9ku9CjkvW1eObzH1cb5/IucBR585JOOFBAztGD8pAIteBPi1bSeF7eDX7e/vr2AMl5NDCJAke4hWkGQWJXqFBPBOK861i9FhbavoLJCsEFiLqGRDzs3YfzM/xZIYt33ZrL+Gmp2lrd3yTSgfap4oY3/h37HYKT0BIHHqeK8l5hUdGdaMdtvNaHqLAwVWNKUt9/J6n0Lp+mXmj2dvf+AryPUdDlUOulTzZi2HnNvLyU9kbK/7tadn4301rtLTVoL7RLuR/LRNSgMSSN6JKMxt7YbJrjPhpqZ0TxKdEY403Uw81qpbiG4Xl0UdldctjsVb+9Xqmo2VrqVlNZ39vFcWsy7ZIpV3Kw9xXo4avHEU1Vjszz8RRlQqOnLoWKK5b4cTs3h+Wwkmknl0q7n09nkOWKxuQmT3OwpzXU1uYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+Ltek8PaWbyPSr/UsZylogYr7tzkD3ANfP8A4i+MvibWZPs+kJHpkUh2qsA8yVs9tx7/AEANdT8UPHV94i1U+D/BQadpW8q4nhP+tPdFPZBzub2PbObPhT4PNoni/Q7y5mF1b28DXFwcfL9pVvlVR12/MCM/3D0zivKrzq158tF+6tGffZVhcBleGVfM4L2sk5RTu3ZK6utlfoekeG7C58PeDIYbqZ7m/hgaaeWVy5eUgs2SeSM8D2Ary3Svizrt5oMd5by+HdUnls9OuXNnHIsdlNcXUULW8x81/n2yMR0I2nKnjPuM0aTRPFIN0bqVYdMg8Gq+k6fa6RpVlpunxeTZWcKW8Ee4tsjRQqjJJJwAOSSa9SMVFJI+Fq1ZVqkqk927/eeZX/j3XNM8XnRry50N54b6zsxYi1ljur+ObYXuIf3rBUTe2chx+6fLLkCuO8E/EPVNE8IW1npsuj6xHbaZLO8dtG+/TGWdEH2kiQ7gRI74Co2Iz1619E0UzM8R1P4qatZ6fLNFqfhi5tYL17f+1IUXyrtBEj/uIZLpPMKsxVtkrnIGAScC1rHxCvptP8WrJqmiWUun2F08GkTRTQX92EtDKJlYTo6KT83yqSFU/ODyPZKKAPMfDnju9u/iGvh66utL8lkJigtVW4mwsQYmVxcF4jnPDw4PADkmvTqKKACiiigAooooAK8li0ODxFPqOpW3w08B3MZ1C8ga4vrgLPM0VxJE8jgWb4LMjN949eTXrVcH4XXT38BasutWX27Tzq+redbfZGu/MH9pXHHlKrF+ccAH1oA4u907SoPCeoeI7X4bfDHUdLsrea5eSxvkmDrEpLhSLLaW+UjGRz1xXuFfPnw9gudO/Za8TaTqWn6jp9/aaXqRlhvLKW3wHWZl2l1Abj+6TjvivdPEGo/2PoOpan5XnfYraW58vdt37ELYzg4zjGcGgCl4yi1G60KWx0hcXN4wtmmzgQRtw8nrkLnGP4iK1NOs4NOsLays4xHbW8awxIP4VUYA/IV5po/xgs9TvvCFommmKXWUla98y4AGmsiSHDfL824wygH5eF3e1dHD8SfC81q86X1ztAiKI2n3CyTCVtsbRRmPdKGIwCgYGgDsKK5LUfiJ4c00J9tuL6JmhW4dDpl0XgjZiqtMojzECQQN4XODirVz4z0SK3Z0vVLfap7BA0cgBuIUd5EJCnAAjc7sEccZ4BAE8eo0eiLqcKM0+lTJfKF6lUP7wD6xlxiuhgljnhjmhYPFIodWHQgjINcDpXxR0i6m1VdQintLaxht5TdLbXEkMoljRwFYxLyS4VVPzPkYXtXW+Htd07XrSWbSpJGSCUwSxywSQSROACVaORVZTgg4IHBFAGpRRRQBh+LPCuj+LLAWmuWa3CJkxvkq8ZPdWHI7exxzXhmvfDzxX8Nb6TW/At/cXdgvzSxAZkCDtInSRfcDI9B1r6Por1cBm+IwS9mvepveL1T/AMjnrYaFXXZ91uea/C74rab4zVLK8CWOtgcwE/JNjqYyf/QTyPfrXpVeNfFv4Sx6p5mveEk+ya1GfNeCI7FuCOdy4+7J7jqffmrPwY+JzeIf+JB4jPk6/bgqruNv2gL1BHaQdx3wT6468Zl9DE0Xjcv+FfFDrH/OP9d7Z0q04S9lW36Pv/wT1yiiivnzsCiiigAooooAKp6zaNqGkX1mknlvcQPCH/ullIz+GauVU1edrXSb24j+/FA8i/UKTQBj/Dm6S88B6DLGNoFnHER6Mi7GH5qa80+LetWz+L7bzSb2wi0smOKCPz/NeWVlYADOeIcfn716d8Polg8CeHkjGB9ggY+5KAk/mTXz/wCHzcm0s7kWd5clBdaeY7SF5HIM5uID8o4DR3DYJwP3Z5rjx8ZSw8lFX9PU6sFJRrxcnY878R/8I9qkg0rwx4durfVxMI5JDF5IiGMsrnOCcDofSrvjPw5cNK1zoMa6JpTNb77fzy7K8fAmdlGOTgnAOMk88ivY9A+E99qGnwWl1CnhvSoJPOiigdZbt3A4Zm5Vc555cnkHGap+I/h54vhtrqxtrS21aKWJkjuoLhYGORgb0cjHvhmFYUaVaNNJLS/V3fr/AMDoejGWDm5e1laVtLKy9NPz6nKeCdY1a4trBtet1XUNH1O3WSZJQSzrMqkMoxglHzkcENn2r6ngniuELwSpKgZkLIwYBlJBHHcEEH3FfPy6NeQ+I4Ly/wBAv9OWFornUrucfuBb27eaSWVirN8u0d8Me1eifAhpz8ObUXgIu/tV00yt1DtO7EH3+YVeXQlGnLmjy3e3yX6nFj5xlNcsuay3+/8AQ1Ph8jM/ia8ICx3esztGoPaMJCT9S0TH8a62uQ+Hm5ZfFUO4lItcuNgPYMkbkf8AfTt+ddfXoHCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeQfGvx5NZY8MeHWd9WusJO8XLRq3RFx/G2fwH147P4l+LovB/hma9+V72X91axN/FIe5HoOp/LvXnHwh8PRWFleeP/GEwDsHnikuDjapzulOe7ZwP/riuLEVJTkqFPd7vsj6XJsLRw1GWa4xXhF2hH+aX+S6/wDAsdn8JfAEPg/ShcXaJJrVyuZpOvlD/nmp9PU9z7AV6BXPeF/GGkeJAq2EssVy0QnFtcxGKUxno4VvvL7rkDvzXQ11U6caUVCOx4mMxlbG1pV67vJ/1b0CiiirOUKKKKACiiigAooooAKKKKACiiigArj7fwZdWbXK6Z4v8QWNtNdT3f2eKOyZI3mlaVwpe3ZsbnbGWNV/jPYXmo+Ap49PN950V5ZTlbKESylEuomYqhVixVQXAAJJUcEZB5JvEXi//hPdIttOj8RzaMbm3huGv7Das0DQgtNhbNRGdxGQ0ysGDAxAdADqbnwlJ4m8PTwN4+1+/wBI1K2aJmhXTik0MikHa623QgnkH6Gux1jT4tW0i+064Z1gvIHt5GjIDBXUqSMgjOD6V4R4Uv8Ax9o/wyhsotN1Kz1GzsLKO1tlsiyC3ygll3+U7faB8wMRU4GCEk61e/4SDx5HY6dLPc6xcZnkU29lpcyXEqbk2b5JdPEYIy4wUhBGDv4NAHer8MPDSTWcsdtKkkMgklKuB9qItWtv3nH/ADzY/d2889zmjd/DzSbPSZU1XxFqDwNBBp0c2o/Y5FhhDgJCFkhMbbmKjLqzk7RnNS/F3Vte02xsE8Nx6sLidpN09jCJVjKqNqyAW1w2GJ4wijI5YVm+L21vWvgZps99a3ya5Kul3F1FBZs88ci3MDysIQpOVwzFdpxg8UAV/EHwusodEfSNA8QXdlqF5ZrbCC4niCXyxSNIC48ssNvmN/qtoAIGMACt+4+Gemz6s142qautubu4vlsVeLyEmnieORx+738iRjgsQCeMDIrh7i48azzxalZ2upajc2I1VdLub+w8iWSMww+WZYwkYVi4kCgqm4KOO9aH9t+Lvs0ot7vxLLoovbZH1ObRFTUI4mikM3l2/kDcBIIV3eUSA743Y3UAdBqHw90Sx029e61zUbHTPs1sJy80CRxtahPKuN7R5V18tT94Iccqa6nwx4ei0CO+K3l5f3V9cG6ubq8ZDJK+xUGQiqoAVFAAUAAV4l41vvGms+CdR07U4/EYS50mcWqWmjB5L+Tz5lVbkCJvJJhEDbR5fLtg5GK9c8fHW3bw7baBd3lkLrVFhvbm1t45Wit/ImYk70dVG9YxuI6kDvggHV0V4ouofEqx0iG4hm1DVL6607UGaC60+KNbeaGWNYWGyNSHdC7BWJDEfKuOKqr4j8droDCRtblmlvQsNzDYyrJCnlZKzb9MyyluhSDg8M47gHt0d3bSXc1pHcQvdQqjywq4Lxq2dpZeoB2tgnrtPpU9eXfCBtevdYv9W8TWN1bX15omliZprZoQ0ym68wYIADDcpKjpuHAyK9RoAK8N+PfgSSMjxp4bDwahaMJbsRcEhekw/wBpcDPtz2OfcqbLGksbxyqrxuCrKwyCD1Bruy7H1MBXVaHzXddUzKtRVaHKzjvhT4zj8a+FYrxtq6hBiG7jHZwPvD2Ycj8R2rs6+bfDyv8ACz44vpTMy6LqhCR7unluf3Z/4C+Vz6bq+jlmiaZ4VkQyoAzoGBZQc4JHbOD+RrqznBQw9dVKH8Oa5o+j6fJ/oZ4Wq5xtP4loySiiivHOkKKKKACsfxlfQ6b4U1e7uT+7jtZOO7EqQFHqSSAB6mtiuO1JD4i8cw6c/Ol6Ksd5cJnHm3TZMKn1CAF/qU9KAItUuLjw18IAZd0V7a6VHbjHVJjGsa/kxFV/DGmrpHj86dp5b7JZ+H7WCc9ndZHWIn/a2q/PoRV/4iqupQ6R4e3AHVr1FlGfm8iL97IR/wB8Kv8AwOjwixvPFvi3UIVY2bzw2iSMMb5IVKyBfVQxxn1DelAHX0UUUAcr8Ttn/CH3Hn82n2i2+0r/AHofPTePoVzn2zTPCzGz8ZeLNLChYmkg1KL1/fIVf/x+Fj/wKrvxBsbnU/BGuWVjF511PaSJHHnBZivb39PfFYdjfw/8JfoOs2BeTTvEVh9md24KyxAyxbvQlWmBHqtAFzwQRaeIPF2nTnbdHUftyr/ehliQKw9RuR1+qmuwrj/H8baV9l8V2anz9K4u1RctNZMf3qe+3iQe6H1NdejK6KyEMrDII7igBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACio7meK1tpbi5kWKCJDJI7nAVQMkk+gFeGeP8A4gXV3EG82Sw0xlDxWiSGOadT91p2UhlDDkRKVO05ZlyoIB7Hf+IdF06Yw6hrGnWsw6pPcojD8Can03VtN1QMdM1C0vAv3vs8yyY+uCa+Q5f7Wnu5l0FDY3ckAdBCsiMMtkHbFzyM8sDkdyeatQ6rPFfSTNZ21rdRKPMlhSUujgf6wurGaP3xhfUUDsereNfCGveMvipaR6rayReG7dcxyK4KmMYLDI6Mzcc4OMeleq65odlrOgz6Pco0dnKioBCdpj2kFSvYFSAR9K8e8E/FqeHybfUzcahbfKjF1U3UZ5GVZPlnXjrhH9mNe06RqdjrFhFe6XdRXVrIMrJE2R9D6H1B5FY06MablJbs9DG5lVxdOlSkko01ZJbeb9X1PmDxPoGq/DzXES/d5NKnumuIJoy0aLKeS8TjLQOe6g4yONy/KPYvhf8AEG31zOk6jd+ZqMZIgndQn2pMA4OPl81QfmA4I+YcEgd5rOl2WtabPp+p26XFpOu143HB9x6EdQRyDXyx8T/C914C1KNLMyJbcTx3EblBOEb5XYDpMm/BZcdUYAfNWx559aUVxPwo8VP4l0KSO8k8zUrFhFO5XaZFIykhA4BIyDjjcrY4xXbUCCiiigAooooAKKKKACsLxtrU2heH5bqyiSa/llitLSOTO1p5pFjj3Y52hnBOOwNbtYXjbRZtd8Py2tlKkN/FLFd2kkmdqzwyLJHuxztLIAcdiaADRdblvdc1jSZoU87S1tw86EhZmkj3EhOdgBHTLfWs3wp4su9X8S6rol9ZafHcafEkksunagbyJGZmHlSExRlJBtztweDmnS+EJptau9Xh17VtLuL9IReWtm1u8LFF24DSQlxwSMgqe/Bqfw74Rj0fV31O41fVdWvjarZJLfvGTHCrFto8tE3HJyWbcx9aAM+18dQ2sWuz65FcJb2GpTWaPZafcXOI440fdJ5avt+8eTgcVbufiF4YtxcM+ou8dvClxPJFazSJFE8YkV3ZUIVSpBBJA6jqCKx/Evwm0TxBJK95d36iW6nu3TbBLGXlVFb5JYnUYEY2sBuXLYbmtzw94J0rQ7C9sojcXNteW0FpMlwysGjigEIHAHVV59ycY6UAO1PxvoenNfCaa9mFi/l3TWmn3F0sLeWJPmaKNgPkZTntmmjx54cOoW1mmoNJJcGFUkjtpXhDTKGiVpQuxGcMpCswJ3DjkVzV78GvD93oWm6VLe6o0NkZm8yYwXDTtLjc0glidSwCgKwUMo6GprL4QeHLLWbDU7YyfaLRLZT51raTmUwIiIxeSFnQ7UXPlsnIyMHmgDqPEni3RvDkiR6tcTJI8Tz7ILWW4ZIlxukcRqxRBkZZsD3qkfiF4a/tR9PW+nkuFmFuTHZTvGZTGJFjEgQoWKEEKDk9Bk8VX8c/DrRvGOoWd/qO6O7tomhWQW1tcAoSDgpcRSKMEcEAHk84qe28B6XbgiOW6AOqRavgGNQJY4kiVQAgATbGvA75wQMAAGX4e+Kuh6j4W0rV7+O/sZr6AzfZVsLmZkCqrOw2xZeNdy/vQNnPWuj0zxZo2qatNpunXT3V1CEMvlW8jRxh41lQtIF2AMjqRk88gZIIHH3Hwa0K507S7O4vr+ddLRoLNrm3s7gwwNt/dbZIGUqCoIZlL8n5sHFdj4a8M2Xh6bUJLFpSb1oXkVgionlQRwqEVFUKNsS8AYznGBgAAwtF8fWsvijWtF1dvs89vqo0+zZLWby5AYIpFDy4MYkLO4ALAkAYHc0vD/xX0nUbu5jvY3trWDTbbUTfRRXEtuVlWRiN7QrtAEY2lsFyxUDcpFajfD+xfxBNqUmp6m8EuopqzaeWi+z/AGlI1RXyI/M4CKdu/GRnFZ0Pwm0WLTW05b7VDp8umRaVc27PEVuY4g/lM5MeQ6mRj8pUE4yCOKAOt8P+ItN1+O5bTZJy9s4jmiuLWW3ljJUMN0ciqwyCCDjB7VUi8aeHptMtb6HVIXhuVgaJVDGVhNII4z5WN43OdvK8HOcYOI/A/g6w8HWlzb6a4dZ3Du32O1tzwMAYt4owfqwJ96ybP4W+HrTULO8iN4ZLXUJtRRWlBUtJj90Rj/VKVQqvYoDk85ALcXxJ8KSQXMy6m4hgi88yPaTqskW8J5kRKYlXcyjcm4cirWreOfD+lX8ljd3c5vUuFtTBBZzzuZWi84KFjRix8v5uM+nXisRPhTo/9nyWFxqOr3Nmti+m2cUs0eLGBmRisRCA5BjjwXLnCAZxV3S/h7ZWWvRa1carq1/qSXhvjLctF88n2ZrfBCRqAuxjwAOQO3FAGf4u+KOkWHhmS90G4N/fPapd26LZzyoqM+0NMVX90CQw+cryp9DXSaRrNzL4t1rQ79Ig9rHDd2skSlRJby71AbJPzK8TgkYBBXgVzUvwm0k2UtpbatrVpbXECW13HDJDi6VJHkTfuiJBBkYZXbkcHNdLpGjXMXi3Wtcv3iL3UcNpaxxMWEdvFvYFsgfMzyuSBkABeTQB84ftAxeIrPxNaRa5cLdWqBmsL1YVjd0JBKsVAG5SP1zxmvU/2bRdXXhPVNV1CaWe7vtQZmllYszhUUZJPuWrufH3hSy8ZeHLjS74BWPzwTAZMMg6MP5EdwTVP4TeHrnwv4EsNKv1VbyJpTLtOQSZGIIPpjFfVYrOKWJyeOHslNNJpK11q7r5pX8zz6eGlDEue6aOvooor5U9AKKKKAA8Vxvw/nS4s9d8QzSItrqV/Lcwysdo+zxqsSMSegIjLfQ5p3j/AFcPa/8ACN6Vcodd1TFukaHc8ETf6yZgOVCpuIJ6nAFVtZtYtY1Sy8HWCeXo1hDHLqQX7piHEVr/AMCxlv8AYXH8VAE3hhm8Q65L4rnUx6akBttKWRdpaIkGS4IPTeVUL0+VQf4qs/C7c3gTTJnzm48y4yf4hJK7hvxDZ/Gt7VLP7XpF3ZRMIvOgeFSBwmVIB/DNY/w2uBceAtBIXY0VnHA6+jxjYw/NTQB0lFFVNM1G11O3aewmE0SyyQlgCMOjlHHPoykfhQBbrzXRtElv/A15p+mSLDf6TrF1JYO33UkjuHZFP+yVbYfZjXpVcn8P8Z8Slfuf21c7fyTP/j26gC3pmo2/jDwxeR7GtppEks7y2c5e2l27XRvpng9wQRwab8O7173wbpouEMd5ax/Y7mMnJSaL924P4qT9CKz/ABWv/CN6zF4rt122hC2+sKucNDnCT4HVoyeTjOwt6Co2vLbwp41uZLyZLfRdeVZknkcLFHeKArLnoPMTaQSeSjdzQB29FICGAKkEHkEUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn/wAZdQMGiWFh5YlivboCaIjiWONS/ln2Z1jU+zGvHfD9jceKvHCAuWuWYxQSSHesT4Ek1y4x87gYwp+UM6j7qAV6z8cLKefR9MuLVGd47loDjt5sbKh9v3nlj8a8q+FOsWej6/b3l7K0S2tzNHMdpwbeVFAl+iyIA3oCG6A4Bn0ZoGiWOg6etppsWxMl5JGO6SZz1d2PLMe5NN13QNK16DydXsLe7UDCs6/On+6w+ZT7gitC2nhuoEntpY5oZBuSSNgysPUEcGpKBHg3jj4JS4lufDFy06E5NncEeYvukhIBPQ4bGcferzS01fxJ4S1aZxdTW99CoDyFWjfbngTqwPTjlwQR0fvX2JWR4g8OaR4hiWPV7GG4KjCSEFZE/wB1xhl/A0AeWeHfjhGUWPxDpcqsU3LNaD74/wBxj29VZqo/E/xv4b8a6JaadpCXN3eLOJfmhMQhXawYs7YAGG5IyOMnpVrW/gPEH3+G9dubRevkXA3gn/eGMfirGsn/AIUr4nlKx3OuQPBkblN1Jgj3Cxrn1xmgZH+zu9xa+LZrQyM0cunsJUHRWjePafykI+pNfRFcl8PvBNn4Ps5BEyTXswVZZUj8tAq/dRFydqjJPJJJJJJJrraBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUEgAknAFeR+KfiffTajNaeDYrGa2hJjl1C5LMhcdRGq43Y/vE4zUznGCvJlQhKbtFHrlFfM2p6/4onm3aj44u7aY9EtIkhQDnqOfTrWxo3j7xf4fuEa7YeJtOdTlCEhnjPYhujA+lYrFUm7XNnhaiV7H0DRXGeBPiLonjB3trVpLTVYhmWxuRtkX3HZh7iuzro3Oe1gooooAKKKKACuO+Juoa5a6Rb2nhqxvJ7y+l8hp7ZRm3XBOdx4QnhQ54XJPOAD2NZviSK/n8PanDo7rHqUltIls7NtCyFSFOe3OKAOO+Ed5pUWgxWudHt9YeeaKVLV/nnKvJtcliXcsqFssSSOela/w3WObSdQ1NG3tqOpXVw0mc7gJWjTHsEjUCvmnw98PfGeq661mukXFr5coM13dK0KRqX2kxswy4URRrgdVV+zV9a6Lptvo2kWenWS7be1iWJB3wBjJ9z1PvQMu1yfw9d408QadIoX7Dq9wiL/sSETL/AOja6yuSs92n/E3UISuINWsI7pGJ6ywt5bgf8BeI/hQI62vOfgNeve+CLlpQRImqXuf+BzNID+IcH8a9EmbZE7DqFJrzj4HL5ehXsY4XdayY92s4CaAPRppEhieWRgqIpZiewHWuY+F8EkXgfTZrggz3vmX8h9TM7S/ycD8Kk+JU0kfgfVo7f/X3UQso/XdMwiGPxet+wtYrGxt7S3G2GCNYkHoqjA/QUAPuIY7m3lgnRZIZVKOjDhlIwQfwrifA19ZRfDjTbbxLc2irHHNayLeOoVlgZ1YEN1wqZPsMmu6r5y+N/wAPtej1251vQLGbU9Ml/fy2sLZdJS3zIEzlg+58kdBK+egoA6r4VajrdprUNuulsfD2pNMyG0DG3sXRmBA3EmPJUqUzjO0rjLAex15X+z3o+vaN4WuotdgNtbSTBrWKVWWfCjYzSKRkEhEPucnvXqlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLWdMtdZ0q607UIhLaXKGORenB7g9iOoPYivnTx54N1Lw3qf2248zy1YvHqduoCP/wBdegRiTkkkDJJVhnZX0xSMqupVwGUjBBGQRQB8o2k+s6NE1xZ/2jY28oEjXMMc8EbE9MyRAxt/vMuT71qWXxC8XxKGg1W5u7dD8+zyZzj/AHjEuD9etey3nhTwfJ4gWyjtFstVkt2uAthPJat5YYKWIiZRyT364PpUVz8MNFuJN73eqluxe68wj8XDGknfYuUXG3MrXPNrP4r60pxJqMbN2SSzjf8AAlZE59q1rD4yXiOXvotOe34CLLHNZySe4OJU/AsK6a6+D+g3MZSS71Eg+0H/AMarA1L4GwZdtI1h4VIyYZYtisfrCyY/I/SmSdV4e+KvhzVp0t7mSbS7pyFVLxQqOT02yAlSD2yRntXe18r67olz4d1JrLW7cTQsyQypJscgMHZHSQKu9G8t8MVDIy4bKnDezfBK+uLnwpdWdzcG6XTb2Szhm67o1CkDJ6gbiB7YoATU/DWkeIviZr41bSdK1CaHQ9PFs2oWSXKws019kgN2JC5AIzgc1xHhXRdO1H4ral4Zl8K+AdR0rSbVZNQvbXw4tuY53+5CuZJATjk5x0YdRXf3+qR6F8SNXub601dra70iwihmstLubtS8c14XXMUbgECRDg4+8KyvAlz4X8GWN5b6dB4uuZr26e8uru78PX7zTyucksy2yj6DH8zQIdo9+fCXwb8SX+j21rH/AGTca1La25jxCvl3tyUTapGFGAMDHHTFdR411HVdO8NHUtJngikhTzJEfS579pMjhVjhkVhz1PIA5OACaz/Belwaz4B1Cw1eyuVstTvtUMlvcxSW0jwTXs7LlWCum5HB7HBqxL8PNAljRJTrUmzcEd9cvi6qwwyhzNuCkAZUHBwMjgUAU9e8S6gPhTaeILWSC21C4hspWMDLPGhlkiDhW5VhhmAPPqPWq2ofFnQtP1nVtMuoLkXOnWt1duIp7WYyJbrvcBY5mdCV5USKmfbBrrpvDulS+H4tDazRdKiWNI7ZCUVVjKlAMEHgqvftWG3w08KtJcM2nzsk8dzE0RvrgxItwCJgke/bHv3HO0DnnrQBDdfEewshP9v0rV7WUWqXdtFLHFvvVeURKsQEh+cu8Y2vtI8xc45xTvvi34d07XNR0vUhNbzWMM87uJ7aYFYQC3yxSs6EgggSKpP1BFdVqXhjR9Tu9Hur+xjnuNIfzLF2ZswtgDPXnoOueQD1ANZKfDfwqtzJMdNkcOJx5Ml5O8CCfPnbImcom/JJ2qOeaAH+AfHmk+N0vv7J3pLZMgmjaaCbAcEqd0Mkic4PG7IwcgV1lZeg6FZ6FDJFYyX7o5BIu7+e7IxwApldio9hitSgAooooAKKKKACiiigAooooAKKKKACiivnv9onxVcjxDaeG/Pu7fS1jjnu2tlI3bmIG5wcqoAz9aASudx8RviJpkGnX2i6G66prM8b2/lwHdHb7hgtI44AGemc15XBcW9jLY6UgzMY+EiXhFUcsfQE15/oNrcRa0LTRUvBFFNlrolljYBuTjO1hgEepr0uGKCJyIggkYZJ6sRn164ya8zGy95RZ6eCjaLaOL8TDW18Qlra/igtW2pGJUKpk9jgEP0IwfWui1ybULJLSe2eAW6OiXMZXnaWAyvpitggEYOMVjeLpDHorKpw8s0Ua/UuP8K5VPmcY2Olw5VJ3KfiaymS7t9S0yU22p2zebbTpwVcdj7HoRX0b8N/FCeMPB9hqwUR3Dr5dzEP+Wcy8Ov58/QivCtZXNqT/dYV0/7Ol69vr3ifRyf3LeXfxjPQt8rY/ECu3BVG1yM48bTS99HutFFFegeeFFFFABRRRQAUUUUAFcj43Y2et+EtSVSxj1L7G+P7k8bJ/wChiOuurmPiHxodrIPvR6lYuPr9pj/xoA6SYqsLmQ4QKSx9u9edfAwEeHrzzOJN9vx/s/Y4Nv6V0XxLuZLXwHrTwHbJJbmBW/u+YQmfqN2fwrP8PWMWheP73TbTP2W50q2lCk/caEmH9VKf980AWPGq/bNe8JaaGID6gbx8d1gjZgP++zHXXVyept5nxP0CM9I9MvZR9TJbr/LNR/Fa2gvPCUVrdwxT20+raVHLFKgZJEOoW4KsDwQQSCDQB2FFfNPxL1Pw74X8TeIbG28FeA7WHR7OC6hh1HSY/N1XfgusDDaBsGf4X5HQDOPTPD2kaDY+P/DF94c0TT9Jj1Dw/fTOtpapAXBlsSofaBkjcevTJoA9KooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoa7qtroekXepag+y2tkLue59APcnAA9TV+sfxN4c07xLaRWmsRyTWkcnmGFZWRXI6btpBIHpmpnzcr5dzbD+y9rH29+S+tt7eXmfOngjxldah8ZLPWdQfH26Y2xTPCI42og9gdv5Zr6F13xZpWh6na6dfNdG9uY2lhigtZZi6qQCRsU9Mjivnr4T+DYPGN5rU8NxJYy2LxS2joNwRmZiuQTkj5PX8a+kdb0TTdesRaa1ZQXcOQwVxkq3qp6qfcYNcGXc/I3Lq7/5n1nGn1ZYqFOho4RUWuy0cfwf4HOp8SvD0sbvbnUJ1QZby7CYgfU7cD8a4jxh8cLWyEltpcdvbXG3Ia6lSWUeuIY2OD7yMg/lW1e/BDwtPcma3m1WyfdvUQXOQrdmAdW59+tJpvwQ8MW9+99fS6hqN27EtLNIqFgecHy1XuScjB59K9E+NPDLa71v4geKZDaxX2oOWBZwFLNkY3E/cjUAlVJAC7mIBPJ+ovh94aTwn4Vs9LBR51zJcSJnDyscsRnnHYZ7AVqaLpGn6JYrZ6RZwWdsvSOFAoJ9T6n3PNX6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr54+O8NzpPjtNRmWM6dqdituPOH7ppELZRj7hsj1xivoeqOtaRp+uadLYavZw3lnJ96KVdympnBTjysqE3CXMj5I0HW7W3tZtEklNuUBNqynaTG3IK56EZxWlbXttaMkrmKBEU/OQPlQ8lOvJzzmvoBPhd4JS0e2Hhuw8piCQUJOR05zmvKvir8H7KyvItS8PaA93pZi2XNpbSsZYnByJEBPIIOCPbNcc8ItWmdkMW9E0cdp/iWXVXNrYIkk5JAuEU+UBj73PX6DNWPEhlj03SZL4x5ivYGuGjztHJ5Htmsn4YGzmtr0xwOL23lMTSSZ3lCcqOvHTHHpXYailq9lLHqHlfZXXbIJThSK4p2hU5UtjshedO7e4zVR/oUn4fzrU+BYlPxPvmiRmiXStkzdlJlBXPucGvJ9WEsOLfQNXv0sghOJTuQY9CeQv1r2j4N+OvAeheGraGS8fT9Tu8PeSX24mWXpkPjG30HYGurCU0ndMwxvOormja57tRUVpcwXltHcWk0c8Eg3JJGwZWHqCOtS16J5gUUUUAFFFFABRRRQAVyXjQPfa34W0mMsBLffbpsdPLt134P1kMVdbXMX5CfEfRi/STTbtE/wB4SQE/pQBW+JpY6Zo8TZ+xzaxZx3Q9YzKMA+xfZn2zT9aMkHxJ8NSWygtcWt3Dc8dIl8tgfwfaP+BGl+KJ/wCKMuUU/vnuLVIR3MhuI9uPfOKfNuPxRsw/3Bo83l59fOi3fpsoAj8Xt/Z/ifwpquD5f2l9OlIHRZ1+Un28yOMfjT/iaJP+EXjkit7m48jU9NuHS2geeTy476B3IRAWbCqxwATgU/4jc+G0Vf8AWNf2Qj/3vtUWK6egDyvxhcaB4uIt9YufHDaOxQzaVF4dvEt59pyN7C080gnGQHA4HFbGm6lBrPxF0abTLDVYbKy0e+hke60q5s40Z5rMogMsaAkiN+BnhTXeUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTV5PJ0m9kxu2QO2OmcKat1Q14FtD1EKCSbaQADv8ppS2ZpSV6kU+6PIf2YosaXr0uR800S/krH+te214t+zGwOia2uRuFxGSPbaf8AA17TXLgf4Ef66nu8VNvNq1+6/wDSUFFFFdZ88FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFR3EKXFvLBKMxyKUYZxkEYNSUUAfEesacfC2u6np2pSXmnzwSmMuodRLCGPltleDlcc1VtlW5ud0MV5qBBO0GJ3J9DvbgV7J8ffDdxB4ns9Wt545ItZeOyeGYkCJ0UkOuODkKRg/wCNZtpCLa1hgVmZYkVAzdTgYya8rE/u5Na6+f8AwD3cJinKK9yN11s7/n+hzmnaDNcqp1RFhtl4W1VtzEf7bf0FWb/SsIV8pZoMY2lQcD0xXQUVyKTWxvWnKu+ao7s43TtQ1jwzdRQ6Breo6daTFsWyDzIEbrnB+7mtS78R+L70Ktx4t1JFHa3CxZ+pArYuLeK4iaOaNXRhgg96XyIs58tM/Suj63O1rnH9Vg3exxk+nm6bffajql2/XdPeO39aktE1HSzv0LXNV0+UHI2XLMhPupOCK69oIm4aND+FZ2pWUaQmWIbSOo7UliZ33G8PG2x6v8IfiHL4mE2j6+sUPiC1TeSnCXUfTzFHY+q9q9Nr5I0/UY9C8TaFrcrFI7K7QTMO0Tna+fbnP4V9bIyuisjBlYZBHIIr1KNT2kbnl1qfs5WQtFFFamQVyPjctZ6x4U1RFLeTqItJPQRzo0ef++/Lrrq5X4oxyv4B1iW3bbPaxC8Q+jQsJR/6BQA3xgqXfiPwjYSruRr57sjt+5hcr+Tsh/Ck8Zr9m8Q+EdTVmBjv2s3weqTRMMH/AIGsZ/Cm6lKs3xD8LO3ET6fevGT3cmDj67d360/4lHZomnyKMyx6tYMg7k/aYxx+BNADfGq/bdf8JaYCQH1A3r47pBGzY/77aOuurk0ja6+Kcku7MWn6QsYU9nnmJJH4QCusoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApk0YlieNidrqVOPen0UAtNTwn9maUw3HiSxl4kUwtj6Fw39K92rwT4Zn+w/jn4h0t8qlyZ1jU/74kX/AMdzXvdceA0pcvZtH0vFa5swdZbVIxkvmkv0Ciiiuw+aCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzj49adNdeBf7QtIzJcaTcx3yqBklVyHx/wFj+VeaQyxzwxzQsGikUOrDuD0r6PnjWaCSKRQ6OpVlYZBBHQ18neFzNYaelsIZZ0W9mt32kYt9rkYwedo/SuDHU7pSO/Azs3E6aim7l/vL+dQ6dqENzJK1q4Z7eUxuGX7rD2PUfzrzLHpXLMkbxttkVlOAcEY4IyD+VJT1aG3iEcMbNYKCxtIlLy2fUloF6vD3MIyU6pkZSs3U7x7baItjROvmR3CsGjkQ9HRhwQfWtZ0WtY6oyhWT0low1a6hihEMr7TcMIRg4PzHH9asvCotTCo+UJtHfoOK4HW9YjaPzLctdSW8sc0jJyqBWBJLdPwr0FZFeISowZGXcD6gjNKcHBIcJqTZwHjDH/AAjd8GG7KqMevzCvXfhd8T7bR7aHw94vmkszCu21ubtGRgo6RyAjgjoG6EV55Z6V/b2vaLpJBMd3fRiUf9M1O5/0FfVl7p9lfoEvrS3uVHQTRq4/UV6eFj7tzzcVJc1iSzuoL21jubOaOe3lXckkbBlYeoI61NUVtbw2sCQW0McMKDCxxqFVR7AdKlrrOQK4/wCKDm68Of2Fbsft+tyLZQqoJIUkGRyB/CqBifwHeuwrG8ReH7bXDaSSXF3Z3do5eC6tJNkseRhhkggqcDIIIOBQBmeIxjxx4NTG2MPdkccZEGAPyLce3tR8QuD4Zbrt1u249c7h09s5/DParFl4W8vVbS/1DWdV1KW0LNBHcvGsaMylS21EXLbSwyc9TVzxNoY1uC02Xc1ld2c4ubeeIK2xwrLyrAhhh2GD+lAGRdTHS/ibbyTkR2mr2AtY3zwbiJ2cIfcpIxHrtNdfXJJ4Uvbu8s5vEOv3OpRWc63MNutvHAnmr91m2jLYJyBkDPrXW0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXNeI9c1Wz1/TNI0PTLG+uby1ubtmvL57ZI0heFSAVikLEmcdh900AdLRXAP4x1xNbTRnt/BC6u/3bE+KHE7cZ4j+ybugJ6dK3/CWt32rvrNvqthbWN7pl6LORLa6a4jfMEMwYM0cZ6TAY29R1NAHkXxWJ8K/GPRPEYyLe48t5WHfb+7kH/fBX8698BDAEEEHkEVznjbwzoXiO2tD4jC+RaSGVSZfLByMFS3XB4PBHQVPb+IvDdtbxwQ61pSRRKEVftkfygDAH3q56NKVOc30ev+Z7OY4+ljMLh4WftKacX2sn7tvRG7RWL/wlnhz/AKD+kf8AgbH/APFUHxX4d/6D+k/+Bkf+NdB4xtUVkL4n0B/ua5pbfS7j/wAa1IpY5o1khdZI2GVZTkEexoAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzz4n06PQvH+t2EZAiuyupQr7SZD49t6n86+hq8J+Oga2+Ivhm5QH9/Y3ELHsdpDDP5msMTDmpM3w0uWqjza90dr7W7PTtKuJLW5vb5YlaM8fO3zkg8HjNdHq3g6f4f+Mks3v59QstXgMsc8yBSJoz8y4HH3SDUfw4jF18XfDSPz5SXM5HuIyAfzNel/tD2uPC+l6si5k0zUYpCfSNsq/wDMVjClzUGnuzadXlrK2x5Drkt614selM41CWWOC2KfeEjMACPoTmvS/GHwrddCia2EurKuJb6yAVHkl/imtwCqq55Lx8LJ/svhq84W4a18a+HZVBONZtwR6gtivq+qwkV7MnFyftD5e1DTLR9DjaySFrAqVXylKrxwyEEAqwPBUgEHggGsbwVqMZjudDnlzdWTFE3dXiPKn8AcV6r8VYLaw8XQpZRRQ3Gp2zyzxyPsgvChAIY9I5dpG2YdMbXDL93hl8OQp4Q8ZaxEyi8s7i1ktg4C3NrKvyvHKv8ACSGA4JVhhgSMGspYXeKem5rHFbSa1K3hXUV0P4g+Hb24BMAujaOPQyjYG/A19T18rQae2o+OvD2nhTul1KGdgOyId7H9P1r6prfCO9NGGKVqgUUUV0nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6l/yVPw9/wBgXU//AEfYV1Vc/wCIfDbavqthqVtrOpaTe2cM1uslksDb45WiZgwmikHWFCCAD19aAPEvhjaeN/Dmuafp8dvqxu7nWrl9eS6sF+ySQE5Fwl15YLOQRhRI3IxtHf2Pwb/yMfjv/sNR/wDpus6P+EX1f/oe/En/AH407/5FrQ8MaANBXUWbUb7UrnULr7XPcXgiDs4ijiAAiRFACxJ/D60AeJ/FHwF4mvPEmsahcJPrFtdMDYvBCH+yJjiMpuBGMdQGBzk4Oa44eCdcBhmj0zUIDGozDNYTgcDHylIWAOPwr6qi1Wzm1m50qObN/bQx3EsW1htjkLhDnGDkxvwDnjnqKr6L4i0jW7rUbfSL+C8l0+UQXXkncschGdu7oSO+CcHg4PFA7nzGmi604JvfD7SK58vaYLkHaM8vm3YN+AXr0om8PatJMr2ujKhjwy7ba5YA88gC1Xkf1r6e07Wre/1jVtNhSVZ9NeNJmYDaxdA4285PB5yBzWnQFz5Ffwrqcy3rX3hafVbkKBbyW0N1B5bcliA0J3EkgZJX7vQiu18AeBfiDZWKX2kXdtoUucrDehsygAg+bCmU5Jzk4YYHSvoWigLmV4Vvr/UvD1ld6xYHTtRkT9/bE52OCQcexxkexFatFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHfj5b/8AE28IXWAR9omgJ9NyZ/pXsVeIfHrxjpE9iukaak+pazYXUdywtV3JblTgh27EgkYHNZ1VeDRpSdppnF+A5/7M+LPhu4dC0cpmsjg/dZ1+U/mK9i+PbwL8KNdS4faZERIh3Z96lQPfivINAuIE+Inhma5/dwm9XdnoshQhQf8AgRAr1L9oiB2+Hy3SEYsb+3unU/xKr4x7nmssM26RriEvanjV9dR6T4l8O6lexB7a3v7eWUEZwM4Lfga+sS6iMyFlCAbixPGPXNfI3jhHukgt1O1ZZ4I2Ps0gzX1Lr2iRat4au9F82S3hng8gSRn5kGMA+/8AWpwbvTKxitUPDfjJ4m0DxB4o0NdJv/tU1mk6yNEjGMFgAF3YwTmqlg9p/wAK50/V7qZotRm1STSY55FMkUkJZ2WKdAcvGCDgj5kJ3L0IMGo/DHx7pLSxWtvZ6vbRRkQyRXAjJOScsjd/YcV5/GtnbSrp+qQ3MN2smZYrmZ45I5wNzMUyFC84GOtNylGTlJCioyioxZ7R8N9O+1fFJL54Gt3s7GTzLWRwzwO5UAhhxJGy5KyLwcEHDAivcq+b/hfbz+KfEVxbWepSwNp1q09tfQAO1pcM6/LnoyOu7dGeGxnggEe0eGfEs1xftofiKBLHxFEhfy0JMN3GODNAx6rnqp+Zeh4wTrRtyKysZVr87u7nUUUUVqZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFXmleIrLx/f63o9npN5Z3tha2jrdX8lvJG0UkzEgLDIGBEo7jpU3hbS9ds/GPiXUNUttMisNSeJ4Tb3kksi+WixgMrRKBkAscMcHjnrXX0UAeV+OPAOt6zqGsS2Q0W4tL+9t7gwXqIzbY7fy+DLBMiNu7+W2VyMqTVfwl8JvKhhg8Ypp+qW6aFDpWNzSFXWW4Yuu5QBhJlVWGCPmAwOvYfEfxTN4P0e11RLVbq3+1LFcR5wwRg3zKfUEDrwc9utaXhXxPpXinTheaPdLKgwHjPDxH0Ze38j2zWftY8/JfU63ga6w6xXL7jdr+fZ9jzG6+GfiW58P+XqNxoeratNcxC6kuokKtbQRGOEI00Eyq+SzsTE3MjgEcGspfg34i8vQlu9Qtrw2VlFa5W6SJ7Vo5WbfDJJaSsMhl+75R+XBJGMe+0VocgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHkV81eLPhR4t0jWr2bwwPt+nXFwZ9yXAjnRCSWi+bg887u9fStFTKKkrMqMnF3R87+EfAHiCe/j1jxBpb2NjphN2ll5ivPdyICVUbchRkfU1wuv+K9W8cyRjX9Sv4Ld7gFLO3QJHG6nJTZ97Kg8ue/rX2FXA+K/hL4U8SX81/c2k9pqMzb3u7OZo3Y9z3XnucZqHStHlhoWqt5c09T591/zLuGC2tPMnu5JIooA335JN4wcCvry38z7PF5+PN2jfjpuxzXGeDvhj4c8KX326ziubvUACFur2bzZEB6heAB+Wa7YsoOCwB+tKjS9lGw61X2sri1nanomlaqGGpabZ3e7APnQq5OOnJFaG9f7y/nRvX+8v51sYlTStLsNJtvs+l2VvZwZzsgjCAn1wO9VfE3h+y8RWC218rpJE4lt7mFtk1tKOkkbfwsM/Q9CCCRWrvX+8v50b1/vL+dAHIaHr99pupw6B4vKC/lJWx1FF2Q6iACcY6RzADlOh5K5GQvYVna7pena7pc2natBFc2cwG6Nj3ByCCOQQQCCOQRkVy9hq994Su4NL8UXL3mlTOIrHW367jgLDc4GFfssn3X6HDfeAO5opCwHUgfWjev95fzoAWik3r/AHl/Ojev95fzoAWik3r/AHl/OloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOL+Mlj9v+G2toBlo41nB9NjBj+gNfN3gIXtl4v0xE1OXQpbnb5d00RZSrfdypIDKxwOeK+v721hvrO4tLuMSW88bRSIejKwwR+INeffF3wBF4n0COTS4Uj1SwTFuqAKJIx/yy/w9D9TXnYzCynL2sd107n2XDee0sLReX19I1G/e0ajdJbO6autb6HoVosyW0S3UqTThQHkRNis3chcnH0yalryj4KePjrNqNA1uQrrNou2NpOGnRexz/GvfuRz616vXZRqxqwUonzeZYGtgMRKhWWq+5ro15P/AIAUUUVqcIUUUUAFFFFABRRRQAUUVyrePdE864jij1u48iaS3eS20O+mj8yNyjgOkJVsMrDIJGQaAOqorj7v4i6DZ2s11eQ+IILaFGklll8PagqRoBkszGDAAAJJNdNfajZaf9mF/eW1qbmZbeDzpVTzZWztjXJ+Zjg4A5OKALVFVbfUbK5vbuztry2mu7TaLiCOVWeHcMrvUHK5HIz1FWqACiiobm7t7Uwi5uIoTNIIohI4XzHIJCrnqcA8D0NAE1FQWN3bX9pDd2NxDc2syh4poXDo6noVYcEe4pbq7t7QRG6uIoBLIsUZkcLvdjhVGepJ6DqaAJqKiuriO0tZri4bZDChkdsE4UDJOB7UzT7yDUbC2vbOTzLa5iWaJ8EbkYAg4PI4I60AWKKKKACiiigAooooAKKKzvEWs2nh/RLzVdRk2WtrGXY9z6KPcnAHuaqEJTkoRV2xNpK7NGuA8N2Ot+ILS9v5fGOt2n/Ezv7dILaCx8uOOG7miQDfbsx+WNeSxJOa4f4DTa94o8Wa74qv7y6i02RyothIfKkkOMDHTCLgZ68j3r034af8i5ef9hrVv/TjcV2ZjgvqNd0HJSaSvbo+3yM6FX20Oe1g/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FrqqK4TU5X/hF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5FpNY8aQaHrqWOtWF3Z2UuBDqLbWgdvQkHK/iK6pSGUMpBB5BHegDlv+EX1f8A6HvxJ/3407/5FqC+8GX9/ZzWl7408QXFrMhjlilttOZXUjBBBtMEV2NFAHE6T4GvtJ063sLHxz4oW1gUJGsi2MhVR0G5rYnA+vFXP+EX1f8A6HvxJ/3407/5Fre1TUrPSbQ3Oo3CQQggbm7n0AHJPsKwz440cPtBuyD0P2Zxn6DGf0oAb/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi1tx6xYy2EF5FcK8E6h4ioJLg+g61Fp2sxahdSQw210FT/AJatHiM+2c9aAMn/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWuqooA5X/AIRfV/8Aoe/En/fjTv8A5FqX4eXd7eeG3bU7yW+uYdQv7T7RKiK8iQ3k0SFgiqudqLnCiulrlfhp/wAi5ef9hrVv/TjcUAdVRRRQAUUVytx4uuP7X1Ow03wxrep/2dMtvPPbPaJH5jRRy4Hmzoxwsqc7cZoA6qiuV/4SjV/+hE8Sf9/9O/8AkqpJ/G+h2fgnT/Fep3L2Gj3sEE6STxksgmClAwTdg/MAeoHrjmgDpqKw5PFejJrl3oy3UkuqWkEdzNbwW8krJG7BVb5VOeT0HIHJwOa3KACiiuKl+IunRaFqusyabq40yxS4kS4FurJdLAxWQxkNheRgCTYW6qCASADkfjB8PLie6/4SnwqrR6pCRLPFDw0hHIkT/bGOR3+vXf8AhH8Qh4xs3tL2Jo9XtYw0xVfklXONw9D0yPy46eiVl2Nnpmm6tcpZWXkXV8DczSR27BJCuF+ZwNob5uFJBPzEA/Ma5lh3Crzwdk90e3PNo4jA/VMVDmlD4JdUuqfdW2/q2pRRRXSeIFFFFABRVLWdUs9F0y41HUpvJs4F3SSbS20Zx0AJPXsKu0AFFUrvVLOz1CwsbibZdXzOtum0neUUs3IGBgAnnFXaACvK113UNB+HN7LotldXWo3Ov6pbQtBZy3S25bULnM0iRqzFFAJ4BycDvXqlcLotp4x0GC8s7PSfD95bPqF7dxTS6xNC7JPcyzAMgtWAIEgBwx6UAeVfDrWr7VfgN8VYdV1PVdTuLM6nElxqCy7vK+zYVQXHByGJQcrnkDcM+nfGTwle+MdN8P2NirAQaqtzLOrqpt1FvOqyjJGSrvGcDJ9utVNZ0LxRd+Etf0LS/C3hDSk1e3uI5ZLfVpVHmTRlGlZVsxubkE5OTjrXplAHhth4H8XaTda3dOs91NqVxYXWpPpl2LeS9wZzcRwOXRkCmSMDLJlFxmpzoXjdX0aQw67OI5ZMWs2q4jhgNwSgnmjukd5FjxklJ1IwOTk13Gu/ETSdE8YWHh2+ilF1ezRQRSJcWxG+T7uYvN84DPG7y8c9cc1V8X+Lb7w/46sLeOzvtQ0xtHu7ye1s0hLho5YAJSZGXhVZxgNzuHBOMAHAX1h4w/tf+y3m12013ULLV1W8k1cm1uZcfuGhjWUiIKGXnYhGf4sE10dtZeNdV10XF3ZavpmmtcaerQSalGG8pIp1uG/dSnGWaPocnCnqOLek/EbzNd1iKOG+1mO4vIE0m0s44lfyWsIbhm3OyLjLk5Zs/MAOwrQf4paQbf7Tb6fq1xaRW0d3ezRxRhbBHZlHmhnDEgo+QgcgKT0xkA4LQvCfivSfCmh6b/ZXiUR2dlNbz29pryxM15tjEU6v9o4twA4EeRgnPlHNdv468O6vq/gfw5DdRXeo6rYXVlc3iWF4bWSYpgSlH3xjPLEZZfUEECiPxzPq3jXw9Z6TaX8OjXF1e28t5KkIhuzDG4Ij+YyAB1PJVQcdSKu+KfiLZ+HdUvrKXR9ZvRYxW811PaJE0cSzu0cf3pFYksp4VT6+tAHDXeiePLrxkZbfT9StdGb7TDJFLqbTRywtbOsRYPduN+/ZkLCuDk72GSYE8N/EW38KWthi7F7A9p5r2t7tjktFhKmCONbiIpIr7dzCRd4GRJj5B2GpfF7Q9LtS2pWd9Z3y3kti9lcy2sMiyRxpIxMjzCLG2WMjEhJ3AAZzT5Pi74dW70GILO0OtfZ/s0wntsgzEBQ0Xm+dwSASIyB645oA5m20LxtDP4ZeT/hINQe3CpcJc3YtoUX7S7ZkMV8zM6xlR8wuAyqoOCz17VXM/DfVLzWfB9pfalN511JLcKz7QuQs8irwABwqgfhXTUAFFFFABRRRQAE4HNfN3xL8QXvxR8a2vhDwu27TIJcyTDlHYcNKT/cUEgep9citz41fEWa7uD4O8HM9xf3DeRdSwcnJ48pCO56Me3T1x2/wi+H8HgfQ/wB/sl1i6Aa6mHIX0jU/3R+p59MfT4KlHKKCx9dfvZfw4vp/ef6f1bgqyeJn7KHwrd/odT4Y0Oz8N6FZ6Tpybbe2TaCernqWPuTkn61lfDT/AJFy8/7DWrf+nG4rqq5X4af8i5ef9hrVv/TjcV81OcqknObu3qzuSUVZHVUUVW1K9g06yluruVYoYxku3QelSMq+JdIh13RbnT59oEq/I7KG2N2bB968XtfiffeFr238MzJa30ljKwlkScSObcDhVAOcjkZ5wAMjrXaaf4i8T6pYLLp0VtMyytIJEXMcsa9Y89mPBHqD2INeKftE6V4Xa8g1ywdbeeUx3E3lgxujGRUb06gk/VSaAPpnRfE2kaxpsV9Z30PkyKDh3CsnswPQ1x3jz4o6Xo0Jh0+8iadjsEyr5hLf3YkHMr+33R3NfM1hq+vwaVPDDPDA1tNJGbqe1S4FxEo3eZGpBbeBgnbwc5OKy725isrlLdmvo9XvWEUtxNiS7wxHG/7sHHVVy2PrigDvtW8Q6r4j15bQ3+oS6uAZDaW84RrWPHLXFwM+Uen7uMcZAJzXJ+INI0iBVlOrWFpqEZ+ZY0nuHZvVmL5z69D7VN4o8O+JJPD/AJ9laX+n6bhXSR0Ik1HGeGlGCW25KqQBgHv19k+GaeEh4YhjuPBd9PKihbicWXnrkgMOhJX5SOwoApfDyLVyNLnsit3pphXeoffHOo42qoGR65JwOmK9ci03Wr5A80kdnHj5IFZlVB6YQj8yfwqnaa/ssYdL8G+HrwbBsjNxbNa20C+pLAE49AMmr/gy91eS71bTtZngvWsJERb2JPL8wsu4qydAV4GR1oASDQdUlAhu9RkS3zkiOdnJ9gSAQPqTXQ6dZQ6fZx2tqrLFGMDcxY+vJPNWaKACiiigAooooAKKK8z+MHiie0tv7C0gk3c6oblklEbhHbakSMcYeQgjrkKrnjg0AN8X/FO30+5uLTRBayyQBt1zcs5jdlIBSJEBaVgTjjCgg88HHHyfFPxjbXkn2+LR4IlkjRIjaTGafepIMUZcFgCpyeMDHUnFS/DD4fNexNci6aHSWK5uYPlkuGXOVgbJMcQYuBIuGcHjA5PrVt4N8NW8Ahj0HSymMHfbI7N9WYEk+5JoGcP4a+LLTM8XiPSmtjG2157Rt4Xlsloj+8AARiSoYAdcV6hZXdvfWkV1ZTxXFtKoaOWJgyuD3BHWvOvE/wAKNNmiu5/DKQ6deTRlHhdA0MgwRxkFom7B0xj0Ncb8OPEU3hbUI4dTuIbS3nvGsrrTppAJYnDBFnC4Cg5KKxUneG34+UkgHv1FFFAgooooAKKKKACuV+Gn/IuXn/Ya1b/043FdVXK/DT/kXLz/ALDWrf8ApxuKAOqooooAK83u4La60n4t219dfY7Se6eGW58syeSraVaKX2jlsA5wPSvSK49vD/iOz1zW7zQ9c0iC21O6S7aG80qSd43WCKEgOtxGCCIQfu9z1oA84+BIsNJ8YXHh3RLfw3rNhZaSjHxNpFkIpHcuo8ieQM4ZyBu4b+EZHp0en+GpfFnwM8DabF9nKi10i4lWckK8UYid14B5KqQPfuOtdV9h8cf9DD4b/wDBDP8A/JlU7y5n+Hfw98P2NpAmr3Nr9g0aIPJ9mWV2aOAOTh9oyQcc/WgDjk+EGoWP2xbTVIb17iygt5Lq7LLLI8d0kilgARhYY0QHOSVGQM5qxN8NdRksdcs307w/Jd31y0w14zut9KhukmEcgEWVAUbRtkI+RcAdrsPxQ1C3nzrfh2G2tFub6yaS11A3D+bawySttQxJlGWJgDkHPVR1qQ/EjWFhkT/hF457/wCz2t6kVlfSXKC3nLgO5jgMgIKcqkb5yCCRkgAqa18MZpPErz6RZaHDZPPaS29026O40xImDSxwIqYIkO4n50yZG3Bqyrv4OXaeGY9P0mPRLO5Om6taTPEpjWSS5kjMLEqmSFSPaSRkcAAituf4qXJtpbmw0nTru1tI7R7yUam6ANcSbFEIMG6THcuI+cjGQal1H4nbdMJWwaGeW51azAS5XfGbJJT5g3RkZbyxwQQu4Z3dCAY2p/DTxHe/EOXXhJokMBluv3kISKWWGWB40SQLbh2YFkyWmYHbkKDirV18Mb+2sLNdEj0KO5TQH026+0ReYlzcM9qWdw0bBwUgZdzAkfJ8pAwG6X8QtftrrxDLe2VreWUV5YWdirXgjdJLiC2KK5EAAQmUuzkkgkqqkYrafXtV1K0udbhspze+Hbi5tJ9GsbppI7ycrGA3mBQXRVdjtMZO48DcoBAOEi+DfiJdFFpJcaW0C6nNeLpvmw+QUkhjQfesjEGVkcgLbgfOSCDk12fjjw5fRfBa10GC1l1O8gfTYjA8zT+YEuoCwaRYwSoUHL+WPlBO3tXQaX4ve78D6nr81rbiawjneS1hmlOGiUkoxlhjdG45BTjPeuXHxO1uJ7hr3wtZRwWsVjc3LR6sXZYbtyibQYAGcEMWUkDjhjmgDn9V+EGsXlhCkQ0i3tvt11cnRIZEFnAsqRKojaW1lXKmJ2/1K8ytgrznXi+FVwsv21vsUmqxXGkvbXk8xlnhjthEJ183y1OXVHGQBvyNwXoKPiL4h6rd+BfEFtpFu326LTNVupb25vxA9vHFcTwI0Rjh+dwY8qMJjCguSdx6Cz+Il6b20t4tIhm0/wDtFNHa5kvytw0/k+YzCERkFe2S4J64xQBx0XwV1ZrTW4L2ewuprq1miS6lnjxdO0qyI08a2iuSCo+ZppCp6ZBrpbj4cXctvr1xb6T4Ys725tbeHT7XYLi2tCgdZQA0IUBkcgMIz945Ujg0/EHxVv7rwVDd6FZwWmpXmgjWkZ7kMLcedFGUIMZDcO3JA5XGO49c057uSyibUoIILsj95FBMZkU+zlUJ/FRQB4n4e+Eeqaa9jPf6f4b1IWmrTXkdlcOvlRwy26IQrJaqgYSJv2rEqnAOQea3Phn8N9U8LeK5dS1G5iuMxTRtdRXEYe63yBgZo1tUZjx1aaQqcgcE49YooAKo6jqtnp1zY293KVnvpvIt41RnaR9pY8KDgAKSWOAO5FXq4zxAy2XxN8L3t7gWc1nd6fDIxwqXLtC6r9XSKQD/AHcd6AOts7u3vrWO5sp4ri3kGUlhcOjD1BHBqavEpfCvjqfSZpZbrWl1O20SBbNY9YZFa+FxOz7wJNrnyzECXypGBzjjNl1DXZ/iWNIsNTvX1/7dqbPImsLNaR25tpvsoe0SU+XsZocl4wdw+82aAPWLzwJ4evNeOsT2k5vmuIrxtt7OkTTRBRHI0SuIywCqMlego8Q+GfDnijVSupF5tQtbYwyR22oTQOsEx5WRYnXKOY+jAg7D6GvLtM8N+PV0C+jvp/E/2hjbEQRzKd7rv8xhI2pF9hyNwV4eilV+8Klj8I+JI77Ub6bTfEUN9qGkWkKT6ZrRk+zzRmYOsgmukL5V0wdzbSXIcMdxAPS7vwH4cuXkc2EkMrzJP5trdTW8iOsIhGx43VkHlqqkKQCByDUU3w68LSraodLKRW0MdssUVzLHHJHGxZElRWCygMSRvDck+pqh4fsPEMfwy1S0ube5tdceG5W2D3ryzFipEbF3mlKMTjjzWC+vpyzeCvFNsb2Wz1DxC80NtpklmJdcldWuRKfte5Wlww2BflYbOTtFAHdaN4T8LprJ1rSU8y6gubggx30skMM7llnCxbzGjFiwYBRz15FaOoeF9H1GfUJryz8yS/S3juT5rjzFgdniHB42szHjGc85rzt9G8WDVfM1m18Q6npJu9RaO20vWBbSpvui0Ds3nxlo/JwFTf8AL0KjtLeeG/FA0+W5lk127lfX7mS4s7bVzFLJpplmMSQt5qomMxN95W2gpuAwtAG34osvBNhqnlaw09nf3csmqPcW9xcwtEdiRPK80RHkxlURTuZUOPWpLTwf4P1rUbi6hjvLm5sbqGK4LX92A1xbhDGZFL4ldRs+dgxPcnmuCk8D+MZbLVNQJ1dNbOhz29gw1lvMSUzzGKJ2EgV3WJowXOV3DOc81b8W+HfGYTVodD067C3uq3d0tzaag0UiBooliO1LqAEEh+WZtu37hzQB6zZ22l+GdF8qJorDTbcs5aaXCJucsxLMe7Mep71p15APDnjW50DWJ7y51Zda+xWa2Mcep+Wgn+zxrcHCOFzv3/e4zyvJyaOo6R8SLjxtqFzpcV1pttIt/FHI9+0tsd0Li2k2vcuAd4jOFgj25/iGaAPYNW1Sz0i2S51GbybdpUh8woxVWdgq7iAdoyQNxwBnk1drwuLTvEOm/DnxlbeKW1OWXUrNLKxs7xw++6kV4x5Tm7uHJZ2TI+QDbkKPmx7NPdR6Toz3WpTqsVrBvnmY8YVfmP6U0nJ2W4N23LC3MLXT2wlQ3CIsjR5+YKxIBx6Eq35GvFPi58UZpLs+FvAzPcanM/kzXMAyUbOPLj9W9WHTtzyPHPEHj/WtT8R65qdrdy2i6on2dkRvuwAjame3A5I65b1Ne/8AwN8F+HtH0aPV9PvbbV9SmXEl5GcrDkcogPK9ecgMfbpX2MsnpZJBYvGe+9OWNtOa2vM9rJ/eeYsTLFP2dLTu/LyJPgz8MYvB9qNS1UJNr06YPdbZT/Ap7t6t+A45PqNFFfL4zGVcbWdes7t/1ZeR30qUaUVCOwVyvw0/5Fy8/wCw1q3/AKcbiuqrlfhp/wAi5ef9hrVv/TjcVymh1VZniWKGbQL9LnHl+Ux59RyP1xWnWJrEgutQhsi6pbQL9qumJxhR91T6AkZPsKAK2qaoui6JHM4hhlaPcdw2xoQu53bH8K9TXxL498WReMPEN3f6i902mWTkJDJkyXTc7Sx6AE4+UYwvvXrvx98YDVotM0i3eSJ9Ub7TMAeYrBCWBb034LEHsFrxrXNHsYb23snuJPt0kDT3EQG7c0sfmIVHfAKrj1+tAEnw9ma71zTNT1GNH+wXMgWNRhWUQtIEx0wCo49K9o8HfDGPxV8PtPvgPPu0vRcv9onaMTcKzNuAO1tx645HHpXMfDn4far441C+WzvINK0XSDJaxuIt7STyqPMbGcEgDB546CvbbP4etd6LBpMXiLV4tLtV2CAxIEeQfxdAWXP8J4NAGtpFnocXh/8AsDX9U0q8aaVpGtRcgLES2QkYzuAU9O9dZpGl2Oj2f2fS7eO2gLFyE/iJ6sT1J9zXBy6VceE9LDavYaZr+joALmSLT0hngXu+xRh1HfGCBzzird54cv8AStPkvfh1erEkse82MrebBJnkPEWPyPjp/CcjIoA9BHSuW8Q6BpMdxNqs2p3eiySYE9xb3fkLIRwNwOVJ/DNY+g6dqOtaYt/pnjDV45wxV4rmGI+VIPvJJHt4IPb06Vn+LNTuYkht/E1pBDqli/2nT5o0aW21AgYaMLglXIONpz6g4oA6D4e3HmXniCCPVp9TtYLmNYJJpxMQpiUnDDjBJPFdnWdoMdv/AGZBPbacunG4RZXg8oRsrEdGA7jpWjQAUUUUAFFFFABXzXq8b+I/HWoW73G9b27e3bBjYxF7jyFBH3gVhhLAHHOG96+lK8B0Tw01reaF4zVS0V/qguZ2OAsQln2JgdTkPnP06dwZ71bwRW1vFBbxrHDEoREUYCqBgAe2KkoooEFfP3xq0ZIfiPaT20cIk1ezMblwBudQY+GJABKsgGSBuVeex+ga+f8A9oKdL7xtoenRThJbeBZJMHG1ZJQDlu3EeeetAI9l8E6jJq/hDRr+4Obie0jaX/rptG7/AMezW3XL/C+FoPh7oCuCC9okuD1G/wCb/wBmrqKACiiigAooooAK5X4af8i5ef8AYa1b/wBONxXVVyvw0/5Fy8/7DWrf+nG4oA6qiiigAooooAKgu7S2vERLy3hnSORJkWVAwV0YMrDPQggEHqCM1PXL/EnRNQ8Q+FpdO0tNOklkljMkd/GjxvGGBYDfHKobjIJjcAjpQBtDSNNWVJF0+zEiTPcKwhXKyuCruDjhmDMCepBOetc1ruh+DdE023tLrwtpLWOo6hDAbeLT4TG07kqkjqQAcZPPJAJxXA6L8G70WCWviBNHvYYLHU4LaJz5iwSXEySQlQIkUbArZKquCRtUdrsPwz1keILC9u4dDvpob+yvG1W4mka8ijhjjV7eMGI/KWRmB3rnccrk5oA7vxB4C8Na5aQQ3Gk2UMlssaW1xBbRLNbojhgkbFTtXjGB2J9as3nh3w1DqD6jP4f05767fypLlNOWSWQuCh3sqE7SpIJbjBOTiud+Ivw/XxhrP2q5g064gj0W9soFugWMd1K0RjlA2kAKEb5hyCRgemTZfDC507UEbTP7NtLPzdJuHjiLLultmlM8hG3Bdw6YY8sV+bHcA7+fwt4fuJ5prjQtKlmmgFrK72cbNJCMYjYkcp8o+U8cD0qVfD2iroh0ZdI04aQwwbEWyeQRnOPLxt689OteA+H/AAJqupXuoaZBpNrayx6HPp9xrD29zbnULhrmFxJK0sKMzFYnOVMgGfvYIrrvE/wv1S78bafqGhw6BY6ZY3lrcwNFHHDOiJIHmViLdncsS5yJkB3HcDkkgHpHhqPw/eeHDBoFpZLojPPbG3ithFCSsjRyr5e0DG5XB4wfcGk1yLw9pOnzXeq2dlHaytbWsjG1D7/3oSBCApJAeQbey7s8cmvI7v4Oal9gis7Ky8PxQQX91cMImjX7fHK8jRmYSWkqq0IcKo2vwTgpxnuPEPgafVPhRY+GSlrdXloLRkGozefGxhkRijSeWCQyqybvLHDfd5IoA6a+8JeG9Qiiiv8Aw/pFzFE0jRpNZRuEMjFnIBXgsSScdSSTWPc/DvR7nxtb+Jpi5u7d1kihS2to1UrHsGZFiEzAddrSFc44wABy9p8OdTi8TW9+thoFoi31teLd28rm4soY40VrGECJQYSVIByow5ymea9boAw7fwh4btmu2tvD2jwteI8dyY7KJTOrEFlfC/MCQMg9cCtTTrG00yyis9OtYLS0hG2OCCMRog9AoGBViuW+IHii68JaXHqcelHULFW23BSbY0IP3WxtORnjtjIqZzUI80tjbD4epiasaNJXk9tUvz0OporyjT/jn4ZuMLd22o2jdy0auo/FWz+lejaBrNlr2mR3+mPJJayfdd4njz9AwBI9xxUU69OppCVzqxmVYzBLmxFJxXdrT79jRooorU88KKKKACiijvQAVm6fqi3OoXlhPGbe8tzuEZbPmRH7si+oPIPoQR6Z0qw/E2mzXCwajpoH9rWBLwc7RKp+/E3+ywH4EKe1AG5RVHSNVtdU0y2vraQCKcYAYgMrcgoR/eBBBHqDUt5fW1nLax3MqxvdS+TCDn532lsD8FJ/CgCzRUcs0cJjEjhTI2xAe5wTj9DXO+I9Wupr9NA0B1GqyoHnuCNy2MJ48xh3c8hF7nk8A0Ablpf213c3UFtIJHtmEcpXkK+M7c+oBGR2zVqqWj6ZbaPp0NlYoVhjB+8csxJyWY92JJJPqau0AFc14+8MP4v0MaSdRlsLSSRWuPKjDPKo5CAk4Azg9D0rpaK0o1p0JqpTdmtiZRU1yvY890D4PeDNH2t/Zhv5V/5aXzmXP1XhP/Ha7y1toLOBYbSCKCFfuxxIFUfQCpqK0xGMr4l3rzcvV3FCnCnpFWCiiiucsK5X4af8i5ef9hrVv/TjcV1Vcr8NP+RcvP8AsNat/wCnG4oA6qvM792v7bUNhIk1zVfsTMD921hBDH/vlH/76r0tztRj6DNeKveJD4cv7tpdsek6UVDHoJbpzlvrjj8aAPB/iZewyT+L/EMNws9zdCLTkjVcLaRvuPlKfURooP8AvEVm6PGL/wAQ2WozKqysIlM5OTHttsx/QblBP0rP0rT9W8S22u+GraHdqdxrML+V3X/WKzH0UDBJ6AVsX0As5vEeoWAdtKtLUwW7AYWdwnko6j3PmN9AaAPoH9mxJdM+Gd9C0fn30Gq3EUpT/lpJkDcT6d69atI10+wP2iWNFQF5JScKO5JJ/ma+dvgBrHiGbxBrUWiLZNoV7bRaoHut4WOQgK6gr33Bsj2r17Q7K+8Y6Za3/iWSIadIS8enW6FY5gG+VpSxJYHGdvTp1oAnuNe1bXkvLXwxpiNbsPLi1W8b/RnGPmIUfM2DwOx9cVHbaNrPhqDToNNUXtja26RP5b7ZXYDBJQ/KR9CDirMsl94SuXcmS90CRs7cZksyew9U9B26V1VvPFd26TW0qyRSDcrqcgigDgLrVLez1e417Qi5lUKNZ0xlKSNGB/rgh/jUdx1XjrXfW8ltf21tdQ+XNE6iWGTGeCOCPwNY/ijT7C+a3+3xywyL/qdQhO17du3zdQD78HvXO+Apb/w5rd14W1hR9nfNzpdyoxHKhOXjH90qTnb2B44oA9CooooAKKKKACiiigAribfwVdQpBpv9tO3huCdbiOwNuvmDa4kWIy5/1YYAgbd2BjdiuynkMUEkixvKUUsETG5sDoM8ZNYHhXxt4f8AFKD+x9Shlmx81u52Sr65Q8/iOK1jRqTg6kYtpbvt6kuSTs3qzo6KKKyKK2pXtvpun3N9eyCK1to2llc9FVRkn8hXzutnceMNdurq9t4E1DVrsW0HzZktsAbxjjiO3yGHP7wrnBAz2n7Q/iI2Oj6bodvIFl1CbzJxt3HyYyDjH+0+wfgeDV74NaOrwS63KpIUNaWpY7ycNmeUt/EzSDbn+7Eg6UDPTIYo4IY4YUCRRqFVVGAoHAAp9FFAgooooAKKKKACuV+Gn/IuXn/Ya1b/ANONxXVVyvw0/wCRcvP+w1q3/pxuKAOqooooAKKKKACuH+Meq61o/g1ZvDFylrq01/aWsMkkauv72dEIIYEYO7Hr6EV3FQXlna30aR3ttDcRpIsqrMgcK6kMrAHuCAQexFAHjGjfFLVLvX9V1O5EdroP9lRTWNheK0RM3nCF9zJG8m4y70ChWztGBzSzfE+7u5INZawuLT+yIdYF3pwnlRLh7eCKVc+ZGjDIbjfGCuTx6+u6lomlap539paZY3nnRCCT7RbpJvjDbgjZByu7nB4zzWVe+B/Ds/h++0e20my061uree2LWNtHC8Ymj8uRkwuAxUKM452jOcUAcm/xGvRqcNhqemGwuYruzMgsrwXCPDPFM6hi0IO4eUcoADypD4znE8RfEfWNU8KyGDTItOe80+21axltdULytE11CgSTEahCwfnDMOo5r1LSPCug6PZQWum6Np1tDDIsyLFaxpiUDAk4A+fBPzdeTWF4b+Geg6HqV/feUt7NeII5FntLWNAoff8AchijVjuCncwZvlHPFAGQ/wARbiHVfs2r2kOmT2N1dW94EvhJakR2a3AZpGhD7cOOgUgg/eHBqad8WL+/eW0h8ORf2mL61s445LqeGJxcRyOsm6W2SQAeUc/uzkHIJ6V6RNoekzzSyzaXYSSzMzSO9uhLlkEbEnHJKAIc9VGOlVtM8J+HdKAGl6BpNkBIso+z2cceHXdtb5VHI3Ng9RuPqaAOZ1PxhqN58IPEfiHT7aOw1axtr9QhlEqxTW5kRmVimHAMZYZUZ4BAyap3nxJvNF03VDrWk2ovdN0a31RhDfFkn82WSNUVjEuPuA529W2gcZPoUWnWUNpLaxWdulrMXaSFYlCOXJLkrjB3FiTnqSc9ayH8EeFJILaF/DGhNDbBlgjOnxFYgxJYKNvy5JJOOuaAOA0/x5qmg3OqLqNj9vsJ9b1G1tZvtzNOGiSSUJ5RQ4iAjK7gxxn7uKk8X+PptQ0S3g09JLKea20XVDPBdHci3F9EjQ8AHG3IJz8wbGMV6LbeGdBtdXm1W20TS4dUm3ebeR2kazPu+9ucDcc98nmorLwh4asUkSy8PaPbJIULrDZRIHKPvUnC84cBh6EZ60AcJY/FfUtSa8fS/BupXlqgn+zyRpcDe0UmzEhMAjGfmI8t5T8uMZ4rs/C2qp4v8NzSX9taqJHktri2jeVwuOGRxLFE6tzypQYqW48GeF7m6u7q48N6LLc3YIuJZLGJnmBIJ3krlskA8+laml6bY6RZJZ6VZW1jZx52QW0SxRrk5OFUACjcabTuj5r1f4S6ovje70bTHQQNA95ZyzEhXjDKNhIH3gWA/I8ZroNL+JPirwPPHpfjfSpbiFflSY4WTaO6uPlkA/P1Ne/YG4HAyOM1BfWVrqFs9tf28Nzbvw0cyB1P1BrgWB9m3KjKz/A+snxT9cjGlmFFVIJW7Sv3T6X6o5nw18RPDHiFUFnqcUNw3/LvcnypM+gB4P8AwEmuuryvxJ8E/DupFpNKkn0qY9o/3sf/AHyxz+TCuWXwH8SfCv8AyLetfa7dfuxJPgY/65yfJ+RNV7avT/iQv5r/ACMXluVYzXCYnkf8tRW/8mWh77RXgn/CxPiPoQK634d8+NRzK9o6/wDj6Hb+lWrX4+xAlb7w9LGw4Pl3Ibn6FRimsfR+02vVES4UzFq9FRqLvGSf6o9xrk/HcM9iLXxLp6s9zpW43ES9Z7RseamO5AAdfdMd646L48+HSD52m6svptSNv/ZxXqGjahDq+kWWo2oYQXcKTIHADAMAcHBIzzzzW1OvTq6Qdzy8ZlWMwCUsTTcU+5PZ3MN5aQXVrIstvOiyRyLyGVhkEexBqauHtdQtvAl9Lp2sXEdr4fnYyaddSnbHASctbseigHJTP8OR/DXTWmvaReAG01WwnB7xXCN/I1seecPr1ncJc+I5rBRsstQtbxIs4AfywZWGO5DDPr+NbOuXseo6v4MktWV45L55CBgkYtpevp1FXLG/trPxNe2N0VRtTcT2kpIKXAWNVdAf7y7c49DkdDjxf4jrqFj8XtC07RtUgs9OimRzCkoWRHlOHIB5+7jGAaBnqviXUpZtclayQyRaPay3Tv8AwGYI21Cf5/Xsa3vCempYaWszEyXt7i5u52+9LKwGT7AdABwAAKyfEKaf4f8AC1zpdtve91CKS3t4V+ea4lZSM479cljwOpNdZax+TbRRn+BAv5CgRJWbqmrR2V5Y2aIZr28crHEDjCLy7k9lUfmSB3qXWdTttH0y4v75ysEK5O0ZZj0CqO5JIAHcmsvwtp1wZbjW9WTbqt8B+7Jz9lhHKQj3HVsdWJ7AUAdDRRRQAUUUUAFFFFABXK/DT/kXLz/sNat/6cbiuqrlfhp/yLl5/wBhrVv/AE43FAHVV89/FOzOnfBrx4tuSTPqzQIFHSMOoVPw5r6Erxz4hwmX4Q+OgmPNhv55unQrKrfywaAPJtL01dP0jxDf2zPHrWuySaWJ4zlokhtw9wV9CzYUn61zvxQ1G2s9Q0TSU2RWEiyQyMBgK3lrEp+i9fxJrU8DfaLo+FtOnnLlbvUbRpMnDNdQq0T/APAgDz7VzPiSGDxzpFs8OLfXreLDwE48xosRzKvuVCSe/wA1AHuHwN8OP4H+CeqarOd1/fRyS8NlQoykYX2JOffIr2BLGex0rTmsdxms4EjaAH5ZUCjK4/vehrnPEVl9j+Gek6PbqoLiytFUcA4KnH/jtdPoGuQ6sZoWRra/t+J7WTh09x6r70AXNM1C11exFxat5kLjayOMMp6FWXsa5G8e48I6ksNkJZbO5YyRwHBVsDLKD1D+nr+FdNJosTXkt1DJJbTuQd8XBz3B7MD6Go9XsotQsI9P1SYLcyMWgniBVkdeVZfRh1oAvaZf2msaetxaOssEgwQRyD3Vh2NZ+taG15pRhhlIurdxPZSEcxOvQZ9O30NYFnZaha3TS2Lwx67Bze2wGyG+TtIo7MfX1yDXSaX4gsdQjX94be4yVaCf5XVh1XnqaALOg6kuq6ZFchDFJyksTdY5Bwyn6GuW1H4efbtQurr/AIS/xjb+fK0vk2+p7I49xJ2ou3hRnAHYVct7mHT/ABYktvIp0/WQVIHAW6QdfYsox9Vrra3oYmph23TdrkThGfxHn3/Csv8AqdvHH/g2/wDsKP8AhWX/AFO3jj/wbf8A2Feg0V0/2piv5/wX+RH1en2PPv8AhWX/AFO3jj/wbf8A2FH/AArL/qdvHH/g2/8AsK9Boo/tTFfz/gv8g+r0+x51cfDcQwSSnxp47cIpYqmqFmOBnAATJPtXk/hf4IeINWvjf6xdNo8DyGVRI/nXR5zkkYAb3JzntX07RXXhuIMbhoSjCSvLrZaenT77mc8HSm02tjO8P6X/AGNpUNl9tvb7yxjz7yXzJG+pwK0aKK8ac3OTlLdnSlZWR86fGnVry1+KMN1aTiJtOto2VSq/Myh5BySO7dB1x3r3DwRax2fg3RIIQAiWUPI7koCT+JJP415L8btMtbbxtpOpX9qHsrvyhJMSxC+UzeYpVeSWR1x/untmvSvhnqAu/ClpZylRe6aosrhA2eUACuPVXTa4I4IYVJR1dFFFAgooooAKKKKACuV+Gn/IuXn/AGGtW/8ATjcV1Vcr8NP+RcvP+w1q3/pxuKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq9zZ2t2ALq2hm/66Rhv51Yootcak4u6ZiS+E/DspBl0DSXx03WUZx+la1tbw2tvHBawxwwRqFSONQqqB0AA4AqWipUUtkaTr1KitOTa82NkRJUKSKroeCrDINZr+HdEdiW0fTiT1Jtk5/Srmo3kOnafc3t22y3t4mmkbGcKoyT+Qrw7WPG+teLbuS306RtNsnAEUYfy2Pq0r8YGDkgEAe9UZHWeM7rw14alaHMLwTOvnaRbDLrJ/DLCq/wCrk/LcPcc+BeKruDU/Hdxfy3c4u1ngSJriEs6YA2hnUbN4Afqfz6j1Dw/pNvBIY9JtUvdVus+TMg2qAeGlBI6gd+27J5AB5i60zUR8XLPQ4rydbKOaNCgAaz81YxjdGTkt0AJ5IoGem+GWTxTqFw+h38lmcAahez4Ooy88Rxg5EUfX5h7Y9a6mfwVC6bYNd8RW3OSYtQbn/vrNeUalp7faY7aMXGm+IoD5KSRSiNpNuB8rdztYHn+7no3HT+CPiLeW11baX4yOGlcwxXzIIyHBwEmUcKT/AHhgeoHWgDr9N8EW9rqdte32sa1q7WzF4ItQuFkjjfGA4UKMsBnBOcZ45rrKKKBBRRRQAUUUUAFFFFABXK/DT/kXLz/sNat/6cbiuqrlfhp/yLl5/wBhrVv/AE43FAHVVw2o6Zbza54g0G9OLTxBaGaMY4DhQkmPfGxvwrua57xrZXE2nw3+nRmTUdNkFzCi9ZABh4/+BKSPrigD40s7bVPCvimXwrqO6HUI1aC0nQ9LiFzJbSD2OcZ9GNa1ta2Pi3xX4b1mxtzFa3mpRXd1CvHkuzrHOn03hW+j1754+8J23jiz0jxV4cSGa/gMc2xlAN1ErBvLyfuSAggHtyDXzdor6l4bg1mK/sL7SbnTtRg1O3gnRtzjeEmjBAwcqQ3/AAEUAfYXjYcaGONp1aD+tWfEegR6t5dxBK1nqtvzb3kf3kP90/3lPcGsnxrfRXPhLTdYgybdbq0vFz/dZx/8VXXRTxT7jDJHIAcEq2cH3oA5bS/GMMM503xKBYarFhXYg+TJnoyt6H3rq2ENzEpOyWPIZSOR7EGsHxfobapbx3FmkR1K1+aLzFykq/xRt7EfkaxdK0tpLBNR8G3b6fPnbNYXRMkJYdY2B5Qg/wAQoA6q6t/tt1zG8FzbHfBOOjAjkfTsRVbyhfTeZGEg1KDHmxuMo4Pr6j0PUUzS9dnuW+zXdg0GoJ9+DzFx9VJxuHuK1HngjntzcKIp5QUQsPx25oAxfiAqw+H1viAHsbqC6U+hEgB/QmumHIyK5n4kgHwPqwIyDGB/48K6OEbYYx6KBQA+iiigAooooAKKKKACiiigDn/HXhm28W+HLjTLrCO2JIJSM+VIPutj06gjuCR3rwzRrvU/CHiCVriZ4NagTF19pkYwugDERuMFmjIB8uRSdgQZHL19J1geLvCOkeLLMQavb7nXiO4jO2WP12t6HupyD3BoAr+HvG2kaw620ky2Op8g2Vy6q5IJBMZztkXIPzISKd8RNa1Hw94UvNU0mCynnt8O4u5jGgTuRj7zdAFyMk4zXEx/DHU9Os7qwtLnS9UsJ3R1TUI2V4SpJynDoCw4YhBkDpVfS/hhrMOorO02k2iqMI/N2YDkEPGjIirIMYDHIGc7elAz0jwZrbeIfDlrqMtubaZy8csWchZEdkbBPbcpx7Vt1S0TTLbRtJtdOsVYW9ugRdxyx9ST3JOST3Jq7QIKKKKACuV+Gn/IuXn/AGGtW/8ATjcV1Vcr8NP+RcvP+w1q3/pxuKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZPDHcQSQzoskUilHRhkMp4II9K56z8DeGrN4mg0i3/AHRygfc6qfUBiRXSUUAc14SgiGo6/O0Y+2C+aBpCORGqq0aD0UK3T1JPevDtJaDUf2obhEjsGura6lLMPMNyFVD1P3NvTjryK9q0CZ4/iD4rs2P7torO7QAcAsjo34/uhXE+FvBWuWfx41zXb1UGiNG8lqwX7zvgHnrnBbNAHa+K9Jsb3X9JW4RJGvWe3ngcZWaNUZw3syHGGGCNxHeuc8U/Cgawkot9ZljZ+N9zCJnweoLAgn2Jyck88100EsepfEe5CtuGjWSxlcfdlnO4/wDjka/99V1VADIU8uFEznaoXPrin0UUAFFFFABRRRQAUUUUAFcr8NP+RcvP+w1q3/pxuK6quV+Gn/IuXn/Ya1b/ANONxQB1VFFFAHFajY3/AIW1C61PRLaS/wBLupDNe6dH/rI3P3pYR3J7p36itTTvFGg6tb7rfUrN8fejlcI6ezI2CDXQ1l6l4e0fU5hNqGmWdxMP+WkkKlvzxmgDE8YaloV74Z1Oyk1bT1823ZVAuE4YDK4GfUCq2mWVt4g0bT/EHh++FvfzwJIZ4G3RyvjlXHfng10dp4c0S0Ia10jT4m9Ut0B/PFcpe+D73w5q0us+BXWJZ38y90ZziC69Wj/55Se44PegDe0PXTc3T6bqcX2XVohkxn7so/vIe4qPWdPvbO9Or6FGslw2Bc2hO0TqO4PZwPzqpJLYeMtOaSyYw6nZtgxSgpNbuP4HHUZxwfxFVNB8YmLV5tG8QJLbXKOFhllXAkHoSOCfcdaAOsH2HVoAHRJQvVXGHQ/zBpbSzlgBhlm+02w5Tzhl1OehPcfrS3Wn291Ok0iMlwn3ZY2Ktx2yOo9jVqEFIlVnMjDgsRgmgDnPiE4fQ4LPq99e29uq+uZAx/RTXT1y/idPtHiXwtCfurcy3H4pGQP/AEKuooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfhp/yLl5/wBhrVv/AE43FdVXK/DT/kXLz/sNat/6cbigDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+oXlvp1hcXt7KsNrbxtLLI3RVUZJ/IVYrkPFbNrev6d4ZiTdakC+1JiMr5Ct8kf1dx0/uo1AFnwHDNNp0ut38BgvtXcXLxMcmKPGIk/BNuR6k101FFAHJXYGkfEayuFRhDrls1rKw+6JoQXjJ9yhkH/AAEV1tc54/sxceG5bpFY3OmOuowbOu+L5se+RuXH+1W7Z3MV5aQXVu4eCeNZI2HdWGQfyNAE1FFFABRRRQAUUUUAFFFFABXK/DT/AJFy8/7DWrf+nG4rqq5X4af8i5ef9hrVv/TjcUAJq3iDWl8UXekaHpOmXS2llBeTT32pPagCV51CgLBJnHkEkkjqKytF8Za3rk00WiQeCNRlh5lS08UPMY+3zBbQ4/GrwdI/iH4reW3e5jXQdPLQIm9pR51/lQvcnpjvmvOPhW+p+JPirL4o8RaNqfh7yLJtM0rSm0m5iWOAHcWlmMYj7HC7upwAMDIB3GsfEG50r4ZXvim40eFry0vHsXsUvCYy6XptSRKYwduRu+5nHGO9efW37QWq3NxHBbeCoJp5WCJHHqzszsTgAAW+ST6Vf8f/APJv3iT/ALGG5/8AT41cv8J9Bs5NN0rWrew/tLU112CCX5nxZQ8N5u1CM892yvtW1OMXFtm9KEXFuR6P8NvipfeLfGNz4e1Lw2NIngtJblmN60rApJGhRkMSEH9569uleqV4B8Nf+TlPFH/Xpf8A/pTb17/UTSTsjOpFRlZGBr3hmDUrpNQs55NO1iMbUvbcDcV/uuDw6+x/DFYl9/atv5J8SaDb6zFGCPtmnD50H/XJuc/7pNd1RUEHn9t4l0vT3kWHW7iPedxg1G1lLIeOASAce3NareNtKYYs4tSvWPRbewlbP0JUCurIB6gGigDkNDg1LWfEqa7qFpLp1lb27W9paTkGVmZgWlYD7vAwB1rr6KKACiiigAooooA83tvHevN4U0zxFfaZ4T0vTNQghuIpNQ8SSQYEiB1VibTbuwegJ6HrViPxprf2Cy1P+zfDV5o9xe21m1zpuvPckedPHCGUfZlVsGQEjcOBVLw5d29p8H/ApubfVCW0qzEV5pun/bJbN/sy4kCbJCOMrnY33ueDXJ+B9Jv9H+Fk0Wo6fPZifxhZ3Fu9zGYri5hbUrXbLNGfuOem0BeFHHcgHvNFFFABRRRQAUUUUAFFFFABRRRQAVyvw0/5Fy8/7DWrf+nG4rqq5X4af8i5ef8AYa1b/wBONxQB1VFFFABUV3cwWdpNdXk0UFtCjSSyyuFSNAMlmJ4AABJJqWuV+LH/ACSzxl/2Bb3/ANEPQAf8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVVviD8QdP8EXGmwX+n6lfS36TPGtksR2iMxhi3mSJ/z0XGM965T/AIXvo/8A0LfiT/vm0/8AkigwqYqjSfLOaT82kdp/wsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVT/h/4zsvG+mXd7p9pfWa2t0bSSK8WMPvEaPkbHYYxIvf1rp6DaMlJKUXdM5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooGcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUAcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUAcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUAcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVVyvxY/wCSWeMv+wLe/wDoh6AOqooooAKKKKACiiigAooooAK57wjpd1a/2hqWqoE1TUpzLKgYMIo1+WKIEcHao5PqzGuhooAKKKKAEIBBBAIPBBrm/A4ls7S90e4XDabcvDEf70DfPEfwVgv1U10tFABRRRQAUUUUAFFFFABRRRQAVyvw0/5Fy8/7DWrf+nG4rqq5X4af8i5ef9hrVv8A043FAEureFpbzX5tXsPEGr6Tcz2sVpKtmtsySJE8rISJoZCCDM/Qjt6VF/wi+r/9D34k/wC/Gnf/ACLXP/GS+1a6TTPDPhn+0/7SvzJczvpcyRXENvEPvKzugGZWhU/MMruHPSuB8bfEW917whdafdXOlaQ502Ez215GXuLy585454oMSKB5bxEE4fqDgDkgHq2ofD+w1DwDc+FLzUNSktrm4a6lvN0QuGla6NyW4j2D94TwExjj3riv+GefD3/Qf8S/9/LX/wCMVcuviRNNq3/CPzPpq6lJrF9p81qN3nR2kcE0kUu3dkFtsfzEYIJwPTjfBvivWfD2gqI9f0KFY/DmjTWWn6q3lBlaFVd42edF4OSeAGOxSy9S1JrZlKUo7M9J8AfCfR/BGvyavp+paveXL2z2m28eEoqM6MSAkanOY16n1r0SvOk8Wz6l8Ftd8RCaK4uYNPvZA8UT2yM0Sv8AdMc7nGVxvjlOeqsOMZ9h428QvrHzDSjpEeuQaKYfIl+0MJLaOXzPNMhGQ0mMFDkdweSNt6sTberPVaK81+J/jm98L65aWVtqOhadDLpl1febqkbOZpYmjCwxhZEyzB24G48cA9KztK+KV7PewadqUNhY61PrNtaDTpN3nraS28chkK7s5Duy7sbeMYzSEet0V8/aB4y8RaJ4Nt4dF/skWel6Fb6lIl3bySSTNJdTxlAyyKEGIwc7W57Ht0d/8QNf0vULrSdWvfD1jLbamLObWp7aRLONDZpcKGjM2Q7F9oJlA46Z4oA9eorxaL4k+KLmxutRit9IgtbCw0+9ngltpi9x9omkQ7G8xdilY9yllY/MMg1U1L4x6lBruvWth/Z93b2llqc8IktxFJDJbIzIsii5eQqSpBLRw7gMrkHgA90orzHWvF3inRp9OtZ4dMurnXIUTSzDbSKkV0XXckpMhLqsbmTcNmRE/AJAr04Zxz1oAKKKKAOK0nwPe6RpVlpun+NvEkNlZwpbwR+VYNsjRQqjJtSTgAckk1LceDLq8a2XU/F/iC+tobqC7+zyx2SpI8MqyoGKW6tjci5wwrgv+Et1xPiHL4k8jVZPCTXj6JEVmj+xsB8iyBN+7zDdBk3bMbWHzHpWJa/EHUZtVfxOt7od7eRaCkk1rawuF09XvIPNjnJkJLojMScJjbkrigD6IorwrxJ4tm8Va9avol3ZyRafrF7a6fd2oaQP/wASaSTdkN8x3uwBUjgDHqTQfiVqdtb+ELWbxD4d1G3vLW1WaW3jWe7aV2CGNojdiTcOAZFWT5ixKKFOQD3WivO/il40vPC+r6NZ2upaFpkN7aXs7XGrRs6l4fJ2RoBImS3mNxknjgcYOOPiB4ol0XWNUGn6fapptrZzS2k0Ejyq08EbtuIcbViZyx4JKqRhT81AHrlFeNL8TtSaeO1Or+GUsmvZbceJDbyGwkCwpIERPOGXLOV4lIyhxk/LWB4J+I8/hn4e2Gnztp0MsGh6XNpUc+4PdtKzpNgbhvChV+7jGecigD6EoryLVPiTqdrb+J7iO50Q3umSzxReHzEft2xJAguHYzKCm0+bwgG0j5+9dN8KfFV/4r0m/uNR/s+TyLnyYp7GaF0kXYrfMsU84RgSRgyHIweM4oA7eiiigArlfhp/yLl5/wBhrVv/AE43FdVXK/DT/kXLz/sNat/6cbigDqqKKKACuV+LH/JLPGX/AGBb3/0Q9dVXK/Fj/klnjL/sC3v/AKIegDzL9pP/AJGHwj/166h/6Ha1ycumxD4Zw6kG/fNqhgx5cf3fKJ+9t3/hu2+2ea9h+Kfw8uPG97o9zaaxFpr6fHcRkS2ZuBIJTEe0iYx5Q9c5rkT8FtfNkLM+NrY2gfzRB/ZMmwPjG7b9pxnHGaD53MMtrV8RKpBJpq2/U0v2av8AkW/En/YZP/pJbVS0TxNd293fWvhnWLe9uL7xY+meZqF1NqCW0H2WSUbU84EfNGwABAPI7DHcfC3wXN4I0fULO41KPUZby9N40sdsYFXMUce0KXf/AJ55znv0rs6D28LTdKjCEt0kvuR88z+JNb1HVv8AhKrmy0nULrRtEnnis/sTviVLuWFpIiZf3ZPlKxOCdoK5/irY034q6zdWUBurzw1YW0199n/tqZ4pbWFfJL7ZI4buQI5YEDdMMjnGeK9uooNzwmXxZqtrqvitbjxHpeoqb/SXtbWHzoWkhmNkpngK3BIg/eNkDcrMTliCVOvqfxJ8R2kOvwxaRbTX/h6OU6iFicIS0qi2aPLAbTEWlbLdFxkZyPX6KAOF+GHi2/8AFGh6nd6gdMc2s5jiuLSeExyLsVvnEU84jIJIILnjBwM4rzeX4ja3q9hY3EniLQ9Oaz1a1W7uLeDfZxJIkww88d4yyJuUcMY2+6Sq7hX0FRQB4TN8ZdTi17UrWxisdXt4La+ljSK3EEqvAMgMouZZNpw3LRxkgZXcDT7v4s6za2eoNa3nh7Wo4Lqzg/tPT4dltAs0cruz+ZchTgxqmTLGMtzzwfb7iJbi3lhcuEkUoTG7IwBGOGUgg+4IIrN0Dw9p2gi5OnR3HmXLB5prm6luZZCBgbpJWZiAOAM4HagCl8O9bvPEXg+w1TUktEupvMDfZJo5Ym2yMoZWjkkXkAHAdsEkZOKg+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IegDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfhp/yLl5/2GtW/9ONxXVVyvw0/5Fy8/wCw1q3/AKcbigDX1zxBo2gRxSa7q2n6ZHKSsbXlykIcjqAWIzWT4r8feGvC+mz3mp6vZZiAIt0uYvNkyAQFVmGTtYN9DmqvxH8Iaj4thtoLHX5dLtkSWO4gVZdk4cAAkxTRNlcNgEsp3HKmsu1+GCQeGNb0r+1A02pWNpZ/avsoBj+zwpGGI3fMCU3bcjGSM96AOsi8W+G5riygi8QaQ898A1pGt7GWuASQDGN2WGQRxnpTV8V6LLqdpY2eo2V3PO7IVgvISY8JI2WUuGIPlOPlDH5SSAFYjjr/AOGN1qPiY6zf6zBM9xJbTXtuIruKGR4CNrRpHdqq8KpG8SYYZ74q23wzgk0PRtMk1FhFYz30srxQbGmFzFPGQDu+UqJ87uc7OgzwAdKnjPwvJYXF9H4k0VrK2cRzXC30RjiY9FZt2AT6GtawvbXUbOK80+5gurSZd0c0EgdHHqrDgj6V5dYfCS4tNPliOrWc95i3SG7miv2kiSHftwft2VYbzgxlAMsMENgekeHbC40vQ7Kyvb+XUbmCMJJdSjDSn1PJP5kn1JPNAEj6VZvrUOrNDnUIbd7VJdzcROyMy4zjkxoc4zx7mrtFFABRRRQAUUUUAUbnSrO61Wy1G4hL3dkJFt3LthN4AY7c7SSBjJGQCQOpzeoooAKKKKAOeu/G/hSyup7W88T6Hb3MBImilv4keMg4O5S2Rg8c1K3irR43meXULOOxis4r43z3cIhMUjMqtnfkAleGICnOAxIIGHaeAIoNZsNQN6jm11q71gp9nHzmeKSMJndxt3g7u+0cDthw/CVreCz+za0i3NlbWcNuz2W6MPb3E0wZ03/Mp84rtBBG0EN6AHcweLfDlwLcweINIlFwAYSl7G3mgs6jbhucmOQcd0YdjXP+KPib4f0vRYL3S9W0LUmnu0skJ1SOOBHbkmSUbtgVQSeCenHNPu/As2rXOs3WvalBNdaron9izPZWhtwib5mLpukcjImUbSTyme+BRsvh1ef2xa6pqmtW095BPZsBa6f9njMVskyqu3zG+Y+cxLZ6AAKAKAJovFOi3niiwvtTgtbNrLTbuYajLqCGKBftCQyplWKEM0ancTkYwQp3AdKvi7w22nx3y+IdHNjJu2XAvY/LbaQGw27BwWAPpketcb/wrG8t7SVdN8Sy2V00NzEtxFblSomvjdHlZAwGCYztZTzuBU8VL4N+GLaBqlnf3erLfzW95d3vzQSHLTxxIcNLLI/HlE5LMTux25AOmTxp4eVLP7drGm6fPdsywQXN9AHlw5T5drkN8wxwT6HByBfi1/R5tZk0iHVtPk1aMFnsluUM6j1MedwHI7V5prvwh1HU9Gj0mPxbNDpwidGg8iYJvad5d4WOdFJ+dVxIHHy5AGa2ND+Ga6T41OtrqX2i1F9c6hFbzG5Lwyzh9+0i48n+NhnyckcE5+agC14u+J2i+HpfEll5kM2s6NYLffYnuEiNyCjvsTktkKmW+XgMp5zW6fGfhddNfUD4k0UWCTfZ2uTfReUsuM7C+7G7AzjOawPGHgK61688Rta6xDaWuvaYmnXUclmZnXYJdjowkUDmY5BU5xwR1pniL4f31/qmoXuj+IJNL+2TQSSQxRSqrLFE0YRmhmikxyGG11+6AdwoA2rTx14eu/Fi+HrfU7WS/ktI7yErcRlZ1cvhY8NlmCoWIA+6ynPNdPXnvgb4e3XhC+0yW01mG4gg01NNuY5bNt0ypLNIjI3m/IczEHIfIHbrXoVABXK/DT/kXLz/ALDWrf8ApxuK6quV+Gn/ACLl5/2GtW/9ONxQB1VFFFABXK/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD0Acj8cviFrngi80CDQYtNf7fHcvK17C8mPLMIULtkTGfNOc56CuE0X4ufEfWmu10yy8Nzm0t3upv9ElXZEuNzfNcjOMjgc1d/ar/wCQx4P/AOuF/wD+hWtT6FeaDp2kzf2bd6Jb6fP4YkjctLCt3JeH7yvk+Zn0X7vp2reEY8l2tTphCPJdq7O7+CPjPVfG/hzUr3XI7FLm11BrRfscTxoUEMTgkM7HOZCOvYV1dj4p8P3+rSaXY67pVzqcZZXtIbyN5lKnDAoDuGO/HFeY/ssf8ibr/wD2Gn/9Jbap7Hw7r1zZ2+hz+H5bM2/iKbVV1iaeApHF9uaceUEdpN7odmGVQNxz6HKatJpGE1aTSPWrO7t723WeyniuIGJAkicOpIJBGRxwQR9RU1eC+JtF+Jcul2MGm22pfboI5HF3HqjZMhuZGVJF+1xpjy9mCUm4baQuKifUNYm+Jg0iC/1K41n7dqbTG31pXtxbG2m+zIbZJf3RVmhGXjU7wDuOakk9/orxh/C/jSxtbeO1uNdurWSw059RhOsEzyzrK32lIZHkzExXbyrIpAwCDzUN5ofjcW2nvb23iCbZcTmKxn1b5YoWlBjFxPHdxyM4UHn9+ApxhjzQB7Auraa/l7dQs2824a0TEy/POu7dEOeXGx8r1G0+hq7XjGk+E/FGlTzW+j2+q2cx8RXV493Nqnm201rIt2Yj5ZlY8PJDvBQFmwTuxkdn8MLK+stKZNX0/XrXUvLiFzNqmqC9SeQA7mhAmcIucnG2POV444AOtu7u2s0R7y4hgSSRIUaVwoZ3YKqjPUkkADqScVPXgt74P8V6hZ3cV5Y6/eQwahZ3sbXGrtDczrHchnRFW8eJSI8kMPJwduACARPNpXxC/wCEtS70221HSdPRbiPN3qbXEQjNs4heTfdyAsJPLLBYRggnewySAe51yvxY/wCSWeMv+wLe/wDoh68Y0K48R+I4dXh8GX+rSJBZ6ct0Zdb+3+dN5spuPJlS52ozKE+VZYjgD7m4V3l5ZavYfATxhBr8t7Jd/wBmaiyi9x5kaGJyqZE85YDsWkZsYz0oA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV+Gn/ACLl5/2GtW/9ONxXVVyvw0/5Fy8/7DWrf+nG4oA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8Z0nxlq2hr4ludS1nTb+20zXZPt9mYX+1Wlk0hXzRmZiEG5GA2Y2q2M5GK2ufFDxLpciJct4fs71tIg1WHTLiGQ3N20s8yrbR4lH7wRpGCQrfMScYIx6B4i13wne6XPZ+KtR0+ys2uHhMd5qMUImMLru5WTkBiuVODyAyjOK1bw6Dpd3L4lvrm0tHnt4rR72e5CRtGHZo1yTt+9I2D1O7vxQB5u/j6/tNVlsZNQ0bQLSTUNQU6lrPmzQ5hkRVhXdOgVyGLY3hQFO1fTG8TfE+61DWdd8Nwy2N1p8tpqdsxW3WGaF4reRs4+0u5UlGGWijBGCpNevzeMPDUGm22oTeItGjsLlikFy99EIpWHUK5bDEegNJqnizRdOZ4pNSsZLxGVTareQpLk7D0d1H3ZEbk9GGM5GQDyjQfE0/hF/EGrvCs2jx3tgmobY2aVEbS7YRsmD/AM9NikEHh+2K9C13xHqPh/4aHW9dNtaaqkETTiK3MsUUrsq7dpkTIBYAs0ijuSBSeK/EPhW90/UbaW/0zVL3SVfUG0yK/USGS2JfDopz8roMhgQCORxV/SfG3h3UNBbVRrekpbQohunF9GyWrsPuSNnCnPHOKAPP/BfxH8ReKZdPs7b+xorie8vbZ7owmSPbCkLo6pHO6nIlIIErDuG7G58M/iNrPinxXLp+oWmn28Iimd7ZZYFubRkkCqroLh5GBBOSYosHHBBr0FfE+gvHaSLrmltHdhTbsLuMiYMwQFDn5ssQox3OOtY+oeP9E+w29zoOoabrYfUbOwkFlepJ5X2iZYwzFd3TcTg4zjGR1oA891HUr/Q/H/jDW3k0NSmp2mlLqF7Ys39nQSW0Um9pPNGIhuwV+UF3DFgOKnb4u3tnpt1c6m+jxxf2VfXFhdbXSLUbmCYonlBnyUdcNtBJwchiOa9C8T+NNN8NeItH0/WZ7OytNQt7mY3t3dLCkZiMICfNwS3m+oxt754SPxrpcV/rkeqXVlp1hpklugvbi6VIpfNiEg5bAHXA5OaAOQ0zx34judTWaRNJOlDWoNIa3S3kE7eZaxy+YJDJtGGkxjbyO46nN+HXim48W/FDSr+8vtLknbw/eF7CzjZZNPY3NtmGdmdt0gxg/KnQ8YINepz+J9AglsYp9c0uOS/Aa0R7uMG4B6GME/OPpms278baUnjLTPDdnd2N5qF08yXEUV2hltNkZfLxjJ5xjnHWgDqa5X4af8i5ef8AYa1b/wBONxXVVyvw0/5Fy8/7DWrf+nG4oA6qiiigArlfix/ySzxl/wBgW9/9EPXVUUAeXeMr34TeM3sn8R+JPD909mJBAya8ICgfbuH7uVc52L1z0rnf+EX+BP8A0GtF/wDCpl/+SK9zop3aGm1seceENb+F3g/TprHw94n8O2ttNMbiRW1tJi0hVVJ3SSMeiKMZxxW7/wALH8D/APQ5eG//AAaQf/FV1VFIRyv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VXM/E3x94OvPht4stbPxZ4fnuZ9Ju44ootRhd5HaFwFUBskkkAAV6hRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK/DT/kXLz/ALDWrf8ApxuK6quF0W08Y6DBeWdnpPh+8tn1C9u4ppdYmhdknuZZgGQWrAECQA4Y9KAO6orlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AMuP4dKusvftqQbJ1QhDb9PtrRHru/g8vH+1u7Y5Z4p8J6l/wrzw5oGivFc3emXOmDzpoxs2QSxFpGjLjIAQsUDZPQHNa/27xx/wBC94b/APB9P/8AIdH27xx/0L3hv/wfT/8AyHQBx+o/CGe8mF8dfA1WWa6ku2EVxFbyicpuVY4bmN1AEajBkYHnIJwRsR/DWGLSdesob6OL+1JbFwy25PkrbRwIE+ZyzA+SSCWyN/fGTsfbvHH/AEL3hv8A8H0//wAh0fbvHH/QveG//B9P/wDIdAHF6d8NdV1L+0hrV7b2Vt/aWsXFlBFbZl/0ozIsskglIZfLl3BAqnoCeK0Nd+FKanIksGrtaTQ2+nwwGKKRAr2vnYYmOVHwwmIwrKRtB3Guk+3eOP8AoXvDf/g+n/8AkOj7d44/6F7w3/4Pp/8A5DoAyfDHw6Gh3Ud0moRi6WyubXfDDKSJJpfMMytNNK+7PUFjkknjpWJpfwjvoNUF/qfih7+58zT3Z3gmYv8AZbnz8ky3EhBfkYXaq5yF6iux+3eOP+he8N/+D6f/AOQ6Pt3jj/oXvDf/AIPp/wD5DoAh8beE77XtY0vUdM1O0sZrO1u7Rhc2JuldLjygxAEibWAj4zkfNyKwrT4WNpc1lcaNrKxXWnvbNaG7tDOgEVobYiRRIpYlSWBBXafUdej+3eOP+he8N/8Ag+n/APkOj7d44/6F7w3/AOD6f/5DoA5NPhJLBYXFla67GttqFtHbal5lgHeQLNJLmAhwIcmVxghwPlxgjNa2heALvStf0+5/tmCXS9PvLy8t7UWJWYtc7ywkm8whsFzg7AcDnPWtb7d44/6F7w3/AOD6f/5Do+3eOP8AoXvDf/g+n/8AkOgDqq5X4af8i5ef9hrVv/TjcUfbvHH/AEL3hv8A8H0//wAh1a8C6XfaR4fNvqq2y3st7eXkiW0rSxp591LMFDMqlsCQDO0cg8UAdBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a blood meal, an infected mosquito (",
"    <em>",
"     Aedes",
"    </em>",
"    ,",
"    <em>",
"     Culex",
"    </em>",
"    ,",
"    <em>",
"     Anopheles",
"    </em>",
"    ,",
"    <em>",
"     Mansonia",
"    </em>",
"    ) introduces third-stage filarial larvae of",
"    <em>",
"     Dirofilaria immitis",
"    </em>",
"    into the skin of the definitive host, which is usually a domestic dog or coyote in the United States (although a wide variety of other animals can also be infected, including felids, mustelids, pinnipeds, beaver, horses, and humans), where they penetrate into the bite wound",
"    <strong>",
"     (1)",
"    </strong>",
"    . In the definitive host, the L3 larvae undergo two more molts into L4 and adults. Adults reside in pulmonary arteries, and are occasionally found in the right ventricle of the heart",
"    <strong>",
"     (2)",
"    </strong>",
"    . Adult females are usually 230 to 310 mm long by 350 &micro;m wide; males are usually 120 to 190 mm long by 300 &micro;m wide. Adults can live for 5 to 10 years. In the heart, the female worms are capable of producing microfilariae over their lifespan. The microfilariae are found in peripheral blood",
"    <strong>",
"     (3)",
"    </strong>",
"    . A mosquito ingests the microfilariae during a blood meal",
"    <strong>",
"     (4)",
"    </strong>",
"    . After ingestion, the microfilariae migrate from the mosquito's midgut through the hemocoel to the Malpighian tubules in the abdomen",
"    <strong>",
"     (5)",
"    </strong>",
"    . There the microfilariae develop into first-stage larvae",
"    <strong>",
"     (6)",
"    </strong>",
"    and subsequently into third-stage infective larvae",
"    <strong>",
"     (7)",
"    </strong>",
"    . The third-stage infective larvae migrate to the mosquito's proboscis",
"    <strong>",
"     (8)",
"    </strong>",
"    and can infect another definitive host when it takes a blood meal",
"    <strong>",
"     (1)",
"    </strong>",
"    . In humans",
"    <strong>",
"     (9)",
"    </strong>",
"    ,",
"    <em>",
"     D. immitis",
"    </em>",
"    larvae tend to follow the same migratory pathway as in the canine host, ending up in the lungs, where they often lodge in small-caliber vessels, causing infarcts and typical \"coin lesions\" visible on radiographs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/imagelibrary/A-F/Filariasis/body_Filariasis_il22.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/imagelibrary/A-F/Filariasis/body_Filariasis_il22.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40134=[""].join("\n");
var outline_f39_12_40134=null;
var title_f39_12_40135="Merkel cell carcinoma - face";
var content_f39_12_40135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50573%7EDERM%2F70535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50573%7EDERM%2F70535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This blue-red, dome-shaped papule on the forehead is a Merkel cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This blue-red, dome-shaped nodule is a Merkel cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40135=[""].join("\n");
var outline_f39_12_40135=null;
var title_f39_12_40136="BCG vaccination";
var content_f39_12_40136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   BCG vaccination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40136/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/12/40136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacille Calmette-Gu&eacute;rin (BCG) is a live strain of Mycobacterium bovis developed by Calmette and Gu&eacute;rin for use as an attenuated vaccine to prevent tuberculosis and other mycobacterial infections. The vaccine was first administered to humans in 1921 and remains the only vaccine against tuberculosis in general use. Several new vaccines against tuberculosis are also in development, and many are designed to boost the effects of BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCG is the most widely administered vaccine in the world; it has been given to over 3 billion individuals, principally in the setting of routine newborn immunization (as dictated by guidelines of the World Health Organization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States BCG was sometimes administered to health care workers at risk for tuberculosis until the middle of the twentieth century, although it was never adopted for routine childhood immunization.",
"   </p>",
"   <p>",
"    Issues related to host immunity, vaccine efficacy, administration, safety, and policy will be reviewed here. Although the major role of BCG is TB prevention, BCG vaccine is also effective for protection against leprosy, Buruli ulcer, and disease due to nontuberculous mycobacteria. In addition, it is used as an immunostimulant in the treatment of superficial carcinoma of the bladder. These topics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39033?source=see_link\">",
"     \"Buruli ulcer (Mycobacterium ulcerans infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"     \"Complications of intravesical BCG immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYCOBACTERIA AND HOST IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually any prior mycobacterial infection (whether naturally-acquired or vaccine-induced) appears to produce some level of protection against subsequent disease due to tuberculosis and, in some cases, to other mycobacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/1\">",
"     1",
"    </a>",
"    ]. Natural infections that confer protection against tuberculosis include prior infection with M. tuberculosis itself or prior infection with nontuberculous mycobacteria (NTM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These observations suggest that protection is conferred by the immune response to common mycobacterial antigens.",
"   </p>",
"   <p>",
"    The magnitude of protection appears to be partial. Although prior infection with M. tuberculosis generally provides protection against recurrent infection in healthy individuals, a subset of patients with HIV infection have been shown to be susceptible to a repeat episode of tuberculosis due to a different strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=see_link&amp;anchor=H17#H17\">",
"     \"Microbiology and pathogenesis of tuberculosis\", section on 'Host factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Durability of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of BCG induced protection against tuberculosis is generally believed to be approximately 10 to 15 years; this is the period for which BCG has been shown to be protective against childhood tuberculosis. However, the duration may vary; long term follow-up of patients in a trial of BCG vaccination initiated in the 1930s among American Indians and Alaskan natives demonstrated that partial protection may last 50 to 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the degree of this protection is NOT sufficient for making clinical decisions regarding diagnosis and treatment of latent TB infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCG vaccine efficacy appears to depend on three factors: the underlying immune status of the recipient, the extent of background exposure to mycobacteria prior to vaccination, and perhaps the potency of the BCG strain used in the vaccine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As newborns have not yet been exposed to mycobacteria, they therefore appear to benefit more from BCG vaccination than older individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The protective efficacy of BCG appears to depend on the extent of background exposure to environmental mycobacteria, which in turn is a function of age. Individuals living in areas endemic for TB appear to have higher background immune responses to mycobacterial antigens than those living in nonendemic areas (other than newborns). Therefore, the beneficial effect of BCG vaccination is diminished relative to individuals outside TB endemic areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both mycobacterial infections and live or inactivated whole cell mycobacterial vaccines confer protection against tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/14\">",
"       14",
"      </a>",
"      ]. Although variations in BCG efficacy have been attributed to differences in potency between BCG strains, it seems unlikely that minor BCG strain differences explain the observed major variations in vaccine efficacy; these variations in efficacy are more likely due to methodologic differences in the trials,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      differences in the other factors outlined above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Active disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A widely cited meta-analysis suggests that BCG vaccination reduces the risk of active TB by about 50 percent, although this figure does not reflect the important differences in efficacy in different age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/15\">",
"     15",
"    </a>",
"    ]. Vaccination of newborns and infants appears to confer protection in about 80 percent of cases, whereas vaccination of older children and adults is considerably less effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest benefit of BCG appears to be diminished risk of tuberculous meningitis and disseminated disease in children (75 to 86 percent efficacy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. However, studies that have evaluated these outcomes are limited by biases in design",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate statistical power.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mycobacteria naive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of BCG immunization in providing protection against subsequent tuberculosis in newborns and infants has been evaluated in four prospective trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. Collectively, these trials demonstrated an efficacy of 73 percent for protection against active disease and 87 percent against death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/18\">",
"     18",
"    </a>",
"    ]. One of these studies was a randomized trial conducted in Chicago in the 1930s in which approximately 3400 infants &le;3 months of age were randomized to receive percutaneous BCG or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/22\">",
"     22",
"    </a>",
"    ]. Followup (ranging from 12 to 23 years) demonstrated protective efficacy of 73 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mycobacteria sensitized",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have failed to demonstrate protective efficacy for administration of BCG vaccination to individuals more than a year of age who may have already been sensitized to mycobacteria. It has been postulated that these individuals likely have some degree of pre-existing mycobacterial immunity as a result of previous exposure to M. tuberculosis (in tuberculosis-endemic regions) or non-tuberculous mycobacteria (in most areas of the world). Therefore, BCG immunization in this group may not provide a meaningful or measurable improvement in the preexisting natural immunity to infection with M. tuberculosis.",
"   </p>",
"   <p>",
"    Notable data for mycobacteria sensitized individuals may be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial in South India initiated in 1980 is often cited to demonstrate that BCG is not effective. This large randomized controlled trial was designed to investigate the efficacy of BCG against tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The study objectives of this trial were twofold: (1) to compare the efficacy of different BCG strains and doses and (2) to assess the efficacy of BCG in individuals with and without prior latent tuberculosis (determined by baseline tuberculin skin testing).",
"      <br/>",
"      <br/>",
"      In reality, however, the trial was largely a study of the effect of BCG in older children and adults, many of whom were already tuberculin positive and all of whom lived in an area of high leprosy prevalence. Over 270,000 subjects were enrolled, but only 1500 (0.6 percent) were mycobacteria-naive newborns. Surveillance for tuberculosis was based on positive chest x-rays, which were only performed at age &ge;5 years; those with positive x-rays had sputum microbiology. Criteria for tuberculosis were limited to positive sputum culture or positive AFB stain, and there were no methods for detecting extrapulmonary tuberculosis.",
"      <br/>",
"      <br/>",
"      Collectively, the preceding diagnostic methods are insensitive for detecting tuberculosis in children. Also, the observed rate of tuberculosis in this large study cohort was half the predicted rate. At most, this trial demonstrated that BCG vaccination of mycobacteria-experienced older children and adults in India does not lead to a reduction in pulmonary tuberculosis among persons with positive sputum cultures and chest x-rays.",
"     </li>",
"     <li>",
"      A trial of BCG vaccination conducted between 1935 and 1938 among Native Americans had the study with the longest period of followup of all BCG vaccine trials reported to date [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/19\">",
"       19",
"      </a>",
"      ]. This trial was a randomized, placebo controlled study of 3287 individuals ages newborns to 20 years (28 percent &le;5 years) with baseline tuberculin screening to exclude those with prior mycobacterial exposure.",
"      <br/>",
"      <br/>",
"      Evaluation of vaccine recipients 11 years after vaccine administration demonstrated 75 percent reduction in radiographically diagnosed tuberculosis; evaluation at 20 years demonstrated an 82 percent reduction in overall mortality due to tuberculosis. The protective efficacy of BCG against active disease due to TB was 70 percent. Evaluation of vaccine recipients 60 years after vaccine administration (the longest follow-up period of any BCG trial) included data for 1998 of the original participants and demonstrated vaccine efficacy of 52 percent against active tuberculosis disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were described in a trial initiated in the 1950s that involving over 25,000 British teenage students (with baseline tuberculin screening to exclude those with prior mycobacterial exposure) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/26\">",
"       26",
"      </a>",
"      ]. Followup at 15 years demonstrated vaccine efficacy of 76 percent against active tuberculosis disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Latent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have evaluated the efficacy of BCG for protection against active (rather than latent) tuberculosis. Latent infection is not generally used as an efficacy endpoint since the presence of latent infection is assessed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (whose utility is limited since BCG itself can sometimes induce a positive tuberculin test). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, interferon gamma release assays (IGRAs) may prove to be useful tools for evaluating the efficacy of BCG in preventing latent infection. This was illustrated in a Turkish study in which 979 children with exposure to pulmonary tuberculosis were evaluated for latent TB infection using a T-cell-based enzyme-linked immunospot assay (ELISpot) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/27\">",
"     27",
"    </a>",
"    ]. BCG vaccination was protective for latent tuberculosis infection (odds ratio 0.60; 95% CI 0.43-0.83). Further prospective studies in other populations are needed to confirm this finding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Areas of uncertainty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of BCG vaccination has not been studied in the setting of drug resistant tuberculosis, although antibiotic susceptibility would not be expected to influence the efficacy of BCG.",
"   </p>",
"   <p>",
"    There are no definitive prospective data on the efficacy of BCG for health care workers or travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Groups to consider for vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus among experts as to whether one strain of BCG is preferable or superior for use in formulating a BCG vaccine. Numerous strains of BCG have been used to produce BCG vaccine, and none of these strains is demonstrably superior in terms of their efficacy or immunogenicity. In the United States two manufacturers are licensed to distribute BCG: Organon Teknika (Tice&reg;) and Sanofi Pasteur (Mycobax&reg;, Connaught strain).",
"   </p>",
"   <p>",
"    There is no evidence that repeat BCG vaccination is more effective than single administration for prevention of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/13,30,31\">",
"     13,30,31",
"    </a>",
"    ]. On the contrary, the host immune response induced by the initial BCG dose may prevent replication of organisms administered in a subsequent vaccine dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard dose of BCG vaccine is 0.1 mg in 1 mL. Other childhood vaccines can be administered simultaneously with BCG.",
"   </p>",
"   <p>",
"    BCG can be administered intradermally (ID) or by multiple percutaneous puncture (MP) using a device with multiple tines. The WHO favors intradermal administration, although percutaneous administration is an acceptable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although intradermal administration appears to result in greater in vitro immunogenicity, skin test conversion, and scarring than percutaneous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/34\">",
"     34",
"    </a>",
"    ], the clinical efficacy of these routes appears comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/33\">",
"     33",
"    </a>",
"    ]. This was illustrated in a study of 11,680 newborn infants in South Africa randomized to receive intradermal or percutaneous BCG; the rate of tuberculosis was equivalent between the groups in the first two years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     Tuberculin skin test",
"    </a>",
"    conversion should not be used as an indicator of BCG vaccine efficacy among vaccine recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/30,31,35\">",
"     30,31,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Safety and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized skin reactions following BCG vaccination are common. More serious adverse effects include osteitis, osteomyelitis and disseminated infection. Potential factors affecting the rate of adverse reactions include the BCG dose, vaccine strain, and method of vaccine administration.",
"   </p>",
"   <p>",
"    As many as 95 percent of BCG recipients have a local reaction at the site of inoculation characterized by formation of a bluish-red pustule accompanied by pain, swelling and erythema within two to three weeks after vaccination. Ulceration with drainage occurs at the vaccine site in about 70 percent of cases, and about 75 percent of vaccinees experience myalgias. After about six weeks the pustule ulcerates, forming a lesion approximately 5 mm in diameter. Lesions typically heal by three months with permanent residual scarring at the puncture site.",
"   </p>",
"   <p>",
"    Less common manifestations include abscess and regional lymphadenitis (1 to 2 percent). These may be accompanied by draining sinus tracts or fistulae; the risk for neonates is higher than for older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of local reactions consists of attentive wound care. Since viable organisms can be recovered from ulcer drainage, vaccination sites should be covered to reduce transmission of the vaccine strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/38\">",
"     38",
"    </a>",
"    ]. Abscess or fistula formation may rarely require surgical drainage. In the setting of suppurative lymphadenitis some favor antimycobacterial therapy, although antimicrobial therapy has not been shown to be beneficial in meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Nonsuppurative lesions are best managed with observation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteitis and osteomyelitis &mdash; BCG osteitis and osteomyelitis are rare; these entities may occur as a result of direct spread from the administration site; less commonly these may also occur as a result of dissemination. Osteitis affecting the epiphyses of the long bones (particularly the leg) can occur 4 to 24 months after vaccination. It has been reported in 0.01 per million vaccinees in Japan (multipuncture technique), and 30 per million in Finland (intradermal technique) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Treatment of osteomyelitis usually consists of surgical evacuation plus administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for 6 to 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/37,43\">",
"       37,43",
"      </a>",
"      ] (BCG is resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , and unlike treatment of M. bovis infection,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      is not generally needed). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16614?source=see_link\">",
"       \"Mycobacterium bovis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"       \"Complications of intravesical BCG immunotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disseminated disease &mdash; Disseminated disease following BCG vaccination occurs most commonly in the setting of immunosuppression. Populations at risk for dissemination include individuals with HIV infection or other immunodeficiency and individuals who have received intravesical BCG for bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/44\">",
"       44",
"      </a>",
"      ]. The risk of disseminated BCG in HIV-infected infants ranges from 403 to 1300 per 100,000 doses administered. Mortality among HIV-infected children with disseminated BCG is about 75 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. In the pre-HIV era the rate of disseminated BCG was reported to be between 0.19 and 1.56 per million vaccinees [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although most cases of disseminated BCG have been reported in the weeks and months following childhood immunization, case reports suggest that reactivation can occur years later in the setting of immunosuppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/45\">",
"       45",
"      </a>",
"      ]. Clinical manifestations and treatment of disseminated disease due to BCG are outlined separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link&amp;anchor=H7#H7\">",
"       \"Complications of intravesical BCG immunotherapy\", section on 'Systemic disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16614?source=see_link&amp;anchor=H12#H12\">",
"       \"Mycobacterium bovis\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with disseminated disease should be treated with INH and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for at least several months. In the setting of immunosuppression, addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      may be beneficial. This was illustrated in a small series of HIV-infected children with BCG induced complications for whom treatment with INH, rifampin and ethionamide was administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety of BCG administration in HIV-infected individuals is an important concern given that it is a live vaccine. Adverse effects due to BCG vaccination may be more frequent among persons who have symptomatic HIV infection than among persons who have asymptomatic HIV infection or are not HIV-infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of BCG related lymphadenitis, local ulceration, and disseminated BCG disease (which can occur several years after BCG vaccination) have been described (in HIV-infected patients). In a retrospective study of 352 HIV-infected children started on antiretroviral therapy, clinically significant complications of BCG immunization were observed in 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/48\">",
"     48",
"    </a>",
"    ]. In some cases these reactions appeared to be due to immune reconstitution inflammatory syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/47,48,54\">",
"     47,48,54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Safety and adverse effects'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tuberculin test interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals who have received BCG vaccine have a tuberculin reaction of 3 to 19 mm in size at two to three months following vaccination. The reaction wanes with time; at more than 10 years after vaccination it is generally &lt;10 mm. However, with repeated tuberculin testing such reactions may be boosted to &gt;10 mm as discussed below.",
"   </p>",
"   <p>",
"    Childhood BCG vaccination is not a major cause of positive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    results in adulthood; in a study including 5952 individuals with history of BCG who underwent tuberculin skin testing 10 to 25 years later, only 8 percent had positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, previous BCG vaccination should NOT influence decisions regarding tuberculin skin testing or interpretation of results in individuals vaccinated more than 10 years earlier. This is especially important since most individuals who receive BCG vaccine come from countries where the incidence of tuberculosis is high. Testing with an interferon-gamma release assay permits distinction between positive tuberculin reactions due to BCG versus tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of serial tuberculin testing, prior BCG vaccination may be associated with boosting. The booster phenomenon is defined as an initially negative tuberculin test (in a patient whose previous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    reactivity has diminished over time), which is then boosted to a positive test by the skin testing procedure itself. If repeated tuberculin testing is planned (such as annual screening for healthcare workers), initial two-step testing should be performed to distinguish tuberculin conversion from boosting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Booster response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GROUPS TO CONSIDER FOR VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to BCG vaccination policy depends on the regional prevalence of TB and is variable around the world. In countries where the prevalence of TB is moderate to high, neonatal vaccination is recommended by the World Health Organization (WHO) and is administered routinely. In some circumstances BCG is also administered for health care workers and close contacts of patients with tuberculosis (particularly MDR TB) with negative tuberculin tests. In some countries BCG is given to children soon after birth with subsequent booster inoculations, although there is no proven benefit to this strategy, even for BCG vaccine recipients who remain negative by subsequent tuberculin testing.",
"   </p>",
"   <p>",
"    In countries with a low burden of TB, universal BCG vaccination is not recommended or required. For example, routine BCG vaccination has never been implemented in the US; instead, TB control measures have focused on detection and treatment of latent tuberculosis. Universal BCG vaccination was utilized for all school children at age 13 and all neonates in high risk groups in the United Kingdom between 1953 and 2005. However, routine BCG vaccination was discontinued in 2005 because of diminishing incidence of TB.",
"   </p>",
"   <p>",
"    The WHO does not recommend use of BCG vaccine in the countries meeting the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Average annual rate of smear-positive pulmonary TB below 5 per 100,000",
"     </li>",
"     <li>",
"      Average annual rate of tuberculous meningitis in children under five years below 1 per 10 million population",
"     </li>",
"     <li>",
"      Average annual risk of TB infection below 0.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns and infants are the demographic group with greatest potential benefit from BCG vaccination, and this intervention has been adopted for prevention of tuberculosis worldwide. BCG vaccination is appropriate for infants and children &le;5 years with high risk for exposure to individuals with active pulmonary tuberculosis. BCG vaccination should be administered to healthy neonates as soon as possible after birth. In addition, immunization of BCG-na&iuml;ve school-age children (aged 7 to 14) not previously vaccinated has been shown to confer partial protection against TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCG immunization practices vary by region depending on the prevalence of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In countries with high prevalence of TB, childhood BCG immunization should be administered routinely. For countries with intermediate to low rates of tuberculosis",
"    <span class=\"nowrap\">",
"     (&lt;5/100,000",
"    </span>",
"    smear positive cases per year), selective childhood BCG immunization for children at particular risk of TB exposure is appropriate. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. For example, BCG immunization may be reasonable for children with exposure to drug-resistant infection.",
"   </p>",
"   <p>",
"    Caution in administering BCG must be exercised in regions with high prevalence of both TB and HIV. The risk of disseminated BCG in HIV-infected infants ranges from 403 to 1300 per 100,000 doses administered; in one series a mortality rate of 75 percent was reported among HIV-infected children with disseminated BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Therefore, BCG vaccination is not appropriate for infants with known HIV infection (or other immunodeficiency), nor for infants with symptoms consistent with HIV infection in the absence of laboratory confirmation of actual HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, BCG vaccination should be administered to asymptomatic infants born to mothers with unknown HIV status in countries with high TB prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/46,64-66\">",
"     46,64-66",
"    </a>",
"    ]. However, for asymptomatic infants with unknown HIV status born to mothers known to be HIV seropositive, the optimal approach to BCG vaccination is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/64\">",
"     64",
"    </a>",
"    ]. In such cases the clinical approach should be based on local factors including TB prevalence, interventions implemented to reduce mother-to-child transmission of HIV, rates of breastfeeding, and clinical resources for HIV diagnosis and post-vaccination follow up to evaluate for disseminated BCG.",
"   </p>",
"   <p>",
"    An international advisory group has recommended that routine childhood immunization be continued until all elements of an HIV testing program can be implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/46\">",
"     46",
"    </a>",
"    ]. Although some favor delaying BCG vaccination for HIV-exposed infants until HIV PCR testing results are available, implementation of this approach requires careful coordination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, delaying BCG vaccine may reduce BCG immunization rates for children who are not HIV positive.",
"   </p>",
"   <p>",
"    BCG-vaccinated infants born to known HIV-positive mothers should be followed clinically to evaluate for signs of disseminated BCG. For infants with exposure to smear-positive pulmonary TB in the neonatal period, BCG vaccination should be deferred until six months of preventative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    therapy have been administered to the infant (so that isoniazid does not inactivate the live organisms in the BCG vaccine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Developed countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United states (and other developed countries) BCG vaccination may be considered in infants and children &le;5 years in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child is exposed continually to an untreated or ineffectively treated patient who has infectious pulmonary TB, and neither separation from infectious patient nor long-term primary preventive therapy is feasible",
"     </li>",
"     <li>",
"      The child is exposed continually to a patient who has infectious pulmonary TB caused by M. tuberculosis strains resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and separation from the infectious patient is not feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Exposure to MDR-TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of BCG vaccination for health care workers, travelers and individuals in the community with exposure to drug resistant tuberculosis is uncertain. However, given the potentially significant risk of MDR-TB treatment failure, together with the relatively low rate of complications related to BCG vaccination in immunocompetent individuals, some favor administering BCG vaccination to unvaccinated, tuberculin negative individuals exposed to multidrug resistant TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/64\">",
"     64",
"    </a>",
"    ]. Further study is needed to reconcile the protective efficacy of BCG vaccination in the setting of multidrug resistant TB exposure among older children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protective efficacy of BCG vaccination in health care workers (HCW) is not certain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/67\">",
"     67",
"    </a>",
"    ]. In settings with low risk of M. tuberculosis transmission, BCG vaccination for health care workers is not warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/67\">",
"     67",
"    </a>",
"    ]. In regions with high risk for TB transmission, careful adherence to TB infection control practices should be emphasized. Despite data demonstrating the limited efficacy of BCG in adults, consideration of BCG vaccination may be appropriate for health care workers from low risk countries caring for patients or refugees in tuberculosis endemic countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of substantial risk for exposure to MDR-TB strains, BCG vaccination for health care workers should be considered on an individual basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/64\">",
"     64",
"    </a>",
"    ]. In such circumstances counseling should be offered regarding the variable data for BCG vaccination efficacy, including discussion of risks and benefits associated with BCG vaccination and potential interference of BCG vaccination with diagnosis of newly acquired M. tuberculosis infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     GROUPS NOT TO VACCINATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety of BCG administration in immunocompromised individuals is an important concern given that it is a live vaccine. BCG vaccination should not be administered to individuals with immune compromise due to HIV infection, congenital immunodeficiency, malignancy, or immunosuppressive drugs. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Safety and adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adults with HIV infection and individuals with HIV infection in areas of low TB prevalence should NOT receive BCG vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/56\">",
"     56",
"    </a>",
"    ]. The role of BCG vaccination for HIV-seropositive children in areas with endemic TB is discussed in the preceding section. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although BCG vaccination has not been associated with harmful fetal effects, it should not be administered in pregnancy since it is a live vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40136/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacille Calmette-Gu&eacute;rin (BCG) is a live strain of Mycobacterium bovis developed by Calmette and Gu&eacute;rin for use as an attenuated vaccine (intradermal or multiple percutaneous puncture) to prevent tuberculosis and other mycobacterial infections. The magnitude of protection appears to be in the range of 80 percent in the first 15 years of life, but is much lower subsequently. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mycobacteria and host immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The greatest benefit of BCG appears to be diminished risk of tuberculous meningitis and disseminated disease in children. Vaccination of newborns and infants appears to confer greater benefit than vaccination of older children and adults. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Active disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized skin reactions are common following BCG vaccination. Management of local reactions consists of attentive wound care; the efficacy of antimycobacterial therapy is uncertain and indolent lesions are best managed with observation alone. Since viable organisms can be recovered from ulcer drainage, vaccination sites should be covered to reduce transmission of the vaccine strain (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Safety and adverse effects'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Serious adverse effects include osteitis, osteomyelitis and disseminated infection. Disseminated BCG infection following BCG vaccination occurs most commonly in the setting of HIV infection and other forms of immunosuppression. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Safety and adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most individuals who have received BCG vaccine have a tuberculin reaction of 3 to 19 mm in size at two to three months following vaccination. The reaction wanes with time; at more than 10 years after vaccination it is generally &lt;10 mm. Therefore, previous BCG vaccination should not influence decisions regarding tuberculin skin testing or interpretation of results in individuals vaccinated more than 10 years earlier. Testing with an interferon-gamma release assay permits distinction between positive tuberculin reactions due to BCG versus tuberculosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tuberculin test interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In areas where the prevalence of TB is high, we recommend that a single dose of BCG vaccination be administered to healthy neonates as soon as possible after birth (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This includes administration of BCG vaccination to neonates born to mothers with unknown HIV status. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BCG should NOT be administered to individuals with immune compromise due to HIV infection, congenital immunodeficiency, malignancy, or immunosuppressive drugs. For asymptomatic infants with unknown HIV status born to mothers known to be HIV seropositive, the optimal approach to BCG vaccination is uncertain and should be considered in conjunction with local factors (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Immunocompromised patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Children'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest NOT administering BCG in the setting of pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Groups not to vaccinate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/1\">",
"      von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/2\">",
"      Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164.",
"     </a>",
"    </li>",
"    <li>",
"     Fine, PE, Carneiro, IA, Milstien, JB, Clements, CJ. Issues relating to the use of BCG in immunization programs: a discussion document. Geneva, Switzerland: Department of Vaccines and Biologicals, World Health Organization, 1999:1-45.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/4\">",
"      Edwards LB, Palmer CE. Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci 1968; 154:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/5\">",
"      Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/6\">",
"      Flahiff, EW. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions. Am Jour Hyg 1939; 30:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/7\">",
"      Bjartveit K. Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis. Int J Tuberc Lung Dis 2003; 7:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/8\">",
"      HEIMBECK J. BCG vaccination of nurses. Tubercle 1948; 29:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/9\">",
"      Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/10\">",
"      von Reyn CF, Horsburgh CR. Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 173:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/11\">",
"      Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004; 291:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/12\">",
"      Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Gu&eacute;rin vaccine. Clin Infect Dis 1995; 20:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/13\">",
"      Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/14\">",
"      Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997; 389:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/15\">",
"      Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/16\">",
"      Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy. A methodological and statistical reappraisal. JAMA 1983; 249:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/17\">",
"      Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Gu&eacute;rin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/18\">",
"      Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/19\">",
"      ARONSON JD. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948; 58:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/20\">",
"      FERGUSON RG, SIMES AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949; 30:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/21\">",
"      ROSENTHAL SR, LOEWINSOHN E, GRAHAM ML, et al. BCG vaccination in tuberculous households. Am Rev Respir Dis 1961; 84:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/22\">",
"      ROSENTHAL SR, GRAHAM ML, LIVERIGHT D, et al. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 1961; 28:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/23\">",
"      Levine, MI, Sackett, MF. Results of BCG immunization in New York City. Am Rev Tuberc 1948; 53:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/24\">",
"      Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res 1980; 72 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     Tripathy, SP. Fifteen year follow-up of the Indian BCG prevention trial. In: International Union Against Tuberculosis. Singapore: Professional Postgraduate Services KK, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/26\">",
"      Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977; 2:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/27\">",
"      Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/28\">",
"      Marsh BJ, von Reyn CF, Edwards J, et al. The risks and benefits of childhood bacille Calmette-Gu&eacute;rin immunization among adults with AIDS. International MAC study groups. AIDS 1997; 11:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/29\">",
"      Waddell RD, Lishimpi K, von Reyn CF, et al. Bacteremia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Gu&eacute;rin (BCG) among HIV- positive children and adults in Zambia. AIDS 2001; 15:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/30\">",
"      Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/31\">",
"      Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005; 366:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/32\">",
"      Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/33\">",
"      Hawkridge A, Hatherill M, Little F, et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 2008; 337:a2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/34\">",
"      Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Gu&eacute;rin. J Infect Dis 1996; 174:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/35\">",
"      Leung CC, Tam CM, Chan SL, et al. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int J Tuberc Lung Dis 2001; 5:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/36\">",
"      Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Gu&eacute;rin. Clin Infect Dis 2002; 34:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/37\">",
"      Kr&ouml;ger L, Korppi M, Brander E, et al. Osteitis caused by bacille Calmette-Gu&eacute;rin vaccination: a retrospective analysis of 222 cases. J Infect Dis 1995; 172:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/38\">",
"      Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette-Gu&eacute;rin immunization in normal healthy adults. J Infect Dis 1994; 170:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/39\">",
"      Caglayan S, Yegin O, Kayran K, et al. Is medical therapy effective for regional lymphadenitis following BCG vaccination? Am J Dis Child 1987; 141:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/40\">",
"      Goraya JS, Virdi VS. Treatment of Calmette-Gu&eacute;rin bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 2001; 20:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/41\">",
"      Grange JM. Complications of bacille Calmette-Gu&eacute;rin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998; 1:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/42\">",
"      Cuello-Garc&iacute;a CA, P&eacute;rez-Gaxiola G, Jim&eacute;nez Guti&eacute;rrez C. Treating BCG-induced disease in children. Cochrane Database Syst Rev 2013; 1:CD008300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/43\">",
"      Segal S, Pollard AJ, Watts C, et al. Osteomyelitis of the humerus complicating BCG vaccination. Arch Dis Child 2006; 91:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/44\">",
"      von Reyn CF. Routine childhood bacille Calmette Gu&eacute;rin immunization and HIV infection. Clin Infect Dis 2006; 42:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/45\">",
"      Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Gu&eacute;rin disease after vaccination: case report and review. Clin Infect Dis 1997; 24:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/46\">",
"      Hesseling AC, Cotton MF, Fordham von Reyn C, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/47\">",
"      Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Gu&eacute;rin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/48\">",
"      Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Gu&eacute;rin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12:e99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/49\">",
"      Ninane J, Grymonprez A, Burtonboy G, et al. Disseminated BCG in HIV infection. Arch Dis Child 1988; 63:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/50\">",
"      Centers for Disease Control (CDC). Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985; 34:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/51\">",
"      Lumb R, Shaw D. Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus. Med J Aust 1992; 156:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/52\">",
"      Pentel P, O'Connell MB. The pressor effect of phenylpropanolamine. JAMA 1989; 262:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/53\">",
"      Wells CL, Jechorek RP, Twiggs LB, Brooker DC. Recovery of viable bacteria from pelvic lymph nodes of patients with gynecologic tumors. J Infect Dis 1990; 162:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/54\">",
"      Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Gu&eacute;rin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/55\">",
"      Menzies R, Vissandjee B. Effect of bacille Calmette-Gu&eacute;rin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145:621.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Weekly Epidemiological Record 23 January 2004; 79:27. file://www.who.int/wer.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/57\">",
"      Pereira SM, Barreto ML, Pilger D, et al. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial. Lancet Infect Dis 2012; 12:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/58\">",
"      Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis 1994; 75:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/59\">",
"      Hersh AL, Tala-Heikkil&auml; M, Tala E, et al. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Gu&eacute;rin in Finland. Int J Tuberc Lung Dis 2003; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/60\">",
"      Fine P. Stopping routine vaccination for tuberculosis in schools. BMJ 2005; 331:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/61\">",
"      O'Brien KL, Ruff AJ, Louis MA, et al. Bacillus Calmette-Gu&eacute;rin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/62\">",
"      Muram D. Labial adhesions in sexually abused children. JAMA 1988; 259:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/63\">",
"      Lallemant-Le Coeur S, Lallemant M, Cheynier D, et al. Bacillus Calmette-Gu&eacute;rin immunization in infants born to HIV-1-seropositive mothers. AIDS 1991; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Weekly Epidemiological Record 25 May 2007; 82:181. Available at: file://www.who.int/wer.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/65\">",
"      The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/66\">",
"      Felten MK, Leichsenring M. Use of BCG in high prevalence areas for HIV. Trop Med Parasitol 1995; 46:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/67\">",
"      Brewer TF, Colditz GA. Bacille Calmette-Gu&eacute;rin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995; 20:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/68\">",
"      Brewer TF, Heymann SJ, Krumplitsch SM, et al. Strategies to decrease tuberculosis in us homeless populations: a computer simulation model. JAMA 2001; 286:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40136/abstract/69\">",
"      Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8022 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40136=[""].join("\n");
var outline_f39_12_40136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYCOBACTERIA AND HOST IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Durability of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Active disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mycobacteria naive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mycobacteria sensitized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Latent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Areas of uncertainty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Safety and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tuberculin test interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GROUPS TO CONSIDER FOR VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Worldwide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Exposure to MDR-TB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Health care workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GROUPS NOT TO VACCINATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39033?source=related_link\">",
"      Buruli ulcer (Mycobacterium ulcerans infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=related_link\">",
"      Complications of intravesical BCG immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16614?source=related_link\">",
"      Mycobacterium bovis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_12_40137="Clinical features and diagnosis of Fabry disease";
var content_f39_12_40137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of Fabry disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Michael Mauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Jeffrey B Kopp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40137/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/12/40137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease, also called Anderson-Fabry disease, is the second most prevalent lysosomal storage disorder after Gaucher disease. It is an X-linked inborn error of the glycosphingolipid metabolic pathway. This results in accumulation of globotriaosylceramide (Gb3) within lysosomes in a wide variety of cells, thereby leading to the protean manifestations of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic provides an overview of Fabry disease, with an emphasis on kidney disease. The cardiac and neurologic manifestations, and the treatment of Fabry disease, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27414?source=see_link\">",
"     \"Neurologic manifestations of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of Fabry disease is estimated to range from 1:17,000 to 1:117,000 males in Caucasian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, the disease is seen across all ethnic and racial groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of Fabry disease is probably underestimated given incomplete ascertainment. This is likely since [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The manifestations of the disease are nonspecific.",
"     </li>",
"     <li>",
"      The diagnosis is often not considered by physicians, given the rarity of the disease.",
"     </li>",
"     <li>",
"      The wrong diagnosis is often made initially. As an example, in the 366 European patients with Fabry disease participating in the Fabry Outcome Survey, the mean delay to correct diagnosis after symptom onset was estimated to be 13.7 and 16.3 years for males and females, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fabry disease as a cause of ESRD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal manifestations occur in approximately 50 percent of affected patients by the age of 35 years, and the incidence increases significantly with age. A significant fraction of patients eventually develops end-stage renal disease (ESRD). As an example, all male patients in one study who survived to the age of 55 years developed ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in a registry of over 2000 patients with Fabry disease (mean age 37 to 40 years), the prevalence of ESRD was much lower (14 percent in men and 2 percent in women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/6\">",
"     6",
"    </a>",
"    ]. By age 55 years, only 32 percent of men and 19 percent of women developed renal events, which ranged from new onset chronic kidney disease (defined as a glomerular filtration rate less than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) to end-stage renal disease.",
"   </p>",
"   <p>",
"    The prevalence of Fabry disease in dialysis populations has been examined in several screening studies. Random screening has identified fewer than 1 percent of hemodialysis patients as having Fabry disease, most of whom were already known to have the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. The following findings from different regions are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      According to the 2010 annual data report by United States Renal Data System, Fabry disease accounted for only 95 new cases of ESRD between 2005 and 2009 (including 80 males and 15 females), which represents approximately 0.02 percent of the incident patients each year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Japanese study, six of 514 (1.2 percent) consecutive males on dialysis had low leukocyte alpha-Gal A levels, and were found to have a gene mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/8\">",
"       8",
"      </a>",
"      ]. Another Japanese study of 696 consecutive patients (295 females) found only four males and one female (0.7 percent) to have Fabry disease, and three were already known to have it [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a nationwide screen of the Austrian dialysis population, 85 of 2480 patients (3.4 percent, similar proportions in male and female) had a positive blood spot test with low alpha-Gal A levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/9\">",
"       9",
"      </a>",
"      ]. Among these patients, only 5 women and 10 men had confirmed low leukocyte alpha-Gal A levels, representing 0.5 percent of the screened population. Only four males (0.16 percent) had the gene mutation, three of whom were already diagnosed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A voluntary Fabry disease registry has been established to better understand the epidemiology and prognosis of the disease (",
"    <a class=\"external\" href=\"https://www.lsdregistry.net/fabryregistry\">",
"     www.lsdregistry.net/fabryregistry",
"    </a>",
"    or 1-800-745-4447).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic defect in Fabry disease is deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), which catalyzes the hydrolytic cleavage of the terminal galactose from globotriaosylceramide (Gb3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/13\">",
"     13",
"    </a>",
"    ]. The alpha-Gal A protein is encoded by a 12-kb gene mapped to the long arm (Xq22.1 region) of the X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/14\">",
"     14",
"    </a>",
"    ]. Several hundred mutations in the alpha-Gal A gene have thus far been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Most kindreds have specific, or private, mutations, and de novo mutations are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gb3 is an intermediate in the degradative pathway of globoside. Globoside, a major glycosphingolipid in the red cell membrane and the kidney, is composed of ceramide attached to three sugar residues and an N-acetylgalactosamine residue (ceramide-Glc-Gal-Gal-GalNAc). Globoside is metabolized in lysosomes, particularly in the spleen, liver, and bone marrow. In the absence of significant alpha-Gal A activity, Gb3 accumulates in various cells and tissues. Tissue accumulation of Gb3 is inversely correlated with residual alpha-Gal A activity in leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accumulation of Gb3 is particularly prominent in the vascular endothelium (at levels up to 460-fold higher than normal), vascular smooth muscle cells, and pericytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]. The deposition of glycosphingolipid in these cells may lead to vascular occlusion, ischemia, and infarction. However, it is possible that accumulation of Gb3 in other cell types within the vessel wall may be important. As an illustrative example, enzyme replacement therapy in adults clears Gb3 from the endothelium but not from the rest of the vessel, and does not reduce the incidence of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Accumulation of Gb3 in autonomic ganglia, dorsal root ganglia, renal glomerular, tubular and interstitial cells, cardiac muscle cells, vascular smooth muscle cells, valvular fibrocytes, and cardiac conduction fibers may lead to the myriad other manifestations of the disease. Accumulation in the cornea also occurs, but is clinically silent. The actual clinical involvement varies significantly among different organs, which likely represents various rates of sphingolipid metabolism in different tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gb3 deposition may be only partially responsible for the manifestations of the disease. Other as yet unexplained factors might also contribute, since disease manifestations may be present in the absence of severe deposits. In one report of 57 symptomatic female patients with confirmed Fabry genotype who underwent a skin biopsy, only one patient had visible glycolipid accumulation in endothelial cells by light microscopy, and 10 to 50 percent had mild accumulation in other cell types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/22\">",
"     22",
"    </a>",
"    ]. However, cardiac, renal or cerebrovascular abnormalities were documented in 90 percent. Electron microscopy and examination of other organs such as kidney or heart were not done in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106177307\">",
"    <span class=\"h2\">",
"     Pathophysiology of renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gb3 accumulation in the kidney is inversely correlated with residual alpha-Gal A activity in leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the magnitude of renal Gb3 content correlates positively with the severity of renal pathologic changes and inversely with kidney function. Thus, accumulation of Gb3 in the kidney is probably responsible for the renal manifestations of the disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Renal manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gb3 accumulation in the kidney occurs preferentially in the glomeruli (especially podocytes, but also in endothelial, and mesangial cells), and in the distal tubule. The predilection for these two locations may explain the early renal manifestations of proteinuria and polyuria. In children with Fabry disease, for example, podocyte Gb3 accumulation was strongly associated with foot process width and the degree of proteinuria, implicating glomerular involvement in the early onset proteinuria observed in this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology underlying the formation of renal sinus cysts, another manifestation in patients with Fabry disease, is unknown. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Renal sinus cysts'",
"    </a>",
"    below.) The presence of cysts is not related to residual alpha-Gal A activity, renal function, or level of proteinuria. It is unclear whether the cysts contain Gb3, or whether this is due to lymphatic overload or other processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although variability exists, the symptoms of Fabry disease tend to appear in a predictable order in classically affected males (",
"    <a class=\"graphic graphic_table graphicRef57531 \" href=\"mobipreview.htm?39/15/40187\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17,19,24\">",
"     17,19,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28738162\">",
"    <span class=\"h2\">",
"     Overview of clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations begin in childhood or adolescence, and include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2,5,19\">",
"     2,5,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe neuropathic or limb pain, which may be precipitated by stress, extremes of heat or cold, and physical exertion. Neuropathic symptoms occur in more than 75 percent of patients with a mean age of onset of 10 years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Telangiectasias and angiokeratomas, the latter commonly in groin, hip and periumbilical areas, are characteristic (",
"      <a class=\"graphic graphic_picture graphicRef81624 \" href=\"mobipreview.htm?37/29/38353\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71039 \" href=\"mobipreview.htm?33/11/33972\">",
"       picture 2",
"      </a>",
"      ). Thickening of the lips and bulbous nose have also been described. Dermatologic manifestations of Fabry disease occur in more than 70 percent of patients with a mean age of onset of 17 years.",
"     </li>",
"     <li>",
"      Renal manifestations such as proteinuria, polyuria, and polydipsia or otherwise unexplained renal insufficiency are common. Renal disease, particularly proteinuria, occurs in more than 80 percent of patients with a mean age of diagnosis of 35 to 40 years. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal manifestations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other nonspecific manifestations, which tend to worsen in early adulthood, include heat, cold, and exercise intolerance, hypohidrosis (or hyperhidrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]), lymphadenopathy, and gastrointestinal symptoms such as abdominal pain and diarrhea. These manifestations occur in 50 to 70 percent of patients, often by the fourth decade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adulthood, there is progressive cardiac and cerebral involvement, which accounts for the majority of deaths associated with Fabry disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac involvement includes concentric left ventricular hypertrophy, heart failure, coronary artery disease, aortic and mitral valve abnormalities, and conduction abnormalities. Cardiac manifestations occur in more than 80 percent of patients with Fabry disease, with a mean age of onset of 42 years. In some patients, these manifestations, particularly left ventricular hypertrophy, are the only recognized manifestations of the disease. In patients who have left ventricular hypertrophy without apparent cause (eg, hypertension, aortic stenosis), the echocardiographic findings may distinguish Fabry disease from other causes of left ventricular hypertrophy (",
"      <a class=\"graphic graphic_figure graphicRef55283 \" href=\"mobipreview.htm?8/61/9175\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=see_link&amp;anchor=H4#H4\">",
"       \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\", section on 'Left ventricular hypertrophy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrovascular involvement may lead to transient ischemic attacks and strokes, and can cause a wide range of neurologic symptoms, including blindness. In addition, enlargement of large cranial arteries (dolichoectasia) may occur. Transient ischemic attacks and strokes occur in approximately 25 percent of patients with a mean age of onset of 40 years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age of symptom onset is more consistent in male hemizygotes than in female heterozygotes; approximately 80 percent of males have neurologic, dermatologic and cardiac manifestations by the second, third and fifth decades of life, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/5\">",
"     5",
"    </a>",
"    ]. Males with atypical variants may present even later in life, diagnosed during evaluations for cardiomegaly or proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations in heterozygous females vary widely from no apparent clinical disease to full expression of the disease, possibly related to random X-chromosome inactivation, although this is not proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Up to 90 percent may have clinical manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal manifestations occur in at least 50 percent of male patients and about 20 percent of female patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. When patients with Fabry disease present with renal manifestations, the principal findings are proteinuria and progressive renal insufficiency. Uncommonly, patients complain of polyuria and polydipsia, or are discovered by the presence of renal sinus cysts on an imaging study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11933193\">",
"    <span class=\"h3\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria, which may be tubular or glomerular in origin, may begin in the early teen years, but more typically appears during early adulthood. As an example, a long-term natural history study from the National Institutes of Health (NIH) reported proteinuria among 66 of 78 (85 percent) male patients with renal disease, with the average age of onset being 34 years (range 14 to 55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. Nephrotic-range proteinuria was uncommon (18 percent of those with renal disease), and only a fourth of them developed nephrotic syndrome. However, among those with progressive kidney failure, 80 percent had nephrotic proteinuria.",
"   </p>",
"   <p>",
"    Adult males with Fabry disease who have the highest levels of proteinuria (urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio",
"    <span class=\"nowrap\">",
"     [UP/Cr]",
"    </span>",
"    &gt;1.5",
"    <span class=\"nowrap\">",
"     gm/gm)",
"    </span>",
"    also have the fastest decline in kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, proteinuria is much less closely associated with renal function decline in adult female Fabry patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Thus, the concept that proteinuria per se is a direct promoter of progression in Fabry disease may be incorrect.",
"   </p>",
"   <p>",
"    In addition to protein, the urine may contain oval fat bodies (tubular epithelial cells with lipid inclusions) with a lamellar structure and a Maltese cross pattern under polarized urine microscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H26#H26\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'The assessment of lipiduria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28738254\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In untreated patients with Fabry disease, progressive CKD develops over time, sometimes resulting in ESRD. In the previously described natural history study from the NIH, the following findings were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-eight percent developed CKD (defined as a serum creatinine concentration &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       &micro;mol/L]),",
"      </span>",
"      which occurred at a median age of 42 years. In those with the lowest enzyme activity, CKD developed at an earlier mean age (22 versus 47 years).",
"     </li>",
"     <li>",
"      Twenty-four patients overall (29 percent), and all who survived to the age of 55 years, eventually developed ESRD (median age 47 years). Progression to ESRD from the diagnosis of CKD occurred over an average of four years (range 1 to 13), corresponding to a mean rate of decline in glomerular filtration rate (GFR) of 12",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 per year. Once CKD developed, the rate of progression to ESRD did not vary with age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings with respect to CKD and ESRD were reported in an English cohort study of 98 hemizygous males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/19\">",
"     19",
"    </a>",
"    ]. Eighty-four percent had proteinuria and 47 percent had decreased kidney function. However, the 31 percent of patients who developed ESRD did so at a younger age than in the study from the United States, with a mean age of dialysis initiation of 37 years; the youngest presented at 18 years of age.",
"   </p>",
"   <p>",
"    However, other studies have reported a much lower incidence of ESRD among older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/6\">",
"     6",
"    </a>",
"    ]. In a registry of over 2000 patients with Fabry disease (mean age 37 to 40 years), only 32 percent of men and 19 percent of women who were 55 years of age or older developed renal events, which ranged from new onset chronic kidney disease (defined as a glomerular filtration rate less than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) to end-stage renal disease.",
"   </p>",
"   <p>",
"    Although there are some conflicting observations in females, increased proteinuria in male patients with Fabry disease appears to correlate with an increased risk of progression to ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2,30-34\">",
"     2,30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of enzyme replacement therapy on the progression incidence and progression of CKD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Isosthenuria and Fanconi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative to other segments, the distal tubules are preferentially affected, leading to decreased urinary concentrating ability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/35\">",
"     35",
"    </a>",
"    ] and polyuria. Polyuria and polydipsia may be the earliest functional symptoms of Fabry renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/36\">",
"     36",
"    </a>",
"    ]. Gb3 deposition in proximal tubules may also produce Fanconi syndrome, which includes the manifestations of proximal renal tubular acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=see_link\">",
"     \"Overview of renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal sinus cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of renal sinus and parapelvic cysts is increased in patients with Fabry disease relative to healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, in one study of 24 patients with Fabry disease and 19 age-matched healthy controls, 50 percent of Fabry patients compared with only 7 percent of controls had renal sinus cysts, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, simple cysts located in renal parenchyma are commonly found in the adult population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, the incidental discovery of multiple renal sinus cysts with an imaging study should raise the possibility of Fabry disease in the appropriate clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the NIH study, only 30 percent of 105 subjects developed hypertension, with over one-half developing increased blood pressure only after the onset of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. Overall, the onset of CKD was followed by the development of hypertension, which was then closely followed by the onset of ESRD before death ensued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this section will focus on the renal evaluation, most of the ensuing discussion is generally relevant to Fabry disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6526061\">",
"    <span class=\"h2\">",
"     When to suspect Fabry disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for Fabry disease should be performed in males or females with the following clinical features suggestive of the diagnosis, particularly:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent episodes of severe pain in the extremities (acroparesthesias)",
"     </li>",
"     <li>",
"      Cutaneous vascular lesions (angiokeratomas)",
"     </li>",
"     <li>",
"      Diminished perspiration (hypohidrosis)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Stroke of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Chronic kidney disease of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Multiple renal sinus cysts discovered incidentally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A family history suggestive of the disorder is particularly helpful. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Renal manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We also recommend an evaluation in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Females known or suspected to be carriers",
"     </li>",
"     <li>",
"      Some family members of newly diagnosed patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific issues related to case finding in family members of patients with Fabry disease are presented below (see",
"    <a class=\"local\" href=\"#H6526096\">",
"     'Evaluation of family members'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial evaluation should consist of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17,24,29\">",
"     17,24,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detailed past medical history and review of systems. Clinical symptoms or signs such as neuropathic pain, heat intolerance (usually associated with exercise intolerance and avoidance of outdoors in summer months), decreased tear, saliva or sweat production, diarrhea, abdominal pain, angiokeratomas and foamy urine should be carefully documented at baseline. Any history of transient ischemic attacks or strokes (particularly involving the posterior circulation), and myocardial disease should be thoroughly explored.",
"     </li>",
"     <li>",
"      Detailed family history that focuses on relatives with unexplained neurologic disease or kidney failure that was transmitted as an X-linked trait. In the NIH series, family history contributed to the diagnosis in 46 percent of patients.",
"     </li>",
"     <li>",
"      Careful physical examination, looking for angiokeratomas, telangiectasias, hypo- or anhydrosis, corneal opacity, edema, abnormal cardiac examination (evidence of left ventricular hypertrophy, arrhythmia). Asymptomatic characteristic corneal opacities (cornea verticillata) that do not affect visual acuity and retinal and conjunctival vascular tortuosity are present in almost all Fabry males [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/1\">",
"       1",
"      </a>",
"      ]. Formal slit-lamp examination may be necessary to appreciate the corneal opacities.",
"     </li>",
"     <li>",
"      Examination of urine sediment and measurement of renal function. With renal involvement, there may be oval fat bodies (degenerating tubular epithelial cells with lipid inclusions) with a lamellar structure and a Maltese cross pattern under polarized microscopy (",
"      <a class=\"graphic graphic_picture graphicRef54906 \" href=\"mobipreview.htm?33/40/34446\">",
"       picture 3",
"      </a>",
"      ); this is similar to what may be seen with nephrotic range proteinuria of any cause. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H26#H26\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'The assessment of lipiduria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrocardiogram to evaluate for left ventricular hypertrophy and conduction defects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6526122\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of clearly established family history and classic phenotype, the diagnosis can usually be confirmed",
"    <strong>",
"     in males",
"    </strong>",
"    if there is low alpha-Gal A activity in leukocytes or plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2,40,41\">",
"     2,40,41",
"    </a>",
"    ]. Analysis of plasma alpha-galactosidase may be less sensitive than assay of enzyme activity in leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutation analysis of the alpha-Gal A gene is required to make the diagnosis",
"    <strong>",
"     in female carriers",
"    </strong>",
"    (unless the woman is an obligate heterozygote [ie, the father is known to have Fabry]), and in males and females with atypical presentations or marginal alpha-Gal A levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17,29,43\">",
"     17,29,43",
"    </a>",
"    ]. Rarely, the diagnosis is made by biopsy of the skin or kidney when other means of diagnosis are unavailable. On the other hand, patients may be incidentally discovered to have Fabry disease if a kidney biopsy is performed to evaluate chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis in classically affected males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of leukocyte alpha-Gal A activity is the standard enzymatic test at most laboratories. The sensitivity and specificity of the alpha-Gal A assay using leukocytes approaches 100 percent in males, but the assay will identify less than 50 percent of female carriers. Based on the available knowledge, neither ESRD nor dialysis affects the enzyme assay.",
"   </p>",
"   <p>",
"    Although different methods have been used to describe the results, enzymatic activity level is most often expressed as the percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. The enzymatic level can vary by population tested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha-Gal A activity in leukocytes is undetectable in over 50 percent of hemizygous males, and is usually less than four percent of normal control levels in the remainder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels in female carriers range from normal to very low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac variants, a form of atypical disease, have one to ten percent of normal activity levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis in females or males with atypical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend genetic testing in females and males with marginal levels of alpha-Gal A activity. Although not required for the diagnosis in most patients, genotyping is recommended for all Fabry families since this knowledge may be particularly relevant for future therapies utilizing synthetic chaperones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/44\">",
"     44",
"    </a>",
"    ]. Only one member of each affected family needs to be genotyped. Since more than 300 distinct mutations have thus far been identified, identification of a mutation in a new family requires essentially complete resequencing of the gene. Genetic analysis is only done at selected laboratories (refer to",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tissue diagnosis in rare settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, biopsy of skin or culture of skin fibroblasts may be helpful in establishing the diagnosis, but is usually done only if no other means of diagnosis are available. Skin biopsy can demonstrate the characteristic glycolipid deposits in a relatively non-invasive way.",
"   </p>",
"   <p>",
"    Kidney biopsy may be helpful in establishing the diagnosis, but it is not typically necessary. The diagnosis is sometimes made by accident when a kidney biopsy is obtained to diagnose the cause of proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. A kidney biopsy may be of particular use when patients have nephrotic syndrome, gross hematuria, or other symptoms that require exclusion of other diagnoses. (See",
"    <a class=\"local\" href=\"#H106177755\">",
"     'Renal pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106177755\">",
"    <span class=\"h3\">",
"     Renal pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney biopsy findings by light microscopy and electron microscopy are characteristic in Fabry disease, whereas immunofluorescence staining does not contribute to the diagnosis. Glycolipid accumulation is observed throughout the kidney:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Light microscopy shows vacuolization of visceral glomerular epithelial cells (podocytes) and distal tubular epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"       2",
"      </a>",
"      ]. This is consistent with the described pattern of glycolipid accumulation, with podocytes and distal tubular cells showing the largest amount. Smaller deposits in cells of the mesangium glomerular endothelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/21\">",
"       21",
"      </a>",
"      ], proximal tubule (",
"      <a class=\"graphic graphic_picture graphicRef54672 graphicRef75690 \" href=\"mobipreview.htm?14/37/14938\">",
"       picture 4A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/21,46,47\">",
"       21,46,47",
"      </a>",
"      ], and in the endothelium of peritubular capillaries and arteries may be difficult to appreciate by routine light microscopy.",
"     </li>",
"     <li>",
"      On electron microscopy, deposits of Gb3 appear within enlarged secondary lysosomes as lamellated membrane structures, called myeloid or zebra bodies (",
"      <a class=\"graphic graphic_picture graphicRef68849 \" href=\"mobipreview.htm?22/57/23448\">",
"       picture 5",
"      </a>",
"      ). These inclusions, composed of concentric layers with a periodicity of 3.5 to 5 nm and with an onion skin appearance, are considered a",
"      <strong>",
"       hallmark",
"      </strong>",
"      of glycolipid storage disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ultrastructural findings on kidney biopsy are highly characteristic and frequently point to the diagnosis. However, lamellar inclusions have been described in other conditions, including silicosis and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. The location of the inclusions is sometimes helpful in making the distinction between these diseases. Lamellar inclusions associated with gentamicin occur in proximal tubules, whereas in Fabry disease, the inclusions are most striking in podocytes and distal tubules.",
"   </p>",
"   <p>",
"    Nonspecific findings in patients with more advanced disease may include focal segmental and global glomerulosclerosis and tubulointerstitial fibrosis, with mesangial deposits staining for C3 and IgM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/53\">",
"     53",
"    </a>",
"    ]. Foam cells may also be seen but are not diagnostic of Fabry disease, as they may be seen in other lysosomal storage diseases (where lipid is in podocytes) and proteinuric states (where lipid is primarily in macrophages) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, renal Gb3 content is significantly higher, and glomerular and tubulointerstitial changes and kidney function worse, in patients with undetectable alpha-Gal A activity compared with those with greater than 1 percent of normal activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease is often misdiagnosed, given its wide range of nonspecific clinical manifestations and relative rarity. It has recently been termed &ldquo;The New Great Imposter&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/55\">",
"     55",
"    </a>",
"    ]. Because of its rarity, patients with Fabry disease are often initially diagnosed with some other condition. The most commonly considered initial diagnoses in patients with Fabry disease in the Fabry Outcome Survey were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatologic conditions including dermatomyositis or rheumatic fever. However, the characteristic heliotrope rash and elevated serum muscle enzymes distinguish juvenile onset dermatomyositis from Fabry disease. In addition, the pain and dermatologic symptoms of acute rheumatic fever are typically self-limited, lasting less than a month. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31079?source=see_link\">",
"       \"Diagnosis of juvenile dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arthritis. However, Fabry disease is not characterized by synovial inflammation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuropsychological disease. However, many common manifestations of Fabry, including proteinuria, left ventricular hypertrophy, and angiokeratomas, are not typical in patients with psychiatric disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibromyalgia. As above, many common manifestations of Fabry, including proteinuria, left ventricular hypertrophy, and angiokeratomas, are not common in patients with fibromyalgia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythromelalgia. However, patients with Fabry disease do not have thrombocythemia, which can cause pain in the extremities of patients with polycythemia vera and essential thrombocythemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9738?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Erythromelalgia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary hemorrhagic telangiectasia. Although patients with Fabry disease may have telangiectasias, they do not typically develop spontaneous epistaxis or gastrointestinal bleeding, as do patients with hereditary hemorrhagic telangiectasia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meniere disease. Although tinnitus is present in nearly 40 percent of patients with Fabry disease, the presence of neuropathic pain, angiokeratomas, and proteinuria helps distinguish it from Meniere disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple sclerosis. However, the presence of angiokeratomas, proteinuria, and left ventricular hypertrophy, which are not features of multiple sclerosis, provide clues to Fabry disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irritable colon. However, neuropathic pain, angiokeratomas, and proteinuria are not features of irritable bowel syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8279?source=see_link\">",
"       \"Irritable bowel syndrome in patients with inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic hypertrophic cardiomyopathy. Echocardiography may be able to distinguish patients with Fabry disease from those with other causes of left ventricular hypertrophy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=see_link\">",
"       \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kidney failure of unknown etiology. When occurring in a young individual, kidney disease of unknown etiology should prompt an evaluation for Fabry disease, particularly other common manifestations (eg, neuropathic pain) and a family history of kidney failure are present. (See",
"      <a class=\"local\" href=\"#H6526061\">",
"       'When to suspect Fabry disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the diagnosis of Fabry disease in patients without a known family history of the disorder is usually made by specialists and subspecialists: dermatologists (28 percent); neurologists (23 percent); nephrologists (19 percent); rheumatologists (2 percent); and cardiologists (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"     2",
"    </a>",
"    ]. Consideration of Fabry disease as a possibility is the major hurdle to making the correct diagnosis in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106178166\">",
"    <span class=\"h1\">",
"     FOLLOW-UP ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once diagnosed, patients with Fabry disease, or asymptomatic carriers, should be followed closely using an interdisciplinary approach that involves routine care by nephrology, cardiology, and neurology, with input from dermatology and ophthalmology as required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17,56\">",
"     17,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annual reevaluation with documentation of any clinical symptoms or signs. The annual exams should also include routine hematology and chemistry profiles, urinalysis, urinary protein to creatinine ratio or albumin to creatinine ratio, and an estimation of renal function such as estimated glomerular filtration rate or measurement of the creatinine clearance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"       \"Calculation of the creatinine clearance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiography and electrocardiography to detect or monitor cardiac abnormalities at least every two years.",
"     </li>",
"     <li>",
"      Asymptomatic female carriers should also have a complete baseline evaluation as above and should be reevaluated every three to five years, with increasing frequency with age. Atypical males with Fabry disease should be evaluated and monitored annually similar to those classically affected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6526096\">",
"    <span class=\"h1\">",
"     EVALUATION OF FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In families known to have Fabry disease, we suggest the following approach in individuals at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At risk or symptomatic male relatives of an affected individual. These males should be screened with an enzymatic assay (blood or leukocyte), even if asymptomatic. If deficient alpha-Gal A activity is found, the individual should undergo comprehensive genetic analysis to identify the lesion, unless the mutation has been identified in the affected relative. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis in females or males with atypical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At risk female relatives of an affected individual, a female with a family history of Fabry disease, or a female with symptoms suggestive of Fabry disease. When testing women, the high false negative rate of alpha-Gal A testing in female carriers must be recognized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17,43\">",
"       17,43",
"      </a>",
"      ]. Given the high variability of enzyme activity level in women, genetic testing of women with normal alpha-Gal A levels should be strongly considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although available, routine prenatal screening is",
"    <strong>",
"     not",
"    </strong>",
"    recommended, as there are no data to suggest efficacy of initiating enzyme replacement therapy during infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/29\">",
"     29",
"    </a>",
"    ]. Prenatal testing involves measuring alpha-Gal A activity in fetal cells obtained through amniocentesis or chorionic villous sampling; the latter allows earlier (9 weeks versus 16 weeks) and faster test results (hours versus 2 weeks). However, a genetic mutation analysis must also be done because the sample may be contaminated with maternal tissue or female fetuses may have variable residual enzymatic activity.",
"   </p>",
"   <p>",
"    Some have advocated screening by testing for elevated urinary excretion of Gb3. Mass spectrometry is one available method, with abnormally high levels being relative to healthy controls tested in the same lab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, urine Gb3 may not always be elevated in heterozygotes and remains a suboptimal marker of Fabry disease. We do not advocate its use either for screening or monitoring treatment response. Screening by testing for urinary lyso-Gb3, rather than Gb3, may prove more promising as a diagnostic and disease severity indicator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40137/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fabry disease, also called Anderson-Fabry disease, is the second most prevalent lysosomal storage disorder after Gaucher disease. It is an X-linked inborn error of the glycosphingolipid metabolic pathway. The metabolic defect in Fabry disease is deficiency or defect in the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), which catalyzes the hydrolytic cleavage of the terminal galactose from globotriaosylceramide (Gb3). This results in accumulation of Gb3 within lysosomes in a wide variety of cells, such as vascular endothelium, autonomic and dorsal root ganglia, renal glomerular, tubular and interstitial cells, cardiac muscle cells, vascular smooth muscle cells, valvular fibrocytes, and cardiac conduction fibers. Accumulation of Gb3 in these cells may produce the many manifestations of the disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of Fabry disease is estimated to range from 1:17,000 to 1:117,000 males in Caucasian populations, although the disease is seen across all ethnic and racial groups. The prevalence of Fabry disease is probably underestimated given incomplete ascertainment due, in part, to the nonspecific manifestations of the disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal manifestations occur in approximately 50 percent of affected male patients by the age of 35 years, and the incidence increases significantly with age. A majority of male patients and a significant fraction of female patients eventually develop end-stage renal disease. Random screening has identified that 0.36 to 1.5 percent of hemodialysis patients have Fabry disease, many of whom were already known to have the disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fabry disease as a cause of ESRD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although variability exists, the symptoms of Fabry disease tend to appear in a predictable order, beginning in childhood or adolescence, in classically affected males (",
"      <a class=\"graphic graphic_table graphicRef57531 \" href=\"mobipreview.htm?39/15/40187\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H28738162\">",
"       'Overview of clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe neuropathic or limb pain, which may be precipitated by stress, extremes of heat or cold, and physical exertion.",
"     </li>",
"     <li>",
"      Telangiectasias and angiokeratomas, the latter commonly in groin, hip and periumbilical areas, are characteristic (",
"      <a class=\"graphic graphic_picture graphicRef81624 \" href=\"mobipreview.htm?37/29/38353\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71039 \" href=\"mobipreview.htm?33/11/33972\">",
"       picture 2",
"      </a>",
"      ). Thickening of the lips and bulbous nose have also been described.",
"     </li>",
"     <li>",
"      Proteinuria, polyuria, and polydipsia or otherwise unexplained renal insufficiency.",
"     </li>",
"     <li>",
"      Heat, cold, and exercise intolerance, hypohidrosis (or hyperhidrosis), lymphadenopathy, and gastrointestinal symptoms such as abdominal pain and diarrhea.",
"     </li>",
"     <li>",
"      In adulthood, there is a high risk of progressive cardiac and cerebral involvement, especially in males.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 80 percent of males have neurologic, dermatologic and cardiac manifestations by the second, third and fifth decades of life, respectively. Males with atypical variants may present even later in life, while clinical manifestations in heterozygous females vary widely from no apparent clinical disease to full expression of the disease, possibly related to random X-chromosome inactivation. (See",
"      <a class=\"local\" href=\"#H28738162\">",
"       'Overview of clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal manifestations occur in at least 50 percent of male patients and about 20 percent of female patients. When patients with Fabry disease present with renal manifestations, the principal findings are proteinuria and progressive renal insufficiency. Less commonly, patients complain of polyuria and polydipsia, or are discovered by the presence of renal sinus cysts on an imaging study. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fabry disease should be suspected in males or females with the following features (See",
"      <a class=\"local\" href=\"#H6526061\">",
"       'When to suspect Fabry disease'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intermittent episodes of severe pain in the extremities (acroparesthesias)",
"     </li>",
"     <li>",
"      Cutaneous vascular lesions (angiokeratomas)",
"     </li>",
"     <li>",
"      Diminished perspiration (hypohidrosis)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Stroke of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Chronic kidney disease of unknown etiology in young adulthood",
"     </li>",
"     <li>",
"      Multiple renal sinus cysts discovered incidentally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial evaluation should consist of a detailed medical history and physical examination looking for suggestive clinical symptoms, a family history of unexplained neurologic or kidney disease transmitted in an X-linked pattern, angiokeratomas, telangiectasias, hypohidrosis, corneal opacities, and an abnormal cardiac exam. Laboratory studies should include a urinalysis looking for proteinuria, an assessment of renal function, and an electrocardiogram. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of clearly established family history and classic phenotype, the diagnosis is can usually be confirmed",
"      <strong>",
"       in males",
"      </strong>",
"      by a low alpha-Gal A activity in leukocytes or plasma. Mutation analysis of the alpha-Gal A gene is required to make the diagnosis",
"      <strong>",
"       in female carriers",
"      </strong>",
"      unless the woman is an obligate heterozygote (ie, the father is known to have Fabry), and in patients with atypical presentations or who have residual alpha-Gal A levels. (See",
"      <a class=\"local\" href=\"#H6526122\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly considered initial diagnoses in patients with Fabry disease were rheumatologic conditions or rheumatic fever. Other often-considered diagnoses include arthritis, neuropsychological disease, fibromyalgia, dermatomyositis, erythromelalgia, hereditary hemorrhagic telangiectasia, Meniere disease, multiple sclerosis, irritable colon, idiopathic hypertrophic cardiomyopathy, and kidney failure of unknown etiology. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once diagnosed, patients with Fabry disease, or asymptomatic carriers, should be followed closely using an interdisciplinary approach that involves routine care by nephrology, cardiology, and neurology, with input from dermatology and ophthalmology as required. (See",
"      <a class=\"local\" href=\"#H106178166\">",
"       'Follow-up assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In families known to have Fabry disease, we suggest screening at risk or symptomatic male relatives of an affected individual, at risk female relatives of an affected individual, females with a family history of Fabry disease, and females with symptoms suggestive of Fabry disease. (See",
"      <a class=\"local\" href=\"#H6526096\">",
"       'Evaluation of family members'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/1\">",
"      Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/2\">",
"      Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/3\">",
"      Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/4\">",
"      Houge G, Skarb&oslash;vik AJ. [Fabry disease--a diagnostic and therapeutic challenge]. Tidsskr Nor Laegeforen 2005; 125:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/5\">",
"      Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/6\">",
"      Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93:112.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/8\">",
"      Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \"renal variant\" phenotype. Kidney Int 2003; 64:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/9\">",
"      Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/10\">",
"      Linthorst GE, Hollak CE, Korevaar JC, et al. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003; 18:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/11\">",
"      Tanaka M, Ohashi T, Kobayashi M, et al. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 2005; 64:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/12\">",
"      Linthorst GE, Bouwman MG, Wijburg FA, et al. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 2010; 47:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/13\">",
"      Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/14\">",
"      Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A 1988; 85:3903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/15\">",
"      Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 2004; 337:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/16\">",
"      Sch&auml;fer E, Baron K, Widmer U, et al. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005; 25:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/17\">",
"      Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338.",
"     </a>",
"    </li>",
"    <li>",
"     Desnick R, Ioannou Y, Eng C.. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al (Eds), McGraw Hill, New York City 2001. p.3733.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/19\">",
"      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/20\">",
"      Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/21\">",
"      Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/22\">",
"      Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005; 84:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/23\">",
"      Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011; 79:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/24\">",
"      Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/25\">",
"      M&ouml;hrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003; 4:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/26\">",
"      Lidove O, Ramaswami U, Jaussaud R, et al. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 2006; 60:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/27\">",
"      Waldek S, Patel MR, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/28\">",
"      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/29\">",
"      Bennett RL, Hart KA, O'Rourke E, et al. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns 2002; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/30\">",
"      Wanner C, Oliveira JP, Ortiz A, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010; 5:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/31\">",
"      Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of Agalsidase Beta Treatment for Fabry Disease: Role of Proteinuria and Timing of Treatment Initiation. Nephrol Dial Transplant 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/32\">",
"      Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/33\">",
"      Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/34\">",
"      Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/35\">",
"      Meroni M, Sessa A, Battini G, et al. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 1997; 122:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/36\">",
"      Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/37\">",
"      Ries M, Bettis KE, Choyke P, et al. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004; 66:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/38\">",
"      Glass RB, Astrin KH, Norton KI, et al. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 2004; 28:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/39\">",
"      Terada N, Ichioka K, Matsuta Y, et al. The natural history of simple renal cysts. J Urol 2002; 167:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/40\">",
"      Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/41\">",
"      Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/42\">",
"      Andrade J, Waters PJ, Singh RS, et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 2008; 3:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/43\">",
"      Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2005; 14:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/44\">",
"      Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J 2005; 19:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/45\">",
"      Blanco J, Herrero J, Arias LF, et al. Renal variant of Anderson-Fabry disease and bilateral renal cell carcinoma. Pathol Res Pract 2005; 200:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/46\">",
"      Chen HC, Tsai JH, Lai YH, Guh JY. Renal changes in heterozygous Fabry's disease--a family study. Am J Kidney Dis 1990; 15:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/47\">",
"      Sessa A, Toson A, Nebuloni M, et al. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 2002; 15:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/48\">",
"      Okuda S. Renal involvement in Fabry's disease. Intern Med 2000; 39:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/49\">",
"      Rodriguez FH Jr, Hoffmann EO, Ordinario AT Jr, Baliga M. Fabry's disease in a heterozygous woman. Arch Pathol Lab Med 1985; 109:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/50\">",
"      Banks DE, Milutinovic J, Desnick RJ, et al. Silicon nephropathy mimicking Fabry's disease. Am J Nephrol 1983; 3:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/51\">",
"      Jao W, Manaligod JR, Gerardo LT, Castillo MM. Myeloid bodies in drug-induced acute tubular necrosis. J Pathol 1983; 139:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/52\">",
"      Houghton DC, Campbell-Boswell MV, Bennett WM, et al. Myeloid bodies in the renal tubules of humans: relationship to gentamicin therapy. Clin Nephrol 1978; 10:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/53\">",
"      Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/54\">",
"      Farge D, Nadler S, Wolfe LS, et al. Diagnostic value of kidney biopsy in heterozygous Fabry's disease. Arch Pathol Lab Med 1985; 109:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/55\">",
"      Lidove O, Kaminsky P, Hachulla E, et al. Fabry disease 'The New Great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet 2012; 81:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/56\">",
"      Weidemann F, Sommer C, Duning T, et al. Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge. Am J Med 2010; 123:658.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/57\">",
"      Fauler G, Rechberger GN, Devrnja D, et al. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom 2005; 19:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/58\">",
"      Kitagawa T, Ishige N, Suzuki K, et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 2005; 85:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40137/abstract/59\">",
"      Auray-Blais C, Ntwari A, Clarke JT, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 2010; 411:1906.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7195 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40137=[""].join("\n");
var outline_f39_12_40137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fabry disease as a cause of ESRD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106177307\">",
"      Pathophysiology of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28738162\">",
"      Overview of clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11933193\">",
"      - Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28738254\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Isosthenuria and Fanconi syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal sinus cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6526061\">",
"      When to suspect Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6526122\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis in classically affected males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis in females or males with atypical presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tissue diagnosis in rare settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H106177755\">",
"      - Renal pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106178166\">",
"      FOLLOW-UP ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6526096\">",
"      EVALUATION OF FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7195|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/61/9175\" title=\"figure 1\">",
"      Echo in Fabry disease with LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7195|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/29/38353\" title=\"picture 1\">",
"      Angiokeratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/11/33972\" title=\"picture 2\">",
"      Elevated papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/40/34446\" title=\"picture 3\">",
"      Vacuolated uroepithelial cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/25/14741\" title=\"picture 4A\">",
"      Glycolipid inclusion bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/44/23239\" title=\"picture 4B\">",
"      Glycolipid Glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/57/23448\" title=\"picture 5\">",
"      Lamellar osmophilic inclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7195|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/15/40187\" title=\"table 1\">",
"      Clinical manifestations of Fabry disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31079?source=related_link\">",
"      Diagnosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8279?source=related_link\">",
"      Irritable bowel syndrome in patients with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/23/40313?source=related_link\">",
"      Treatment of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_12_40138="Cardiotoxicity of nonanthracycline cancer chemotherapy agents";
var content_f39_12_40138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Justin Floyd, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/12/40138/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/12/40138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease.",
"   </p>",
"   <p>",
"    Among the serious complications that have been reported are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmias",
"     </li>",
"     <li>",
"      Myocardial necrosis causing a dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Vasospasm or vasoocclusion resulting in angina or myocardial infarction",
"     </li>",
"     <li>",
"      Pericardial disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide range of chemotherapy agents have been associated with cardiotoxicity, of which the anthracyclines and related compounds are the most frequently implicated agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cardiotoxicity of chemotherapy agents other than the anthracyclines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    will be reviewed here. The cardiotoxicity of trastuzumab is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIMETABOLITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (FU) is widely used in various chemotherapy regimens and is the second most common cause of chemotherapy-related cardiotoxicity, after anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cardiac symptom due to 5-FU is chest pain, which can be either nonspecific or anginal, and is associated with electrocardiographic (ECG) changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative incidence of symptoms induced by 5-FU is illustrated by a review that included 377 evaluable cases reported in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"     4",
"    </a>",
"    ]. Cardiac events occurred within 72 hours of the first cycle of 5-FU in 69 percent of cases, ECG changes in 69 percent, and elevated cardiac enzymes in 12 percent. Clinical symptoms included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angina - 45 percent",
"     </li>",
"     <li>",
"      Myocardial infarction - 22 percent",
"     </li>",
"     <li>",
"      Arrhythmias - 23 percent",
"     </li>",
"     <li>",
"      Acute pulmonary edema - 5 percent",
"     </li>",
"     <li>",
"      Cardiac arrest - 1.4 percent",
"     </li>",
"     <li>",
"      Pericarditis - 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality rates range from 2.2 to 13.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]; in this review, 8 percent of the patients with FU-induced cardiotoxicity died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying mechanism of toxicity is not well established. Many early reports described coronary artery ischemia that was thought to result from vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, other pathophysiologic mechanisms have also been postulated, including myocarditis, a thrombogenic effect due to endothelial cytotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/16-19\">",
"     16-19",
"    </a>",
"    ], and takotsubo cardiomyopathy, a type of transient cardiomyopathy that is precipitated by physical or emotional stress, and thought related to exaggerated sympathetic stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/13,20-22\">",
"     13,20-22",
"    </a>",
"    ]. The EKGs of patients with presumed takotsubo cardiomyopathy often reveal ST segment elevation, and cardiac enzymes are frequently mildly elevated, mimicking an acute myocardial infarction. Most of the reported cases have occurred in patients without preexisting heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Incidence and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of 5-FU related cardiotoxicity ranges from 1 to 19 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1-6,23\">",
"     1-6,23",
"    </a>",
"    ], although most series report a risk of 8 percent or less. Risk appears to be related to the method of 5-FU administration, the presence of coronary artery disease, and the use of concurrent radiation or anthracyclines.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of the literature, the risk of cardiac toxicity with 5-FU was between 1.6 and 2.3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1\">",
"       1",
"      </a>",
"      ]. Concurrent radiation therapy was a predisposing factor.",
"     </li>",
"     <li>",
"      The risk appears higher with infusion (both long-term and short-term schedules) as opposed to bolus regimens. In one series, 28 of 367 patients (8 percent) receiving a high-dose continuous infusion of 5-FU developed cardiotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/5\">",
"       5",
"      </a>",
"      ]. In a second report of 106 patients receiving short-term infusional 5-FU as a component of the FOLFOX regimen (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 1",
"      </a>",
"      ), nine developed chest pain during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/3\">",
"       3",
"      </a>",
"      ]. The onset was during courses 1, 2, 6, and 8 in three, four, one, and one patient(s), respectively.",
"     </li>",
"     <li>",
"      The presence of coronary artery disease increases the likelihood of cardiotoxicity; however, most cases of cardiotoxicity occur in patients without heart disease, and preexisting cardiac disease is not predictive of cardiotoxicity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a series of 1083 patients treated with 5-FU for a variety of neoplasms, the incidence of cardiotoxicity was higher in patients with known cardiac disease (4.5 versus 1.1 percent in those without heart disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report of 106 patients receiving short-term infusional 5-FU for colorectal cancer, nine patients developed cardiotoxicity, only one of whom had a prior history of cardiovascular disease; the other seven patients with a prior history of cardiovascular disease did not develop cardiotoxicity during treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of vasospasm has been seen when patients are carefully monitored for evidence of toxicity. This was illustrated by a study of 102 consecutive patients receiving 5-FU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/6\">",
"       6",
"      </a>",
"      ]. All patients were monitored with 12-lead ECG, echocardiography, and radionuclide ventriculography prior to the first cycle, and Holter monitoring during the 5-FU infusion; the same examinations were repeated three months later. Reversible symptoms of angina lasting up to 12 hours were observed in 19 patients within 24 hours of starting 5-FU, and these lasted up to 12 hours after completion of treatment. None of these 19 patients had known coronary artery disease, and there was no evidence of coronary artery disease in the six patients with severe symptoms in whom coronary angiography was carried out. In addition, both bradycardia and ventricular extrasystoles were significantly more frequent during treatment than in the three months following therapy.",
"     </li>",
"     <li>",
"      Electrocardiographic evidence of silent ischemia and increases in plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) during chemotherapy suggest that subclinical cardiotoxicity may be more frequent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/2,3,6\">",
"       2,3,6",
"      </a>",
"      ]. However, the clinical significance of these findings remains uncertain, given the lack of long-term left ventricular dysfunction seen in patients who develop cardiotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac symptoms usually resolve with termination of 5-FU treatment and antianginal treatment. In the review cited above, 69 percent of patients responded to conservative antianginal therapy; however, as noted above, 8 percent died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rechallenging patients who have had 5-FU related cardiac toxicity is controversial. In some patients, a switch from infusional to bolus 5-FU may allow treatment to be successfully resumed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, in the review cited above, cardiac symptoms were reproducible with rechallenge in 47 percent, including one patient treated with an oral fluoropyrimidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptoms were also elicited when the same patients were treated with lower doses or different schedules. Furthermore, 13 percent of those reexposed to 5-FU died.",
"   </p>",
"   <p>",
"    There are conflicting results in the literature about the role of calcium channel blockers or nitrates in preventing symptoms with fluoropyrimidine retreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1,24,26-31\">",
"     1,24,26-31",
"    </a>",
"    ]. In the review cited above, prophylactic coronary vasodilators had limited efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in general, rechallenge is not recommended. If it is attempted, patients need careful observation during drug infusion.",
"   </p>",
"   <p>",
"    However, in some cases, symptomatic patients may benefit from stress testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary angiography with appropriate intervention if indicated; this approach may improve the patients' overall prognosis by increasing their ability to tolerate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-FU is associated with chest pain for which multiple mechanisms have been proposed, including coronary artery vasospasm, endothelial injury, and a transient stress-induced cardiomyopathy. In severe cases, FU cardiotoxicity can be manifested as angina, myocardial infarction, or life-threatening arrhythmias. Patients with a prior history of cardiac disease who are treated with 5-FU need careful monitoring during therapy. Treatment should be discontinued if coronary symptoms develop, and readministration of 5-FU is generally not recommended for those with cardiac symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a fluoropyrimidine that is metabolized to 5-FU, which is the active anticancer moiety. The cardiac toxicity of capecitabine is similar to that reported with infusional 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, patients who previously experienced cardiotoxicity with 5-FU may have recurrent toxicity with capecitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of cardiotoxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ranges from 3 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The most frequent clinical manifestation is angina; arrhythmias, myocardial infarction, and death have been reported but are much less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/33,36-42\">",
"     33,36-42",
"    </a>",
"    ]. It is presumed that the mechanism is similar to that seen with 5-FU, with coronary artery vasospasm being most likely. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Fluorouracil'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The spectrum of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    -induced cardiotoxicity is illustrated by the findings in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial in which 153 patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      for advanced colorectal carcinoma, 10 cases of cardiotoxicity were observed (7 percent), eight of which occurred during the first cycle of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/33\">",
"       33",
"      </a>",
"      ]. Angina occurred in seven patients, and there was one case each of sudden death, heart failure, and ventricular fibrillation.",
"     </li>",
"     <li>",
"      In a retrospective series of 78 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , seven (9 percent) developed symptoms of substernal chest pain or chest discomfort suggestive of cardiotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/37\">",
"       37",
"      </a>",
"      ]. None had documented preexisting heart disease. Abnormalities were present in three of five patients evaluated by ECG, but elevations of cardiac enzymes were not observed. Recurrent symptoms were observed in one of three patients who were rechallenged at a lower dose (1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day rather than 1650",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      In a literature-based review of 53 patients with reported",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      cardiotoxicity, the reaction was fatal in six (11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/43\">",
"       43",
"      </a>",
"      ]. Rechallenge led to symptom recurrence in 10 of the 16 patients in whom it was attempted, and neither dose reduction nor medical prophylaxis influenced the outcome of rechallenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fludarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    , a purine antagonist used in hematologic malignancies, has been reported to cause hypotension and chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, the combination of fludarabine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    has been associated with severe cardiac toxicity in at least seven cases when used as the conditioning agent for bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/45\">",
"     45",
"    </a>",
"    ]. The use of either agent alone in high doses has only rarely been associated with cardiac toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pentostatin and cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    (2'-deoxycoformycin) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine) are additional purine antagonists used in hematologic malignancies. Both have rarely been reported to cause ischemia and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no definite cardiac toxicity has been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , there are rare reports of syncope, myocardial infarction, supraventricular and ventricular arrhythmias associated with its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple cases of pericarditis have been attributed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and this can progress to pericardial effusion and cardiac tamponade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Corticosteroid therapy may be beneficial in the treatment of this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MICROTUBULE-TARGETING DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, myocardial ischemia and infarction, and other vasoocclusive complications have been reported with the vinca alkaloids. These complications have been reported most commonly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , but have also been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/54-61\">",
"     54-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia and heart block are the most frequently described cardiac effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , although these usually are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The overall incidence of cardiac events in the National Cancer Institute database was low, and routine cardiac monitoring is not required for patients without risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a phase II series of 140 women with ovarian cancer, in whom transient asymptomatic bradycardia occurred in 29 percent. More serious cardiac toxicity (atrioventricular conduction block, ventricular tachycardia, cardiac ischemia) was seen in 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiomyopathy is reported when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Heart failure has developed in up to 20 percent of patients treated with paclitaxel plus doxorubicin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], although an increased incidence of cardiotoxicity was not seen in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/66\">",
"     66",
"    </a>",
"    ]. The development of heart failure may occur at cumulative doxorubicin doses that are much lower than would be expected with doxorubicin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link&amp;anchor=H26026452#H26026452\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\", section on 'Anthracycline/taxane combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nanoparticle albumin-bound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel, Abraxane&reg;) has the same cardiac toxicity profile as the non-albumin bound formulation. Asymptomatic ECG changes, including non-specific changes, sinus bradycardia, and sinus tachycardia, are most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/70\">",
"     70",
"    </a>",
"    ]. Rare cases of chest pain, supraventricular tachycardia, and cardiac arrest have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction abnormalities, cardiovascular collapse, and angina have been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/71-74\">",
"     71-74",
"    </a>",
"    ], although there is no convincing evidence that causally links docetaxel to these complications.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    appears to potentiate the cardiotoxicity of anthracyclines. This was illustrated by a trial in which 50 women with newly diagnosed stage III breast cancer were treated with docetaxel plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/75\">",
"     75",
"    </a>",
"    ]. Heart failure developed in 8 percent, with a mean decrease in ejection fraction of 20 percent. The total doxorubicin dose was &lt;400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in all of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32128127\">",
"    <span class=\"h2\">",
"     Eribulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     Eribulin",
"    </a>",
"    mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. In an uncontrolled open-label EKG study in 26 patients, corrected QT (QTc) prolongation was observed on day 8 of treatment, with no QTc prolongation seen on day 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/76\">",
"     76",
"    </a>",
"    ]. The FDA-approved labeling recommends EKG monitoring in patients who have heart failure or bradyarrhythmias, and for those who are receiving other drugs known to prolong the QTc interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). The drug should be avoided in those with congenital long QT syndrome. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2666169\">",
"    <span class=\"h2\">",
"     Ixabepilone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    &nbsp;is an epothilone, a class of non-taxane tubulin polymerizing agents. It is approved as monotherapy and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for treatment of metastatic breast cancer.",
"   </p>",
"   <p>",
"    In a trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    , the frequency of adverse cardiac events (myocardial ischemia, ventricular dysfunction) was higher in the combined arm than with capecitabine alone (1.9 versus 0.3 percent), and supraventricular arrhythmias were seen with combined therapy (0.5 percent) but not with capecitabine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/77\">",
"     77",
"    </a>",
"    ]. Given that cardiotoxicity was not reported in a phase II trial of ixabepilone monotherapy conducted in 126 women with advanced breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/78\">",
"     78",
"    </a>",
"    ], it is possible that it is the combination of ixabepilone plus capecitabine that is cardiotoxic. However, the approved manufacturer&rsquo;s labeling for ixabepilone suggests caution in patients with a history of cardiac disease and discontinuation of therapy in patients who develop cardiac ischemia or impaired cardiac function during therapy. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ALKYLATING AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has been associated with an acute cardiomyopathy that is associated with high dose protocols; the cardiotoxicity is not related to cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. This was illustrated by a series of 32 patients treated with a dose of 180",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given over four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/79\">",
"     79",
"    </a>",
"    ]. Nine of these patients developed heart failure within three weeks of treatment, and six died.",
"   </p>",
"   <p>",
"    The incidence of cardiotoxicity may be particularly high in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as part of a program of high-dose chemotherapy followed by autologous stem cell rescue. Adverse prognostic features for this group include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with lymphoma, as opposed to breast cancer",
"     </li>",
"     <li>",
"      Prior radiation to the mediastinum or left chest wall",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Prior abnormal cardiac ejection fraction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reported complications include hemorrhagic myopericarditis resulting in pericardial effusions, tamponade, and death, typically within the first week after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. Most pericardial effusions can be treated with glucocorticoids and analgesics without serious sequelae. These complications may be due to endothelial capillary damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    has been associated with arrhythmias, ST-T wave changes, and heart failure in a dose-related manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. These cardiac complications, when symptomatic, are generally reversible with medical management. Controversy exists whether there is increased cardiotoxicity when ifosfamide is used in combination with anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/87-91\">",
"     87-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiotoxicity due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    can be manifested by supraventricular tachycardia, bradycardia, ST-T wave changes, left bundle branch block, acute ischemic events, myocardial infarction, and ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. This toxicity may be related to electrolyte abnormalities secondary to cisplatin-induced nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    has also been associated with vascular toxicities that include Raynaud's phenomenon, hypertension, and cerebral ischemic events. The increased risk of late cardiovascular toxicity in young men who have been cured of testicular germ cell tumors using cisplatin-based chemotherapy is of particular concern. The long-term consequences of treatment in this group are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link&amp;anchor=H17#H17\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Treatment-related complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Busulfan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     Busulfan",
"    </a>",
"    is used at high doses as part of the preparative regimen for bone marrow transplantation. One case of endocardial fibrosis has been reported that was attributed to busulfan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ANTITUMOR ANTIBIOTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mitomycin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    C causes DNA alkylation and cross-linking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/95\">",
"     95",
"    </a>",
"    ]. Heart failure has been observed in patients treated with mitomycin C, with the incidence increasing at cumulative doses &gt;30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/96\">",
"     96",
"    </a>",
"    ]. Cardiotoxicity may be additive when mitomycin C is given with anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. Histologically, the damage resembles radiation-induced cardiac injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bleomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    has been associated with several different forms of cardiotoxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericarditis is an uncommon but potentially serious complication associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      . In a series of 88 patients with lymphoma receiving bleomycin, pericarditis was observed in two cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acute onset of substernal chest pain has also been reported in less than 3 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/102\">",
"       102",
"      </a>",
"      ]. There are no consistent signs or symptoms associated with these events and long-term cardiac sequelae have not been observed. Treatment is supportive and discontinuation of the drug is not needed, as further infusions do not usually cause recurrence of the symptoms.",
"     </li>",
"     <li>",
"      Coronary artery disease, myocardial ischemia, and myocardial infarction have been observed in young patients during and after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -based chemotherapeutic regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/103-105\">",
"       103-105",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link&amp;anchor=H17#H17\">",
"       \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Treatment-related complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MONOCLONAL ANTIBODIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    is a monoclonal antibody that binds to a specific epitope of the HER2 protein and inhibits signal transduction induced by peptide growth factors interacting with their receptors. Trastuzumab has been associated with the development of a cardiomyopathy that is typically manifested by an asymptomatic decrease in the left ventricular ejection fraction (LVEF) and less commonly by clinical heart failure.",
"   </p>",
"   <p>",
"    The cardiotoxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a monoclonal antibody against the CD20 antigen on normal and malignant B lymphocytes, is used to treat a variety of malignant and benign hematologic conditions.",
"   </p>",
"   <p>",
"    Arrhythmias and angina have been reported during less than 1 percent of infusions, and acute infusion-related deaths have been seen in less than 0.1 percent. These deaths appear to be related to an infusion-related complex of hypoxia, pulmonary infiltrates, adult respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/106-108\">",
"     106-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term cardiac toxicity has not been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been sporadically reported in several trials of bevacizumab given in conjunction with anthracyclines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in women with metastatic breast cancer, an indication for which bevacizumab is not longer approved. It has not been reported in patients treated with bevacizumab for other advanced cancers.",
"   </p>",
"   <p>",
"    In contrast with heart failure, ischemic cardiac events are increased in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Cardiac toxicity in patients treated with bevacizumab is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21640522#H21640522\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Left ventricular dysfunction and myocardial ischemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H291526440#H291526440\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Arterial thromboembolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    targets the CD52 antigen that is present on the cell membrane of most T and B lymphocytes. Alemtuzumab is used to treat",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -resistant chronic lymphocytic leukemia and other lymphoproliferative disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    therapy of patients with T cell lymphomas (mycosis fungoides, Sezary syndrome) is associated with a significant risk of heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmias. Among eight patients treated at M D Anderson Cancer Center, heart failure developed in three, atrial fibrillation in one, and ventricular tachycardia in one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/109\">",
"     109",
"    </a>",
"    ]. Two patients previously had been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , but no other causes of cardiac toxicity were identified. The mechanism of this toxicity is not known, and all patients had partial or total resolution of symptoms after discontinuing treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    binds to the epidermal growth factor receptor, blocking interaction with its ligand. It is used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    to treat refractory metastatic colorectal cancer. Patients treated with combinations containing 5-FU and cetuximab have experienced a range of cardiac events; it is not clear that all of these events can be attributed exclusively to the 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     TOPOISOMERASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    has been linked to the development of myocardial infarction and vasospastic angina in several case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. Additionally, etoposide is often a part of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens that have been associated with acute and delayed cardiac toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link&amp;anchor=H17#H17\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Treatment-related complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     BIOLOGIC RESPONSE MODIFIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicities of biologic response modifiers are generally not due to a direct cytotoxic effect of the drugs, but rather reflect alterations of cellular physiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Interferon-alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-alfa (IFNa) is used as an adjuvant in patients with melanoma and to treat advanced melanoma and renal cell carcinoma. The cardiovascular side effects of IFNa include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial ischemia and infarction, which are generally related to a prior history of coronary artery disease. These may be due to increased fever or associated flu-like symptoms that increase myocardial oxygen requirements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial and ventricular arrhythmias have been reported in up to a 20 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/115-118\">",
"       115-118",
"      </a>",
"      ], and two cases of sudden death have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/114\">",
"       114",
"      </a>",
"      ]. It is unclear whether prior heart disease is linked to an increased risk of arrhythmias.",
"     </li>",
"     <li>",
"      Prolonged administration of IFNa has been associated with cardiomyopathy, manifested by a depressed ejection fraction and heart failure. The cardiomyopathy was reversible upon cessation of IFNa infusion in some but not all cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/119-122\">",
"       119-122",
"      </a>",
"      ]. The pathogenesis of IFNa-induced cardiomyopathy is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Interleukin 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients receiving high-dose interleukin-2 (IL-2) develop a capillary leak syndrome associated with increased vascular permeability and hypotension. This results in cardiovascular symptoms similar to those of septic shock, with an increased heart rate and cardiac output and a decrease in systemic peripheral resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These symptoms are partially responsive to fluid replacement therapy but patients often require vasopressors as well. These symptoms usually peak about four hours after each dose of IL-2 and worsen with further treatment. The decreased systemic vascular resistance may not return to normal for up to six days after IL-2 has been discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/123\">",
"     123",
"    </a>",
"    ]. It is not known whether the decrease in peripheral vascular resistance is a direct or indirect effect of IL-2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IL-2 also is associated with direct myocardial toxicity although the mechanism of this is unclear. In patients with underlying coronary artery disease, ischemia, myocardial infarction, arrhythmias, and death have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/124\">",
"     124",
"    </a>",
"    ]. Ventricular and supraventricular arrhythmias have been reported to occur in 6 to 21 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/123,125,126\">",
"     123,125,126",
"    </a>",
"    ]. This is illustrated by a series of 199 patients in which 6 percent developed arrhythmias, including ventricular tachycardia, and 25 percent had elevated creatine kinase (CPK) MB levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/126\">",
"     126",
"    </a>",
"    ]. Supraventricular tachycardias were usually responsive to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Denileukin difitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;Denileukin difitox is a fusion protein of diphtheria toxin and the IL-2 protein that targets cells expressing the IL-2 receptor. A potentially fatal capillary leak syndrome has been associated with therapy with denileukin difitox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/127\">",
"     127",
"    </a>",
"    ]. Hypersensitivity reactions have been associated with drug administration and may be manifested by hypotension, chest pain, and tachycardia. Other reported cardiovascular manifestations include myocardial infarction, arrhythmias, and congestive heart failure. Special caution should be taken when treating patients with known cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     DIFFERENTIATION AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     All-trans retinoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;All-trans retinoic acid (ATRA) is used to treat acute promyelocytic leukemia. Approximately 10 to 15 percent of patients develop the differentiation syndrome (previously called the \"retinoic acid syndrome\"), which can cause pericardial effusions (including the potential for cardiac tamponade) and myocardial",
"    <span class=\"nowrap\">",
"     ischemia/infarction.",
"    </span>",
"    The differentiation syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Administration and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Arsenic trioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    is used to treat relapsed acute promyelocytic leukemia. Serious adverse events attributed to treatment with arsenic trioxide include the \"differentiation syndrome\" similar to that seen with ATRA, and cardiac abnormalities. These complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Arsenic trioxide plus ATRA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     MULTITARGETED KINASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950869\">",
"    <span class=\"h2\">",
"     Tyrosine kinase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H505828945\">",
"    <span class=\"h3\">",
"     Antiangiogenic TKIs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h4\">",
"     Sorafenib and sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    are orally active multi-targeted tyrosine kinase (TK) inhibitors that are used for the treatment of metastatic renal cell carcinoma. In addition, sorafenib is used in the treatment of advanced hepatocellular cancer, and sunitinib is used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory gastrointestinal stromal tumors (GIST) and for advanced pancreatic neuroendocrine tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190949047#H190949047\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical trials, both drugs have been associated with a small but definite risk of cardiotoxicity.",
"   </p>",
"   <p>",
"    However, a major problem with defining the precise rate of cardiotoxicity associated with both drugs (and its reversibility) is that phase III trials have not pursued cardiac endpoints, and the identification of cardiac side effects with both drugs has predominantly been based on the occurrence of clinical symptoms. Further detailed prospective study of cardiotoxicity of these agents is needed. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21640522#H21640522\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Left ventricular dysfunction and myocardial ischemia'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In addition to declines in LVEF and clinical heart failure, reported ECG changes have included changes in rhythm, conduction disturbance, change in axis or QRS amplitude, ST or T wave changes, and QTc prolongation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H1063204941#H1063204941\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Prolongation of the QTc interval and cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have suggested that patients receiving these drugs be treated as \"stage A\" heart failure patients, ie, at risk for heart failure, but without structural heart disease or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/128\">",
"     128",
"    </a>",
"    ]. The 2005 American Heart Association (AHA) heart failure guidelines (with 2009 focused update) recommend that patients receiving potentially cardiotoxic agents undergo baseline noninvasive assessment of left ventricular function, monitoring for symptoms and signs of heart failure, and management of cardiovascular risk factors including control of blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H2#H2\">",
"     \"Prognosis of heart failure\", section on 'Stages of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our view and that of others, patients receiving these drugs should be monitored closely for signs and symptoms of heart failure, and physicians should have a low threshold for evaluating for LV dysfunction. However, obtaining a baseline assessment of LVEF in all patients receiving these drugs is not supported by compelling data. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H78098454#H78098454\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Sunitinib and sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15669151\">",
"    <span class=\"h3\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    targets VEGFR1, 2, and 3 in addition to RET, KIT, PDGFR alpha and beta, fibroblast growth factor receptor (FGFR) 1 and 2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. It has been approved in the United States for treatment of refractory metastatic colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In placebo-controlled clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    has been associated with an increased incidence of myocardial ischemia and infarction but heart failure has not yet been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H78098554#H78098554\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Regorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2285886\">",
"    <span class=\"h3\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is an orally active multi-targeted TK inhibitor that is used mainly for treatment of medullary thyroid cancer. In clinical trials, vandetanib has been associated with prolongation of the QTc interval, torsades de pointes, and sudden death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H1063205064#H1063205064\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Vandetanib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Because of the risk of cardiotoxicity, the FDA-approved labeling includes a black box warning to correct hypocalcemia, hypokalemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypomagnesemia prior to drug administration. In addition, given the long half live of the drug (19 days), EKGs are recommended to monitor the QT interval at baseline, at two to four weeks, and 8 to 12 weeks after starting treatment, and every three months thereafter. Monitoring of serum potassium, calcium, and magnesium levels as well as TSH is recommended on the same schedule. Concurrent administration of drugs known to prolong the QTc interval should be avoided (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). Largely because of the cardiovascular risk,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    is only available through a restricted distribution program (the Vandetanib Risk Evaluation and Mitigation Strategy [REMS] Program). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=see_link&amp;anchor=H10576313#H10576313\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Vandetanib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    , a small-molecule inhibitor of Bcr-Abl, KIT, the platelet-derived growth factor receptor, and the SRC family of tyrosine kinases, is used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML), which is characterized by the presence of the fusion protein Bcr-Abl that functions as a tyrosine kinase, and gastrointestinal stromal tumors (GIST), which are characterized by mutations in KIT or PDGFR genes. In an early report of patients treated for Ph+CML, imatinib was associated with the development of severe heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/130\">",
"     130",
"    </a>",
"    ], prompting the manufacturer to revise the drug labeling to include warnings about possible heart failure.",
"   </p>",
"   <p>",
"    Laboratory studies indicate that adverse cardiac events in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    are likely mediated by inhibition of c-Abl:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      -resistant mutant of c-Abl are largely protected from imatinib cardiotoxicity, suggesting that c-Abl has a previously unrecognized function in myocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A structurally reengineered form of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      that inhibits KIT but not c-Abl retains antitumor activity in a murine GIST model, but has fewer adverse effects on the heart [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the biologic rationale for potential cardiotoxicity in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , subsequent publications indicate a low incidence of clinically significant heart failure in CML clinical trial settings (no more than 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/132\">",
"     132",
"    </a>",
"    ]); an increased risk for heart failure or left ventricular dysfunction has not been observed in patients receiving imatinib for the treatment of GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Cardiovascular'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H12#H12\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Side effects and their management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the cardiac consequences of long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy remain unknown. Importantly, none of these reports was based on studies in which cardiac function was prospectively monitored. Assessment was based primarily on adverse event reports, which may not reflect the true incidence of cardiac disease. In the only study to prospectively assess left ventricular function in 59 patients with CML who were treated with imatinib, there was no evidence of deterioration over the initial 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/136\">",
"     136",
"    </a>",
"    ]. In the lone prospective study in which patients receiving imatinib for GIST were monitored with serum levels of brain natriuretic peptide (BNP), two of 55 patients followed over a three-month period had substantial increases in BNP (4 percent), suggesting the possibility of subclinical heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H31#H31\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Cardiac biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional information from well-designed prospective studies with objective cardiac monitoring is needed to determine the incidence and clinical significance of heart failure attributable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , both in patients with CML and GIST. Until then, some have suggested that patients receiving imatinib for either CML or GIST be thought of as stage A heart failure patients, ie, at risk for heart failure, but without structural heart disease or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/128,135\">",
"     128,135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 AHA heart failure guidelines (with 2009 focused update) include recommendations for stage A patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/129\">",
"     129",
"    </a>",
"    ]. These guidelines recommend that patients receiving cardiotoxic agents undergo noninvasive assessment of left ventricular function. Other recommendations for stage A patients at high risk for heart failure include monitoring for symptoms and signs of heart and management of cardiovascular risk factors including control of blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H2#H2\">",
"     \"Prognosis of heart failure\", section on 'Stages of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, obtaining a baseline assessment of LVEF in all patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (particularly for GIST where it is not even clear that there is a risk of cardiotoxicity) is not supported by compelling data. In our view, patients receiving imatinib should be monitored for signs and symptoms of heart failure, and physicians should have a low threshold for formal assessment of LV dysfunction.",
"   </p>",
"   <p>",
"    Guidelines for management of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    toxicity from the National Comprehensive Cancer Network suggest only that patients with cardiac disease or risk factors for heart failure who are receiving imatinib be monitored carefully, and that any patient with signs or symptoms consistent with heart failure be evaluated and treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with these guidelines, and do not obtain a baseline assessment of LVEF prior to starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23522343\">",
"    <span class=\"h3\">",
"     Nilotinib, dasatinib, bosutinib, and ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    are three second-generation multitargeted tyrosine kinase inhibitors that are used for the treatment of Ph+CML; all target Bcr-Abl, while nilotinib also targets KIT and PDGFR, dasatinib targets KIT, PDGFR and the SRC family of kinases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    targets VEGFR, PDGFR, fibroblast growth factor receptor (FGFR), the SRC family of kinases, KIT, RET, TIE2 and FLT3, and bosutinib targets the SRC family of tyrosine kinases.",
"   </p>",
"   <p>",
"    Cardiac effects have been described with each of these agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      have been associated with QT prolongation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/139\">",
"       139",
"      </a>",
"      ]. Abnormalities in potassium and magnesium levels must be corrected prior to drug initiation, other drugs that may affect the QTc interval should be avoided, caution should be used in patients at risk for QT interval prolongation, and serial electrocardiograms should be followed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Cardiovascular'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although a definite causal relationship has not been established,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      has also been associated with chest pain, pericardial effusion, ventricular dysfunction, and heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/140\">",
"       140",
"      </a>",
"      ]. The FDA-approved labeling states that 1.6 percent of 258 patients taking dasatinib developed cardiomyopathy, heart failure, diastolic dysfunction, fatal myocardial infarction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/141\">",
"       141",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 4 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      have developed serious heart failure or left ventricular dysfunction, with some fatalities. In addition, approximately 1 percent of patients have developed symptomatic bradyarrhythmias, and 5 percent supraventricular tachyarrhythmias (predominantly atrial fibrillation). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21640522#H21640522\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Left ventricular dysfunction and myocardial ischemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H1063204941#H1063204941\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Prolongation of the QTc interval and cardiac arrhythmias'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although clinical heart failure is not described, fluid retention occurs with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      and may manifest as pericardial effusion or pulmonary edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is an orally active tyrosine kinase inhibitor that affects both",
"    <span class=\"nowrap\">",
"     HER2/neu",
"    </span>",
"    (erbB-2) and the epidermal growth factor receptor (EGFR, also called erbB-1). Biomarker data suggest that inhibition of HER-2 is more important than is blockade of EGFR in stopping tumor growth. This effect on the",
"    <span class=\"nowrap\">",
"     HER-2/neu",
"    </span>",
"    has raised particular concern because of the cardiotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early clinical studies suggest activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    in women with inflammatory breast cancer and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -refractory advanced breast cancer. In addition, preliminary results support the possibility that this drug, unlike trastuzumab, may penetrate the central nervous system and be effective against brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of brain metastases in breast cancer\", section on 'Targeted agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emerging data from the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    trials suggest that lapatinib may differ from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    not only in terms of antitumor efficacy but also in terms of its cardiac safety profile:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial, in which",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      was compared to capecitabine alone in women with advanced breast cancer, treatment-related cardiac events were infrequent (4 of 155 receiving combined therapy compared to one of 145 patients treated with capecitabine alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/143\">",
"       143",
"      </a>",
"      ]. Furthermore, three of the four were asymptomatic and not associated with a drop in LVEF. The fourth developed Prinzmetal's angina, which resolved on discontinuation of lapatinib, but there was an unexplained subsequent drop in LVEF. There were no differences in the mean LVEF between treatment groups at the scheduled assessments.",
"     </li>",
"     <li>",
"      Global experience with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      -related cardiotoxicity was reviewed in a pooled analysis of 3689 patients enrolled in clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/144\">",
"       144",
"      </a>",
"      ]. Only 60 (1.6 percent) patients exposed to lapatinib had a cardiac event; 53 were asymptomatic declines in LVEF and only seven (0.2 percent) had symptoms of a decline in cardiac function. Furthermore, of the 552 patients previously treated with anthracyclines, only 12 (2.2 percent) had a decreased LVEF while on lapatinib, as did 14 (1.7 percent) of the 826 patients previously exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      . The decrease in LVEF was rarely severe; the mean nadir was 43 percent. Of the 40 patients whose outcome was determined, 35 (88 percent) had partial or full recovery regardless of whether or not lapatinib was continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these preliminary results compare favorably with historical experience of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity (5 percent objective evidence of cardiac dysfunction, 2 percent symptomatic heart failure, and 1 percent severe [NYHA class III or IV, (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 3",
"    </a>",
"    )] heart failure), the patients enrolled in these trials were highly selected. Additional clinical data and longer follow-up will be required to fully assess whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    has a more favorable cardiotoxicity profile than trastuzumab.",
"   </p>",
"   <p>",
"    Early results suggest that the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is not incrementally more cardiotoxic than trastuzumab alone, although clinical experience and follow-up duration are both limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/145\">",
"     145",
"    </a>",
"    ]. Combinations of these two drugs should be considered experimental and is not recommended outside of a clinical trial.",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer&rsquo;s package insert recommends that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    be discontinued for a drop in the LVEF to &lt;50 percent, for those whose LVEF drops below the institution&rsquo;s lower limit of normal, and for any patients who develops clinical heart failure during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/146\">",
"     146",
"    </a>",
"    ]. Dose reduction is recommended if the LVEF recovers to normal after a minimum of two weeks and the patient is asymptomatic. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8214830\">",
"    <span class=\"h3\">",
"     Crizotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     Crizotinib",
"    </a>",
"    , an orally active inhibitor of the anaplastic lymphoma kinase (ALK), is approved for treatment of advanced or metastatic non-small cell lung cancer (NSCLC) if the tumor contains a characteristic EML4-ALK fusion oncogene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    QTc interval prolongation has been observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    . The FDA-approved manufacturer&rsquo;s labeling recommends avoiding the drug in patients with congenital long QT syndrome and that patients with heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking other medications known to prolong the QTc interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ) undergo periodic monitoring with electrocardiograms and serum electrolytes. Treatment interruption is advised if QTc interval exceeds &gt;500 ms during treatment, with permanent discontinuation if it recurs or is accompanied by an arrhythmia, heart failure, hypotension, shock, syncope, or torsade de pointes.",
"   </p>",
"   <p>",
"    In addition to QTc interval prolongation, asymptomatic profound sinus bradycardia (heart rate &le;45) was reported in 8 of 40 patients enrolled to a clinical trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    in advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/147\">",
"     147",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Given that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    is a CYP3A4 substrate, it should be used with caution in patients who are receiving other drugs that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950925\">",
"    <span class=\"h2\">",
"     Vemurafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    , an orally available inhibitor of some mutated forms of BRAF, is approved for treatment of metastatic melanoma with a V600E BRAF mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link&amp;anchor=H100472992#H100472992\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Vemurafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    has been associated with prolongation of the QTc interval. The FDA-approved manufacturers&rsquo; labeling recommends that the drug not be given to patients with congenital long QTc syndrome, or to those who are receiving other drugs that prolong the QT interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Furthermore, it is recommended that ECG and electrolytes be monitored before treatment and after dose modification. For patients starting therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    , ECGs are recommended at day 15, monthly during the first three months of treatment, and every three months thereafter; more often as clinically indicated. If the corrected QT interval (QTc) exceeds 500 ms, treatment should be temporarily interrupted, and electrolyte abnormalities sought and corrected.",
"   </p>",
"   <p>",
"    Given that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    is a CYP3A4 substrate, it should be used with caution in patients receiving other drugs that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Diethylstilbestrol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diethylstilbestrol (DES) is a synthetic estrogen that was used to treat advanced prostate cancer and breast cancer. Multiple studies demonstrated an increased risk of cardiovascular death in patients treated with DES. This agent is no longer commercially available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1353?source=see_link\">",
"     \"Initial hormone therapy for metastatic prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Estramustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/4/35909?source=see_link\">",
"     Estramustine",
"    </a>",
"    is a conjugate of nitrogen mustard and estradiol that is used in the treatment of prostate cancer. A range of cardiovascular complications, including coronary ischemia, has been reported in as many as 10 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H13#H13\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Estramustine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Serotonin antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although usually well tolerated, the serotonin antagonist receptors, often used during chemotherapy as antiemetics, have some potential for cardiac effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/148\">",
"     148",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials in healthy subjects and patients undergoing chemotherapy have demonstrated transient asymptomatic ECG changes (increases in PR interval, QRS complex duration, and QTc interval) following administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/149-154\">",
"     149-154",
"    </a>",
"    ]; chest pain has been attributed to ondansetron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/155\">",
"     155",
"    </a>",
"    ]. Since almost all of these studies excluded patients with preexisting cardiac disease, the clinical significance of these events in such patients, particularly those receiving cardiac medications, is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7757908\">",
"    <span class=\"h2\">",
"     Proteasome inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    are proteasome inhibitors that are used for the treatment of refractory multiple myeloma.",
"   </p>",
"   <p>",
"    In clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    , a second-generation proteasome inhibitor, new onset or worsening of preexisting heart failure with decreased left ventricular function or myocardial ischemia has been reported in approximately 7 percent of patients, and deaths due to cardiac arrest have occurred within one day of drug administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/156\">",
"     156",
"    </a>",
"    ]. In addition, pulmonary arterial hypertension has been reported in 2 percent of patients treated with carfilzomib.",
"   </p>",
"   <p>",
"    In a phase II trial of 266 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    monotherapy for relapsed myeloma, ten experienced heart failure (3.8 percent), four (1.5 percent) had a cardiac arrest, and two (0.8 percent) had a myocardial infarction during the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/157\">",
"     157",
"    </a>",
"    ]. The risk did not appear to be cumulative, at least through 12 cycles of therapy. However, the magnitude of the attributable risk, risk factors and natural history, including reversibility, of carfilzomib-related cardiac toxicity remain incompletely characterized. Recommended dose modification based upon cardiac toxicity is available in the FDA-approved manufacturer&rsquo;s package insert. &nbsp;",
"   </p>",
"   <p>",
"    Cardiotoxicity might represent a class effect as heart failure events (acute pulmonary edema, cardiac failure, cardiogenic shock) have also been described in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , a first-generation proteasome inhibitor. However, causality remains unclear. In a phase III trial comparing bortezomib versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for relapsed myeloma, the incidence of treatment-emergent cardiac disorders during treatment with bortezomib or dexamethasone was 15 and 13 percent, respectively; seven patients receiving bortezomib (2 percent) and eight patients receiving dexamethasone (2 percent) developed heart failure during the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/158\">",
"     158",
"    </a>",
"    ]. There were eight deaths thought possibly related to study drug; four in the bortezomib group (including three from cardiac causes and one from respiratory failure), and four in the dexamethasone group (three from sepsis and one from sudden death of unknown cause). As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    , cardiac dysfunction does not appear to be cumulative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Histone deacetylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reversible acetylation of histones, a family of nuclear proteins that interact with DNA, is an important mechanism by which gene expression is regulated. Removal of acetyl groups by histone deacetylase (HDAC) stabilizes the interaction between DNA and histones, repressing transcription. Inhibitors of HDAC reacetylate histones, thereby reactivating transcription of dormant tumor-suppressor genes.",
"   </p>",
"   <p>",
"    Two HDAC inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    [suberoylanilide hydroxamic acid, SAHA] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    [depsipeptide]) are approved in the United States for the treatment of cutaneous T-cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Romidepsin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Vorinostat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both drugs have been associated with transient electrocardiographic changes (including prolongation of the QTc interval (",
"    <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"mobipreview.htm?26/24/27008\">",
"     waveform 1",
"    </a>",
"    ) and ST segment and T wave changes) in some but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/160-162\">",
"     160-162",
"    </a>",
"    ]. Supraventricular and ventricular arrhythmias including nonsustained ventricular tachycardia are rare in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    , and evidence of acute or cumulative cardiac damage has not been seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine ECG monitoring is not recommended for either drug in the manufacturer's FDA-approved package insert. However, both drugs should be used with caution in patients with significant heart disease, congenital long QT syndrome, and those who are receiving other drugs that prolong the QTc interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ) or inhibit CYP3A4, which is the principal enzyme responsible for the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/163\">",
"     163",
"    </a>",
"    ]. In addition, serum potassium and magnesium levels should be in the normal range before drug administration, since hypokalemia and hypomagnesemia predispose to arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors have been shown to improve outcomes and slow disease progression in patients with left ventricular systolic dysfunction due to a variety of causes. However, the role of ACE inhibitors in the treatment of patients with chemotherapy-induced cardiotoxicity is less clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H35#H35\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Prognosis and treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate question relates to the potential protective effect of ACE inhibitors for preventing the development of left ventricular dysfunction in response to chemotherapy in patients who are at risk. Patients with elevations in serum cardiac troponin levels in response to chemotherapy may be at an increased risk for developing impaired left ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential protective effect of ACE inhibitors in patients with elevated serum cardiac troponin following chemotherapy was evaluated in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/12/40138/abstract/164\">",
"     164",
"    </a>",
"    ]. From a total population of 473 cancer patients treated with a variety of high-dose chemotherapy regimens, 114 patients with an elevated troponin T were randomly assigned to one year of treatment with the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (2.5 mg daily, titrated to a maximum of 20 mg daily), or to no enalapril. After one year, patients assigned to no treatment had a significant reduction in LVEF, while those in the ACE inhibitor group did not (LVEF at 12 months 48 versus 62 percent). In addition the primary end point, an absolute reduction in LVEF of 10 percent or more, was reached in 43 percent of the untreated patients, but in none of the patients treated with enalapril.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease.",
"   </p>",
"   <p>",
"    A wide range of chemotherapy agents has been associated with cardiotoxicity Among the serious complications that have been reported are (see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmias (eg, histone deacetylase inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocardial necrosis causing a dilated cardiomyopathy and clinical heart failure (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vasospasm or vasoocclusion resulting in chest pain or myocardial infarction (eg, fluoropyrimidines, particularly infusional administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Transient stress-induced cardiomyopathy (fluoropyrimidines)",
"     </li>",
"     <li>",
"      Pericarditis (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heart failure, myocardial ischemia, and cardiac arrest (proteasome inhibitors)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/1\">",
"      Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/2\">",
"      Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/3\">",
"      Jensen SA, Hasbak P, Mortensen J, S&oslash;rensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28:5280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/4\">",
"      Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/5\">",
"      de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/6\">",
"      Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003; 65:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/7\">",
"      Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/8\">",
"      Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients. Med Sci Monit 2002; 8:PI51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/9\">",
"      Sch&ouml;ber C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/10\">",
"      Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/11\">",
"      Jeremic B, Jevremovic S, Djuric L, Mijatovic L. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990; 2:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/12\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/13\">",
"      Dalzell JR, Samuel LM. The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs 2009; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/14\">",
"      Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/15\">",
"      S&uuml;dhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/16\">",
"      Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/17\">",
"      Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/18\">",
"      Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/19\">",
"      Jensen SA, S&oslash;rensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012; 69:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/20\">",
"      Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012; 30:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/21\">",
"      Basselin C, Fontanges T, Descotes J, et al. 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 2011; 31:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/22\">",
"      Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010; 40:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/23\">",
"      Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/24\">",
"      Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003; 88:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/25\">",
"      Lestuzzi C, Viel E, Picano E, Meneguzzo N. Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil. Am J Med 2001; 111:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/26\">",
"      Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/27\">",
"      Kleiman NS, Lehane DE, Geyer CE Jr, et al. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med 1987; 82:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/28\">",
"      Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemother Pharmacol 1999; 43:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/29\">",
"      Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990; 29:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/30\">",
"      Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/31\">",
"      Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110:1623.",
"     </a>",
"    </li>",
"    <li>",
"     Ewer M, Benjamin R. Cardiac complications. In: Cancer Medicine, 6th, Holland J, Frei E III, Kufe DW, et al (Eds), Lea &amp; Febiger, Philadelphia 2003. p.3197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/33\">",
"      Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/34\">",
"      Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/35\">",
"      Aksoy S, Karaca B, Din&ccedil;er M, Yal&ccedil;in S. Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother 2005; 39:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/36\">",
"      Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/37\">",
"      Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/38\">",
"      Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/39\">",
"      Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/40\">",
"      Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004; 100:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/41\">",
"      Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/42\">",
"      Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/43\">",
"      Manojlovic N, Babic D, Stojanovic S, et al. Capecitabine cardiotoxicity--case reports and literature review. Hepatogastroenterology 2008; 55:1249.",
"     </a>",
"    </li>",
"    <li>",
"     Gutheil J, Finucane D. Antimetabolites. In: The Chemotherapy Sourcebook, 3rd, Perry MC (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.208.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/45\">",
"      Van Besien K, Devine S, Wickrema A, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/46\">",
"      Grem JL, King SA, Chun HG, Grever MR. Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy. Am J Hematol 1991; 38:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/47\">",
"      Koczwara B, Spangenthal E, Bernstein SH. The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 1997; 26:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/48\">",
"      Gasser AB, Ti&egrave;che M, Brunner KW. Neurologic and cardiac toxicity following iv application of methotrexate. Cancer Treat Rep 1982; 66:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/49\">",
"      Kettunen R, Huikuri HV, Oikarinen A, Takkunen JT. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol 1995; 75:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/50\">",
"      Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005; 25:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/51\">",
"      Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995; 19:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/52\">",
"      Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/53\">",
"      Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984; 144:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/54\">",
"      Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986; 70:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/55\">",
"      Harris AL, Wong C. Myocardial ischaemia, radiotherapy, and vinblastine. Lancet 1981; 1:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/56\">",
"      Kantor AF, Greene MH, Boice JD, et al. Are vinca alkaloids associated with myocardial infarction? Lancet 1981; 1:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/57\">",
"      Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/58\">",
"      Somers G, Abramov M, Witter M, Naets JP. Letter: Myocardial infarction: a complication of vincristine treatment? Lancet 1976; 2:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/59\">",
"      Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep 1982; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/60\">",
"      Zabernigg A, Gattringer C. Myocardial infarction associated with vinorelbine (Navelbine). Eur J Cancer 1996; 32A:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/61\">",
"      Cargill RI, Boyter AC, Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir Med 1994; 88:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/62\">",
"      Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; :117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/63\">",
"      Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/64\">",
"      Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/65\">",
"      Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/66\">",
"      Lluch A, Ojeda B, Colomer R, et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer 2000; 89:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/67\">",
"      Rahman Z, Champlin R, Rondon G, et al. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 1997; 24:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/68\">",
"      Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/69\">",
"      Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003; 97:40.",
"     </a>",
"    </li>",
"    <li>",
"     Abraxis oncology: Abraxane (albumin-bound paclitaxel). Schaumburg, IL, USA. January, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/71\">",
"      Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993; 53:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/72\">",
"      Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/73\">",
"      Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/74\">",
"      Gon&ccedil;alves A, Viret F, Ciccolini J, et al. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res 2003; 9:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/75\">",
"      Malhotra V, Dorr VJ, Lyss AP, et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer 2004; 5:377.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf (Accessed on November 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/77\">",
"      Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/78\">",
"      Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/79\">",
"      Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/80\">",
"      Slavin RE, Millan JC, Mullins GM. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol 1975; 6:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/81\">",
"      Appelbaum F, Strauchen JA, Graw RG Jr, et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/82\">",
"      Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/83\">",
"      Lichtman SM, Ratain MJ, Van Echo DA, et al. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst 1993; 85:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/84\">",
"      Nieto Y, Cagnoni PJ, Bearman SI, et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 2000; 6:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/85\">",
"      Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/86\">",
"      Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/87\">",
"      Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/88\">",
"      Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/89\">",
"      Bramwell V, Quirt I, Warr D, et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1989; 81:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/90\">",
"      Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/91\">",
"      Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/92\">",
"      Tomirotti M, Riundi R, Pulici S, et al. Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP). Tumori 1984; 70:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/93\">",
"      Mortimer JE, Crowley J, Eyre H, et al. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer 1992; 69:1220.",
"     </a>",
"    </li>",
"    <li>",
"     Perry MC. Effects of chemotherapy on the heart. In: Cancer and the Heart, Kapoor AS (Ed), Springer Verlag, New York 1986. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/95\">",
"      Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997; 76:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/96\">",
"      Verweij J, van Zanten T, Souren T, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987; 60:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/97\">",
"      Verweij J, Funke-K&uuml;pper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988; 5:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/98\">",
"      Buzdar AU, Legha SS, Tashima CK, et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 1978; 62:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/99\">",
"      Verweij J, van der Burg ME, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/100\">",
"      Ravry MJ. Cardiotoxicity of mitomycin C in man and animals. Cancer Treat Rep 1979; 63:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/101\">",
"      Durkin WJ, Pugh RP, Solomon J, et al. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 1976; 33:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/102\">",
"      White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987; 59:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/103\">",
"      House KW, Simon SR, Pugh RP. Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease. Clin Cardiol 1992; 15:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/104\">",
"      Edwards GS, Lane M, Smith FE. Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease. Cancer Treat Rep 1979; 63:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/105\">",
"      Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980; 64:1159.",
"     </a>",
"    </li>",
"    <li>",
"     Rasool HJ. Antibodies. In: The Chemotherapy Sourcebook, 3rd, Perry MC (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.394.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/107\">",
"      Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 2003; 60:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/108\">",
"      Millward PM, Bandarenko N, Chang PP, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005; 45:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/109\">",
"      Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/S&eacute;zary syndrome. Blood 2004; 104:655.",
"     </a>",
"    </li>",
"    <li>",
"     Percy Ivy S, Chen H. IND safety report: cardiac events. May 20, 2005 (letter).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/111\">",
"      Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/112\">",
"      Schecter JP, Jones SE, Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both. Cancer Chemother Rep 1975; 59:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/113\">",
"      Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J 1996; 60:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/114\">",
"      Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/115\">",
"      Martino S, Ratanatharathorn V, Karanes C, et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. J Cancer Res Clin Oncol 1987; 113:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/116\">",
"      Friess GG, Brown TD, Wrenn RC. Cardiovascular rhythm effects of gamma recombinant DNA interferon. Invest New Drugs 1989; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/117\">",
"      Budd GT, Bukowski RM, Miketo L, et al. Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy. Cancer Chemother Pharmacol 1984; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/118\">",
"      Grunberg SM, Kempf RA, Itri LM, et al. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985; 69:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/119\">",
"      Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/120\">",
"      Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ 1990; 300:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/121\">",
"      Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989; 321:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/122\">",
"      Zimmerman S, Adkins D, Graham M, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 1994; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/123\">",
"      Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/124\">",
"      Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/125\">",
"      Crum E. Biological-response modifier--induced emergencies. Semin Oncol 1989; 16:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/126\">",
"      White RL Jr, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74:3212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/127\">",
"      Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/128\">",
"      Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/129\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/130\">",
"      Kerkel&auml; R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/131\">",
"      Fern&aacute;ndez A, Sanguino A, Peng Z, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117:4044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/132\">",
"      Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/133\">",
"      Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/134\">",
"      Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/135\">",
"      Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010; 116:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/136\">",
"      Estabragh ZR, Knight K, Watmough SJ, et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 2011; 35:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/137\">",
"      Perik PJ, Rikhof B, de Jong FA, et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008; 19:359.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/139\">",
"      Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25:3362.",
"     </a>",
"    </li>",
"    <li>",
"     Bristol-Myers Squibb Company: Sprycel (dasatinib) prescribing information. Princeton, NJ 2006.",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=32204&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30878ec315457e3b38 (Accessed on November 22, 2010).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/143\">",
"      Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/144\">",
"      Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679.",
"     </a>",
"    </li>",
"    <li>",
"     Storniolo AM, Koehler M, Preston A, et al. Cardiac safety in patients with metastatic breast cance treated with lapatinib and trastuzumab (abstract). J Clin Oncol 2007; 25:6s.",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808 (Accessed on February 05, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/147\">",
"      Ou SH, Azada M, Dy J, Stiber JA. Asymptomatic profound sinus bradycardia (heart rate &le;45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 2011; 6:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/148\">",
"      Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/149\">",
"      Grote TH, Pineda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 1997; 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/150\">",
"      Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/151\">",
"      Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997; 54:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/152\">",
"      Hunt TL, Cramer M, Shah A, et al. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/153\">",
"      Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996; 37:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/154\">",
"      Rubenstein EB, Gralla RJ, Hainsworth JD, et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer 1997; 79:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/155\">",
"      Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet 1992; 340:1107.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf?et_cid=29661884&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f202714lbl.pdf (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/157\">",
"      Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/158\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/159\">",
"      Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/160\">",
"      Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12:3762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/161\">",
"      Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006; 12:3997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/162\">",
"      Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/163\">",
"      Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/12/40138/abstract/164\">",
"      Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2812 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40138=[""].join("\n");
var outline_f39_12_40138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H54\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIMETABOLITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fludarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pentostatin and cladribine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MICROTUBULE-TARGETING DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32128127\">",
"      Eribulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2666169\">",
"      Ixabepilone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ALKYLATING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Busulfan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ANTITUMOR ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mitomycin C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bleomycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      TOPOISOMERASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Etoposide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      BIOLOGIC RESPONSE MODIFIERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Interferon-alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Interleukin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Denileukin difitox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      DIFFERENTIATION AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      All-trans retinoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Arsenic trioxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      MULTITARGETED KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H950869\">",
"      Tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H505828945\">",
"      - Antiangiogenic TKIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Sorafenib and sunitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15669151\">",
"      - Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2285886\">",
"      - Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23522343\">",
"      - Nilotinib, dasatinib, bosutinib, and ponatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8214830\">",
"      - Crizotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H950925\">",
"      Vemurafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      MISCELLANEOUS AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Diethylstilbestrol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Estramustine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Serotonin antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7757908\">",
"      Proteasome inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Histone deacetylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 1\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 3\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2812|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?26/24/27008\" title=\"waveform 1\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_12_40139="Parenteral antibiotics for infections due to MRSA";
var content_f39_12_40139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral antimicrobial therapy for infections due to methicillin-resistant Staphylococcus aureus (MRSA) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        30 mg/kg IV every 24 hours in 2 equally divided doses; not to exceed 2 g/24 hours unless concentrations in serum are inappropriately low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Daptomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Skin and soft tissue infection",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 mg/kg IV once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacteremia",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 mg/kg IV once daily*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        600 mg IV (or orally) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftaroline",
"       </td>",
"       <td>",
"        600 mg IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tigecycline",
"       </td>",
"       <td>",
"        100 mg IV once, thereafter 50 mg IV every 12 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously.",
"     <br>",
"      * Because daptomycin exhibits concentration-dependent killing, some experts recommend doses of up to 8 to 10 mg/kg IV once daily, which appear safe, though additional studies are needed",
"      <sup>",
"       [1,2]",
"      </sup>",
"      .",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177-80.",
"       </li>",
"       <li>",
"        Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245-9.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40139=[""].join("\n");
var outline_f39_12_40139=null;
var title_f39_12_40140="Causes of pediatric acute airway obstruction";
var content_f39_12_40140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acute upper airway obstruction in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristic features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Radiographic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epiglottitis (supraglottitis)",
"      </td>",
"      <td>",
"       Fever, toxic appearance; anxiety out of proportion to degree of respiratory distress; \"tripod\" and/or \"sniffing\" posture; drooling",
"      </td>",
"      <td>",
"       Swollen epiglottis (\"thumb sign\") on lateral neck radiograph",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laryngotracheitis (croup)",
"      </td>",
"      <td>",
"       Typically occurs in children 6 to 36 months; \"barking\" cough, stridor; \"steeple sign\" on anteroposterior neck radiograph",
"      </td>",
"      <td>",
"       <p>",
"        Tapering of upper airway (\"steeple sign\") on anteroposterior neck radiograph",
"       </p>",
"       <p>",
"        Subglottic narrowing and distended hypopharynx on lateral neck radiograph",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial tracheitis",
"      </td>",
"      <td>",
"       Fever, toxic appearance",
"      </td>",
"      <td>",
"       Intraluminal membranes and tracheal wall irregularity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uvulitis",
"      </td>",
"      <td>",
"       Swelling and erythema of the uvula",
"      </td>",
"      <td>",
"       Radiographs usually not necessary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foreign body",
"      </td>",
"      <td>",
"       History of sudden onset of choking (though this history is frequently absent); hoarseness or stridor with laryngeal or upper esophageal foreign body",
"      </td>",
"      <td>",
"       Visualization of radio-opaque foreign body; upper esophageal foreign body may cause distortion or deviation of extrathoracic trachea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Retropharyngeal abscess",
"      </td>",
"      <td>",
"       Typically occurs in children aged two to four years; neck pain, fever, pain with swallowing; drooling; unwillingness to move the neck; trismus; midline or unilateral swelling of posterior pharyngeal wall",
"      </td>",
"      <td>",
"       Widening of the retropharyngeal space and reversal of the normal cervical spine curvature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peritonsillar abscess",
"      </td>",
"      <td>",
"       Typically occurs in older children and adolescents; drooling; trismus; muffled voice; tonsillar swelling with deviation of the uvula",
"      </td>",
"      <td>",
"       Radiographs usually not necessary for diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Angioedema",
"      </td>",
"      <td>",
"       Rapid onset without prodromal viral illness; swelling of lips and tongue; urticarial rash; dysphagia without hoarseness; possible history of previous attack",
"      </td>",
"      <td>",
"       Radiographs usually not necessary for diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital anomalies (eg, laryngeal web, laryngomalacia)",
"      </td>",
"      <td>",
"       Generally have a chronic course and lack systemic symptoms (unless airway narrowing is exacerbated by concomitant infection)",
"      </td>",
"      <td>",
"       Radiographs usually not necessary for diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory diphtheria",
"      </td>",
"      <td>",
"       Gradual onset of symptoms: sore throat, malaise, and low-grade fever; presence of diphtheritic membrane",
"      </td>",
"      <td>",
"       Radiographs usually not necessary for diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thermal or chemical injury",
"      </td>",
"      <td>",
"       History of exposure; lack of fever or prodromal illness",
"      </td>",
"      <td>",
"       Radiographs usually not necessary for diagnosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40140=[""].join("\n");
var outline_f39_12_40140=null;
var title_f39_12_40141="Office-based self assessment of pediatric emergency readiness";
var content_f39_12_40141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Office-based self assessment of pediatric emergency readiness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         As you answer these questions, you may be better able to identify those areas where your office preparedness can be enhanced.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Have you ever experienced emergencies in your office setting? What were they, and how often have they occurred?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. What is your office setting (freestanding office, clinic-based, health center-based, hospital-based, other)? Are there resources on site but outside of your office that you could call on during an office emergency (security, other medical or dental professionals in the same building, hospital code team)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. What are the high and low staffing points during the times when your office is open? Include nights and weekends if applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. What is the emergency readiness of the staff present during those times? Include any training in:",
"        <ul>",
"         <li>",
"          First Aid and Cardio-Pulmonary Resuscitation (CPR)",
"         </li>",
"         <li>",
"          Basic Life Support (BLS) or Advanced Life Support (ALS)",
"         </li>",
"         <li>",
"          Pediatric Advanced Life Support (PALS)",
"         </li>",
"         <li>",
"          Advanced Pediatric Life Support (APLS)",
"         </li>",
"         <li>",
"          Emergency Nurse Pediatric Course (ENPC)",
"         </li>",
"         <li>",
"          Other Continuing Medical Education (CMEs), etc.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Have non-clinical staff been trained to recognize a potential or actual emergency?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. What anticipatory guidance and education do you provide parents regarding injury prevention, first aid and CPR training, recognizing and responding to emergencies, and accessing emergency medical services (EMS)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Is your waiting room under direct observation or screened frequently by a clinical staff member? What child-proofing measures have you implemented?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Do all staff know how to access the EMS system? Are staff able to give location of and directions to the office, level of clinical staff present, age and condition of the child (including vital signs if appropriate), desired transport location, and the level of emergency response required (eg, First Responder [ie, police or fire department], BLS [basic life support, emergency medical technician] or ALS [advanced life support, paramedic]).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9. Do you have specific telephone triage protocols for non-clinical and clinical staff? Are all staff currently trained in them?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10. How do you ensure getting the closest available ambulance? Is it 911? a private ambulance? How long does it take for EMS to respond to a call from your office?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11. What is the transport time from your office to a site of definitive care, such as the nearest emergency department or the nearest pediatric center?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12. Have your local EMS providers ever been to visit your office for a non-emergency call, or to receive experience in evaluating pediatric patients?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13. What level of provider comes when you call 911? First Responder (ie, police or fire department), BLS (Basic-Level EMTs), ALS (paramedics)? Does your local EMS have the necessary equipment and expertise to manage children?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14. Do you know the point of entry (hospital of initial destination) for your local 911 response team? (EMS is required by regulation to transport to the closest appropriate hospital, unless they have a state-approved point-of-entry plan to allow a bypass.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15. If EMS does not go directly to a pediatric center on a 911 call, how do you emergently transport a child to the desired pediatric center when necessary?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16. Does your office use oxygen? If so, how is it supplied? Do all clinical staff know how to operate the oxygen canister? Where is the key kept?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17. What dosage strategy do you use in the office (code card, length-based tape, dosage book, no strategy)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18. What airway equipment do you stock? Do all clinical staff know how to locate, choose and use the appropriate size equipment for any given child?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19. What equipment and supplies do you have on site to provide you and your staff with universal precautions?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20. Does your practice care for any children who are technology-dependent or have special health care needs? Do you have need for any additional equipment or expertise, should a technology-dependent child have an emergency in your office?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        21. Do you have written office protocols for the common office emergencies, such as respiratory distress, anaphylaxis, sepsis, dehydration, supraventricular tachycardia? Are all clinical staff appropriately and currently trained in them?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        22. How do you document events during an office emergency (assigned role, tape recorder, retrospective, other)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        23. How do you and your clinical staff maintain skills and readiness? Examples include attending nursery deliveries, moonlighting in the urgent care or pediatric emergency departments, being a PALS or APLS instructor, holding regular \"mock\" office codes and scavenger hunts for infrequently used equipment, and providing expert review of pediatric runs for your local EMS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24. How do you document parent education, staff training, protocols, and stocking for emergencies?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25. What is your risk management company's policy regarding emergency preparedness of your office?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        26. Are there other aspects of your office practice that you think could be improved in order to achieve fewer office emergencies and better outcomes?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Massachusetts EMSC Task Force. Office Preparedness for Pediatric Emergencies, 3rd ed, O'Malley, P (ed), Massachusetts Department of Public Health, Massachusetts 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40141=[""].join("\n");
var outline_f39_12_40141=null;
var title_f39_12_40142="Rx sexual dys in uremic women";
var content_f39_12_40142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Approach to sexual dysfunction in uremic women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 369px; background-image: url(data:image/gif;base64,R0lGODlh4gFxAcQAAP///4CAgEBAQMDAwAAAAPDw8ODg4DAwMNDQ0KCgoFBQUGBgYLCwsCAgIHBwcJCQkBAQEH9/fz8/P7+/v8/Pzy8vL+/v75+fn6+vr9/f309PT19fXx8fH29vb4+Pjw8PDyH5BAAAAAAALAAAAADiAXEBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanlwYGIwMirU0OCCsCMKosCQlACAUxu6i/VwEBIwQitCbFRQKvKckuuCzCQLEtyyLUwNlS0iLJwwULAgsFAwQBuQMKCq8BBgEMuQAGDyQG4QqyBgkBAvQA6QoaMJO3T0A8AgzEAUAQbx6AhAIY/GsFToADcgrE8eI2IiG+AgF4gcSo8R+DcAgS/y4QkWDVO4UAEggQMMxAgwXDWv5Tx06ltp9E+AkLkKyYAnoMEBggMEBpA1VPARCgiQDCRgf1ZCFo8E9ggacGDhgocGDggAa70ErNpSBBAasAAsRqUEBf3GEHciVVCuDBSo4PFdSl+4BWv4Wr/MYVYKAq21zWCDz+x6st2QetltmEukoygLZAQ/8IsGCA6aIAFihgsEqqiAfD4tJztiBXVBIJwhUbcGzZA6wArLE6Js3bsNoAwELALEIYggMkCjxQcIAWYAU4AwhMfWAlAOnUrcc2HrwVeXcCGgwT7jt2gNnNY4uen4Mj6pgLIJiPz9/ZVgYKlODAAp3909sA3AjnCv9xw5D3X4DyBFDdXbyRcMAD5IhHQj+mDcALA0yJcGGGd3XDX2Tx2SSRNOwh6F6D/NEnow32mfiKAw3y8pwxsjgT3HYbSrSUgcYMkJCIZh1zQI8xpteKLQUUI8xbq9RFAC8ylThCABDWZdNZnWGpoWslokghdKmtJ1F5OwbHpJYzxhlDja5JONNGB2Al4QHj4YYmCVtZtNuBADjQXVkkDACBAHyaqGUCaIbFaC7SMFAdYwk0IM6YIxjK6HMSQVpApptqSZ6Z0ixQnQLDWGpYK3v2CaectC6B3A4VrnBrrbyCYlMPuabwa6/EFmvsscgmq6wdCAjT2goDnWCLDNgIKEv/tDxUJEsJ0ExrLQvYouALAhkt4cuymKhmZF4osLcCNDIouGFmQSxADy8lSANvCfK26wI1aOGbRLUk+IjuIluNYAAEzSWElU04xUUQPwmQq8AqprkzVHMlJarOdhXFZs0wD7RW8WLjTIRLySxtK4I9Bslzk3zyhEPTRDHNJLKRrxi5GD4SV5TyCS2Vcw4JDsy05kvAJQCgYCrnIhOBE8cclzv6rJJ0RP+Ykwu5XB9siFwWmifRUZftd5aH6kn3V0imGVpoq8e8LBZZrSCKY3mu2SsCBAbsfWQAEDiQwN5vCZych5ZdOBCiEUvj4WeQGdkbA9MtJJFRSLnM7wBLNUWC/0RfdXY2PRb1FSDhhicg2FldpdUjTQZYQzpYTCl1d79iAwKYmRUKN2iRRHKzFS8QDOXjb0VuJUw4fBeTcG4AJC+MlLH9Sv0ICByTDt/coymNNOipxzdYXEF6ct+rPWuCmYkmrR+Zwb+CvQjr8JhrcSNYM4D8++kLTYTSO0Js728FIpLwiMS3CkkDb93o0EASZJqymEYWZlpG/pjSITi1ZUmJ8t6rQsgfZzVgRetphV8c4I//mS8ZuZnfCeAnAkthMID1MxEFi7Q/GBXJhtFrTmkyVsBBvGVbhXEUC4OzpuE1UEN+M4Y/PHckAJTliCK4IZlkwpXgTBFOZ6nbCODyHv/wiSBxczuTCCJmja/QZSEfosVurjEMn82LTFvCCgSTsUTbrS42zPsKA0HojGWQbY+8OAu+PFfEP4CtO/iaCiQfMiEn+k885ZgJLQpAnQNAqFOHasVzGJVCPEIgHpw8gCdndUITWGqS/YKUOoaRqlWVMjXAcRUh43KpysSjfwEcAVkEQB3zMCpljJqJLLgBDlVKRFGkdFR5hllMXmIFUoxaUyMRYTAyDKsIt3FBF2lgMN6hIFjbDEU3x7CrIRywBQ6pQTnDdQJ0pvOe+MynPvfJz2x1EAXeqoYTAiqDeQTgFaM6mgkS+suFKBRc3GooDvaFA4KagJ79TMNZ5BJO3Ej/dAXrJKcMoNEve57AcAM4gEQegJkFAIcELB2AS5uzDozyi4GAoQE3cmoDigLTGBmFQ672lo6SmOYhSuPY0Ijhk++EIzZOUwdIDlOopBoNHTzJYkboUTHMZGxmJNDOQXNGtZP6o4afdGWAvsktjF0LVnFRD4IGxDt+pMw0KzNZ92gnl3A8KQEI2kn+YvI0kQglkRR5qswiV7WzBtUMuQINXxTjHLrYRXBiXAvlrNiKvVlEOleMyu1UkbvNmDZgqJPrlBznJ9C5jhzjVNiABMYlRm4JaIXJiERZtBIUQQp0/GhMbNM4uMId7htWWUBppircf0CAVaddReoyF7m3cXZu/2lzzdpK99gzQLMBwAHPhJy1nFdYjyglMI7zSDPCXPkPgGSCTXNY+lLwsShakX2FABiZIW3+Dyt7fel/4zIOCA7HHtBhmHYZJM2/KU9L2rOuqRgoX9mArxgKrt5d1gu9BbrXpt3lggMhNCIH1sROUpFgeuOT0g5p8cNARNWLfseOWw6HeGYkYcFUcL9ZVe8BDHBAFZ3IDYNx8Kgc+eAyX2QjBpfJfnjEXosveGEGmjPEXohsjnJ2FygVg6qMNA4WF/LEIh0SUVdaCJr2CzsyC4dF2nQFmgI5XHaspGfD/YcruJIwJpagXM/pU0pjVM4vciSMzQFOkRnYpv3yDUCfef/mH8eMwSZaGcRYzkKuyIILTUHPWdVhVypXueMSjbJRlywSNRElIT2p0j2rsm+rJrQhgzRTpX9WJdTsBMJ8hXpb2Kzva7wDpGTMZB+yEmYn/0iCVsqjOs0SdN1iZYxLaUWTS1ZzNF21YBxn+ttSYCsNrgzucp+hnePGtLnXze52u/vdgECABCdng8xGwd4vONc1tKK4GxSAkT5Ngb5jYNESyFt08H7DPhagnna8gKchVYIzIs4CglmDYDdAgJ6Y3AJqUBwFAecXTlRl24Rr9BhdhZVRM4JM2hXMJwx5GVcLq1QsIcCrJ3E0zICmj8Bu7Zlek4pPGNCzFWENZvHQCUD/tqMTfgAtqoLhh2MlFhMsqQIyfKXrQGIuD64a4Ko7z0dBKqYOjLUC6u4D3/FM3gb3yhWziOnLSpRL7248Bo1km26A4J6eg/Lj3wxrzEK4oihWPeQ7uBOdZ9pSRa5NpR1eAY1m7oYo3wQoJcG5yANC675lvCUXw6M7c/v8MgUrRjOl1QrhvdI2yq5H89756RqnznbvEqp6DxYvp4jBH+REZYHn/XKNiZcbATjxH/CdOH/Q56juuSJAvgGONZahvm2lOsfC2Ac+aGFiQv/ZNtINZvEt2YruX1/2Pq49ZG9/5LxhqPsrNvUJIbTA9su6SAMqUK5iHEzyrNAfyZAr9bND/+9lPtcnLwBRAAZRR2OyaCHkfEFUKFRDfsVTSvakIAsQZ+q3fjgGZlIhJnEhbGSSIEDiR16URff3Fn42JPujR2gWSfzhRjD4NxuBOpaDJGwSR2WWY1a0EptXftahaMk2ApoSD5HBC1zDgoRifkD4OSzxJxtoezg2agFCKtAjKZ5DHjHxJ8nkaFRoX5qCa4HiAE60arCSJyMYGzMlTa+ETJ0VSuWhSy92eyMAGkNCJFjogDA1TiOTJ2NIgUzIQP0TaksVhYmwK+SWLzTDAx1liI4IT7GViGG1iDrwTo94iZiYiZq4ifPxdQjXAuqWA92SdiswcD5AMaIkgpwYGkKhKv8ugG+jkRMf9T43UnKVGCAKKIirOB/cgCghsxANQQ+x4RGyoHRvlSg5lxIw8Ys1ozM4UxEXIRM3AzE5gTFZFRdNFVYO0zKYMVUhERx8hVMds4vZ8EBRoTftYHorUQwAMhggsR69NUGM4RibhY7XFTl4oRfy5kvZpRno0xmT8XKfkVoHVV2psVzDA3fkWI6aAgESwWG0ABpRYRTZIRC8gWAaNomOUlnPs1/iQ0sB0CYvww8GqF8DUGFlpIW8p0DmNUYTViHBt5DluB70MGWiwxsQ+GVeNTnLEWRVtCWyIgw2KW8MJpR1oyJPZmZMppKOkkNR9pJypGIy+Qvm6CEQsC3/21KEOtQlqwBojaKRaUhpaLQ3UwI43wEpa6QmzbNmb5JTfGSD+CNpUHmCZDaVqGA8aHFqgDROfBRqiUFs0eKA0qCXWzhLJeIqjKEqxDRrI0RtaZhex4SEr7BXjrZoFfKFdpmZLvBxmtmZPcCZnhmaojmapFmapnmaqJmaqrmarNman3BUrhmbJsBTsumatFmbrHmbuKmaurmbqNmbvmmawBmcpDmcxCmaxnmcnpmcyqmZzNmcdvmc0CmT0jmd5Fid1ilUQ7Gd3Nmd3vmd4Bme4jme5Fme5lmeOnOe6rme7Nme7rmeoWiIQvGe9Fmf9nmf4Jme+Lmf/Nmf5Hkz1EmJ/5yAnY5AoCZnoI2AoIugoO/GoIrgoIgAoewmoYdAoYVgoeWGoYSgoYLAoZnmoYEAon8got1Fon5gonyAohmlonvAonngovsEo3ggo3ZAo/hko3WAo3Ogo9vEo3Lgo3AApAUkpG9ApG1gpAeDpGygpGrApMjSAAQQpQSQYZsApVJKpZlgpVGKpZm4AFJKAGmlCV4qpWGaLl9appiYAF9Ke5igplLKppbgplEKp4+4FFJqi5Zgp1GKp5SgpwTAp454AFGaZ5ogqARAqJhgqIiKiWRIALHXCY36qJsQqQsJIp7xCZY6i5iQqTIZpaS4CZ4KCqG6kIwiCqUKCqe6kGQTCv+r+gmtSo6YFwqx+gmzmp22equ4mqu6uqu82qu++qvAGqzCOqzEWqxzEG2toXHy8KlLgHFnEHI00CH9BgPOGggdwqxF4FObVIwN9W+AooqFoC6Wgg60AK1KIIlhIKHmoB0a+ALougfrmhHTWgRuuRAb9606lgiktzBEclQwM1beyAv6QDEW0xp2hSVPYzLisAo9R0tY0w9lV3M7MY7PN1gphzRJhY2f5Vc1REzXknM9c43t0A4p11fCATZCcg+ASiZVRIwsIQ41kXThV1VhM7LPMrAGUbASayQcKzQ6khFL47FT4AxZglRAY7SsAVjfoFg0G7RAw4wwA6C8ZxekgRL/BPEdTodyC3uh9WVBGgI5x0FLd8Z6IaEYfAd7MfE6hPdcDUI7n2W2dBN3iqEw//gjY9URiAeQn3ExCdOONjF6XBFdUuG2qjWPgbs7oKN6LJAMiuG3dOG3FGg7eTu4DrdnbFO2KwF3wZUwR/EQujMWlqc5Q9tsKSEYf2spdQFYbHtdgpO3mYN59gi2KzZigEcke5Mlr9Vmg0BjJtYm0pBhDPNhRBKTqTZYbFY3hdSEMal7MOUecFkC/yMA86OFFCkMArFoKAkfOIa9A3Qz47e4yVQZFZkOlia87yW9wXRjZRaTi6YarCFAwkAT1UcFPqJB47sa6guRyIe+8wuRvruI/8NDQTCZSBGpXyuLB+8EOCbWQ08pvBVif6nWIsGSvERifyUmRjtlYzUEQjJmIhxiGu+oQ0spe4tGGteaf3jUDF2BhDupgFBmvuuiRd3kwFHZQQ4YQwgyRKCDfOYjBT5CFx/sIQoigBbUFPzHwwdVxEQZI7wHf8vwwAsCPu96B2OWRCY2lsOAv99Dw3Q5h32hR4SHvD8VPF+UZkWbRWzJg2cWQCXMlYvWaG9yf9r1RguRhJzJuNbBlYgjPdABQYbkgukbxWXmgZZJR4qURb7wk1BAG3rixt6xxN9xlVm0xoksAGIJF3uzY92nghWCKEdCZ4bwSHelIbJ0M5R5LUu4Sf/LVma39kxiTDyXucpWmFmO2S9m+Jhk4iliIZivJk1vJivYpFJ/uLgjoFyF4pcKKCj440mV5yGrgmYXlcrfscol3EtbmE1yOLQz8ZXHzChjoZgHVTd6aYbZTJiyZHiabB1h6Mpqhh2bpCq4Jgn4gm7Hgi/iZqxEAM/gWiyB0mv4/M8AHdACPdAEXdAGfdAIXZuwCQoL7QkNvYtOmgYRfQYTfSwVbQYXTQYZTSwbPQYdna4CuokfDdKsGtKaONJggNJeoNJxwtJd4NJbANP0IdNaQNNYYNOsaNKZgNNWwNM/4dNVANRTINTAQNTboNOXYNR3idRJzdSVoNSnANVPINX/TUDVpGDVTIDVSqDVJS0KXI0EX90JWjqlnjDWXHoJZr2LYxqlaHoJaw2mnfDWbf2IckoAdFoJdX3Xk5DXu+inBxwJft0Jgb2LigoKhe0Jh72LlPoJiw2pUSqpm8ipmBqlmnoJkk2Oo/oJmd0Jm72KqfoJn90Job2Kr+oJpT2g+5yJteoJq80JrZ3QsB3bsj3btF3btn3buJ3bur3bvN3bvv3bwB3cwj3cxD0D0loD1boE5loP2CoDygoD3poD0dauOgCLnfLXQjDdMxBQy10D1u0E3V1QzX0F6+ps8RKfQ2Cc4f0CJlVPx/DcN8APRBcxPvBxUyzIOyDfMuXUEQWW/5+piDJAoRa63vTbsR17tFMTsywxsz/XHFiDGzD7EEWnsd7BjNBYAAFbIkj3Mk9Vfon1WYACtBLuCqyhskSiE3YRdnF1UHaR4TyLrqT3HYLFDq5QfiDrVCWBsg2WMwBKE1KFtTRhdVcrVuitAjGeSCLbVGBTR09iM+5hVANAUdIIVQn7sl7KL7RzsQc7sS1XuQ2TOkgVESCxJRgeDhdhsq8wNa0BEA6n4xRe4zh+EVvAuCvhuAUAuZf2aJP7eM+C5423OZMRu/pokNIQebkgu9LALkmhMIjrOvjTEoqbQxUieNNTFl9HC4RuuNEgbIJLHpvLFZ2bFGEBuoE8OZJHMv8BYpCp9lvj/XCcXreLlwtXKR0lIruaa1yJ4kuZ5zaBYSUlIHp99z9xO1lzt1wCeRTHYxeIMmiK3iyanruHOxaWjriaBRqJro9zHr6fcb/lSyjnO70mgL9kwnxp6L9QCLwb5j348JEbBoUjUBjxOwyAMyzfK+kopxsMBJMuqYcpkFPZ+5jt2z7wS0AGUz63hGEumWrtXQP+7ryPCV6T4xzszr6UaPBlJu4Gs0O4dz3fMR3jRYkByBjlxRJzVzFQuGjGe3PSd5Ld60PjE5LurgW78UZB7MJNRjzLcMTdtEByt0RpOJTopHxGuSAMPPSzqcMu8R7DgMLDk2pMn+9yxHv//A5yYZrBAA/M+ZHD15rCSHlfJqJ8Cv/dI1X1I1wi4GEVRl8cKpZTXW+BI5TCWiI8KnbB6RfyEUJrVxm8GNwnLUJBJkxEnh7OX4DHcaHH38DH39HMawz3aRQlZ9QAdCxmkgxHZlkXWsxsZIQhmAySVPIdz3LIZGYTvyckw4O/WWLH/4AmFXL5E7YCb/EKBpAUaQwX+GgjhkzHcZz6afloAcL6ps99MW8Dr/8yss8jj/kKZVGWvOBZhraIg5YmZbbH+bLyUoSCZhyEyHANJVMl3mA+nV8X2AvGSIUkoN+WnF/5rf4EtJG5yDwTZLjM1eR5zxzI3+H+jLySgxlqjDmP/9gGAkAQAMxxLAWQHIpAjuUhCAZwr/PB3MpyIxoCBwEwEBiFC2RwWATQEkcAgiZAiEiAJ67bRShmgoHopH0IFTBtMSBWsQS7rXcxU0PF2CoNO1AiQQkkeBUaHlKF0ZC5HbDdxIQdOGTlKOAVSCpU1t2RjBkhFdAEcN0YzFSRAWSebCYAAqBedRHIpcweEMoSqMjQGMTQFdjNATigNJDFzT3FxJgAI05TV1tf3/gaNGAjanPfNNh0k7PeLOyWq6+zt7u/w8fLz3ebGib8rPuK0/f7Awk5gMVdE4E38P3rUoxSwoYOH0KMKFGdvUL81gVMN3Ejx44eP4IMKXIkyZImT/+iTKlyJcuWLl/C3BgIBwJfhhwMjDgz5kgDNsDs5Cl0KFGH9nB6AQVllbsp1SoWbVgxAaEGNSNCjap160cCCYYctBEg2J8Fnx5cGoeD2JACBpbsGsBgCaMGAQYYkEJiwKVVWUUCfSAL7kEGlwoEECBYBAOwgwcVTnujsQI/c0ENIBBA44DOmjUmMKxARWeqJQRUTvRiMmoseRMLzryZK+3aGwmQUSAYlK0ACA48INP2QT4cukoEGZCJUGIDQXLgHQBBzTaf/P6C3FZTsLLlUBwUeHBA+XUeugF0V0Bo+A/DbhsgrvHcAO6cWegPsA8WrQgIDkKPtk0BEGxXQoDw/UH/nk/12dYgDp05KM8TU/CGg1KY7fQbTYHwxUkRTjn1gBYBCIbdRw8wRAWHm2B4Q4WhVHFDhy36MIIywjxRUQwVKdWGFjUGoEwDDigHAJDKOPVihA0Ks6Q7EyKh5IVkOCXjTCAigWMoVkIyIgkmetQklkttSSaUY7aoWGfKaUmHFzsW0iMnanZWQHgKQDBKcHUmSQaYTvLUJKDrPOHAbn5ayAOZVbICgQ1u5SmCYFoOcACXVFgKBRZ/cvQHEABESuKigbxoKKgqiNpiAJuwEswjW9jUpZtdgGIYJ6tmY8Aq4+Haap+wDkqboMGSYwsKKigZzaheRFODCcd66OIgVTby/ypKbqAmA7QtmnmLCs+msOwxOrh6gzOTdAFnUnpwMq4cBkjCEDLv/upGisQSNSy++wrFaUJK8RtwNfoKXLBK/v4DsMEL40Awww9DHDHEDktcscUXR0gxxhtz3PFLGnscssgjh6kFySejnPJDIKvcMjwQumwxyzHTXM7MNRN7M847T6Mzz0v6/LPQsg5dcNBF83w00lspvTTNTTudr8lRU91u1YBCffXILjQgRFBa25Y12B4rQIDZtoyd8dRp8/zA2ZqxzeTacdeMwNtM0c303HnH3IDZEPAt7N6Bq7yA2awSHpXYiUOcgNmLMS515DHTR4B9k8e0OOYGHwDO5oEO/v+5xw4UJ3pLfp8NuOkjM6DR6ioZfjbir3scK+0oOX425Lfz3vspb1/uO0p4A4oAJQUEv4Lrrx9gtufCH1yUzlMYb4jmYBNBQOnQo2RKfAHAYUN+RuDdmACKJhZuaVKsMmJj4NHlBVtamM8DKboOQBVfAoQbnwuyEOJ7qArd5xhgtuVxrySmMIsIfhAD/pEJIG4hhANI0Jj+/KdNXjGSApzzPACM5xi+gU9eALCABbDJPwlAgA2II8IVIGEKDAyAAwn4ObOpJYEnMYXqQBWKt1iqh7KAQHBuAIERlOJWr3KGtahgFxrWgIjt81I20DKDU21pCj0E3PXAJgcdRg8HXHj/AhEZ4IALdiEYV8TNmpRorjdG60Hj6YxrsOVGED6gAFOA0pbGaLXbBeBeYFRgFxTAgw4ZiQmOSOOjiqCYTwkDRbyAY5uyQSAg+IQVbWAIjuCAhBBecAqGNMImuqg1BChqkCaxRRT4QAsAuBA9eMtFADXBiQIIgQiUbCKm5DAWHRBiFggQBiz4p0gfxJAJVsCCKVXpzGdCM5rSnCY1q2nNa2Izmw2CmTa7+TQbejOcHWumOMs5KHKaM50OQqc628kVdroznpKTJz0fBs96JnAASNwnP/vpz38CNKACHShBE/OCgiI0oQpd6D6JpxK8PCiHDslkPyh6CNNYNHGJYShH/zvq0Y+CNKQcXY1L0GYEuEXENP1Q6SFiwFKNgpN795QQCk3IwP2lAAG7MMDu8qJP1SiKL9QRgYyotAwEFDF9tgvA+7KxBC2scE9keAtkHrMaCLEFPF9wAQ8YoCivwnAB4/gKA4EKicbkg6q7SIANSsiWcAVrpnSTKzws10E1kICFsExBqO4lHeocwACjwIs4ChBCJlZCAHYZQAVP4wUCmEcwIWysYu8Sg/QQIoQzJMFxGJATVAh2DLjsDHwSMBpPuYc+sgjsYLdACPXI0js0EoxncxZT6NH1HY4cQwzudEV0oCeHITroCyRpJlk9cBVHHIE9oBSEESwhgiOIESk1VP+J6WbKCw8gbl4bYBAFrOIKo6TDdkewGiZSd0ZUQsICDClRJ+U2bfFtx4eyxNk8Uq8BtuqCU2i4pnId97qf8MuaiHemOY5PKSPAUn/XwKiGobAz47hiBMcgJ/9K2E0L5lCU1nuQBUDAoWqj5nzZYYodedJFyvACiOADBDSGMFKbrfBiLleoPF6SCtIlQahwrILGjmBAj1LLH3yBBQcgmRKSxOULC/AhF+sYsT02Eg++YoQbNDautxVeiQmVLhIUM7o5KESVmMEDZCxgxWhAzRoi2IoWPNZbvVykgi14gnCx4BJtblYOzcwCVuiCGCfgwSiccBAd8ACx4CJNLLAlANv/AW3LvutyQ4CrDoV5mSXfcBmlq9Zpf2yDHZimSEsKkryRfTpqqcZn5iTdu1Wz+mOu5h2siZVJtpzaEMT7Gj2A4rFaFw3YILmnaRYgGEgjIigIU4dVkF0xYQsN2tOQyxJcoxdSgldGen7UU1lzPkGMZX4HQSqbXqCC1zzSrPwlbFmduhqdnmJSB+HfE4CCPrS6W6tKZXFfTjqbcc4akAHvSGKQB7i/jkUc1QGtYckw2RFO0KbKeTgUFjvDHyQIlz5hrcKCDBy8PdwAqnNhEVJbBIbz5rWZJYRnG4vGUyhc4QwCOIkHzhFhjCFEI3qAccfwXCiKvIiV+Hl0lbLFMo2h/7wb/XIEAQJdJMD2OlR+o9LP2yXrGhGJphARJEokMmknzeYbwXlnAiGMfbqoMwiu4xVjUKk1YUFOb+wThiHasAHzd+0wCoQj/dLA/2r4LjthIzfduGyjid10YG8pCQZUJuteAcbKyTELGymC41E+gqPsUJ+K/Km7N71RAxmIEHZRhMY6OQlGDryQW5Vu+0B+U7He1+KtF5BDzqRaWE4GGX7jS1qu9gq+p/MqXOkHUi0D0UzH9PDP4LkiFDqJOZBDomXF5zfPrgyLnNXsz5l4iehsH+/lXQYmMIEMdOQCF1CJ+rtxla9/PyI6y4gOJyABCUygIxGIgEr2PzAtIAX8df/fSPgfAFwABmiABqAfAESABGwABWTABUwA/1GABkgABtxAB9wfBjKgBGgABQCABWyABPAfAGTACJKgFzTgBwJABV7gDURABsRgCZqfCV5AA15ABSqgCmKABHTADeSgB0yABTRgBFgAA/LfBdxfCYqgBIDH/bAVY0DQxtSePBWgD1qAB2wAAHTAFlIABkzAB2hADFZABlgA/gEABloAB2SAB2hAC2JgBeRfB/CfHALABpTgDbghHGZAGZ5h/hEACWbAE/jfBHDAEHKAEWrhY2GgBngAAEhAIk4AHjLgFhbiEWrA+lXA+nnWCSlHyhkJAk1M/BVM9bDE++CaUFxh/tn/HwB8wBHeQCsCgAeQYBECwARo4AdMwAVsIghSQCJGwAhSQAXAYB4aYC/OYi2moB8h4S1KwA2goSyKUSw+Ixq6Ig58QDPKYCRGwDAyXYBV4UeE40o8GDXMl4AQw7FRw+E5xCo6I/fJYjCa3/lhQAWAYDR2gCTKoflRQDwa4y3m4/5twDyiHzMW4jNCIisi5DS+ozX60f5lAAdg4P5J45wgyh9JzDi+SVEZwWWsAlmNA1M5hkgyhFoBgQuMCP+ogP8Ehbidxrfdz/qE1VjxjxbY21lNYRdQBjPZBSww0E6yhiHJhijqXwlGYzWuXwvKoiHCIgVEwA9agBxSwBH2oAV8/wAItqBVHiEddsFUpiH+cUBTzsor3iH/yeJRPlYGPqI1agAGTsAbUiQxlqVVop9bBFLaBR4VkiJWIJd8cINp6RE4QJaRlEhkxRZsEUh4vNAFNZaVdcHDBUHEeSJiqBBgolaAnBzH+YnK6eSBFAAL5MfHpRZ8mMAE4UeubcQFcAAHrB9aUsD9XaA08qIEVAAGRKUHymE90qYvVgBtJmEFJKAx6qY9HiNtYiAXeAAHeKBZIiRa1gJtbsARWuNr3h8I+t8G9OYYpmFv1oAwvYhG3txeQgRiaUm2aYqb7JGVpNcmDEmRLFcSRQqjEF0UCd3Z/Uh4gYGiFEHVfQnR9IBZBP9J2eHlkfBFKnEf27Dj0IAnQz7DI0wJeiLBmXAYK6BFnhDeRTLK29GRLNiRfeLlUlxYhEEUYlmIVOkR8kGBiSpMgvIMi/7MghqRCswYeR2PYGKZ1x2DYEzZrhxBjYEQGbyc6GGS5d0lJywZN6Dek60eiUICq7hFvThpMOTDpjjbxcAoylzpmuGBlgiaMRhLuHzpt9yZCsQLK9jSbyCTFzQf8AmTMHQpodGALk1fM/jn7tELiroLa9nBatiLAE7TlZJaLazEpokOoJKMoRZLWqqEqSmeeEYOog4gREBqyExqpDZEpdLczvDaOyDP5mAqx3zqSLgoRpri5IQqxpwqNgj/UEfGTxe4JIB00LwZjqyGJCq2KlDGZP6wFSFEYQlJIfyM2tKkqsw4qktcnAj4pRdQHHsYiFsUgWUK5mt10HOMJjGgEGX+B4V4mGtxkAdpzbA+W7G2xNFVkhM93bKMVxGYJy2QqLoC6I1Q0ZZwS7t+q7gSDrg+xTSWq4YmmIfJyYPSK52wSbxqa5nQ69Xga8Qk7DRsXik10YCM3rIkKSzV6C69Ua/YJSdpgShVGd8RzaiezMLak72uhPHFEU3oAN5NQfRBXzHo58faaWC16cbGUCzk5YE6jcgyjM5aajmgzt9A088SgBD1LMPEzuFA09ESQPYVrcHkzuNA09MSwO40/63BVI7ZoKbwXK3lVC3ENA8BfJAqfW3Ydq3AZM/2qNLZlu3DGNAGRVPbEuXa4gsOTRPdyu3CfNE05e3dGkyRSpPf8q3AoBI1DW7gGu7hIm7iKu7iMm7jOu7jQm7kSu7kUm7lWu7lYm7mAsZAdKrmgg0CFFiRZEPyvJQhNNVWCICjlAlL8BRTuWrowh6ybepaVJvnrhQNPZFalOo3HgI6csULYJwobFSVfkTr8IXJuEoDmIVGBKCiIoKxmYPt9oNTRBVeEAJODZAXgKQILNbvHoGusBcMoG1JlKOCBUNe2IAD0MDLphFhbEO7Se88JMliUU8L1VAXQCt0jJ9Q5BwKIf/B0aVEJhjoh/aGAdQKK0hdF2CWYQld/Movnq6sFdlXIeFnORYFKAxChDLkSRjwABOwhVCJ+oYY961n6DlwPPzKlgDHiVrNlFgwUWCGEEwdIp3ETxmC3C2FCcTdRV5KwZ7wA3/oHqWYoBzp6qJueClTH/Cv36XdXTbcgU5ZsP4wO6TwFITZBNPuoBkx27wwDovWHRwWs4ypCU/xwkzHA2QtUZxxGpcx37yN8kYhbbwxOuxvGyNNQb3N20yCB5cEHuex2eyxHVONH//xC7BxyQzUH5uNIQsySjQvRLwfIohYPOjxGdlGJfNxI5OEFP/DI4OwiyQEHNdxIVQvsoYLUJD/ALrFRb9JYT7UDySoJLPRcTzwLKu9wGGQj2ls76+yBRms6mmM0liMRRSSpCwoLwwAEGy4G8ne8GK53P8WyB/UhFUs3HWoXGSW0DNHhEu+cq7qMv/QZFndZCtrsouQAH8EQGWeVrR263Mca2mWUAHzRmQxMKJkHD9QnE4ol9ahB5GQhtmRyM4FXtDtM3NFBGSSECFMZjr/R/6a3GqF1maGYjlf2H26iOxFy9GNFxwFmA/XV9rNp0T0SIFRKJ6wcBZ4KGKpUYSS9EPMJ0ETjTCsa35SHXfdbCNX9Id+5yP40Yp+Mh/JSefpnT67iI/yqFMIROwNtOW9HkTwK9thMdml/12IAh6TCnKtOOwNFPHNqushldKUzkqp7MbL9gnEfh5EKAX2GckJUIJ0+BIkmMEuAZ9aP4RZU8GtbRLRFPHEel6U1akdy4ESu6nLWiwdmKygWR1ehukv0MGvNN/wzO6ipiybpsJga3GhyamZ3XQ5cwTI1nBkOwmhcnZKeHbiMOpoo3Zqq/Zq8w5os7bcMuNrJ+5QbgG+sUK3rQC5fQVJwaqdmAz4yHY5nSa3wtay0i+ZroeSbUIIVUpwmxMzTtcTFd0qBENlRdCz/oClOXc4Qfdd6B0obAMPJBccEQjRbrc29cIu2fUOG0GmMBBWQ4JdnLc49SliPbZS7CkeBPYr0TkH8c5392EaQvx32WLaRQz4gSN4giv4gjN4gzv4g0N4hEv4hFN4hVv4hWN4hmv4hnN4h3v4hz9ECAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Palmer, B. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40142=[""].join("\n");
var outline_f39_12_40142=null;
var title_f39_12_40143="Asthma annual mortality";
var content_f39_12_40143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Number and rate* of asthma deaths, by year and International Classification of Diseases&bull; (ICD) - United States, 1980 to 2004&Delta;&loz;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per million population. Age-adjusted to 2000 US population.",
"     <br>",
"      &bull; During 1979 to 1998, ICD-9 was used to classify deaths. In 1999, ICD-10 was implemented.",
"      <br>",
"       &Delta; Data from 2008: 3397 deaths, 11 deaths per million population",
"       <sup>",
"        [1]",
"       </sup>",
"       .",
"       <br>",
"        &loz; Data from 2009: 3388 deaths, 11 deaths per million population",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.",
"     <br>",
"      <br>",
"       References:",
"       <ol>",
"        <li>",
"         Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2008. National Center for Health Statistics. Vital Health Stat Series No. 10 (59) 2011. file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf (Accessed on July 7, 2012).",
"        </li>",
"        <li>",
"         Kochanek KD, Xu J, Murphy SL, et al. Deaths: Final data for 2009. National Center for Health Statistics. Vital Health Stat Series No. 3 (60) 2011. file://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_03.pdf (Accessed on July 7, 2012).",
"        </li>",
"       </ol>",
"       <p>",
"        &nbsp;",
"       </p>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_12_40143=[""].join("\n");
var outline_f39_12_40143=null;
